

Local Interactions: Determinants of Protein Structure

And

Guides for Structure-Based Drug Design

A Dissertation Presented

by

Raphaël Geney

to

The Graduate School

in Partial fulfillment of the

Requirements

for the Degree of

Doctor of Philosophy

in

Chemistry

Stony Brook University

August 2005

Stony Brook University

The Graduate School

Raphaël Geney

We, the dissertation committee for the above candidate for the

Doctor of Philosophy degree,
hereby recommend acceptance of this dissertation.

Iwao Ojima

Distinguished Professor, Department of Chemistry

Carlos L. Simmerling

Associate Professor, Department of Chemistry

Kathlyn A. Parker

Professor, Department of Chemistry

Nicole S. Sampson

Professor, Department of Chemistry

Robert C. Rizzo

**Assistant Professor, Department of Applied Mathematics and Statistics
Stony Brook University**

This dissertation is accepted by the Graduate School

Dean of the Graduate School

Abstract of the Dissertation

Local Interactions: Determinants of Protein Structure

And

Guides for Structure-Based Drug Design

by

Raphaël Geney

Doctor of Philosophy

in

Chemistry

Stony Brook University

2005

A new computational docking protocol has been developed and used in combination with conformational information inferred from REDOR solid state NMR experiments on microtubule-bound 2-(p-fluorobenzoyl)paclitaxel to delineate the tubulin-bound structure of paclitaxel. Conformationally constrained macrocyclic taxoids bearing linkers between various positions have been designed and synthesized with a view to enforce this REDOR-Taxol conformation. One of these analogs, SB-T-2053, inhibits the growth of MCF-7 and LCC-6 human breast cancer cells (wild type and drug-resistant strains) on the same order of magnitude as paclitaxel. Moreover, SB-T-2053 induces in vitro tubulin polymerization at least as well as paclitaxel, which directly validates our drug design process.

Improvements in the modeling of solvation effects in molecular simulations have also been addressed. Accurate modeling of these effects is a key undertaking of computational chemistry, as most chemical processes happen in a solvent. Free energy profiles of salt bridge formation between oppositely charged amino acid side chains were calculated both in explicit solvent and in a generalized Born (GB) continuum solvent model to quantify a suspected over-stabilization of protein side chains ion pairs in GB, relative to explicit solvent. Salt bridges are found to be excessively stable in GB by as much as 4 kcal/mol, which is consistent with previous reports describing radically different structural ensembles for proteins with ionizable groups in GB and explicit solvent.

A simple empirical correction is proposed, in which the intrinsic GB radii of hydrogen atoms bound to charged nitrogen atoms are reduced. This effectively increases the desolvation penalty of cationic side chains, while minimally affecting the solvation energy of the rest of the protein. The thermodynamics of salt bridge formation are considerably improved by this correction, which further permitted a close reproduction of the experimental Trp-cage miniprotein temperature melting profile, otherwise distorted by prevalent non-native salt bridges.

In loving memory of Adrien and Thérèse,

Contents

List of Tables	viii
List of Figures.....	ix
List of Abbreviations	xii
Acknowledgments	

Chapter 1

Introduction.....	1
1.1 Cancer Today	1
1.2 The Taxanes	4
1.2.1 From Discovery to the Clinic.....	4
1.2.2 Mechanism of Action.....	10
1.3 Tubulin Biochemistry	13
1.3.1 Microtubule Function.....	13
1.3.2 Dynamic Instability.....	15
1.3.3 Microtubule and Tubulin Structure.....	16
1.4 Molecular Mechanics Background	21
1.4.1 Force field	21
1.4.2 Energy Minimization	23
1.4.3 Phase Space Sampling Algorithms	24

Chapter 2

Determining the Bioactive Conformation of Taxol®.....	29
2.1 Introduction.....	29
2.2 Computational Protocol	31
2.3 Results and Discussion	31
2.3.1 Conformation of Paclitaxel in β -Tubulin.....	31
2.3.2 Guided Docking of Taxoids in β -Tubulin	35
2.3.3 Analysis of Paclitaxel Binding Site Models	38
2.4 Conclusions.....	38

Chapter 3

Design and Biological Evaluation of Conformationally Constrained Taxol®

Analogs.....	39
3.1 Previous Designs.....	39
3.1.1 C2 Benzoyl to C3' Phenyl Tethering: 'C-Linked' Taxoids.....	39

3.1.2 C2 Benzoyl to C3' Benzamido Tethering: 'N-Linked' Taxoids	43
3.2 Early Design Attempts	45
3.2.1 Synthetic and Analytical Methods	45
3.2.2 Biological Activity	50
3.2.3 Summary	51
3.3 SB-T-2053	52
3.3.1 Biological Activity	55
3.3.2 Conformational Restriction to the Binding Conformation	60
3.3.3 Summary	63
3.4 Conclusions	64
3.4.1 Advantages of Structure-Based Design Approaches	64
3.4.2 Drug Design Possibilities Opened	64
Chapter 4	
Investigation of Salt-bridge Stability in the Generalized Born Model.....	68
4.1 Introduction	68
4.2 Methods	69
4.3 Results and Discussion	71
4.3.1 Unstable Behavior of the 17/9 Anti-Influenza Fab H3 Loop in GB Simulations	71
4.3.2 Potentials of Mean Force as Measures of GB Deviation from Explicit Solvent Behavior.....	74
4.3.3 GB Model Parameterization and Rationale for Reduced H ^{N+} Radii.....	76
4.3.4 Reparameterization of GB ^{HCT} for Improved Handling of Ionic Interactions.....	78
4.3.5 Validation of Radii Modifications on Test Peptides.....	82
4.3.6 Thermodynamical Behavior of the Trp-Cage Miniprotein.....	84
4.4 Conclusions.....	92
Bibliography	94
Appendices.....	121
Appendix A: REDOR-Taxol in β -Tubulin Binding Site	122
Appendix B: SB-T-2053 in β -Tubulin Binding Site.....	147

List of Tables

3.1. <i>In vitro</i> cytotoxicities and tubulin-polymerization assays of C4-C2' and C14-C3'N linked macrocyclic taxoids 3.14 and 3.15	50
3.2. <i>In vitro</i> cytotoxicities and tubulin-polymerization assays of C4-C2' and C14-C3'N linked macrocyclic taxoids 3.30 and 3.31	55
4.1. Parameter sets used in AMBER GB implementations.	77

List of Figures

1.1	Evolution of the leading causes of death in the United States between 1975 and 2002.....	2
1.2	Human impact of cancer in relation to other causes of death, and leading cancer types in the United States	3
1.3.	Structures of paclitaxel, docetaxel and 10-Deacetylbaccatin III	7
1.4.	Early semisynthetic approaches towards paclitaxel.....	8
1.5.	Summary of paclitaxel SAR studies	9
1.6.	Compared microtubule formation mechanisms in presence and absence of paclitaxel.....	12
1.7.	(A) Schematic features of the metaphase mitotic spindle. (B) Chromosome translocation by microtubules during the different stages of mitosis. (C) Microtubule dynamic instability	14
1.8.	Microtubules of various protofilament (pf) counts. 13-pf microtubules can only close with a ‘seam’ wherein unlike tubulin monomers are in lateral contact.....	19
1.9.	(A) Structural view of the α - β tubulin dimer from the inside of the microtubule. (B) Details of the β tubulin subunit with key structural elements indicated. (C) Diagrammatic primary sequence topology of β -tubulin	20
2.1.	Structures of paclitaxel, docetaxel, photoaffinity probe [³ H]7-BzDc-paclitaxel, conformationally constrained taxoid SB-T-14801. 2-FB-PT is also shown, with intramolecular REDOR-NMR distances indicated.....	30
2.2.	REDOR-NMR constrained Monte Carlo conformational search on 2-FB-PT: representative structures of the 16 conformational clusters.....	33
2.3.	Guided docking protocol diagram	34
2.4.	Proposed β -tubulin-binding models of paclitaxel. Overlay of the docked REDOR-Taxol and T-Taxol structures.....	36
2.5.	Docked complex of SB-T-14801	37
3.1.	‘C-linked’ macrocyclic taxoids.....	41
3.2.	Structures of non-taxane microtubule stabilizing agents	42
3.3.	‘N-linked’ macrocyclic taxoids.....	44
3.4.	Target restrained macrocyclic taxoids	47
3.5.	Synthesis of C4-C2’ linked taxoids 3.14 and 3.14(H)	48

3.6. Synthesis of C14-C3'N linked taxoids 3.15 and 3.15(H)	49
3.7. Synthesis of C4-C2' linked taxoid 3.30	53
3.8. Synthesis of C14-C3'N linked taxoid SB-T-2053.....	54
3.9. Effect of calcium on microtubules polymerized by paclitaxel and SB-T-2053.....	57
3.10. SB-T-2053 competitively inhibits [³ H]paclitaxel binding to microtubules as potently as paclitaxel.....	58
3.11. Tubulin polymerization and microtubule stabilization assay for 5 μM paclitaxel or SB-T-2053 (3.31) and various concentrations of tubulin (A), or 5 mg/mL tubulin and various concentrations of drug (B).....	59
3.12. Conformational diversity in constrained taxoid SB-T-2053: comparison of the C13 side chain dihedral angle distributions for paclitaxel, SB-T-2053 and Kingston et al. compound 13a of Ref. 192 in water.....	61
3.13. Overlay of REDOR-Taxol with SB-T-2053.....	62
3.14. Overlaid structures of paclitaxel in the REDOR-Taxol conformation and C14-C3'N linked macrocyclic taxoids of variable linker length.....	66
3.15. Top: Direct overlay of the paclitaxel and epothilone A bound conformations in the β-tubulin binding site from PDB entries 1JFF and 1VTK. Bottom: Proposed C1 and C14 paclitaxel-epothilone hybrid constructs.....	67
4.1. Root-mean-square deviation (RMSD, Å) of Fab 17/9 H3 loop backbone heavy atoms, and salt bridge distance (Arg97 Cζ - Glu100 Cδ, Å) as a function of simulation time, in different conditions at 300K: (a) GB ^{HCT} from native, (b) GB ^{HCT} with uncharged Arg97 and Glu100 side-chains from native, (c) TIP3P explicit solvent simulation from salt bridge conformation, (d) TIP3P from native.....	72
4.2. Fab 17/9 H3 loop in native conformation (N), transient intermediate state with inverted Tyr98 ψ and Asp99 φ dihedral angles (I), and stable salt bridged conformation with bidentate H-bond (SB), taken from a standard GB ^{HCT} simulation.....	73
4.3. Fab 17/9 antibody Arg97...Glu100 ion pair PMF as a function of the inter- charged groups distance (Arg97 Cζ - Glu100 Cδ), at 300K.....	75
4.4. Potentials of mean force for the Fab 17/9 H3 loop Arg97...Glu100 ion pair in different solvent models, at 300K.....	80
4.5. GB ^{HCT} simulations of the Fab 17/9 H3 loop with 1.1 Å H ^{N+} radii at 300K, initiated from the X-ray (a), or SB conformations (b). (c) Simulation from the SB state with neutralized Arg97 and Glu100 side chains and 1.1 Å H ^{N+} radii.....	81
4.6. Potentials of mean force of salt bridge formation for the Ac-AEAAARA- NH2 and Ac-AEAAAKA-NH2 helical peptides in various solvent models at 300K.....	83

4.7. Trp-cage TC5b. (a) Reference NMR structure (model 1 of PDB entry 1L2Y). (b) 267K GB ^{HCT} 1.1 REMD global free energy minimum, exhibiting most native like features (1.8 Å 3-18 RMSD). (c) 267K standard GB ^{HCT} REMD global minimum and (d) second-lowest free energy minimum, both adopting distorted conformations (2.8 and 3.7 Å 3-18 RMSD, respectively) with multiple salt bridges, not seen in the NMR set	88
4.8. Two dimensional free energy maps in kcal/mol from REMD data. Top row: GB ^{HCT} replicas at 267 K and 304.5 K. Bottom row: GB ^{HCT} 1.1 replicas at corresponding temperatures	89
4.9. (a) Salt bridge formation PMFs along the Asp9 C γ - Arg16 C ζ distance coordinate for native and non-native ensembles at 304.5K from REMDs in GB with different radii sets or TIP3P water at 306K. (b) Native state stabilization by salt bridge, $\Delta\Delta G_F$, as calculated from Eq. 4.5, and folding free energy, ΔG_F , in GB ^{HCT} with 1.3 Å and 1.1 Å H ^{N+} radii	90
4.10. Experimental (CD, NMR CSD) and simulated melting curves for the TC5b miniprotein	91

List of Abbreviations

10-DAB III	10-deacetylbaccatin III
2-FB-PT	2-(<i>p</i> -fluorobenzoyl)paclitaxel
Boc	butoxycarbonyl
BzDC	benzodihydrocinnamoyl
CD	circular dichroism
CDR	complementarity determining region
CIP	contact ion pair
CSD	chemical shift deviation
DAPI	4'-6-diamidino-2-phenylindole
DMAP	4-dimethylaminopyridine
DMSO	dimethyl sulfoxide
DNA	deoxyribonucleic acid
EC	electron crystallography
EE	1-ethoxyethoxyl
EM	electron microscopy
Fab	fragment antigen binding
FDA	Food and Drug Administration
GB	generalized Born
GBSA	generalized Born/surface area
GDP	guanosine diphosphate
GTP	guanosine triphosphate
Hsps	heat shock proteins
LPS	lipopolysaccharide
MAP	microtubule-associated protein
MAPK	mitogen-activated protein kinase
MC	Monte Carlo
MD	molecular dynamics
MTB	microtubule
MTOC	microtubule-organizing center
NCI	national cancer institute
NMR	nuclear magnetic resonance
PB	Poisson-Boltzmann
PCD	programmed cell death
PDA	pairwise descreening approximation
PDB	protein databank
pf	protofilament
PME	particle-mesh Ewald
PMF	potential of mean force
PTX	paclitaxel
RCM	ring-closing metathesis
REDOR	rotational-echo double resonance
REMD	replica exchange molecular dynamics
RISM	reference interaction site model

RMSD	root mean square deviation
RNA	ribonucleic acid
SAR	structure-activity relationship
SEER	Surveillance Epidemiology and End Results
SSIP	solvent-separated ion pair
TIP3P	transferable intermolecular potential 3 points
TNF- α	tumor necrosis factor- α
US	umbrella sampling
vdW	van der Waals
z-VAD-fmk	benzyloxycarbonyl-Val-Ala-Asp(OMe)-CH ₂ F

Acknowledgments

First and foremost, I want to thank my two advisors, Prof Iwao Ojima and Prof. Carlos Simmerling for welcoming me in their labs and schedules, supporting me for the last five years, and always keeping my best interest in mind. Each in their own way, their great drive towards scientific excellence has greatly inspired me and will leave a lasting impression I can always look up to. I sincerely feel it is a rare chance to come across such brilliant individuals, let alone two of them at the same time! Thanks to both of them for the flexibility they showed helping me reach my learning objectives and allowing me to achieve my lifelong aspiration to somewhat contribute to the progress of scientific knowledge and its dissemination.

I wish to thank the members of my thesis committee (Profs. Parker, Sampson, Rizzo, and Sieburth) for their time spent assessing my progress, accessibility, and good counsel at the various stages of my graduate life in the Chemistry Department.

I also wish to extend special thanks to Dr. Viktor Hornak for his relentless technical assistance with our computer systems and ample research advice.

Thanks to our many collaborators on the anticancer drug design project: Shujun Xia and Prof. Susan Horwitz at Albert Einstein College of Medicine, Paula Pera and Dr. Ralph Bernacki at Roswell Park Cancer Institute and Dr. Muriel Cuendet of the University of Illinois at Chicago, for performing all of the biological tests described herein and making this research at all possible.

To all Simmerling and Ojima lab members: spending such long hours in the lab together will for sure make us a tightly knit family. Thanks also to all the students of the Chemistry Department and 'Mega Meeting' labs for the scientific insights and plain fun they provided through talks and informal discussions. I hope to have provided some in return.

At this time my special thoughts go to Dr. Sylvia Tracz, to whom I most profoundly wish a complete and rapid recovery.

Even after all these years, I will not forget to thank Prof. Anthony Smith and Catherine Ponthus, at the CPE Lyon study abroad office for facilitating my coming to Stony Brook and keeping in touch with me throughout my graduate years. Thanks also to the Rhône-Alpes region for a generous study abroad fellowship, which helped me get settled enormously.

Thanks to all my extended family and friends for always being supportive, providing strong moral support and being present - if only over the phone - in times of need. Special thanks to Jerome Lauret for providing expert assistance in my first years at Stony Brook, mostly in the form of a four-wheeled vehicle.

Thanks to my parents for allowing me to stand here today and, although half-heartedly, letting me pursue a graduate degree 3582 miles away from home.

Finally, my greatest thanks go to Julie who deliberately chose to be by my side throughout this precarious endeavor and the rest of our lives.

Parts of Chapters 2 and 3 of this dissertation contain material reprinted from Geney *et al.* (2005): 'Use of the Tubulin Bound Paclitaxel Conformation for Structure-Based Rational Drug Design.' *Chemistry & Biology* **12**(3): 339-348. Some co-authors listed in the publication directed and supervised the research that forms the basis for this thesis or dissertation. Permission was granted by Cell Press to include this article in the present dissertation, in accord with Cell Press Transfer of Copyright Agreement Version Number: 1/2002, Cell Press rev. 6/2004.

Figure 1.7 is reprinted from *Current Biology*, Vol 14, Gadde, S., Heald, R., 'Mechanisms and molecules of the mitotic spindle', Pages R797-R805, Copyright (2004), with permission from Elsevier.

Figures 1.8 and 1.9 are reprinted from *Organic & Biomolecular Chemistry*, Vol 2, Amos, L. A., 'Microtubule structure and its stabilisation', Pages 2153-2160, Copyright (2004), with permission from The Royal Society of Chemistry.

Chapter 1

Introduction

1.1 Cancer Today

Cancer is a major health concern worldwide, with over 10 million new cases diagnosed and 7 million deaths every year, i.e. 12.5% of deaths worldwide. The number of cases is expected to increase to 15 million new cases per year by 2020, mainly as a consequence of world population ageing, and the spread of the Western lifestyle.¹ In the United States alone, cancer is second only to heart disease as a cause of death (Figure 1.1), but first in terms of person-years lost, with lung cancer as the leading type of malignancy (Figure 1.2). The threat posed by cancer was recognized in 1971, with the legislation of the National Cancer Act, which increased research funding and launched the development of several national research centers, making the conquest of cancer a 'national crusade'.²

Considerable progress has been made since then towards the understanding of the mechanism of the disease and its control, both in terms of prevention and therapy. One third of cancers could be avoided by conforming to healthier habits (ceasing tobacco usage, consuming healthy food, avoiding exposure to carcinogens), and fortunately, close to half of the new cases of cancer are now diagnosed at an early stage and an ablative treatment, such as surgery or radiotherapy, can be used to remove the malignant tumor.¹ In the remaining cases, however, the cancer spreads by metastasis and the only chance of survival lies in chemotherapy. Several cancers, such as leukemia, lymphomas, and sarcomas, can be effectively treated by chemotherapy, and long-term survival has improved notably for breast cancer, the most common malignancy in women. The drugs most commonly used in cancer treatment are the *Vinca* alkaloids (vinblastine, vincristine, vindesine, vinorelbine), anthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone), epipodophyllotoxins (etoposide, amsacrine, teniposide), camptothecins (irinotecan, topotecan), cisplatin, and the taxanes: paclitaxel (generic name for Taxol[®], licensed to Bristol-Myers Squibb), and docetaxel (generic for Taxotère[®], licensed to Sanofi-Aventis).

Despite this pharmacological arsenal, there is still dire need for more effective therapies and palliative care and pain management strategies to reach even the pragmatic goal of turning rapidly fatal cancers into manageable chronic illnesses.




Figure 1.1. Evolution of the leading causes of death in the United States between 1975 and 2002 (Source: NCI, SEER Cancer Statistics Review 1975-2002).




Figure 1.2 Human impact of cancer in relation to other causes of death (left), and leading cancer types (right) in the United States (Source: NCI, SEER Cancer Statistics Review 1975-2002).

1.2 The Taxanes

The taxanes Taxol®³ (paclitaxel) and Taxotere®⁴ (docetaxel, Figure 1.3), currently serve as two leading chemotherapeutic drugs in the clinic.⁵⁻⁷ Both drugs bind to the β -tubulin subunit of the α,β -tubulin heterodimer and act through an anti-mitotic mechanism of action based on stabilization of microtubules (MTBs), thus disrupting the mitosis of cancer cells and eventually leading to apoptosis, the programmed cell death.⁸⁻¹¹ The following is a more detailed account of their discovery and mechanism of action at the cellular and sub-cellular levels.

1.2.1 From Discovery to the Clinic

The discovery of paclitaxel can be traced back to 1962 in Gifford Pinchot National Forest (WA), where under a U.S. Department of Agriculture plant screening program, the botanist Arthur S. Barclay gathered leaves, twigs and bark from the Pacific yew tree (*Taxus Brevifolia*) for biological pre-screening. Bark extracts rapidly showed high activity in leukemia models. However, the feat of isolating paclitaxel and elucidating its extremely complex novel structure was delayed until 1971 due to supply difficulties and equipment limitations. This was accomplished by Mansukh C. Wani and Monroe E. Wall, working under a Cancer Chemotherapy National Service Center contract from the National Cancer Institute (NCI) at the Research Triangle Institute (NC) using X-ray analysis and published in a 1971 landmark paper.³ Their findings were stupefying: paclitaxel was composed of a tricyclic taxane core ring system (A, B and C rings) fused to a 4-membered oxetane ring (D ring), with an *N*-benzoylphenylisoserine side chain at the C13 position. The molecule possessed eleven stereocenters (Figure 1.3).

Under a 1989 Cooperative Research & Development Agreement, Bristol-Meyers-Squibb obtained the rights from NCI to further develop and market paclitaxel (Taxol®). However, paclitaxel development had to face two very serious obstacles that definitely hampered the introduction of the drug to the clinic: its extremely poor solubility in common pharmaceutical excipients and the very limited supply available from natural sources.

The solubility issue could be solved by formulating paclitaxel in a vehicle of 50% ethanol and 50% polyethoxylated castor oil (Cremophor EL), a formulation responsible for a high rate of hypersensitivity reactions in patients not preemptively treated with an antihistaminic-corticosteroid combination.¹²

The supply question was even problematic, as harvesting the entire bark of a 40-foot Pacific yew tree, which could easily be more than 200 years old, yields only half a gram of paclitaxel and requires the felling of the tree. This consideration set off a major environmental controversy about the preservation of the old-growth Pacific Northwest forest and its ecosystem.¹³ Other methods had to be devised to secure the supply of this promising drug candidate. Fortunately, in 1980, 10-deacetylbaccatin III (10-DAB III), a natural product isolated from the European yew (*Taxus baccata*), was identified as a readily accessible possible starting material for the semisynthesis of anticancer

taxoids.^{14,15} This compound comprises the tetracyclic skeleton of paclitaxel without its C13 isoserine side chain (Figure 1.3) and can be isolated from the leaves of the European yew tree, a renewable source, in relatively good yield (1 g / 1 kg of fresh leaves).¹⁶

With the discovery of 10-DAB III, paclitaxel and its congeners could be prepared through semi-synthesis by attaching the chiral C13 side chain. Different approaches to the side chain have been proposed and investigated.

In 1988, the first semi-synthesis of paclitaxel utilizing 10-DAB III was accomplished by Greene and Potier using a direct esterification of modified 10-DAB III and *N*-benzoyl-(2*R*,3*S*)-phenylisoserine (Figure 1.4a).¹⁷ However, this high temperature coupling process induces significant epimerization at the C2' position of the C13 side chain. An improved process was disclosed by Holton in a 1990 patent application, claiming that (3*R*,4*S*)-*N*-benzoyl-3-*O*-EE-4-phenylazetid-2-one (EE = 1-ethoxyethoxy), could be directly coupled with 7-TES-baccatin III in the presence of 4-dimethylaminopyridine (DMAP) and pyridine, to afford the 7-TES-2'-*O*-EE-paclitaxel in 92% yield; subsequent deprotection affording paclitaxel in 90% yield (Figure 1.4b).¹⁸ The limitations of this protocol include the necessity of a large excess of β -lactam (5 equivalents), long reaction times, and the restriction to *N*-benzoyl protected β -lactams.

A more practical and efficient semi-synthesis of paclitaxel was proposed by Ojima which relied on the ' β -Lactam Synthone Method'.^{19,20} The optically active β -lactam (3*R*,4*S*)-3-hydroxyl-4-phenylazetid-2-one could be prepared via a lithium chiral ester enolate-imine cyclocondensation in high yield and enantioselectivity.²¹⁻²³ Coupling of the β -lactam with 13-*O*-metalated derivatives of 7-TES-baccatin III was then performed. A variety of bases were examined, and NaHMDS was found to be the best for this ring-opening coupling.^{22,23} In this case, the ring-opening coupling proceeds smoothly at -30 ~ 0 °C using only a slight excess of *N*-acyl- β -lactam to give the coupling product within 30 min in excellent yield (Figure 1.4c). The subsequent deprotection affords paclitaxel with high overall yield.

These semisyntheses and their variants allowed the securing of an inexhaustible supply of paclitaxel from 10-DAB III and also proved pivotal in the definition of an exhaustive structure-activity relationships (SAR) model (Figure 1.5).²⁴⁻²⁶ Interestingly enough, though, since 2002, paclitaxel is produced for Bristol-Myers-Squibb entirely by Phyton Biotech, Inc., using *Taxus chinensis* needle cells cultures, following a licensed USDA patent.²⁷ Paclitaxel is directly obtained from the fermentation broth after chromatography and recrystallization.²⁸

Paclitaxel obtained FDA regulatory approval in December 1992 - 30 years after its initial discovery- for the treatment of metastatic carcinoma of the ovary, subsequent to failure of first-line chemotherapy. This indication was augmented to first line treatment in June 2000. A second indication was approved in April 1994: the treatment of breast cancer after failure of anthracycline combination therapy; a third in June 1998, in combination with cisplatin, for the first-line treatment of non-small cell lung cancer in patients who are not candidates for surgery or radiation therapy. Lastly, paclitaxel is also indicated for second-line treatment of AIDS-related Kaposi's sarcoma (approved: August 1997).

Docetaxel, the first semi-synthetic analog of paclitaxel and only other taxane marketed thus far, received FDA approval for second-line treatment of both metastatic breast and non-small cell lung cancers, respectively in May 1996 and December 1999. Approval for first-line treatment of non-small cell lung cancer in combination with cisplatin was granted in November 2002, while a last indication for treatment, in combination with prednisone (a corticosteroid), of metastatic prostate cancer was approved in May 2004 (Source: FDA Center for Drug Evaluation and Research).

The proven clinical efficacy of these two taxanes and the uniqueness of their mechanism of action have resulted in both of these drugs reaching 'blockbuster' status, each with worldwide sales well in excess of \$1 billion per year.






Figure 1.3. Structures of paclitaxel, docetaxel and 10-deacetylbaccatin III (10-DAB III).

(A) Original Greene-Potier semi-synthesis of paclitaxel.



(B) Holton's 1990 semi-synthesis of paclitaxel.



(C) Ojima's β-Lactam Synthon Method semi-synthesis of paclitaxel.




Figure 1.4. Early semisynthetic approaches towards paclitaxel.




Figure 1.5. Summary of paclitaxel SAR studies.

1.2.2 Mechanism of Action

Paclitaxel was originally believed to be yet another mitotic spindle poison akin to vincristine, vinblastine, colchicines, or podophyllotoxin.²⁹ These agents act by binding to tubulin, the main protein component of the cytoskeleton, inhibiting its ability to form microtubules, thereby arresting the cell division cycle in metaphase.

Increased impetus in the development of paclitaxel came in 1979, when its unique mechanism of action at the cellular level was unveiled by Dr. Susan B. Horwitz at the Albert Einstein College of Medicine of Yeshiva University, New York City.⁸ Indeed, it was found that paclitaxel was actually promoting the assembly of stable microtubules *in vitro*, suggesting that the mechanism of action of paclitaxel could be related to its ability to modulate cellular microtubules. The drug promotes microtubule assembly *in vitro* in the absence of GTP or MAPs and the microtubules assembled by paclitaxel are stable to depolymerization by cold or calcium, which readily depolymerize normal microtubules (Figure 1.6).^{8,30,31} Until recently, paclitaxel was unique in its ability to assemble microtubules in the absence of GTP and microtubule-associated proteins (MAPs) that are normally required for microtubule assembly.

Paclitaxel is believed to induce apoptosis in cells through a variety of mechanisms. Cells treated with high concentrations of paclitaxel (μM) exhibit a reorganization of the microtubule cytoskeleton with the formation of microtubule bundles and multiple asters. Such cells have a larger population of their tubulin content in polymeric form, compared to untreated cells and are arrested in the G₂/M phase of the cell cycle.^{9,32,33} Normal mitosis is disrupted with a block appearing between the metaphase and anaphase. This leads to the activation of the mitotic checkpoint and eventually brings cells into apoptosis.

Lower concentrations of paclitaxel (30-100 nM), that do not increase the amount of microtubule polymer, are still effective due to their suppression of microtubule dynamics. Indeed in Caov-3 ovarian adenocarcinoma cells and A-498 kidney carcinoma cells incubated with 30 nM paclitaxel, the mean shortening rate of microtubules was reduced by 31% and 26%, respectively. Simultaneously, the average growth rate of microtubules was lowered by 24% in Caov-3 cells and 18% in A-498 cells. This resulted in the dynamicity (the summed gain and loss of tubulin subunits at the microtubule ends and a measure of overall dynamic instability) being significantly reduced in both cell lines: 31% in Caov-3 cells treated with 30 nM paclitaxel and 63% in A-498 cells treated with 100 nM paclitaxel. In each case, cell cycle progress was blocked at the metaphase/anaphase transition which inhibited cell proliferation.¹¹


At even lower concentrations of 3-7 nM, paclitaxel induced apoptosis in approximately 30% of A549 lung carcinoma cells, even though these concentrations were not sufficient to induce mitotic arrest.³⁴ However, alterations were visible in cellular microtubule morphology: partial parallel alignment of microtubules, microtubule bundle formation and multiple asters. Since microtubules are crucial for the transport of

intracellular vesicles, the maintenance of cell shape, the mobility of the cell and other essential cellular functions, it is likely that the impairment of the microtubule network in cells treated with low levels of paclitaxel still triggers the apoptosis process.

Other cellular effects not directly related to the stabilization of microtubules have been reported for paclitaxel. For example, paclitaxel induced the phosphorylation of the anti-apoptotic protein Bcl-2 in leukemia, prostate and ovarian cancer cell lines.³⁵⁻³⁹ Screening a library of phage-displayed peptides with a biotinylated derivative of paclitaxel also identified the loop region of Bcl-2 as a paclitaxel-binding peptide.⁴⁰ Deletion of this loop region in Bcl-2 blocked the apoptosis-inducing effect of paclitaxel and its phosphorylation of Bcl-2.⁴¹ Bcl-2 derives anti-apoptotic activity from its ability to dimerize with Bax, a pro-apoptotic protein.⁴² Serine phosphorylation of Bcl-2 leads to the loss of anti-apoptotic activity due to decreased affinity for Bax.³⁶

In the murine macrophage cell line RAW 264.7, paclitaxel mimics the ability of bacterial lipopolysaccharide (LPS) to induce tumor necrosis factor- α (TNF- α) gene expression.^{43,44} SAR studies on paclitaxel revealed that its effect on TNF- α gene expression is distinct from its known effects on microtubules.⁴⁴ Heat shock proteins (Hsps) of the 70- and 90-kDa families from murine macrophages were identified as binding biotin-labeled paclitaxel.⁴⁵ Furthermore, geldanamycin, an inhibitor of the Hsp 90 family, blocked the effect of both paclitaxel and LPS on TNF- α gene expression.⁴⁵ Paclitaxel, like LPS, also rapidly induced the tyrosine phosphorylation of mitogen-activated protein kinase (MAPK) in murine macrophages, thereby elevating its enzymatic activity.⁴⁶

It is likely that the cytotoxic effects of paclitaxel all are based on its interaction with microtubules resulting in the activation of various signal transduction pathways in all cells except murine macrophages, which appear to present distinct receptors shared by paclitaxel and LPS.



Adapted from: Nicolaou, K.C. et al., Chemistry and Biology of Taxol. *Angew. Chem. Int. Ed. Eng.*, 1994, 33(1): p. 15-44.

Figure 1.6. Compared microtubule formation mechanisms in presence and absence of paclitaxel.

1.3 Tubulin Biochemistry

1.3.1 Microtubule Function

Microtubules are fundamental structural component of all eukaryotic cells and play a crucial role in the cell cycle. Throughout interphase (Figure 1.7b), microtubules help maintaining the shape of the cell and serve as a scaffold for the localization of the organelles and for the transport of vesicles and granules.^{47,48} Microtubules act to provide a network for microtubule motor proteins, such as kinesin and dyneins and to transport 'cargo' in a polarized manner throughout the cell.⁴⁹⁻⁵¹ Microtubules are also involved in the formation of cilia, centrioles and flagella in eukaryotes.⁵²⁻⁵⁴ However, the most important function of microtubules is their involvement in the formation of microtubule spindles that are needed to partition and move duplicated chromosomes into daughter cells during the mitotic phase of the cell cycle (Figure 1.7b).⁵⁵⁻⁵⁷

When eukaryotic cells enter mitosis, their microtubule network undergoes major reorganizations. In early prophase, the centrosome replicates, with each new one becoming a microtubule-organizing center (MTOC). The microtubule minus ends remain associated with the centrosome, the location of the γ -tubulin ring complex, and the plus ends move outward toward the cell membrane. The duplicate centrosomes move to opposite poles of the cell with microtubules forming a bipolar spindle (Figure 1.7a). During metaphase, microtubule spindles interact with the kinetochore regions of the chromosomes.⁵⁵ In anaphase, microtubules attached to kinetochores depolymerize and drag the chromosomes towards each pole.⁵⁶ At telophase, the nuclear membrane reassembles and microtubule spindles reorganize into typical interphase microtubule arrays. The growth rate of microtubules increases 20- to 100-fold during mitosis relative to interphase. These rapid dynamics make mitotic spindles highly sensitive to microtubule-targeting drugs, such as taxanes, colchicines and vinca alkaloids.⁵⁸

Microtubule polymerization is initiated at the MTOC and α,β -tubulin subunits are added to assemble the microtubule polymer. In 1989, Oakley *et al.* discovered that the centrosome is composed of γ -tubulin forming ring structures of 10 to 13 units. These rings serve as templates for microtubule polymerization with the minus end of the microtubule remaining bound to the MTOC while α,β -tubulin heterodimers are added.^{59,60}




Figure 1.7. (A) Schematic features of the metaphase mitotic spindle. (B) Chromosome translocation by microtubules during the different stages of mitosis. (C) Microtubule dynamic instability. Adapted from Ref. 57.

1.3.2 Dynamic Instability

The rapid reorganization of the microtubule network required for mitosis is made possible by the ‘dynamic instability’ of microtubules (Figure 1.7c). Indeed, microtubule ends have the ability to alternate between persistent phases of growth and shortening.⁶¹ The abrupt transition from rapid growth to shortening is termed *catastrophe* while the switch back to growth is called a *rescue*.⁶²

Microtubule assembly and disassembly are regulated through GTP hydrolysis at the β -tubulin subunit.^{63,64} In the polymerization phase, GTP-bound tubulin subunits are added to the ends of microtubules. The GTP on β -tubulin is rapidly hydrolyzed to GDP and phosphate (Pi) during polymerization, while GTP bound to α -tubulin is non-exchangeable and is not hydrolyzed.⁶⁵ The plus end of microtubules are stabilized by a circle of GTP bound tubulin, the ‘GTP cap’, maintaining the more curved GDP bound subunits into a linear arrangement (Figure 1.7c).^{66,67} Upon depolymerization, GTP, bound to the last ring of α,β -tubulin heterodimer, is hydrolyzed. Without this ‘GTP cap’, α,β -tubulin heterodimers dissociate from the ends of microtubules, forming ring-like structures.⁶⁸

Microtubule dynamics are regulated by a variety of endogenous factors. Microtubule-associated proteins (MAPs) such as MAP4⁶⁹ and tau⁷⁰ are known to promote the assembly of microtubules and stabilize polymerized microtubule arrays. There are also proteins that destabilize microtubules (*catastrophins*): stathmin⁷¹ and XKCM1,⁷² for example. Microtubule dynamics are also regulated by various natural products evolved by plants, fungi, or sponges that do not wish to be eaten by eukaryotes.⁵⁸ Colchicine and vinca alkaloids inhibit the assembly of microtubules by binding to the tubulin heterodimer and favoring a bent conformation similar to the GDP bound dimer, which results in the depolymerization of microtubules.^{73,74} On the other hand, paclitaxel and the recently discovered epothilones,⁷⁵ discodermolide,⁷⁶ eleutherobin,^{77,78} and sarcodictins⁷⁸ all promote the assembly and stability of microtubules.⁷⁹ However, at low concentrations, both paclitaxel and vinblastine suppress microtubule dynamics. At 3-64 nM, vinblastine suppressed the rate of microtubule growth and shortening in interphase BS-C-1 cells.⁸⁰ At 32 nM, vinblastine decreased the overall dynamic activity of microtubules by 75%. Substoichiometric levels of paclitaxel, between 0.001 to 0.01 mol of paclitaxel/mol of α,β -tubulin potently and selectively suppressed the rate and extent of shortening at the plus ends of microtubules in an *in vitro* assay using bovine brain microtubules.⁸¹

1.3.3 Microtubule and Tubulin Structure

Structurally, microtubules are composed of linear polymers, protofilaments, formed by α,β -tubulin heterodimers.⁸² Within each protofilament, α,β -tubulin heterodimers are arranged with the β -tubulin subunit pointing toward the plus end of the microtubule and the α -tubulin subunit at the minus end.⁸³ Microtubules are hollow tubes approximately 24 nm in diameter and several μm in length. Typically, they are assembled from 13 protofilaments arranged parallel to a cylindrical axis (Figure 1.8). However, depending on the conditions, the number of protofilaments present in the microtubule can vary from 9 to 13. For example, the majority of microtubules formed with paclitaxel consist of only 12 protofilaments.⁸⁴ Lateral contacts occur between like tubulin subunits, that is, α - α or β - β , corresponding to a B-lattice.⁸⁵ Microtubules composed of 13 or 14 protofilaments can only close with a 'seam' where each α -tubulin monomer makes lateral contact with a β -tubulin subunit (Figure 1.8).

α,β -Tubulin

The tubulin heterodimer is composed of globular α - and β -tubulin. These monomers are approximately 40% identical in amino-acid sequence and each has a molecular weight of approximately 50 kDa (~440 residues). Each tubulin monomer can incorporate a GTP molecule. Upon polymerization, the GTP bound to β -tubulin is hydrolyzed by the incoming α -tubulin subunit. GTP bound to α -tubulin is buried in the interface between α - and β -tubulin and therefore is not hydrolyzed. Each of the tubulin subunits is highly conserved among species.⁸⁶

In 1998, Nogales and Downing generated a 3.7 Å resolution model for the α,β -tubulin heterodimer by electron crystallography of two-dimensional zinc-induced tubulin sheets.⁸⁷ This structural model was later refined to 3.5 Å resolution by reprocessing with a more complete dataset.⁸⁸ Docking this high resolution model in a 20 Å resolution cryo-electron microscopy (cryo-EM) map of frozen-hydrated microtubules, allowed to reconstitute an approximate structural model for the α,β -tubulin heterodimer in the microtubule arrangement.⁸⁹ This microtubule model was later improved to 8 Å resolution, a level of detail sufficient to resolve secondary structure elements.⁹⁰ The α - and β -tubulin monomers are ellipsoids approximately 46 x 40 x 65 Å in size. These models provide deep insight into lumenal, outside, longitudinal and lateral surfaces of α - and β -tubulin subunits (Figure 1.9).

The N-terminal 1-205 amino-acid residues form the nucleotide binding domain, the center section of the β -tubulin sequence contains the paclitaxel binding site and the C-terminal tail is exposed on the outside surface of microtubules to make contact with MAPs. These three domains are close to each other on the three dimensional structure and coordinate to regulate the conformation of the tubulin subunit. The majority of the outside (external) surface of the microtubule is composed of C-terminal helices H11 and

H12 and the loop between H10 and β -strand S9. The inside (luminal) surface of the microtubule is formed by several loops: H1-S2 loop, H2-S3 loop and S9-S10 loop (L loop, Figure 1.9).^{89,90}

Two types of longitudinal interactions occur along the protofilament axis: interdimer interactions and intradimer interactions. The intradimer interaction is stronger than the interdimer interaction as the α - and β -tubulin subunits normally bind tightly together to form a functional unit. The nucleotide (GTP/GDP) binding site is located in the center of the interdimer and intradimer interfaces. When a tubulin heterodimer is added to the plus end of the microtubule, contact is made between the α -tubulin of the incoming heterodimer and the β -tubulin exposed at the former plus end. The minus end of α -tubulin is assumed to then contribute an essential residue to the catalytic site of β -tubulin.⁹¹ The α subunit minus end thus serves as a GTPase activating protein for β -tubulin of the adjacent dimer in a protofilament. The GTP bound to the final incoming β -tubulin subunit remains unhydrolyzed and forms a circle of GTP bound β -tubulin, the so-called 'GTP cap' (Figure 1.7c). Unpolymerized tubulin dimers with GDP bound have a curved conformation. However, the GDP bound dimers along the microtubule are constrained to form straight protofilaments by contact with neighbouring subunits of the lattice. In microtubules, nucleotide hydrolysis causes a 2-4 % reduction in the length of the tubulin dimer.⁹² The conformational energy stored in the lattice is then released during depolymerization.⁹³

The S7-H9 loop (M loop, Figure 1.9) is the central element involved in lateral interactions between tubulin subunits of neighboring protofilaments. The M loop comprises the most divergent peptide segment between α - and β -tubulin sequences: AEKAYHEQ in α -tubulin compared to RGSQQYRA in β -tubulin. In the structural models, it makes close contact with the H3 helix, the C-terminal part of the H2-S3 loop and part of the H1-S2 loop of the adjacent tubulin monomer.⁸⁹ The interaction of the M loop with H3 had been suggested by early biochemical studies.^{94,95} The M loop points away from the tubulin surface, which allows the required conformational flexibility necessary to accommodate microtubules of as few as 9 or as many as 18 protofilaments. The loop preceding the H3 helix, the T3 loop (Figure 1.9), is near the binding site for the γ -phosphate of GTP and is probably influenced by the hydrolysis of GTP in β -tubulin, by analogy to what is observed in FtsZ, the bacterial homolog of tubulin.⁹⁶ The current hypothesis is that hydrolysis of GTP in β -tubulin induces a conformational change in H3 mediated by T3 and therefore the interaction between neighboring protofilaments is weakened.

In their initial α,β -tubulin dimer model,⁸⁷ Nogales *et al.* placed docetaxel as a placeholder in the region of the density map attributable to paclitaxel, which was actually used to stabilize the 2D tubulin zinc sheets. As this region falls near the M loop of β -tubulin (Figure 1.9), paclitaxel is proposed to stabilize microtubules by interacting with the M loop, effectively overriding the structural effect of GTP hydrolysis and thereby enhancing lateral interactions between protofilaments.

Interestingly, in α -tubulin, the S9-S10 loop (L loop, Figure 1.9) is 8 residues longer because of a conserved TVVPGGDL insert, which extends into the paclitaxel binding

site.⁸⁷ It is therefore assumed that this loop is responsible for the permanent stabilization of the α -tubulin conformation, in addition to the absence of GTP hydrolysis in this subunit, making the dynamics of the two ends of the tubulin dimer more dissimilar to induce polarity. The highly conserved paclitaxel site has also been suggested to be the interaction site for select MAPs, such as neuronal proteins MAP2 and tau.⁷⁴ Tau, in particular includes a THVPGGN repeat similar to the α -tubulin L loop extension, and was shown to bind competitively with paclitaxel.⁹⁷




Figure 1.8. Microtubules of various protofilament (pf) counts. 13-pf microtubules can only close with a 'seam' wherein unlike tubulin monomers are in lateral contact. Adapted from Ref. 74.




Figure 1.9. (A) Structural view of the α - β tubulin dimer⁸⁷ from the inside of the microtubule. (B) Details of the β tubulin subunit with key structural elements indicated. The putative colchicine binding site encompasses Cys354,⁹⁸ shown as a yellow ball-and-stick model, near the interface with α -tubulin in the heterodimer. (C) Diagrammatic primary sequence topology of β -tubulin. Adapted from Ref. 74.

1.4 Molecular Mechanics Background

Molecular simulations of biological systems permit the study of the interplay between structure, dynamics and function down to the atomic level. Since many of the problems that one would like to address in biological systems involve large numbers of atoms, it is not yet practical to treat these systems using a quantum mechanical description. This is particularly true of the tubulin-paclitaxel interaction we planned to study, as β -tubulin itself incorporates nearly 3400 atoms.

In molecular mechanics, instead of solving the full Schrödinger equation for the molecule, the focus is on nuclear motions, in accordance with the Born-Oppenheimer approximation. Indeed, nucleons have masses nearly 2000 times larger than that of an electron, which means the electrons can adjust almost instantaneously to a change in position of the nucleus. Molecular mechanics methods cannot therefore calculate properties that depend on the electronic configuration of the molecule: bonding pattern, reactivity, excited states, *et cetera*. However, molecular mechanics is the only practical choice to simulate large systems, such as biological macromolecules, and with appropriate parameterization is able to predict some experimental properties as accurately as quantum methods. The great computational speed of molecular mechanics also allows for its use in the simulation of whole thermodynamic ensembles, conformational searches, and docking, that require large numbers of energy evaluations.

The two essential components of molecular mechanics are (i) an energy function parameterized from empirical data that implicitly incorporate all the relativistic and quantum effects, and (ii) a simulation algorithm capable of efficiently integrating the classical laws of motion.

1.4.1 Force field

Central to the concept of molecular mechanics is the definition of a potential energy function used to describe the relationship of the structure, \mathbf{r} to the energy, V , of the system of interest. Towards this end, potential energy penalties are associated with the deviation of bonds and angles in the simulated molecule from their reference equilibrium values, obtained either from experiment or high precision quantum calculations (Eq. 1.1). The potential function also contains terms to describe long range non-bonded interactions. This partition of the energy function according to the different internal coordinates makes it convenient to parameterize the corresponding energy terms independently. The functional form of the potential energy expression and the entire set of parameters needed to fit the potential energy surface constitute the *force field*.⁹⁹

The following equation describes the functional form of the widely used AMBER force field,¹⁰⁰ however, it remains largely valid for other pairwise additive force fields, including CVFF¹⁰¹ used in InsightII:

$$\begin{aligned}
V(\mathbf{r}) = & \sum_{bonds} K_r (r - r_{eq})^2 \\
& + \sum_{angles} K_\theta (\theta - \theta_{eq})^2 \\
& + \sum_{dihedrals} \frac{V_n}{2} [1 + \cos(n\Phi - \gamma)] \\
& + \sum_{\substack{nonbonded \\ pairs}} \left[\frac{A_{ij}}{R_{ij}^{12}} - \frac{B_{ij}}{R_{ij}^6} + \frac{q_i q_j}{\epsilon R_{ij}} \right]
\end{aligned} \tag{1.1}$$

The first three summations in Eq. 1.1 are performed over bonds, angles and torsions. The torsion terms also include ‘improper’ terms, calculated for groups of 4 atoms not sequentially bonded. The main usage of these improper terms is to maintain planarity around sp^2 hybridized atoms. The final summation refers to non-bonded interactions, which include electrostatic and van der Waals (vdW) components. The 1,2 (between neighbors) and 1,3 (between second neighbors) interactions are excluded from the non-bonded term summation while 1,4 electrostatic and vdW interactions are usually scaled by separate empirical factors.¹⁰⁰ The vdW term is commonly calculated by a 6-12 Lennard-Jones potential, empirically accounting for London dispersion forces at long internuclear distances R_{ij} and enforcing the Pauli Exclusion Principle by a steep energy term at small values of R_{ij} .

The electrostatic interactions are most commonly computed by a pairwise Coulombic potential between fixed atomic point charges (Eq. 1.1). Such an additive model does not explicitly treat electronic polarizability. Instead, polarizability is incorporated implicitly by deliberately assigning atomic charges that overestimate molecular dipoles.^{102,103} This overestimation is designed to approximate electrostatic interactions that occur in the aqueous environment common to biomolecules. Fast-paced development in the explicit treatment of polarizability has been ongoing over the past decade or so, and have recently been reviewed.^{104,105} However, due to their added computational cost, polarizable force fields have not yet gained popularity for biomolecular simulations.

The focus of force field improvement efforts has recently been shifted to the refitting of torsion parameters.¹⁰⁶ Traditionally, torsion parameters were dealt with at the last stage of the fitting process and were the least rationally justified of the force field terms. A variety of approaches have been proposed to assess and correct these terms¹⁰⁷⁻¹¹⁴, most of which attempt to reproduce high precision dihedral maps of the alanine dipeptide obtained via *ab initio* quantum mechanics.¹¹⁵ The efforts toward this direction have resulted in several promising applications such as the correct prediction of peptide structures^{116,117} or side chain rotamer libraries.¹¹⁸

1.4.2 Energy Minimization

In computational chemistry, one is particularly interested in the geometry of stable and transition states of our systems, which correspond to minima and saddle points of the energy surface, respectively. However, except for the simplest of molecular systems, the potential energy is a complex, multidimensional function of the atomic coordinates. So in order to identify these geometries, computational chemists have employed or adapted some of the many optimization algorithms long devised by mathematicians.

For a system of potential energy $V(x_1, \dots, x_N)$, with N degrees of freedom of coordinate x_i , a minimum point of the potential energy is located when for all i ,

$$\frac{\partial V(x_1, \dots, x_N)}{\partial x_i} = 0 \text{ and } \frac{\partial^2 V(x_1, \dots, x_N)}{\partial^2 x_i} > 0 \quad (1.2)$$

The two most frequently used minimization techniques in molecular mechanics are the *steepest descent* and *conjugate gradient* methods described below. In both methods, the atomic coordinates of the system are iteratively changed ($\mathbf{x}_k \rightarrow \mathbf{x}_{k+1}$) as the system progressively approaches the minimum location.

Steepest descent

In the steepest descent algorithm, the system is moved in the direction of the net force acting on the system, opposite to the energy gradient $\mathbf{g}_k = \nabla V(\mathbf{x}_k)$. In a real-life geographical analogy, this would correspond to walking straight downhill along the direction of steepest slope. How far to go on the direction of the net force is decided by either locating a minimum along this direction - a computationally demanding approach - or by taking steps of arbitrary length.

The exclusive reliance of steepest descents on gradients is both its weakness and its strength as convergence is slow near the minimum because the gradient approaches zero, but the method is extremely robust. It is the method most likely to generate a lower-energy structure regardless of the nature of the energy function or initial starting position. Therefore, the steepest descent method is often used when the gradients are large and the configurations are far from the minimum. This is commonly the case for initial relaxation of poorly refined experimental data or for manually built models. As a result, more refined minimization algorithms often begin with a small series of steepest descents steps.

Conjugate gradients

In the steepest descent method, both the gradients and search directions of successive steps are orthogonal, leading to oscillations as the path persistently overcorrects for poor choices of directions in earlier steps.

In the original conjugate gradient method of Fletcher and Reeves,¹¹⁹ the search direction vector \mathbf{s}_k from \mathbf{x}_k is computed from the gradient at that point and the previous search vector \mathbf{s}_{k-1} :

$$\mathbf{s}_k = -\mathbf{g}_k + \gamma_k \mathbf{s}_{k-1} \quad (1.3)$$

with the scalar γ_k given by:

$$\gamma_k = \frac{\mathbf{g}_k \cdot \mathbf{g}_k}{\mathbf{g}_{k-1} \cdot \mathbf{g}_{k-1}} \quad (1.4)$$

A line search is then conducted along this new direction, rather than in the gradient direction, as was the case in steepest descent. This particular construction has the remarkable property that the next gradient, \mathbf{g}_{k+1} , is orthogonal to all previous gradients, $\mathbf{g}_0, \dots, \mathbf{g}_k$ and that the next direction, \mathbf{s}_{k+1} , is conjugate to all previous directions, $\mathbf{s}_0, \dots, \mathbf{s}_k$,

i.e. $\mathbf{s}_i \cdot \mathbf{V}'' \cdot \mathbf{s}_j = 0$, $i \neq j$, where $\mathbf{V}''_{ij} = \frac{\partial^2 V}{\partial x_i \partial x_j}$ is a positive-definite matrix. The attribute

'conjugate' is thus somewhat misplaced, and the algorithm should rather be called the *conjugate directions* method. The method converges in approximately N steps, for a system of N degrees of freedom.

1.4.3 Phase Space Sampling Algorithms

The central goals of molecular simulations are to generate thermodynamic ensemble averages and observe configurational transitions. Following Boltzmann's ergodic hypothesis, which states that due to thermal motion, a single system runs through all states of the thermodynamic ensemble in the limit of infinite time, we take the assumption that a sufficiently long time average derived from a single molecular simulation is equivalent to the statistical ensemble average. Molecular systems have to exhaustively sample phase space, in order to adequately approximate this condition of infinite time, and therefore efficient sampling schemes such as those described below have been developed to allow the calculation of statistical ensemble averages on computationally tractable time scales.

Molecular Dynamics

Following the Born-Oppenheimer approximation, we assume that a molecular system of N particles of masses m_i can be described by classical mechanics. For each particle, Newton's equation of motion is given by:

$$\mathbf{F}_i = m_i \mathbf{a}_i \quad (1.5)$$

where F_i is the force exerted on particle i , and a_i its acceleration. As the force derives from the gradient of the potential energy,

$$-\frac{\partial V(r_1, \dots, r_N)}{\partial r_i} = m_i \frac{\partial^2 r_i}{\partial t^2} \quad (1.6)$$

Several finite difference integrating methods can be used to iteratively solve this differential system, which can only be solved analytically for the simplest of molecular systems. Variants of the Verlet algorithm¹²⁰ of integrating the equations of motion (Eq. 1.5) are perhaps the most widely used method in molecular dynamics. The advantages of Verlet integrators is that these methods require only one energy evaluation per step, require only modest memory, and also allow a relatively large timestep to be used. The Verlet leap-frog algorithm¹²¹ employed in both AMBER and InsightII functions as follows:

- the velocities, $\mathbf{v}(t + \frac{1}{2}\delta t)$, are first calculated from the velocities at $t - \frac{1}{2}\delta t$ and the acceleration at time t :

$$\mathbf{v}(t + \frac{1}{2}\delta t) = \mathbf{v}(t - \frac{1}{2}\delta t) + \delta t \cdot \mathbf{a}(t) \quad (1.7)$$

- updated positions, $\mathbf{r}(t + \delta t)$, are then deduced from the new velocities and current positions, and the new acceleration calculated from the forces:

$$\mathbf{r}(t + \delta t) = \mathbf{r}(t) + \delta t \cdot \mathbf{v}(t + \frac{1}{2}\delta t) \quad (1.8)$$

$$\mathbf{a}(t + \delta t) = \frac{\mathbf{F}(t + \delta t)}{\mathbf{m}} \quad (1.9)$$

- the system is then iterated to the next δt . But as the positions literally ‘leapfrogged’ past the velocities, it is necessary to take an average in order to synchronize the velocities (kinetic energy) and positions (potential energy):

$$\mathbf{v}(t) = \frac{1}{2} \left(\mathbf{v}(t + \frac{1}{2}\delta t) + \mathbf{v}(t - \frac{1}{2}\delta t) \right) \quad (1.10)$$

The time step of integration δt must be chosen small enough so that even the fastest atomic motions get sampled adequately, to avoid instabilities and allow conservation of the energy. As a C-H bond vibrates with a frequency on the order of 10 fs, all-atom molecular simulations are limited to time steps of about 1 fs. As bond vibrations are of little interest in non-spectroscopic studies, holonomic restraints are usually applied to bond lengths¹²²⁻¹²⁵ to rigidify them and therefore extend the time step to ~2 fs.

The first application of molecular dynamics to a biological macromolecule dates back to 1977, when McCammon and Karplus simulated the bovine pancreatic trypsin inhibitor protein in the gas phase for 9.2 picoseconds.¹²⁶ Since then, owing to the considerable progress in computer power, molecular dynamics simulations have become a routine tool for understanding the structure and motion of biological systems. In comparison to the early BPTI studies, current state of the art simulations now involve tens of thousands of atoms for tens of nanoseconds¹²⁷ or hundreds of atoms for microseconds.¹²⁸

Monte Carlo Sampling

In contrast to molecular dynamics, Monte Carlo simulations directly generate configurations for a system by making successive random changes to the positions of its components. The Monte Carlo method thus samples a $3N$ -dimensional space for a system of N particles, and does not require momentum information. In the Metropolis implementation¹²⁹ popular in the statistical thermodynamics field, the energy is calculated at every step, and the random move is automatically accepted if the new configuration is lower in energy. If the energy increases, the Boltzmann factor for the move at the simulation temperature, $\exp(-\Delta V/k_B T)$, is compared to a random number taken from a uniform distribution between 0 and 1. If the Boltzmann factor is larger than the random number, the move is accepted. If not, the move is rejected and the initial configuration is retained for the next random move.

More concisely written, each random move is accepted with the following probability:

$$p_{acc} = \min\left(1, \exp\left(-\frac{1}{k_B T} \Delta V(r_1, \dots, r_N)\right)\right) \quad (1.11)$$

Iterations are performed until the configurational space has been sufficiently sampled to generate ensemble averages with satisfying statistics. This particular Monte Carlo scheme effectively performs an ‘importance sampling’ by focusing on the generation of the high probability, low energy configurations that dominate the mean properties of the ensemble. However, in contrast to molecular dynamics, there is no physical time connection between the sampled configurations, which precludes the direct derivation of kinetic information.

The sampling efficiency of the Monte Carlo algorithm depends primarily on the choice of random displacement. Usage of the Monte Carlo sampling scheme in all-atom molecular simulations has been so far limited to small conformational moves, as the ruggedness of the potential energy surface (in the form of steric clashes) leads to very few moves being accepted in large systems such as proteins, with excessive computational time wasted on the energy evaluation of rejected moves.

Replica Exchange Molecular Dynamics

Complex biomolecular systems with many degrees of freedom may become trapped in low-energy regions of the thermally accessible space, using MD or MC simulations at constant temperature.¹³⁰⁻¹³² Such simulations may display all attributes of a converged simulation, while producing erroneous results because of this sampling bias. Such simulations are known to suffer from the *quasi-ergodicity* problem. A variety of methods have been proposed to tackle this problem,¹³³ with one of them, the replica exchange method¹³⁴ (also referred to as parallel tempering¹³⁵) quickly gaining popularity in the molecular dynamics simulation community.¹³⁶⁻¹⁴³

In replica exchange molecular dynamics (REMD), a generalized ensemble is constructed from N non interacting copies of the system of configurations \mathbf{x}_i , $i = 1, \dots, N$, each at a different temperature T_i . The state of this generalized ensemble is

denoted $X = \{\mathbf{x}_1, \dots, \mathbf{x}_N\}$. Because the replicas are fully independent, the weight factor of the generalized state is simply the product of all replica Boltzmann factors:

$$W_{REM}(X) = \exp\left(-\sum_{i=1}^N \beta_i H(\mathbf{r}_i, \mathbf{p}_i)\right) \quad (1.12)$$

where $\beta_i = \frac{1}{k_B T_i}$ is the inverse temperature, and \mathbf{p}_i and \mathbf{r}_i are the replica momentum and position vectors. Replica temperature exchanges are allowed to take place within the generalized ensemble, altering the state of the system. In the case of an $i \leftrightarrow j$ permutation the state goes from X to X' :

$$X = \{\dots, \mathbf{x}_{i,T_i}, \dots, \mathbf{x}_{j,T_j}, \dots\} \rightarrow X' = \{\dots, \mathbf{x}_{i,T_j}, \dots, \mathbf{x}_{j,T_i}, \dots\} \quad (1.13)$$

To maintain detailed balance in this equilibrium ensemble, microscopic reversibility has to be satisfied:

$$W_{REM}(X) \cdot \rho(X \rightarrow X') = W_{REM}(X') \cdot \rho(X' \rightarrow X) \quad (1.14)$$

with $\rho(X \rightarrow X')$ denoting the probability of a transition from X to X' . Using the following momenta scaling condition introduced by Sugita and Okamoto for molecular dynamics applications of the replica exchange method:¹³⁴

$$\begin{cases} p_{i,T_j} = \sqrt{\frac{T_j}{T_i}} p_{i,T_i} \\ p_{j,T_i} = \sqrt{\frac{T_i}{T_j}} p_{j,T_j} \end{cases} \quad (1.15)$$

the exchange probability is expressed by:

$$\rho(X \rightleftharpoons X') = \frac{\rho(X \rightarrow X')}{\rho(X' \rightarrow X)} = \exp(-\Delta) \quad (1.16)$$

where

$$\Delta = (\beta_i - \beta_j)(V_{j,T_j} - V_{i,T_i}) \quad (1.17)$$

and V_{i,T_i} is the potential energy of replica i at its original temperature T_i .

As in the Monte Carlo sampling algorithm, the preceding probability can be enforced by a Metropolis criterion¹²⁹:

$$\rho(X \rightleftharpoons X') = \min(1, \exp(-\Delta)) \quad (1.18)$$

In practice, replicas are simulated simultaneously and independently for a certain number of MD steps. Then, pairs of replicas at neighboring temperatures are tested for exchange with a probability calculated by Eq. 1.18. If the exchange is accepted, the temperatures of the two replicas are swapped, and the velocities scaled accordingly (Eq. 1.15). Otherwise, if the exchange is rejected, each replica will proceed with its own trajectory. This algorithm is particularly well suited for calculations on clusters of poorly communicating processors, as the temperatures are the only information exchanged, and rather infrequently.

A comparison of this algorithm with constant temperature molecular dynamics applied to a peptide at room temperature showed that this algorithm decreased the

sampling time by a factor of 20 or more and sampled a 5 times larger conformational space for an identical number of iterations.^{139,144}

Chapter 2

Determining the Bioactive Conformation of Taxol®

2.1 Introduction

Over the last two decades, various biological and pharmacological activity data as well as structure-activity relationships have been reported for paclitaxel and its congeners (taxoids).¹⁴⁵⁻¹⁴⁷ Structural biology investigations into the paclitaxel-tubulin interactions has so far culminated in the determination of the electron crystallographic (EC) structure of the α,β -tubulin heterodimer bound to paclitaxel at 3.7 Å resolution and its subsequent refinement to 3.5 Å resolution.^{87,88} Although representing a seminal achievement, this EC structure lacks the atomic resolution necessary to ascertain the structure of paclitaxel in the β -tubulin binding pocket and the intermolecular interactions responsible for the stabilizing effect of the drug on microtubules.

Solution¹⁴⁸ and solid phase^{149,150} NMR studies, photolabeling studies¹⁵¹⁻¹⁵³ as well as computational modeling¹⁵⁴⁻¹⁵⁶ have provided additional information regarding the binding structure and location of paclitaxel. The set of computational protocols described below has been developed in order to unify these highly valuable pieces of information into a more detailed description of the tubulin-binding mode of paclitaxel and its analogs.




Figure 2.1. Structures of paclitaxel, docetaxel, photoaffinity probe [3H]7-BzDc-paclitaxel, 153 conformationally constrained taxoid SB-T-14801. 2-FB-PT 150 is also shown, with intramolecular REDOR-NMR distances indicated.

2.2 Computational Protocol

To determine the bound conformation of paclitaxel in β -tubulin, 2-(*p*-Fluorobenzoyl)paclitaxel (2-FB-PT) was modeled from the X-ray structure of paclitaxel¹⁵⁷ in Macromodel 6.5 (Schrödinger Inc.) by substituting an F atom at the *para* position of the C2 benzoate group. Monte-Carlo conformational searching was conducted with energy minimization on the isolated 2-FB-PT molecule in the gas phase using the Monte Carlo Multiple Minimum (MCMM) procedure^{158,159} (4000 MC steps, minimization for 1000 steps with Polak-Ribiere conjugate gradients) and MM3* force field,¹⁶⁰⁻¹⁶³ well suited for the conformational analysis of small molecules. All side chain rotatable bonds were allowed to vary. 1371 structures were found within 50 kJ/mol which complied with both REDOR NMR distances. These conformers were clustered according to their C13 and C2 side chains dihedral angles using the Xcluster facility packaged with Macromodel 6.1. 16 clusters were obtained at the 1356 clustering level, comprising 124, 250, 76, 236, 1, 129, 243, 220, 69, 1, 1, 1, 2, 1, 1 and 16 members, respectively. A representative structure for each cluster was selected as the structure with minimal root mean square distance to the centroid of all cluster members, regardless of its energy relative to the global minimum of the conformational search.

All 16 representative conformations of paclitaxel (Figure 2.2) were then manually docked into the paclitaxel binding site of β -tubulin, following the same procedure: their taxane skeleton (carbon atoms of the A, B and C rings) was overlaid with that of docetaxel present in the deposited β -tubulin EC structure (PDB ID: 1TUB). The benzodihydrocinnamoyl (BzDc) linker was modeled and attached to C7 of paclitaxel in InsightII 2000 (Accelrys Inc.). Finally, the linker was attached to the C α of Arg282 by merging the two fragments, thus creating an elongated C-C bond (Figure 2.3).

The docked molecular complex was allowed to minimize for 1000 steps, with the conjugate gradients method, CVFF force field and distance dependent dielectric. The BzDc linker was then erased and H atoms were added to reconstitute the free paclitaxel ligand and the protein after a binding domain comprising all residues within 10 Å of the bound 7-BzDc-PTX has been defined. A second minimization is then conducted on the non-covalent complex of paclitaxel with this 10 Å binding domain (same conditions as first minimization). The approach was identical for all the taxoids docked.

2.3 Results and Discussion

2.3.1 Conformation of Paclitaxel in β -Tubulin

Solution^{148,164-166} NMR spectroscopy and X-ray crystallography^{4,157} of paclitaxel and its analogs have provided rich information about the various conformations paclitaxel can adopt in the unbound state. This information is only of limited use since ligands commonly undergo large conformational changes upon binding to their targets.¹⁶⁷

Recently, a fluorinated paclitaxel analog, 2-FB-PT, was used bound to microtubules in solid state $^{13}\text{C}\{^{15}\text{N}$ or $^{19}\text{F}\}$ -double-REDOR-NMR experiments.¹⁵⁰ After three months of data acquisition, Schaefer and his collaborators were able to determine two ^{13}C - ^{19}F intramolecular distances for 2-FB-PT in the bound state (d1 and d2 in Figure 2.1).

Molecular Dynamics (MD) simulations were initially conducted on 2-FB-PT *in vacuo* at increasing temperatures from 300K to 500K (InsightII 2000, Accelrys, CVFF force field). Unfortunately, some side chain bonds (e.g. C2'-C3') of the molecule present a high-energy barrier to rotation, impeding adequate sampling. For this reason, we switched to a Monte-Carlo (MC) conformational search.¹⁵⁸ The two intramolecular distances determined were then used as constraints in an extensive MC conformational search on 2-FB-PT *in vacuo*. Conformational diversity in the set of resultant minimized structures was assessed by performing a cluster analysis on the 1371 retained conformations with energies within 50 kJ/mol of the global minimum. Sixteen clusters were formed according to the values of 10 dihedral angles of the C13 and C2 side chains. A representative structure for each cluster is shown in Figure 2.2. Remarkably, most of these structures have their C3' benzamido moiety pointing in the same direction as the C2 fluorobenzoate group, as seen for docetaxel in its X-ray structure⁴. Also, to accommodate the REDOR-NMR geometric requirements, the entire C13 side chain has to move away from the C2 fluorobenzoate, unlike in the 'hydrophobic collapse' conformation observed for the free drug in polar solvents.¹⁶⁴⁻¹⁶⁶




Figure 2.2. REDOR-NMR constrained Monte Carlo conformational search on 2-FB-PT: representative structures of the 16 conformational clusters.




Figure 2.3. Guided docking protocol diagram (L=BzDc linker).

2.3.2 Guided Docking of Taxoids in β -Tubulin

The exact orientation of paclitaxel in β -tubulin has been much debated.^{150,153} Some agreement was nevertheless found between the electron crystallographic density and three photoaffinity labeling experiments.^{151-153,168} It is worth mentioning that a C7-benzodihydrocinnamoyl (C7-BzDC) derivative of paclitaxel (Figure 2.1) labeled exclusively the Arg282 residue in the M loop of β -tubulin. This specificity prompted us to model this covalent complex. This way, translational and rotational motions of the ligand are hampered, while the ligand evolves in its most likely position. A two-step procedure was then adopted in order to get a refined binding site model. First, the complex formed by β -tubulin and the bound C7-BzDC paclitaxel in the possible bioactive conformation inferred from the Monte-Carlo conformational search were modeled and minimized. The carbonyl carbon of the benzophenone moiety (i.e., as α -hydroxy radical) was connected to the α -carbon of Arg282, since the excited state of the benzophenone moiety would selectively abstract hydrogen from the α -position of an amino acid residue because of the captodative stabilization of the resulting radical species.¹⁶⁹ The peptide backbone atoms of the protein were kept fixed at all times during the minimizations, while side chain atoms were free to move, allowing the reorganization of side chains upon binding of modified taxoids (partial induced-fit). After cleavage of the BzDC linker, a free ligand-binding site complex, comprising only residues within 10 Å of any ligand or linker atom is minimized again under the same conditions.

The procedure was applied to paclitaxel, starting from all 16 conformations retained from the Monte-Carlo conformational search of 2-FB-PT. The REDOR-NMR distances were verified after docking and used as a filter to determine the tubulin-bound paclitaxel conformation. However, none of the representative structures could strictly maintain both distances in the allowed REDOR-NMR ranges after docking. Two factors could contribute to that: (i) the availability of large empty spaces in the binding site, and (ii) the fact that the REDOR distances were derived from microtubules (MTBs) while the EC structure corresponds to the Zn-sheet form of tubulin, which might present some structural differences to the MTB form. The structure deviating the least from the two REDOR-NMR restraints (i.e., $d_1 = 9.38$ Å, $d_2 = 9.97$ Å) was selected as our tubulin-bound paclitaxel structure, and denominated 'REDOR-Taxol' (Figure 2.4).

A significant asset of this guided docking protocol is the total flexibility of the protein side chains during the minimization stages. This allows docking of heavily modified or bulky taxoids, under the assumption that their baccatin skeleton remains in the vicinity of paclitaxel in the binding pocket. Figure 2.5 shows an example of a tubulin-bound macrocyclic paclitaxel analog, SB-T-14801, a surprisingly active analog in its series (IC₅₀ 71 nM against the LCC6 lung cancer cell line).¹⁷⁰ The protein shows extensive rearrangements induced by the connection of the C2 and C13 taxoid side chains: in particular, the His227 side chain has to rotate, and face the C2 benzoyl group of the taxoid, confirming that even partial flexibility of the protein allows the binding site to accommodate bulkier analogs.




Figure 2.4. Proposed β -tubulin-binding models of paclitaxel. Overlay of the docked REDOR-Taxol (green) and T-Taxol (yellow) structures. The overlay is performed by matching the protein backbone, which is kept fixed throughout the docking process.




Figure 2.5. Docked complex of SB-T-14801.

2.3.3 Analysis of Paclitaxel Binding Site Models

While preliminary results of this work were obtained, producing the REDOR-Taxol structure, Snyder *et al.* reported a binding site model for paclitaxel by docking 26 experimentally observed unbound paclitaxel conformers into the Zn-sheets EC density map.¹⁵⁵ Although this approach also resulted in an extended bioactive conformation for paclitaxel, ‘T-Taxol’, the resolution of the EC map appears insufficient for unequivocal selection of the optimal binding conformation of paclitaxel. It is worth pointing out that T-Taxol does not comply with the REDOR-NMR distances, with values of 9.32 Å and 8.11 Å for d_1 and d_2 , respectively (measured on 2-FB-PT in the T-Taxol conformation), denoting that in T-Taxol, the C2 and C3’ side chains are more collapsed than those deduced by the REDOR-NMR experiment.

The main difference between Snyder’s T-Taxol and our REDOR-Taxol is the conformation of the C13 side chain. In order to fairly compare REDOR-Taxol to T-Taxol, we docked the T-Taxol structure into the β -tubulin binding site using our guided docking protocol. This procedure caused a small but significant realignment of the T-Taxol conformation and an overlay of the resulting pose with REDOR-Taxol is shown in Figure 2.4. The two models locate their C3’ phenyl rings in nearly identical loci. However, the C2’-hydroxyl group which usually forms an intramolecular H-bond with the C1’-carbonyl oxygen in the free drug is pointed towards His227 in the REDOR-Taxol structure, forming a very buried H-bond of increased strength. This makes a sharp contrast to the more solvent exposed H-bond between the C2’-hydroxyl and the backbone carbonyl oxygen of Arg359 in the T-Taxol binding pose.

Additionally, the internal energy of the ‘unbound’ form of paclitaxel detached from tubulin *in vacuo* is ~ 10 kcal/mol lower in the REDOR-Taxol conformation than in the T-Taxol conformation (CVFF force field, InsightII). This energy difference mostly arises from torsional terms, and suggests that the REDOR-Taxol structure is a less strained conformation requiring less stabilizing interaction with the protein to make the overall association favorable.

However, due to the low resolution of the tubulin EC density map, direct experimental evidence is lacking to confirm or rule out one of these two conformations as the bioactive form, assuming it is unique.

2.4 Conclusions

A bioactive structure of paclitaxel, REDOR-Taxol, has been proposed on the basis of detailed computational analysis of the combined data from the REDOR-NMR, the electron crystallography and photoaffinity labeling experiments. Although the REDOR-Taxol structure shares similar features to Snyder’s T-Taxol,¹⁵⁵ the REDOR-Taxol structure allows strong H-bonding between the C2’ hydroxyl group of paclitaxel and the His227 residue in contrast to T-Taxol having H-bonding between the C2’-OH and Arg359 in the β -tubulin S9-S10 loop.

Chapter 3

Design and Biological Evaluation of Conformationally Constrained Taxol® Analogs

In order to confirm the proposed REDOR-Taxol conformation identified in Chapter 2, a typical synthetic approach is to construct conformationally constrained analogs which retain potencies similar to that of the lead compound, paclitaxel. The inclusion of protruding cyclic restraints at various positions also helps delineate the essential intermolecular contact areas of the binding site and further refine the pharmacophore model. This chapter briefly reviews previous approaches towards bioactive conformationally constrained analogs of paclitaxel and presents our successful design of potent restrained paclitaxel analogs based on the REDOR-Taxol bound conformation.

3.1 Previous Designs

3.1.1 C2 Benzoyl to C3' Phenyl Tethering: 'C-Linked' Taxoids

Following up on their discovery of the 'hydrophobic collapse' conformation of taxoids in polar solvent,^{166,171,172} the Georg group was the first to attempt the connection of paclitaxel pharmacophoric elements in order to mimic this biologically relevant conformation. To enforce the short C2-benzoate to C3'-phenyl distance observed in the DMSO-d₆/D₂O NOESY experiments, they synthesized a series of taxoids bearing various 2 atom linkers between these positions (Figure 3.1). Heck cyclization provided olefins **3.1** and **3.2**, with subsequent hydrogenation yielding the saturated analog **3.3**. A separate synthetic approach provided lactone **3.4**.¹⁷³ None of these four compounds demonstrated any measurable activity *in vitro* in the microtubule polymerization assay, nor did they compete with paclitaxel for tubulin binding. These adverse results strongly suggested that the polar conformation was not the bioactive one and that conformational rearrangements occurred in the binding process.

A similar approach to a tethered polar conformation was taken in the Ojima lab, starting from a 2D NOESY NMR study of nonataxel (**3.5**, Figure 3.1), a highly bioactive C10-acetyl docetaxel derivative with isobutenyl groups in place of the C2 and C3' phenyl moieties.¹⁵⁴ Similarly to paclitaxel, in a polar DMSO-d₆/D₂O mixture, nonataxel adopted the hydrophobic collapse conformation, with strong NOE signals between the C2 and C3' isobutenyl groups. The modeled nonataxel structure derived from simulated annealing incorporating NOE restraints then served as a template for generating conformations of paclitaxel and other MT-stabilizing agents (epothilone B, discodermolide and eleutherobin, Figure 3.2) compatible with a common pharmacophore hypothesis based on SAR information. The resulting 3D pharmacophore inspired the design and synthesis of paclitaxel-epothilone hybrid SB-TE-1120, (**3.6**, Figure 3.1) bearing a macrocycle

connecting the C2 and C3' positions. Interestingly, the C2 phenyl tether is branching from the *ortho* position rather than *meta* in the first series of inactive C-linked compounds by Georg *et al.* (**3.1-3.4**). SB-TE-1120 was the first macrocyclic restrained taxoid to represent a viable lead, as it maintained 37% of the tubulin polymerization activity of paclitaxel and substantial activity against the LCC6-WT human breast cancer cell line ($IC_{50} = 0.39 \mu\text{M}$; i.e. two orders of magnitude larger than paclitaxel).¹⁵⁴

An entire series of related macrocyclic taxoids was prepared using ring-closing metathesis (RCM), by connecting the C2 and C3' positions with tethers of varied length and composition (**3.7**, Figure 3.1).¹⁷⁴ The cell growth inhibition effect of these compounds was variable, with IC_{50} against the LCC6-WT cell line ranging from over 10 μM to sub-micromolar for two compounds (**3.8** and **3.9**, Figure 3.1), comparably to SB-TE-1120. Two other compounds in this series, with 2.33 and 4.1 μM IC_{50} against the LCC6-WT cell line, were also assayed for their tubulin polymerization ability. It was found that their activity in this test was 19% and 21% that of paclitaxel in the same assay, correlating well with the 3 orders of magnitude decrease observed in cytotoxic activity.

In spite of the increased mobility of the C2-C3' tether employed in compounds of this series, relative to the compounds of the Georg *et al.* study, their diminished bioactivity possibly indicated that they too were unable to adopt the tubulin-bound conformations of paclitaxel and nonataxel. Another explanation to this loss of bioactivity could be that the binding of paclitaxel to β -tubulin is a stepwise process requiring conformational rearrangements not possible in those restrained analogs. Alternatively, the molecule could adopt the appropriate conformer, but the bulk of the added tether might generate unfavorable steric contacts with the protein.










Figure 3.1. 'C-linked' macrocyclic taxoids.

3.1.2 C2 Benzoyl to C3' Benzamido Tethering: 'N-Linked' Taxoids


As it became apparent from the cryo-EM studies of Nogales et al.^{87,155} that the bound conformation of paclitaxel in β -tubulin was not the collapsed one observed in polar solvents, but rather an extended structure similar to that of docetaxel in the solid phase,⁴ our group became interested in studying a new series of macrocyclic taxoids wherein a tether links the C2 carboxylate and C3'N acyl positions (**3.10**, Figure 3.3).¹⁷⁵

All compounds in this series exhibited some level of growth inhibition against the LCC6-WT cell line. Seven out of twelve compounds exhibited single digit micromolar IC₅₀ values, while the remaining five compounds were sub-micromolar with IC₅₀ between 0.09 and 0.70 μ M, the most active being **3.11** (Figure 3.3). While an IC₅₀ of 0.09 μ M represents a 30-fold reduction in cytotoxic activity, relative to paclitaxel, it nevertheless shows a 4-fold improvement from the lead C-linked taxoid. Interestingly, the same growth inhibition assay conducted on the multi-drug resistant variant of the cell line (LCC6-MDR) demonstrated a 1.4 to 33 resistance index for compounds in the N-linked series, as opposed to 112 for paclitaxel, suggesting that the P-glycoprotein might not recognize these macrocyclic analogs as well as the parent drug.


A second synthetic approach towards N-linked macrocyclic paclitaxel analogs was also explored, wherein a highly regioselective Heck macrocyclization is employed to close the macrocyclic ring.¹⁷⁰ In spite of their higher structural rigidity, *exo* isomers were found to be more cytotoxic than their *endo* counterparts. Indeed, against the LCC6-WT breast cancer cell line, the IC₅₀ values of **3.12-*exo*** and **3.13-*exo*** (Figure 3.3) were 0.067 and 0.071 μ M, respectively, while that of **3.12-*endo*** was 0.530 μ M, showing an 8-fold reduction in activity. Although slightly better than that of the best N-linked compound obtained by RCM,^{154,174} the bioactivity of these *exo* isomers was still 15 times inferior to that of paclitaxel in the same assay.




3.10 Template for N-linked macrocycles via RCM



3.11



3.12-exo: R=Ph
3.13-exo: R=CHC(Me)₂



3.12-endo: R=Ph
3.13-endo: R=CHC(Me)₂

Figure 3.3. ‘N-linked’ macrocyclic taxoids.

3.2 Early Design Attempts

Visualizing the paclitaxel binding model, we noticed that space was left unoccupied around the paclitaxel structure. We therefore set off to introduce conformationally restraining groups that would fill these empty volumes and lower the entropy loss upon binding, while causing minimal disruption to the binding interactions and possibly adding further stabilizing interactions via the restraining moieties.

The REDOR-Taxol conformation of paclitaxel suggested that the C4 acetyl and C13 side chains were in close proximity in the bioactive conformation. Furthermore, the β -tubulin binding site of paclitaxel is a deep crevice of which paclitaxel only occupies the most superficial region. This incited us to insert a linking moiety connecting the C4 acetyl and C2' positions in restrained taxoid **3.14** (Figure 3.4). The binding model also opens the possibility of inserting linking moieties in the vast hydrophobic cluster formed by the C3'N and C2 benzoyl groups and the imidazole of His227. Accordingly, we designed C14-C3'N linked taxoid **3.15** (Figure 3.4) in which a short (four C atoms) linker should lock the C13 side chain in an unequivocal conformation close to the bioactive with minimum impact on the original binding interactions of the taxoid by avoiding steric clash with His227 of the core β -tubulin helix, H7.

Compounds **3.14** and **3.15** were also selected as our targets because our laboratory had greater experience in the synthesis of isobutenyl β -lactams, which enabled increased bioactivities relative to paclitaxel when incorporated in taxoids of the 2nd generation.^{176,177} In particular, **3.14** was chosen as a target because β -lactam chemistry readily allows modification at the C2' position and the SAR studies of paclitaxel showed that longer side chains at the C4 position enhanced the activity slightly.²⁴

3.2.1 Synthetic and Analytical Methods

The synthesis of the designed C14 to C3' and C4 to C2' restrained taxoids was performed by Dr. Xudong Geng of the Ojima laboratory. RCM¹⁷⁸ was used as the key reaction based on the previous successful applications of this protocol in constructing C2-C3',^{154,174} and C2-C3'N¹⁷⁵ linked macrocyclic taxoids. The precursors of RCM, i.e., dienes, were synthesized through our highly efficient β -lactam-baccatin ring-opening coupling protocol.^{20,179,180}

The syntheses of C4-C2' linked taxoids require a C4 modified baccatin **3.16**. This baccatin was synthesized using a reported protocol by Kingston *et al.*¹⁸¹ with modifications. As shown in Figure 3.5, baccatin **3.16** was coupled with β -lactam **3.17**,¹⁸² which bears an allyl group, to afford diene **3.18** in 60% yield. A certain amount (22%) of C13 Boc baccatin **3.19** side product was isolated, presumably because the 13-oxygen anion of baccatin **3.16** might attack the Boc carbonyl group due to the steric hindrance of the C2 carbonyl group in β -lactam **3.17**.

Diene **3.18** was then subjected to RCM reaction using 'Grubbs's catalyst'¹⁷⁸ to afford macrocyclic taxoid **3.20** in 70% yield. Desilylation using HF-pyridine gave C4-C2' linked taxoid **3.14** in 60% yield. Interestingly, only the *Z*-isomer of **3.14** was obtained.

Hydrogenation of **3.14** using palladium on carbon as catalyst afforded saturated macrocyclic taxoid **3.14(H)** in quantitative yield.

The C13 side chain precursor for C14-C3'N linked taxoids, β -lactam **3.21**, was prepared as shown in Figure 3.6. *N*-H β -lactam¹⁸³ **3.22** was treated with 2-allylbenzoyl chloride¹⁸⁴ to give β -lactam **3.21** in 80% yield.

In order to synthesize the C14-C3'N linked taxoids, it is necessary to introduce an olefin moiety at the C14 position of baccatin. This was realized by allylation of the 14-OH of the derivative of a naturally occurring baccatin, 14 β -OH-10-DAB.¹⁸⁵ As shown in Figure 3.6, 14-OH-10-DAB was first treated with excess amount of TESCl and imidazole to afford 7,10-di-TES-14 β -OH-10-DAB **3.23** in 70% yield. Then, 10-acetylation of **3.23** using LiHMDS and AcCl at -40 °C provided baccatin **3.24** in 93% yield. The silyl groups of **3.24** were removed using HF-pyridine and selective TES protection of the C7 OH of baccatin **3.25** using TESCl and imidazole gave 7-TES-14-OH-baccatin **3.26** in good yield. Finally, in the presence of NaHMDS, **3.26** was treated with allyl iodide to afford **3.27** with an allyl ether moiety attached to the C14 position.

As shown in Figure 3.6, coupling of baccatin **3.27** and β -lactam **3.21** gave diene **3.28** in 80% conversion yield. RCM reaction gave the desired macrocycle taxoid **3.29** in 80% yield. The silyl groups were then removed with HF-pyridine to afford **3.15** (*E*-isomer only). Finally, hydrogenation of **3.15** using Pd on carbon as catalyst gave **3.15(H)** in 80% yield.




Figure 3.4. Target restrained macrocyclic taxoids.




Figure 3.5. Synthesis of C4-C2' linked taxoids 3.14 and 3.14(H).




Figure 3.6. Synthesis of C14-C3'N linked taxoids 3.15 and 3.15(H).

3.2.2 Biological Activity

The synthesized macrocyclic taxoid **3.14**, **3.14(H)**, **3.15**, and **3.15(H)** were tested for their cytotoxicities and tubulin binding activities. The tubulin polymerization assays were performed in the laboratory of Prof. Susan Horwitz at the Department Molecular Pharmacology of the Albert Einstein College of Medicine. Cell growth inhibition assays were conducted by Paula Pera in the laboratory of Dr. Ralph Bernacki at Roswell Park Cancer Institute. The assay results are summarized in Table 1.

Table 3.1. *In vitro* cytotoxicities (IC₅₀, nM^a) and tubulin-polymerization assays of C4-C2' and C14-C3'N linked macrocyclic taxoids **3.14** and **3.15**.

Taxoid	LCC6-WT ^b	LCC6-MDR ^c	MCF7-S ^d	MCF7-R ^e	Tubulin pol.
Paclitaxel	4.0±0.15	379±7.0	2.2±0.18	1185±40	100%
3.14	91±2.8	230±23	35±1.9	365±32	9%
3.14(H)	283±30	629±46	105±7.3	904±19	NT
3.15	213±17	2130±97	463±33	>3000	60%
3.15(H)	461±35	1933±163	764±45	2818±138	NT

^aThe concentration of compound which inhibits 50% of the growth of human tumor cell line after 72 h drug exposure; ^bLCC6-WT: human breast carcinoma; ^cLCC6-MDR: MDR1 transduced line; ^dMCF7-S: human breast carcinoma; ^eMCF7-R: MDR phenotype human breast carcinoma; NT: not tested.

The C4-C2' linked taxoid **3.14** exhibits strong potency against LCC6-WT and MCF-7 human breast cancer cell lines with IC₅₀ values of 0.091 and 0.035 μM, respectively. These cytotoxicities are 16-20 times less potent than paclitaxel against the same cell lines. However, taxoid **3.14** is 1.5-3 times more potent than paclitaxel against drug-resistant cancer cell lines (LCC6-MDR and MCF7-R), suggesting that the introduction of a macrocycle linking the C4 and the C2' positions might disrupt the binding of P-glycoprotein to this taxoid and thus offset the effect of this 'efflux pump', believed to be responsible for multi-drug resistance.¹⁸⁶⁻¹⁸⁸ The hydrogenated taxoid, **3.14(H)**, was approximately 3 times less potent than **3.14**, although it still exhibited more potent cytotoxicity than paclitaxel against MCF7-R breast cancer cells.

Macrocyclic taxoid **3.15**, which bears a tether connecting the C14 and the C3'N positions, exhibited cytotoxicities 2-10 times weaker than that of **3.14** and its potency was significantly lower than that of paclitaxel in all tested cancer cell lines (5-250 times less active). The hydrogenation of **3.15** resulted in analog **3.15(H)** with further loss of

activity (2 times less active) against drug-sensitive cell lines (LCC6-WT and MCF7-S) but seemed to slightly increase the potency against drug-resistant cell lines (LCC6-MDR and MCF7-R).

Intriguingly, taxoid **3.14**, which is 3 to 10 times more cytotoxic than taxoid **3.15**, exhibits only 9% of the binding ability of paclitaxel while **3.15** possesses 60%. The fact that the more cytotoxic taxoid exhibited less tubulin polymerization ability suggested a poor ability for compound 2 to cross the cancer cell membrane, resulting in insufficient concentrations of the agent in the cytoplasm. Alternatively, compounds **3.14** and **3.14(H)** might be taking advantage of the other mechanisms that taxoids operate by to kill cancer cells.

As paclitaxel has been shown to induce apoptosis in HeLa¹⁸⁹ and prostate cancer cells,³⁶ our collaborator, Dr. Muriel Cuendet at the Department of Medicinal Chemistry and Pharmacognosy of the University of Illinois at Chicago, investigated the apoptosis-inducing abilities of novel taxoids **3.14** and **3.15** in KB cells. 4'-6-Diamidino-2-phenylindole (DAPI, a fluorescent DNA dye) staining of KB cells treated with taxoids **3.14** and **3.15** evidenced the formation of apoptotic bodies with IC₅₀ values of 289 nM (**3.14**) and 795 nM (**3.15**), compared to 12.3 nM for paclitaxel in the same assay. In order to further elucidate the mechanism underlying the pro-apoptotic effects of the taxoids, their effect on the activities of various caspases was studied. Apoptosis induced by **3.14** and **3.15** was only marginally reduced by the addition of Z-VAD-fmk (Z-Val-Ala-Asp(OMe)-CH₂F), a caspase-1,-3,-4,-7 inhibitor. This suggests that **3.14** and **3.15** induce apoptosis via a caspase-independent mechanism, identically to paclitaxel, and in contrast to most DNA-damaging agents.^{190,191}

3.2.3 Summary

Although the project goal to match or exceed the *in vitro* biological effects of paclitaxel was not achieved by the compounds in this series, the tubulin polymerization assay still ranked **3.15** as the best macrocyclic taxoid ever tested in our lab, with an activity 60% that of paclitaxel. The *in vitro* tubulin polymerization assay provides the clearer test of our restrained analog design process, as it is not affected by cellular permeation or active transport issues. On the other hand, compound **3.14** fared honorably in the cellular growth inhibition assay with a 91 nM IC₅₀ against the LCC6-WT cell line ranking it among our top macrocyclic compounds.

Apoptosis probing assays confirmed that these macrocyclic taxanes, like paclitaxel, induce a caspase-independent pathway to programmed cell death (PCD), especially **3.14** which is otherwise a weak tubulin polymerization inducer. This shows that strong tubulin polymerization ability is not a requirement for induction of PCD and underlines the fact that cellular permeability is of utmost importance when designing taxoid anticancer drugs, as **3.15** could not translate its significant *in vitro* polymerization ability into an effective cell growth inhibition activity.

3.3 SB-T-2053

After the relative setback of our first series of restrained taxoids, the idea came to us to revert to conformationally restrained analogs of first generation taxanes, as Kingston *et al.* were experiencing some success with C4 acetyl to C3' phenyl restrained compounds in that series.^{181,192} Also, direct comparison to the REDOR-Taxol conformation and the paclitaxel biochemical data would be facilitated and could provide an accurate measure of the perturbation introduced by the conformational restraint.

Synthesis of these 1st generation-based restrained analogs once again made use of the RCM reaction¹⁷⁸ and was performed by Liang Sun in the Ojima laboratory. The isobutenyl moieties of β -lactams **3.14** and **3.15** were replaced by phenyl groups, and conformationally restrained paclitaxel analogs **3.30** and **3.31** could be obtained by following protocols very similar to those of our earlier approach (Figures 3.7 and 3.8).




Figure 3.7. Synthesis of C4-C2' linked taxoid 3.30.




Figure 3.8. Synthesis of C14-C3'N linked taxoid SB-T-2053 (3.31).

3.3.1 Biological Activity

The activities of **3.30** and **3.31** were compared to those of paclitaxel in the *in vitro* tubulin polymerization assay and against human mammary and lung cancer cell lines. The results, compiled in Table 3.2, show that neither of the two compounds could match the cytotoxic activity of paclitaxel on the cell lines studied. In particular, **3.30** was surprisingly inactive against all strains of LCC6 and MCF7 cancer cells and was not tested for *in vitro* tubulin polymerization. Compound **3.31** (SB-T-2053), on the other hand, achieved the highest cytotoxicity levels ever encountered for a restrained macrocyclic taxoid in our group. IC₅₀ values were 15 and 42 nM against the LCC6-WT and MCF7 cell lines, respectively, corresponding to only 3.3- and 14-fold reductions in activity relative to paclitaxel. These ratios were even improved in the resistant variants of these two cell lines (1.4 and 2, respectively), as SB-T-2053 appeared to be slightly less subject to MDR than paclitaxel.

Table 3.2. *In vitro* cytotoxicities (IC₅₀, nM^a) and tubulin-polymerization assays of C4-C2' and C14-C3'N linked macrocyclic taxoids **3.30** and **3.31**.

Taxoid	LCC6-WT ^b	LCC6-MDR ^c	MCF7-S ^d	MCF7-R ^e	Tubulin pol.
Paclitaxel	4.5±0.8	323±23	3.0±0.3	518±71	100%
3.30	>10000	>10000	5636±214	>10000	NT
3.31	15±1.6	455±38	42±2.3	1066±59	100%

^aThe concentration of compound which inhibits 50% of the growth of human tumor cell line after 72 h drug exposure; ^bLCC6-WT: human breast carcinoma; ^cLCC6-MDR: MDR1 transduced line; ^dMCF7-S: human breast carcinoma; ^eMCF7-R: MDR phenotype human breast carcinoma; NT: not tested.

Above all, and directly validating our design approach, SB-T-2053 showed a level of *in vitro* tubulin polymerization activity comparable to that of paclitaxel. SB-T-2053, like paclitaxel, induces tubulin polymerization in the absence of GTP that is normally required for microtubule assembly. Furthermore, the microtubules formed in the presence of SB-T-2053 and paclitaxel were both stable against calcium-induced depolymerization (Figure 3.9). The calculated critical concentration of protein required to achieve assembly is approximately 0.08 mg tubulin/ml for both drugs.

Furthermore, a competitive binding assay indicated that both paclitaxel and SB-T-2053 effectively displace [³H]paclitaxel from microtubules (Figure 3.10). This result provides strong supporting evidence that SB-T-2053 binds to the paclitaxel-binding site on the microtubule *in vitro*.

In an attempt to evidence possible differences between the dose-dependent microtubule stabilization effects of SB-T-2053 and paclitaxel that could explain the lower toxicity of the former on cancer cells, the microtubule polymerization assay was repeated

at a series of drug to tubulin concentration ratios (Figure 3.11). At all drug/tubulin ratios, the polymerization profiles were nearly indistinguishable, once again stressing the similarity in the biological profiles of SB-T-2053 and its parent drug paclitaxel, *in vitro*.




Figure 3.9. Effect of calcium on microtubules polymerized by paclitaxel and SB-T-2053 (3.31).




Figure 3.10. SB-T-2053 competitively inhibits $[^3\text{H}]$ paclitaxel binding to microtubules as potently as paclitaxel.




Figure 3.11. Tubulin polymerization and microtubule stabilization assay for 5 μ M paclitaxel or SB-T-2053 (3.31) and various concentrations of tubulin (A), or 5 mg/mL tubulin and various concentrations of drug (B).

3.3.2 Conformational Restriction to the Binding Conformation

In order to measure the level of conformational restriction imposed by the C14-C3'N linker, we conducted a Monte Carlo conformational search on SB-T-2053 in a simulated aqueous environment (GBSA¹⁹³) using Macromodel 6.5 (Schrödinger, Inc.). Performing the same calculation on paclitaxel provided a reference state from which the perturbation can be assessed. Our attention focused on the C13 side chain dihedral angles since they should be the ones most affected by the introduction of the constraint. Figure 3.12 shows the dihedral angle distributions for both SB-T-2053 and paclitaxel and compares those to the reference values of the REDOR-Taxol and T-Taxol conformations.

The C13-O13 torsion angle remains quite distributed in SB-T-2053, covering the same range as paclitaxel, with surprisingly low propensity for the -105° and -150° peaks seen for paclitaxel. The next torsion angle, around O13-C1', is for the ester linkage and mostly centered on 0° . However, paclitaxel in solution also adopts the reversed conformation (i.e., 180°) in lesser extent, contrary to SB-T-2053. The last two dihedral angles, around C1'-C2' and C2'-C3' are where the most flexibility is observed in paclitaxel. Indeed, except for the 90° to 150° region, the O13-C1'-C2'-O2' dihedral angle can adopt every value, with peaks at 10° , -30° , -75° , -120° and -165° . In sharp contrast, SB-T-2053, does not show any density between 0 and 90° . In the 50 kJ/mol energy range scrutinized, no SB-T-2053 structure was detected that matched REDOR-Taxol or T-Taxol. However, a peak of the probability density exists near each of the two reference conformations at -15° and -150° . In addition, the T-Taxol value should be quite unfavorable since it corresponds to a fully eclipsed conformation.

The O2'-C2'-C3'-N3' dihedral angle distribution shows the most striking effects of the conformational constraint: while paclitaxel exists in 4 major conformations, SB-T-2053 is restricted to only two, each of them reproducing the value observed in either REDOR-Taxol (176°) or T-Taxol (-67°). Therefore, we conclude that the constraint introduced is quite effective in restricting conformational diversity while enriching the solution ensemble in bioactive conformations.

Additionally, very little reorganization of protein side chains is observed after docking of SB-T-2053, as compared to REDOR-Taxol (Figure 3.13), confirming the benign nature of our perturbation on intermolecular interactions.




Figure 3.12. Conformational diversity in constrained taxoid SB-T-2053: comparison of the C13 side chain dihedral angle distributions for paclitaxel (brown) , SB-T-2053 (red) and Kingston et al. compound 13a of Ref. 192 (cyan) in water. The reference values for REDOR-Taxol (blue) and T-Taxol (green) are indicated by vertical lines.




Figure 3.13. Overlay of REDOR-Taxol (green) with SB-T-2053 (blue). The overlay is performed by matching the protein backbone, which is kept fixed during docking.

3.3.3 Summary

The C4-C2' restrained paclitaxel analog **3.30** showed surprisingly weak activity against cancer cells suggesting that the C4-C2' linker might be too bulky to be accommodated in the β -tubulin paclitaxel binding site. Analogs with smaller C4-C2' linker length might be able to perform considerably better, as the groups of Kingston and Snyder have shown that a reduction in a similar C4-C3' linker could have dramatic improvements in the biological activities of macrocyclic taxoids. In particular, compound 13a in Ref. 192 (Figure 3.12), with a 2-atom linker between the C4 acetate methyl and the *ortho* position of the C3' phenyl group showed 186 times higher activity than the equivalent 5-atom linked compound.¹⁹² The conformational restriction imposed by the 2 atom C4-C3' linker of this compound is compared to that of SB-T-2053 in Figure 3.12. Although this drug was designed to adopt the T-Taxol conformation, it appears to more closely mimic our REDOR-Taxol conformation.

On the other hand, the biological activities of the C14-C3'N restrained analog were enhanced to levels comparable with paclitaxel by substituting the C3' isobutenyl, typical of 2nd generation taxoids,^{176,177} with the original phenyl group of paclitaxel and docetaxel.

Considering that SB-T-2053 is comparable to paclitaxel in the induction of microtubule polymerization, the small differences in IC₅₀ values between paclitaxel and SB-T-2053 could be due to cell permeability and solubility factors. The same observation was made in the case of the isobutenyl analog **3.15** which retained 60% of the tubulin polymerization ability of paclitaxel but was only 50 times less active than paclitaxel in cancer cell growth inhibition (Table 3.1). A number of factors could specifically account for this phenomenon. Firstly, these compounds could suffer from low permeation into cells because their structures are fixed in an extended conformation, similar to the one observed in non-polar solvent NMR of paclitaxel or the in the crystalline environment, which could hinder their partitioning into the aqueous cellular interior and lead to an accumulation of the drug in the cell membrane. As the cellular interior is a complex milieu, there is also the possibility that these drugs bind to an unrelated protein or other entity, thus thwarting their binding to cellular tubulin. Alternatively, because of the C14-C3'N conformational restriction, these compounds may not be able to access the β -tubulin binding site as well in live MAP-decorated microtubules as in the purified microtubules of the *in vitro* test. Indeed, the paclitaxel binding site lies on the luminal side of the microtubule,^{89,90} which would suggest that paclitaxel has to diffuse through the microtubule wall at great speed in order to keep up with the fast growth of the tubule.¹⁹⁴

3.4 Conclusions

3.4.1 Advantages of Structure-Based Design Approaches

Prior to the release of the tubulin dimer structure, scientists relied on ‘ligand-based’ approaches, referring to the vast SAR available for paclitaxel to identify positions that could be linked to produce more potent cytostatic agents by restriction of binding entropy loss. This resulted in more or less a hit-or-miss approach, as reflected by the few compounds that retained a level of activity similar to paclitaxel in the early macrocyclic taxoids series. By including structural data at the core of our design process, we were able to identify two good MTB-stabilizing compounds in a set of just six synthesized designs, one of which is as potent as paclitaxel in the growth inhibition of cancer cell lines. Underlining the value and sensitivity of binding site information. Out of the six synthesized analogs, five showed submicromolar activities against mammary and lung cancer cell lines, showing the remarkable improvement in the quality of synthetic candidates made possible by a precise 3D binding site modeling.

3.4.2 Drug Design Possibilities Opened

This study sanctions the viability of drug design and discovery of new generation taxoids and new microtubule-stabilizing agents based on the refined structural information of drug-protein complexes following the typical medicinal chemistry approach of generating constrained analogs of the bioactive conformation. In just two synthetic rounds, a lead compound with tubulin polymerization activity at least as potent as paclitaxel could be isolated.

Following the example of Kingston and Snyder,¹⁹⁵ we now suggest that varying the linker length could produce refined mimics of the REDOR-Taxol conformation and generate stronger binders of β -tubulin. The synthesis of such a series of analogs, with either one less or one more atom in the C14-C3’N linker is currently underway in the Ojima laboratory (Figure 3.14).

Another exciting recent development in the chemical biology of microtubule stabilizing agents was the production of a α,β -tubulin dimer structure with epothilone A (Figure 3.2) bound at the paclitaxel binding site.¹⁹⁵ With such a model at hand, we propose to overhaul the original common pharmacophore hypothesis with the 3D information from these epothilone A cryo-EM studies. Indeed, cross information from the epothilone A and paclitaxel bound tubulin dimer structures opens the way to understand drug-protein interactions at this binding site and delineate a diminutive epothilone-paclitaxel structure maintaining the key drug-tubulin interactions.

Along these lines, new hybrid designs have been proposed to answer persisting questions about the importance of the C13 side chain of paclitaxel, and how it is replaced in the epothilone family. In these designs, we propose to attach the epothilone thiazole side chain either at the C1 or C14 positions of the baccatin scaffold, with and without a

C13 phenyl isoserine side chain (Figure 3.15). This proposition originates from the comparative observation of the overlaid epothilone A and paclitaxel structures in their respective zinc sheet tubulin dimer environment, and detection of a near-perfect overlap between the C1 of paclitaxel and the thiazole side chain bearing C15 of epothilone A. While functionalization of the baccatin C1 position might be an insurmountable task, due to the low reactivity of its shielded tertiary alcohol, the C14 position of 14 β -hydroxybaccatin should provide a close surrogate and is readily amenable to chemical modification.




Figure 3.14. Overlaid structures of paclitaxel in the REDOR-Taxol conformation and C14-C3'N linked macrocyclic taxoids of variable linker length.




Figure 3.15. Top: Direct overlay of the paclitaxel (white sticks) and epothilone A (pink sticks) bound conformations in the β -tubulin binding site (shown as lines) from PDB entries 1JFF¹⁵⁵ and 1VTK.¹⁹⁵ Bottom: Proposed C1 (left) and C14 (right) paclitaxel-epothilone hybrid constructs.

Chapter 4

Investigation of Salt-bridge Stability in the Generalized Born Model

4.1 Introduction

One of the greatest challenges in the application of computation techniques to biological systems is the accurate determination of protein and RNA three-dimensional structures. The native structure of proteins is maintained at the edge of thermodynamic stability, the free energy of unfolding being in the range of a few kcal/mol. A dominant contributor to stability is the hydrophobic effect, but other important stabilizing factors include van der Waals interactions, hydrogen bonds, and electrostatic interactions, notably salt bridges.¹⁹⁶⁻¹⁹⁸ However, the stability of salt bridges, i.e., the net balance of favorable Coulombic interactions between opposite charges and their costly desolvation, as well as the extent of their involvement in native state stabilization remain ambiguous.¹⁹⁹⁻²⁰⁴ Nevertheless, salt bridges have been linked to the thermal stability of hyperthermophilic proteins.^{196,205-210}

Molecular simulations have proven to be valuable tools for probing the various interactions that define the protein native state and characterize possible folding pathways towards it.²¹¹ Recently, continuum solvent simulations²¹²⁻²¹⁷ have become popular alternatives to their more computationally demanding explicit solvent counterparts, as their lack of solvent friction increases conformational transition rates significantly,²¹⁸⁻²²⁶ allowing for faster sampling of the configurational space. Furthermore, because continuum solvent models implicitly average over the water and counterion distributions, this averaging does not need to be done by the simulation itself which leads to considerable simplification when calculating thermodynamic properties.²²⁷ Lastly, some macroscopic solvent properties, such as dielectric effects, are difficult to reproduce accurately with explicit solvation.²²⁸ The ability to build these into implicit solvent descriptions may actually give them some advantage for certain kinds of simulations.

Due to its computational efficiency, the generalized Born (GB) implicit solvent model^{193,229,230} has become a popular choice to accelerate molecular dynamics (MD) simulations and to study large scale conformational transitions. However, this model lacks structural water features and has been reported to yield higher fluctuations than explicit solvent simulations.²³¹ To some extent, this might be a consequence of the improved conformational sampling, which lets the simulation more quickly find non-native structures that are energetically favored by the particular force field. But it also seems likely that the current generation of GB models do not have as good a balance between protein-protein and protein-solvent interactions as do the more widely tested explicit solvent models. More particularly, we¹¹⁶ and others^{140,142,232,233} have observed

that salt bridges were frequently too stable in the GB implicit water model, causing salt bridged conformations to be oversampled in MD simulations, thus altering the thermodynamics and kinetics of folding for small peptides. A clear illustration was given by Zhou and Berne,¹⁴⁰ who sampled the C-terminal β -hairpin of protein G (GB1) with both a surface-GB (SGB)²³⁴ continuum model and explicit solvent using a replica-exchange molecular dynamics (REMD)¹³⁴ protocol. The lowest free energy state with SGB was significantly different from the lowest free energy state in explicit solvent, with incorrect salt bridges formed at the core of the peptide, in place of hydrophobic contacts. Zhou extended this study on GB1 by examining several force field-GB model combinations,²³² with all GB models showing erroneous salt-bridges. Nevertheless, as the MD simulation community envisions characterizing entire folding landscapes and pathways, implicit solvent models like GB could be beneficial in supplementing the more slowly-converging explicit models, but should be devoid of structural bias in order to maintain comparable levels of accuracy.

In this study, the Potential of Mean Force (PMF) of salt bridge formation is calculated for two residues in a solvated protein environment. Masunov and Lazaridis²³⁵ performed similar calculations on isolated side chain pairs in coplanar monodirectional approaches and concluded that CHARMM GB²³⁶ matches the explicit solvent contact minimum energy to within 1kcal/mol for both the Arg⁺...Glu⁻ and Lys⁺...Glu⁻ pairs. In our case, comparisons between the GB models implemented in the AMBER package (GB^{HCT 237-240}, GB^{OBC 241,242}) and TIP3P explicit water salt bridge PMFs confirm the excessive strength of salt bridges in the AMBER GB models, at least, and offer a way to assess their parameterization. A simple empirical change in the assignment of GB atomic radii for hydrogen atoms of charged protein groups is investigated and shown to significantly improve the GB PMF of our test salt bridge system. This parameter change is further examined on a range of control systems by comparison to explicit solvent and experimental data.

4.2 Methods

All calculations were performed using the AMBER suite of programs²⁴³, versions 7 and 8, with the ff99 force field¹⁰⁷ modified to improve agreement with *ab initio* relative energies of alanine tetrapeptide conformations (frcmod.mod_ghpsi.1).^{115,116} The Trp-cage simulations employed an optimized version of this force field, refit to also capture *ab initio* relative energies of the glycine tetrapeptide.²⁴⁴

Bonds involving hydrogen atoms were constrained using the SHAKE algorithm,¹²² and a 2 fs integration time step was adopted. Explicit solvent simulations were performed with the TIP3P water model,²⁴⁵ widely popular for its computational simplicity and near-experimental bulk permittivity.^{228,246-248} The Fab 17/9 (PDB ID:1HIL²⁴⁹) H3 loop fragment and the small helical peptides were placed in truncated octahedral boxes with respectively 5 or 6 Å minimum buffer clearance from the solute.

The Particle Mesh Ewald²⁵⁰⁻²⁵³ (PME) treatment of long-range electrostatics was used with a direct space cutoff of 8 Å in constant pressure simulations at 1 bar. Implicit

solvent runs employed the GB^{HCT} 237,239,240 or GB^{OBC} 242 models with no cutoff and modified Bondi radii.²⁵⁴ Radii reductions in GB^{HCT} were further applied to hydrogen atoms bonded to nitrogens of N2 and N3 AMBER types,¹⁰⁰ as in Arg, Lys and charged N-terminal groups.

In the PMF calculations, the varied reaction coordinate was the distance between the carbonyl carbon of the acidic side chain (C γ in Asp, C δ in Glu) and either N ζ of Lys or C ζ of Arg, the geometric center of the ionized guanido group. In all cases, the backbone atoms were positionally restrained with sufficient force to prevent significant conformational changes (1 kcal/mol.Å² force constant for the Fab 17/9 H3 loop, 10 kcal/mol.Å² for the test helical peptides). All PMFs were calculated using Umbrella Sampling (US)²⁵⁵ with the reaction coordinate constrained to a narrow range by application of a harmonic biasing potential $V(r) = k_{\text{umb}}(r - r_0)^2$. US windows were centered every 0.5 Å of the coordinate range (3 to 11.5 Å) and a 1 ns MD run was performed for each. Umbrella potentials with $k_{\text{umb}} = 10$ kcal/Å² were applied in all windows, to enforce continuous sampling of high-energy regions. The biased frequency distributions were converted to free energies using the WHAM method,²⁵⁶ as implemented by Roux.²⁵⁷ Additional windows were placed at 3.25, 3.75, 4.25, 4.75, 5.25, 5.75 Å for TIP3P simulations, in order to improve sampling of the barrier region. Data from the first 200 ps of each US window were discarded and only the last 800 ps were analyzed.

To extensively explore the conformational space of the TC5b miniprotein (NLYIQWLKDGPPSSGRPPPS) in the GB^{HCT} solvent model, we employed replica-exchange molecular dynamics simulations (REMD^{134,135}) using REMD as implemented in AMBER 8. TC5b was modeled in its zwitterionic form, with ionizable residues in their expected ionization state at pH=7, for a total of 304 atoms. The 267-715.7 K temperature range was covered using 16 replicas (267.0, 285.1, 304.5, 325.2, 347.3, 370.9, 396.1, 423.0, 451.8, 482.4, 515.2, 550.2, 587.6, 627.5, 670.2, 715.7 K), resulting in average exchange acceptance probabilities in the 22-32% range. Starting from arbitrary pre-equilibrated initial structures with 1.8 to 6.4 Å backbone RMSD to model 1 of the NMR set²⁵⁸ for residues 3 to 18, exchanges were attempted and replica conformations recorded every 500 MD steps (1 ps). The Berendsen temperature coupling scheme²⁵⁹ was applied with a 0.1 ps heat bath coupling constant for all replicas (1ps for non-REMD simulations). After a 9 ns thermal equilibration period, data was accumulated for 50 ns for each temperature. In GB^{HCT} with standard H^{N+} radii (1.3 Å), REMD runs were extended to 92 ns in an effort to improve the convergence of the ensembles.

Lower bound estimates of the sampling uncertainty and convergence of our simulation protocols were derived by splitting datasets in half and comparing individual half-length averages to the full-length values.

4.3 Results and Discussion

4.3.1 Unstable Behavior of the 17/9 Anti-Influenza Fab H3 Loop in GB Simulations

In the course of our research on loop structure modeling^{260,261}, our attention focused on the H3 CDR loop of the 17/9 anti-influenza antibody.²⁴⁹ In preliminary GB^{HCT} MD simulations, its experimentally determined native structure appeared highly unstable, with backbone transitions of nearly 1 Å RMSD magnitude occurring within a few ns (Figure 4.1a). This seems unlikely to be attributable to a poorly refined experimental structure, since the 1HIL structure was solved at a reasonable 2.0 Å resolution, and the H3 loop under study is rather well defined, with maximum backbone and side-chain atomic B-factors of 22.08 and 44.82 Å², respectively. Nevertheless, this loop incorporates intrinsic flexibility as revealed by crystallography studies that indicate substantial loop rearrangement occurs upon binding to a nonapeptide antigen.²⁴⁹

The H3 loop and its surroundings incorporate numerous charged residues, and during simulation, the flexible Arg97 side chain (the Kabat antibody sequence numbering convention²⁶² is followed throughout this paper) associates with Glu100, thereby irreversibly shifting the backbone in a bent non-native conformation (Figure 4.2). This transformation happens through an intermediate where Tyr98 and Asp99, at the tip of the loop, have simultaneously undergone backbone conformational transitions (Figure 4.2), yet maintaining the hydrogen bond observed between the Arg97 and Tyr98 side-chains in the native state. Rapidly following, the last step of this transformation is the conversion of Arg97 from a polyproline II to a left-handed α -helix conformation, simultaneous to salt bridge formation (Figure 4.2). This last step generates a ~ 14 kcal/mol drop in potential energy, which effectively locks the loop in the non-native conformation (Figure 4.1).

Artificially neutralizing both the Arg97 and Glu100 side chains prevented this behavior (Figure 4.1b), clearly suggesting the electrostatic nature of the phenomenon, and in particular an imbalance between GB desolvation energy and Coulombic attraction. This control run also evidenced that backbone parameters alone are not responsible for the observed conformational transition.

Additionally, a TIP3P/PME explicit solvent simulation initiated from the salt-bridged structure saw several openings of the Arg97 \cdots Glu100 ion pair (Figure 4.1c). However, this was not accompanied by rearrangement of the backbone back to the X-ray conformation during the 10 ns, a process assumed to be slow in explicit solvent. The native loop conformation was also stable throughout a 10 ns TIP3P/PME run started from the X-ray structure, with no salt bridge formation observed (Figure 4.1d).




Figure 4.1. Root-mean-square deviation (RMSD, Å) of Fab 17/9 H3 loop backbone heavy atoms, and salt bridge distance (Arg97 C ζ - Glu100 C δ , Å) as a function of simulation time, in different conditions at 300K: (a) GB^{HCT} from native, (b) GB^{HCT} with uncharged Arg97 and Glu100 side-chains from native, (c) TIP3P explicit solvent simulation from salt bridge conformation, (d) TIP3P from native. The RMSD fit to the X-ray conformation is performed over the restrained, non-loop atoms of the fragment. Relative potential energy values, window averaged over 25ps, are also reported for implicit solvent simulations in kcal/mol. The backbone transition and concomitant salt bridge formation in GB^{HCT}, not observed with neutralized side chains or explicit solvent, induce a 14 kcal/mol reduction in potential energy.




Figure 4.2. Fab 17/9 H3 loop in native conformation (N), transient intermediate state with inverted Tyr98 ψ and Asp99 ϕ dihedral angles (I), and stable salt bridged conformation with bidentate H-bond (SB), taken from a standard GB^{HCT} simulation. Loop backbone heavy atoms are colored yellow while interacting charged side chains are colored by element. H-bonds are indicated by dashed orange lines.

4.3.2 Potentials of Mean Force as Measures of GB Deviation from Explicit Solvent Behavior

Owing to the difficulty of directly comparing simulations with experimental salt bridge stability data, mostly of mutational origin, explicit water simulations with the simple TIP3P model²⁴⁵ were chosen as our reference for evaluating the PMF profile of the Fab 17/9 H3 loop Arg97...Glu100 salt bridge in GB. As no computationally tractable model - especially not the rigid non-polarizable TIP3P model - is presently able to correctly reproduce all experimental properties of water,²²⁸ we cannot claim to accurately reproduce experimental ion pair behaviour. However, the inclusion of solvent discreteness provides a significantly less crude approach than the ad hoc GB model, and is used here for consistency with previously published ion pair solvation studies.^{235,263-268}

PMFs were obtained in GB^{HCT} and TIP3P explicit solvent using umbrella sampling²⁵⁵ along the intersidechain distance, with the loop backbone restrained in the SB conformation (Figure 4.2). The resulting TIP3P profile (Figure 4.3) consists of a series of well-defined minima: the contact ion pair (CIP) at 3.9 Å, corresponding to the free energy minimum, is accompanied by two solvent-separated ion pair (SSIP) minima at 6.4 Å and 8.2 Å, corresponding to the insertion of one or two TIP3P molecules in the intersidechain volume.^{264,269} Qualitatively, the overall shape of the PMF is in good agreement with that reported by Lazaridis for an isolated Arg⁺...Glu⁻ pair in a coplanar monodirectional approach.²³⁵ Quantitatively, however, our method yields a barrier height of 6 kcal/mol for going from the CIP to the first SSIP in TIP3P, while the PMF they reported for the isolated Arg⁺...Glu⁻ ion pair in the coplanar, double H-bonded approach presents a 7.7 kcal/mol barrier to escape the contact minimum.²³⁵ This slight difference is readily justified by the different solvent exposure levels, approach geometries (cf. Figures 4a,b of Ref. 235) and presence of a very polar environment around the Fab 17/9 ion pair, with the possibility for Arg97 to also interact with Glu96. Gruia *et al.* similarly calculated the potential of mean force of the Arg105...Glu135 salt bridge on the surface of truncated Staphylococcal nuclease, after observing in explicit water molecular dynamics simulations that breaking this salt bridge was the rate limiting step of the early unfolding transition.^{270,271} Using umbrella sampling, they measured a ~7 kcal/mol transition barrier height for breaking the contact minimum of the two charged side chains.

In contrast to the TIP3P profile, the GB^{HCT} salt bridge PMF shows no depiction of the various SSIPs and grossly overestimates the TIP3P CIP-SSIP energy difference by 3.8 kcal/mol. The activation energy barrier to breaking the salt bridge is also overestimated by almost 2 kcal/mol, providing clear direct evidence for our hypothesis that salt bridges were too stable in this GB model.

The manifestly insufficient desolvation penalty experienced by the salt bridge in GB^{HCT} prompted us to reexamine the parameterization of this GB solvent model, and in particular its handling of cationic protein side chains.




Figure 4.3. Fab 17/9 antibody Arg97...Glu100 ion pair PMF as a function of the inter-charged groups distance (Arg97 C ζ - Glu100 C δ), at 300K. The GB^{HCT} PMF overestimates the contact ion pair stability by as much as ~4 kcal/mol. The loop backbone conformation is restrained in the SB state (Figure 4.2). Error bars on both curves estimate the sampling error and were derived by separately considering the first or the second half of the dataset.

4.3.3 GB Model Parameterization and Rationale for Reduced H^{N+} Radii.

The original Born model computes the electrostatic reversible work required to move a charged sphere from a vacuum environment into a continuous high dielectric region. The result is proportional to the square of the charge, and inversely proportional to the size of the ion.²⁷² These ideas were extended to the case of non-spherical solutes in the generalized Born theory^{193,229}, which evaluates the electrostatic component of the solvation free energy in the following way:

$$\Delta G_{elec} = -\frac{1}{2} \sum_i \sum_j \frac{q_i q_j}{f_{GB}} \left(1 - \frac{1}{\epsilon_{out}}\right) \quad (4.1)$$

f_{GB} is designed to interpolate between an effective Born radius α_i at short interatomic distance r_{ij} , and r_{ij} itself at long distances. Various functional forms are possible for f_{GB} , but AMBER employs the analytically differentiable one originally proposed by Still et al.¹⁹³:

$$f_{GB}(r_{ij}, \alpha_i, \alpha_j) = \left[r_{ij}^2 + \alpha_i \alpha_j \exp\left(-\frac{r_{ij}^2}{4\alpha_i \alpha_j}\right) \right]^{\frac{1}{2}} \quad (4.2)$$

The effective Born radius α_i corresponds to the radius that would return the electrostatic energy of the system using the original Born equation if all atoms $j \neq i$ in the solute were uncharged. Therefore, α_i reflects the degree of burial of atomic charge q_i from the solute-solvent dielectric boundary. The computation of effective radii in the particular AMBER GB model discussed here (GB^{HCT})^{239,240} follows the pairwise descreening approximation (PDA) of Hawkins et al.,^{237,238} wherein the molecule is described as a set of atomic spheres of radii ρ_i (Eq. 4.3). The corresponding volume integrals can be calculated analytically even when spheres i and j overlap, following Equation 13 in Hawkins et al.²³⁷ An additional atom-dependent screening parameter S_i is required in order to avoid over-counting overlap volume between two or more neighboring spheres j , leading to Eq. 4.4.

$$\alpha_i^{-1} = \rho_i^{-1} - \frac{1}{4\pi} \sum_{j \neq i} \int_{sphere_j} \frac{1}{r^4} dV \quad (4.3)$$

$$\text{with } \rho_i = S_i (R_i + b_{offset}) \quad (4.4)$$

Although many combinations of S_i , R_i and b_{offset} could be used, the GB^{HCT} model of AMBER employs screening parameters from the TINKER molecular modeling package²⁷³ and Bondi radii²⁵⁴ slightly modified for hydrogen atoms, to reflect their bonding environment (Table 1).^{239,240} The original b_{offset} value of -0.09 Å, suggested by Still et al.¹⁹³ is employed for GB simulations of proteins in AMBER.

Table 4.1. Parameter sets used in AMBER GB implementations. The superscript on H atoms indicates the heavy atom to which it is bound. The H^N R_i value was increased in AMBER7 to stabilize Watson-Crick hydrogen bonds in a 10-base pair DNA duplex.²⁴⁰

Atom	R _i (Å), GB ^{HCT} AMBER6 ²³⁹	R _i (Å), GB ^{HCT} AMBER7,8 ²⁴⁰	R _i (Å) GB ^{OBC} 242	S _i ²⁷³
H ^C	1.3	1.3	1.2	0.85
H ^N	1.2	1.3	1.3	0.85
H ^O	0.8	0.8	1.2	0.85
H ^S	0.8	0.8	1.2	0.85
C	1.7	1.7	1.7	0.72
N	1.55	1.55	1.55	0.79
O	1.5	1.5	1.5	0.85
F	1.5	1.5	1.5	0.88
P	1.85	1.85	1.85	0.86
S	1.8	1.8	1.8	0.96

4.3.4 Reparameterization of GB^{HCT} for Improved Handling of Ionic Interactions.

In order to correct the stability of the native Fab 17/9 H3 loop conformation, we reasoned that smaller effective GB radii for atoms involved in the salt bridge would increase their desolvation penalty, thus balancing an otherwise dominating Coulombic attraction. Intuitively, formally charged nitrogens can be seen as having increased electronegativity relative to uncharged nitrogens. This should translate in hydrogen atoms bonded to them (H^{N+} atoms) being assigned smaller dielectric radii than H^N atoms, following the suggestion by Tsui and Case that hydrogen GB radii should decrease with increasing electronegativity of their bonding partner.²³⁹ This reasoning is further substantiated by the lower electron density around H atoms in the ammonium ion, relative to ammonia (14% decrease, based on HF/6-31+G* calculations performed with the GAMESS program²⁷⁴). Radii reductions were applied only to hydrogens bonded to nitrogens of N2 and N3 AMBER types,¹⁰⁰ as found in Arg, Lys, and charged N-terminal residues. His protons were not considered, thus far, as their involvement in ionic pairs is less frequent^{275,276} and generally weak.²³⁵ Reducing only the radii of H^{N+} atoms also does not greatly affect the overall protein solvation energy (<8 % in preliminary tests), while specifically weakening the ion pair. Interestingly, similar ad hoc corrections have been recently proposed by both the Levy and Honig groups, in which additional dielectric screening is applied to oxygen and nitrogen atoms of formally charged groups either through Eq. 4.2²³³ or Eq. 4.4.²⁷⁷

The GB^{HCT} salt bridge PMF profiles are very sensitive to the choice of H^{N+} radii applied, as a 0.1 Å decrease in radius can produce up to a 3 kcal/mol decrease in stability (Figure 4.4). Both 1.3 Å and 1.2 Å H^{N+} radii (the standard values in AMBER 7²⁴⁰ and 6²³⁹ GB^{HCT}), overestimate the TIP3P salt bridge stability by as much as 3.8 and 2.4 kcal/mol, respectively. A 3.8 kcal/mol free energy error by itself is on the same order of magnitude as the folding free energies at room temperature¹⁹⁷ and can have profound consequences on the stability of the ion pair and the structural arrangement of residues around it. In comparison, the 1.1 Å profile adequately captures the energy difference between CIP and SSIP, while the intermediate 1.15 Å H^{N+} radii profile comes close to reproducing the CIP→SSIP barrier height, barely underestimating it by 0.5 kcal/mol. All GB PMFs lack the solvent-separated minima observed with explicit solvent models, resulting in an absence of barrier to salt bridge formation. This limitation of GB, typical of continuum solvent models,²³⁵ stems from the omission of solvent molecularity and is only addressed in more computationally intensive implicit models such as the RISM formalism,²⁷⁸⁻²⁸¹ molecular surface area-based solvent models^{282,283}, or specifically parameterized PB models.^{284,285}

Employing the recently developed GB^{OBC} model of Onufriev, Bashford and Case (model II in Ref. 242) with their suggested Bondi radii²⁵⁴ modified only for H^N atoms

(1.3 Å instead of 1.2 Å) also produced an improved salt bridge profile relative to standard GB^{HCT} , with the PMF just slightly underestimating the CIP→SSIP barrier height by 0.5 kcal/mol and the stabilities of the SSIPs by 0.8 kcal/mol. As a simple PDA-based GB model with no depiction of solvent discreteness cannot capture both the barrier height and the CIP-SSIP energy difference, it is reasonable to prioritize the correct reproduction of the CIP-SSIP energy gap over the barrier height, since in absence of solvent discreteness, salt bridge formation is a barrierless downhill process and accurate kinetic behavior cannot be reproduced.

Dynamics were then run on the Fab 17/9 H3 loop with H^{N^+} radii set to 1.1 Å (Figure 4.5a), and while the native state could be maintained for an extended period of time (>8ns), the conversion of the native X-ray structure (N) to the salt bridged conformation (SB, Figure 4.2) observed in standard GB^{HCT} still occurs. Because of computational limitations, we could not run a significantly longer or several independent simulations on this system, which would be necessary to fully characterize its kinetic behavior. Yet, a simulation initiated from the SB conformation showed repeated openings of the ion pair, but those events were too transient (<0.5 ns) to allow the loop backbone to relax back to the native conformation (Figure 4.5c). In contrast, simulations of the SB conformation conducted with the standard radii showed no reopening of the salt bridge. Also encouraging was the reduced 10 kcal/mol energy drop accompanying the N→SB transition, down from 14 kcal/mol in standard GB^{HCT} (Figure 4.1a). This energy difference matches the 4 to 5 kcal/mol free energy correction visible in the GB^{HCT} 1.1 salt bridge PMF, relative to standard GB^{HCT} , and suggests that additional factors are also responsible for the excessive stability of Fab 17/9 H3 loop non-native conformations. We then took a more systematic approach that is less dependent on a correct backbone parameterization in order to characterize the influence of H^{N^+} GB radii reductions on native state stability.




Figure 4.4. Potentials of mean force for the Fab 17/9 H3 loop Arg97...Glu100 ion pair in different solvent models, at 300K. The distance coordinate is measured between C ζ of Arg97 and C δ of Glu100. See Table 4.1 for the full list of atomic radii used in GB^{HCT} and GB^{OBC}.




Figure 4.5. GB^{HCT} simulations of the Fab 17/9 H3 loop with 1.1 Å H^{N+} radii at 300K, initiated from the native X-ray (a), or SB conformations (b). Even with reduced H^{N+} radii, the X-ray loop conformation converts to SB with a 10 kcal/mol decrease in potential energy. The salt bridge, however, reopens transiently in the SB simulation. (c) Simulation from the SB state with neutralized Arg97 and Glu100 side chains and 1.1 Å H^{N+} radii. Uncharging the salt bridging side chains effectively breaks the salt bridge, but the backbone does not relax back to the native conformation.

4.3.5 Validation of Radii Modifications on Test Peptides

To assess the relevance of our radii reduction to other systems, including lysine side chains, we studied the PMFs of side chain ion pairs in small Ala-rich hexapeptides restrained in α -helical conformations. Oppositely charged side chains were spaced one α -helix turn apart (i,i+4) to create favorable salt-bridge orientations (Figure 4.6).^{286,287} For these simple systems, a stronger positional restraint (10 kcal/mol force constant) was necessary to maintain the backbone in a fully helical conformation.

These exposed salt bridges (Figure 4.6) displayed markedly reduced stabilities, compared to the Fab 17/9 H3 loop ion pair, due to the absence of a second interacting anionic side chain and the large conformational entropy of the opened state.²⁸⁸ In particular, the (i+4) Glu,Arg ion pair, directly comparable to the Fab 17/9 H3 loop ion pair, shows only a 1.2 kcal/mol barrier in TIP3P explicit solvent. This is accompanied by a \sim 4 kcal/mol decrease in the CIP-SSIP relative stability from the corresponding pair in Fab 17/9. The same qualitative trend is followed by the GB PMFs, with standard GB^{HCT} still overestimating the stability of the CIP by 2 to 2.5 kcal/mol, while GB^{HCT} 1.1 falls in close agreement with the TIP3P profile. This improvement suggests that the H^{N+} radii reduction empirically parameterized on the Fab 17/9 salt bridge can be advantageously transferred to other Arg⁺...Glu⁻ ion pair geometries.

As observed by Masunov and Lazaridis,²³⁵ the Lys⁺...Glu⁻ PMFs tend to be less pronounced, with GB PMFs following, if not accentuating this trend. The discrepancy in interaction energy between GB^{HCT} and TIP3P only fluctuates between 0.7 and 1.6 kcal/mol here, while GB^{HCT} 1.1 falls within 0.5 kcal/mol of the explicit solvent result. These PMF profiles suggest that the GB radii adjustment, while not as crucial as in the stronger Arg⁺...Glu⁻ pair, still has the potential to improve the energetics of the Lys⁺...Glu⁻ pair appreciably.




Figure 4.6. Potentials of mean force of salt bridge formation for the Ac-AEAAARA-NH₂ (left) and Ac-AEAAAKA-NH₂ (right) helical peptides in various solvent models at 300K. Error bars correspond to separately considering the first or the second half of the dataset.

4.3.6 Thermodynamical Behavior of the Trp-Cage Miniprotein.

As the Fab 17/9 H3 loop native conformation instability appeared to be a coupled salt bridge/backbone problem, we focused our validation effort on Trp-cage TC5b, a miniprotein whose fold has been successfully predicted using long molecular dynamics simulations in implicit solvent,¹¹⁶ and for which experimental thermodynamic data is available.²⁵⁸ Even with long MD simulations, there is no assurance that the thermodynamical behavior of protein chains has been sampled to convergence, as some conformational barriers are simply too high to cross on computationally accessible time scales at room temperature. Therefore, we turned ourselves to generalized ensemble techniques to evaluate the effect of our GB correction on the thermal stability of charged residue-bearing proteins. However, even generalized ensemble methods such as REMD¹³⁴ can require long simulation times to converge, that is why we focused our attention on the TC5b miniprotein construct, a small model (304 atoms), with protein-like features: a stable fold including tertiary structure and well-defined two state folding kinetics.^{258,289} The TC5b construct features an Arg⁺...Asp⁻ i/i+7 ion pair purposely introduced during the original protein design to generate a stabilizing salt bridge between these positions²⁵⁸ (Figure 4.7a). A Glu5Gln mutation was further introduced to avoid forming an unfavorable Glu-X-X-X-Asp like-charge interaction in the α -helical N-terminal segment of the construct.

Although we and others have performed folding simulations of TC5b to near NMR conformations and submitted close to experimental folding rate values,^{116,117,290} because of sampling and potential energy accuracy issues, it has proven more challenging to reproduce its full thermodynamic characteristics and in particular experimental melting profiles. The free energy landscape of folding for TC5b has been previously explored by all-atom REMD simulations both in explicit solvent with OPLS-AA²⁹¹ by Zhou¹⁴³ and implicit solvent using GB^{HCT} and the AMBER ff94¹⁰⁰ force field by Pitera and Swope.¹⁴² Both of these studies predicted significantly higher melting temperatures than the experimental value of 315K (440K in TIP3P, ~400K in the GB study), raising legitimate doubt about the ability of these force-field/solvation model combinations, parameterized for near-room temperatures, to model temperature-dependent behavior. Additionally, in the implicit solvent study, distorted hydrogen-bonding patterns in solvent-exposed regions of the miniprotein were found to cause the largest deviations from the experimental NMR restraints.¹⁴²

Two REMD simulations were performed on the TC5b construct: one in GB^{HCT} with the standard radii of AMBER8 (modified Bondi²⁴⁰), and another with H^{N+} radii set to 1.1 Å, as found optimal for the reproduction of the TIP3P salt bridge PMF in the 17/9 antibody H3 loop study. The simulations covered an extensive temperature range (267K - 715.7K) to ensure that high energy barriers did not prevent exhaustive conformational sampling.

Figure 4.8 shows the TC5b free energy landscapes at various temperatures projected on 2D contour maps using as reaction coordinates the RMSD of backbone heavy atoms in residues 3 to 18 (corresponding to the well-defined region of the 1L2Y PDB NMR

ensemble, with model #1 as reference) and the Asp9 C δ - Arg16 C ζ salt bridge distance, to highlight the importance of this ion pair in determining the overall structure of the miniprotein. The lowest free energy basin in standard GB^{HCT} at 267 K (the replica temperature nearest to 0°C, where experimentally the folded fraction is maximal²⁵⁸) comprises only non-native conformations, with a global minimum at 2.8 Å 3-18 backbone RMSD (Figure 4.7c) and an almost equiprobable ($\Delta G \sim 0.13$ kcal/mol) other minimum at 3.7 Å (Figure 4.7d). Cluster analysis on the structures comprising this unfolded basin reveals dominant, enthalpically favored ionic networks involving nearly all formally charged moieties of the miniprotein (C-terminal carboxylate, Lys8, Asp9) clustering around Arg16 (Figure 4.7c,d). Again, these formations underline the insufficient desolvation penalty incurred by charged groups in the standard GB^{HCT} model, as the NMR ensemble shows only one such ionic interaction: the Asp9 \cdots Arg16 salt bridge. In addition, the Arg16 side chain is not well resolved by the NMR assignment,¹¹⁶ suggesting ample conformational freedom, incompatible with the rigid and thermodynamically stable ionic networks observed in Figure 4.7c,d.

At 267K, while the folded region (RMSD < 2.5 Å) is 1 kcal/mol higher in free energy than the global minimum in standard GB^{HCT}, it is the lowest free energy basin in GB^{HCT} 1.1, with a free energy minimum at 1.8 Å RMSD, and 4.5 Å salt bridge distance. Structures in this basin still display most of the features of the TC5b native fold: a 2-8 helix (mainly α -helical, according to DSSP²⁹²) and a second helical segment between residues 11 and 14, with equal proportions of 3_{10} - and α -helical conformations. As a representative structure of the GB^{HCT} 1.1 267K free energy minimum ensemble shows (Figure 4.7b), the largest deviation from the NMR reference conformation (Figure 4.7a) occurs between the 3_{10} -helix and the C-terminal polyproline II segment at Ser14 and the flexible Gly15, inducing a slight shift in the location of the polyproline II helix. Nevertheless, the key hydrophobic cage motif remains well preserved, with Tyr3, Trp6, Pro12, Pro18, and Pro19 clustering nearly as well as in the NMR models. As in the NMR models, the Asp9 \cdots Arg16 salt bridge is present while the Lys8 side chain is fully solvent exposed and does not take part in intramolecular ionic interactions.

Interestingly, in standard GB^{HCT}, the salt bridge distance distribution is shifted towards longer distances by almost 0.5 Å in the low RMSD ensemble, reflecting the preferential formation of a monodentate H-bond in the near-NMR ensemble ion pair (Figure 4.7b), while in distorted low free energy structures, a bidentate interaction is favored by the recruitment of Lys8 in the ionic network (Figure 4.7c,d). The relative stability of these distorted low energy structures quickly decreases with temperature, since already at 304.5K, the folded ensemble is more stable by 0.08 kcal/mol. However, the most striking difference between the two GB parameter sets lies in the composition of their respective non-native ensembles, as in the GB^{HCT} 1.1 simulation, the unfolded state shows a nearly random distribution of ion pair distances with little residual salt bridge formed, while in standard GB^{HCT}, almost all structures have the ion pair formed (Figure 4.8).

Salt bridge formation PMFs were calculated at 304.5K from the GB1.3 and GB1.1 REMD populations and compared to one derived from a short (26 ns) REMD in TIP3P explicit solvent started from the NMR-derived conformation (Figure 4.9a). This simulation time is sufficient to effectively sample salt bridge distances in the folded state. More details on this explicit solvent REMD simulation will be published elsewhere. The

GB^{HCT} 1.1 salt bridge PMF for the native ensemble shows much improved agreement with its TIP3P counterpart, only overestimating the SSIP stability by ~0.7 kcal/mol, while standard GB^{HCT} overestimates it by as much as ~2.7 kcal/mol.

To follow the influence of ion pair strength on the overall stability of the TC5b miniprotein, we calculated the stability contribution of the salt bridge to the folding free energy, $\Delta\Delta G_F$, defined as the difference in free energy of folding of the protein with and without the salt bridge (Eq. 4.5).²⁹³ This quantity corresponds to the free energy difference between forming the salt bridge in the folded and unfolded states:

$$\begin{aligned}\Delta\Delta G_F &= \Delta G_F^{sb} - \Delta G_F^{nosb} \\ &= (G_F^{sb} - G_U^{sb}) - (G_F^{nosb} - G_U^{nosb}) \\ &= (G_U^{nosb} - G_U^{sb}) - (G_F^{nosb} - G_F^{sb})\end{aligned}\quad (4.5)$$

Therefore, assuming REMD generates a converged thermodynamic ensemble at each of the replica temperatures, $\Delta\Delta G_F$ was calculated for all REMD temperatures by:

$$\Delta\Delta G_F = -RT \ln \left(\frac{p_U^{nosb} \cdot p_F^{sb}}{p_U^{sb} \cdot p_F^{nosb}} \right) \quad (4.6)$$

where p_U and p_F stand for the unfolded and folded fractions in the absence or presence of the Asp9...Arg16 salt bridge (*nosb* and *sb* superscripts, respectively). An RMSD cutoff of 2.5 Å was adopted to define the folded state as it clearly corresponds to the peak of the barrier between native and non-native basins in the 2D PMFs (Figure 4.8). We defined salt bridged states as having an Asp9 C γ - Arg16 C ζ distance \leq 5.5 Å. This value corresponds approximately to the peak of the CIP→SSIP transition barrier in the explicit solvent salt bridge PMF (Figure 4.9a).

Figure 4.9b simultaneously shows $\Delta\Delta G_F$ and the overall folding free energy, ΔG_F , for both the standard GB^{HCT} and GB^{HCT} 1.1 REMD simulations. At 304.5K, the salt bridge stabilization of the folded state is ~1.4 kcal/mol in GB^{HCT} and ~1.8 kcal/mol in GB^{HCT} 1.1, well within the range of experimentally observed values.²⁹⁴

At low temperatures, the Asp9...Arg16 salt bridge in standard GB^{HCT}, although intrinsically stronger (Figure 4.9a), actually stabilizes the native state less than in GB^{HCT} 1.1. This phenomenon stems from the almost equally strong stabilization of non-native conformations by the salt bridge, as observed in the two compact 267K GB^{HCT} free energy minima (Figure 4.7c,d). On the contrary, past 340K, the salt bridge contributes more strongly to folded state stability in standard GB^{HCT} than in GB^{HCT} 1.1, at least partly accounting for the increased high-T stability of TC5b in standard GB^{HCT}.

Interestingly, in both GB^{HCT} and the improved GB^{HCT} 1.1 solvent models, salt bridge stabilization decreases much more slowly than the overall protein stability with increasing temperature, and remains stabilizing at elevated temperatures, providing a rationale for the increased number of ionic pairs observed in proteins from hyperthermophilic organisms.^{196,205,207-210} In addition, the GB^{HCT} model used here, with its constant water dielectric of 78.5, is expected to provide only an underestimation of salt bridge stability at high temperature, as experimentally the dielectric constant of water continuously decreases with temperature, to reach only ~55 at 100°C and 1 atm,²⁹⁵ thus favoring Coulombic interactions even more at high temperatures.²⁹⁶

Finally, still using a folding criterion of 3-18 backbone RMSD \leq 2.5 Å, it is possible to generate melting curves for TC5b in each of the GB models and compare them to

experiment (Figure 4.10). The standard GB^{HCT} yields a melting profile shifted upwards by ~30K relative to the NMR and CD experimental profiles, as reported by Pitera and Swope.¹⁴² In addition, the prevalence of enthalpically stabilized non-native structures is responsible for the drop in folded fraction at low temperature seen in the GB^{HCT} profile and even prevents reaching the melting transition midpoint (Figure 4.10). In sharp contrast, the melting temperature measured by cubic spline interpolation of the melting profile in GB^{HCT} 1.1 (314K) is in excellent agreement with the experimental value of 315 K.²⁵⁸ Furthermore, the entire simulated melting profile falls in very good overall agreement with experiment, only departing noticeably (~10% of fraction folded) from the experimental curves at extremes of the temperature range. We therefore concur with the earlier conclusions by Zhou¹⁴³ and Pitera¹⁴² that current force fields are most accurate around room temperature, where they were parameterized. This is especially true of the GB component of the energy function, which most commonly fails to include the temperature dependence of the dielectric constant. However, current force fields are expected to predict near-room temperature melting temperatures and we show here that in GB^{HCT}, this ability was only obscured by incorrectly treated ionic interactions.

As it was not necessary to parameterize the potential function against variable temperature data to capture the most important features of the melting profile and a correct T_m value, we believe that the large overapproximations of T_m by earlier REMD studies^{142,143} might originate from insufficient sampling caused by overwhelming salt bridges in GB or solvent friction in TIP3P, preventing reaching ergodicity in either case. In the Pitera and Swope study, the mostly helical TC5b native structure might also have drawn stability from the helical bias of the AMBER ff94 force field²⁹⁷ that they employed. Although Pitera and Swope employed an energy function very similar to ours (AMBER ff94/GB^{HCT}), they did not report observing the distorted structures with ionic networks we encountered in GB^{HCT}. Possible reasons for this discrepancy could be the small number of replica exchanges attempted in their protocol (400) hampering the sampling of remote regions of the folding landscape by low temperature replicas, or the excessive stability of helices in ff94 preventing formation of non-native conformations.




Figure 4.7. Trp-cage TC5b. (a) Reference NMR structure (model 1 of PDB entry 1L2Y). (b) 267K GB^{HCT} 1.1 REMD global free energy minimum, exhibiting most native like features (1.8 Å 3-18 RMSD). (c) 267K standard GB^{HCT} REMD global minimum and (d) second-lowest free energy minimum, both adopting distorted conformations (2.8 and 3.7 Å 3-18 RMSD, respectively) with multiple salt bridges, not seen in the NMR set. The protein backbone is shown in tube representation colored by secondary structure type (α : purple, 3_{10} : pink, turn: cyan, coil: white) while Trp-cage motif residue side chains are colored as in Ref. 258: Tyr3 (orange), Trp6 (magenta), Pro12 (red), Pro17 (black), Pro18 (green), Pro19 (blue). Salt bridge forming side chains are colored by atom. H-bonds between ionized side chains are indicated by orange dotted line.




Figure 4.8. Two dimensional free energy maps in kcal/mol from REMD data. Top row: GB^{HCT} replicas at 267 K (left) and 304.5 K (right). Bottom row: GB^{HCT} 1.1 replicas at corresponding temperatures. The Asp9...Arg16 salt bridge is present in nearly all GB^{HCT} conformations, while it is observed to break more frequently in GB^{HCT} 1.1, particularly for non-native conformations. The average salt bridge distance is shorter in the non-native conformations favored by GB^{HCT} . The folded ensemble, which is not the lowest energy basin at 267K, becomes progressively more stable with rising temperature in GB^{HCT} .




Figure 4.9. (a) Salt bridge formation PMFs along the Asp9 C γ – Arg16 C ζ distance coordinate for native and non-native ensembles at 304.5K from REMDs in GB with different radii sets or TIP3P water at 306K. All curves were smoothed by taking 4-point moving window averages. (b) Native state stabilization by salt bridge, $\Delta\Delta G_F$, as calculated from Eq. 4.5 (dashed lines), and folding free energy, ΔG_F (solid lines), in GB^{HCT} with 1.3 Å (red) and 1.1 Å (green) H^{N+} radii. Error bars correspond to separately considering the first or second half of the dataset.




Figure 4.10. Experimental (CD, NMR CSD)²⁵⁸ and simulated melting curves for the TC5b miniprotein. Error bars estimating the sampling uncertainty were determined by considering separately the first and second halves of the data set, each 45 ns in GB^{HCT}, and 25 ns in GB^{HCT} 1.1.

4.4 Conclusions

Simple GB models based on the pairwise descreening approximation are a popular choice for molecular simulations as they allow significant computational speedup over more accurate GB implementations or PB equation-based implicit solvent models.²⁹⁸ It is therefore important to ensure that they can achieve an adequate level of accuracy.

Using potentials of mean force, we were able to quantify the problematic over-stabilization of ionic pairs observed in the standard GB^{HCT} implementation of the AMBER package. A simple empirical reduction of the GB radii of H^{N+} atoms from 1.3 to 1.1 Å allows a close reproduction of explicit solvent CIP-SSIP relative energies in both the Fab 17/9 H3 loop Arg97...Glu100 ion pair, and test model helical peptide systems. However, in the absence of solvent discreteness, salt bridge formation remains a kinetically downhill process and therefore GB models cannot be expected to accurately reproduce the kinetics of conformational transitions. This shortcoming has started to be addressed,^{216,217} notably by explicitly including the first solvation shell around solutes in mixed explicit/implicit solvent models.²⁹⁹⁻³⁰⁵

From our preliminary results, the recent GB^{OBC} model represents a sizeable improvement in the depiction of ion pair interactions, as its PMF of the Fab 17/9 H3 loop salt bridge nearly reproduces the barrier height and CIP-SSIP relative stabilities. However, GB^{HCT} 1.1 more closely captures the TIP3P CIP-SSIP relative energy for ion pairs, at least in the peptides and small proteins that we studied. It is likely that a similar fitting of intrinsic radii could result in improved fit for GB^{OBC} as well.

By comparing experimental thermal denaturation data to REMD simulations of the Trp-cage miniprotein TC5b, we confirmed that charge-charge interactions clearly outweigh the desolvation penalty incurred by ionized side chains upon salt bridge formation in the standard GB^{HCT} model of AMBER. In sharp contrast, the same GB model with only reduced H^{N+} Born radii closely captures the thermodynamics of the Asp9...Arg16 salt bridge and for the first time allowed the generation of a near-experimental melting profile for TC5b. The GB^{HCT} 1.1 T_m value of 314 K falls in remarkable agreement with the experimental value of 315 K, while the standard GB^{HCT} profile barely approaches the melting transition midpoint and shows a majority of non-native structures at low temperature. While the GB model is expected to be capable of correctly predicting thermodynamical observables at or around room temperature, we acknowledge that our reproduction of the TC5b melting profile might be fortunate, as GB^{HCT} was not parameterized to reproduce the temperature dependence of water solvation. This study also provides further indication that strong electrostatic interactions are not predominant factors in protein native state stability, as they can stabilize non-native states by similar or even greater amounts, depending on the unfolded state topology.^{204,294} Nevertheless, from our corrected GB REMD simulation of the TC5b miniprotein, it appears that native state stabilization by ionic interactions decreases at a

slower rate than the overall protein stability with increasing temperature, providing a rationale for the observed preponderance of charged amino acid residues in the proteins of thermophilic organisms.^{196,205,207-210}

Bibliography

- (1) Stewart, B. W.; Kleihues, P. *World Cancer Report*; WHO: Geneva, **2003**.
- (2) Retting, R. A. *Cancer Crusade: The Story of the National Cancer Act of 1971*; Joseph Henry Press: Washington, **1977**.
- (3) Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant Antitumor Agents .6. Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from *Taxus-Brevifolia*. *J. Am. Chem. Soc.* **1971**, *93*, 2325-2327.
- (4) Gueritte-Voegelein, F.; Guenard, D.; Mangatal, L.; Potier, P.; Guilhem, J.; Cesario, M.; Pascard, C. Structure of a Synthetic Taxol Precursor - N-Tert-Butoxycarbonyl-10-Deacetyl-N-Debenzoyletaxol. *Acta Crystallogr. Sect. C-Cryst. Struct. Commun.* **1990**, *46*, 781-784.
- (5) Crown, J.; O'Leary, M.; Ooi, W. S. Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience. *Oncologist* **2004**, *9*, 24-32.
- (6) Crown, J.; O'Leary, M. The Taxanes: An Update. *Lancet* **2000**, *355*, 1176-1178.
- (7) Rowinsky, E. K. The Development and Clinical Utility of the Taxane Class of Antimicrotubule Chemotherapy Agents. *Annu. Rev. Med.* **1997**, *48*, 353-374.
- (8) Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of Microtubule Assembly In Vitro by Taxol. *Nature* **1979**, *277*, 665-667.
- (9) Schiff, P. B.; Horwitz, S. B. Taxol Stabilizes Microtubules in Mouse Fibroblast Cells. *Proc. Natl. Acad. Sci. USA* **1980**, *77*, 1561-1565.
- (10) Horwitz, S. B. Mechanism of Action of Taxol. *Trends Pharmacol. Sci.* **1992**, *13*, 134-136.
- (11) Yvon, A. M. C.; Wadsworth, P.; Jordan, M. A. Taxol Suppresses Dynamics of Individual Microtubules in Living Human Tumor Cells. *Mol. Biol. Cell* **1999**, *10*, 947-959.
- (12) Hardman, J. G.; Limbird, L. E.; Gilman, A. G. *Goodman & Gilman's the Pharmacological Basis of Therapeutics*; Tenth ed.; McGraw-Hill Professional: New York, **2001**.

- (13) Anonymous. Demand for Yew Tree Concerns Environmentalists. *The New York Times*, Late City Final Edition, New York, May 3 **1987**, p 29.
- (14) Chauviere, G.; Guenard, D.; Picot, F.; Senilh, V.; Potier, P. Structural-Analysis and Biochemical Study of Isolated Products of the Yew *Taxus-Baccata* L (Taxaceae). *Comptes Rendus De L' Academie Des Sciences Serie II* **1981**, *293*, 501-503.
- (15) Gueritte-Voegelein, F.; Senilh, V.; David, B.; Guenard, D.; Potier, P. Chemical Studies of 10-Deacetyl Baccatin .3. Hemisynthesis of Taxol Derivatives. *Tetrahedron* **1986**, *42*, 4451-4460.
- (16) Senilh, V.; Blechert, S.; Colin, M.; Guenard, D.; Picot, F.; Potier, P.; Varenne, P. Evidence of New Taxol Derivatives Extracted from *Taxus-Baccata*. *J. Nat. Prod.* **1984**, *47*, 131-137.
- (17) Denis, J. N.; Greene, A. E.; Guenard, D.; Gueritte-Voegelein, F.; Mangatal, L.; Potier, P. A Highly Efficient, Practical Approach to Natural Taxol. *J. Am. Chem. Soc.* **1988**, *110*, 5917-5919.
- (18) Holton, R. A. *Method for Preparation of Taxol*; European Patent Office, **1990**; EP0400971
- (19) Ojima, I. *The Organic Chemistry of β -Lactam Antibiotics*; Georg, G. I., Ed.; VCH Publishers: New York, **1992**, pp 197-255.
- (20) Ojima, I. Recent Advances in the Beta-Lactam Synthon Method. *Acc. Chem. Res.* **1995**, *28*, 383-389.
- (21) Ojima, I.; Park, Y. H.; Sun, C. M.; Brigaud, T.; Zhao, M. Z. New and Efficient Routes to Norstatine and Its Analogs with High Enantiomeric Purity by Beta-Lactam Synthon Method. *Tetrahedron Lett.* **1992**, *33*, 5737-5740.
- (22) Ojima, I.; Sun, C. M.; Zucco, M.; Park, Y. H.; Duclos, O.; Kuduk, S. A Highly Efficient Route to Taxotere by the Beta-Lactam Synthon Method. *Tetrahedron Lett.* **1993**, *34*, 4149-4152.
- (23) Ojima, I.; Zucco, M.; Duclos, O.; Kuduk, S. D.; Sun, C. M.; Park, Y. H. N-Acyl-3-Hydroxy-Beta-Lactams as Key Intermediates for Taxotere and Its Analogs. *Bioorg. Med. Chem. Lett.* **1993**, *3*, 2479-2482.
- (24) Nicolaou, K. C.; Dai, W. M.; Guy, R. K. Chemistry and Biology of Taxol. *Angew. Chem.-Int. Edit. Engl.* **1994**, *33*, 15-44.

- (25) Georg, G. I.; Chen, T. T.; Ojima, I.; Vyas, D. M. *Taxane Anticancer Agents: Basic Science and Current Status*; American Chemical Society: Washington D.C., **1995**; Vol. 583.
- (26) Suffness, M. *Taxol: Science and Applications*; CRC Press: New York, **1995**.
- (27) Christen, A. A.; M., G. D.; Bland, J. *Production of Taxol or Taxol-Like Compounds in Cell Culture*; United States Patent Office, USA, **1991**; 5,019,504
- (28) Ritter, S. K. In *Chemical & Engineering News*: Washington, **2004**; Vol. 82, pp 25-30.
- (29) Fuchs, D. A.; Johnson, R. K. Cytologic Evidence That Taxol, an Anti-Neoplastic Agent from *Taxus-Brevifolia*, Acts as a Mitotic Spindle Poison. *Cancer Treatment Reports* **1978**, *62*, 1219-1222.
- (30) Hamel, E.; Delcampo, A. A.; Lowe, M. C.; Lin, C. M. Interactions of Taxol, Microtubule-Associated Proteins, and Guanine-Nucleotides in Tubulin Polymerization. *J. Biol. Chem.* **1981**, *256*, 1887-1894.
- (31) Schiff, P. B.; Horwitz, S. B. Taxol Assembles Tubulin in the Absence of Exogenous Guanosine 5'-Triphosphate or Microtubule-Associated Proteins. *Biochemistry* **1981**, *20*, 3247-3252.
- (32) Herman, B.; Langevin, M. A.; Albertini, D. F. The Effects of Taxol on the Organization of the Cytoskeleton in Cultured Ovarian Granulosa-Cells. *Eur. J. Cell Biol.* **1983**, *31*, 34-45.
- (33) Rowinsky, E. K.; Donehower, R. C.; Jones, R. J.; Tucker, R. W. Microtubule Changes and Cyto-Toxicity in Leukemic Cell Lines Treated with Taxol. *Cancer Res.* **1988**, *48*, 4093-4100.
- (34) Torres, K.; Horwitz, S. B. Mechanisms of Taxol-Induced Cell Death Are Concentration Dependent. *Cancer Res.* **1998**, *58*, 3620-3626.
- (35) Haldar, S.; Jena, N.; Croce, C. M. Inactivation of Bcl-2 by Phosphorylation. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 4507-4511.
- (36) Haldar, S.; Chintapalli, J.; Croce, C. M. Taxol Induces Bcl-2 Phosphorylation and Death of Prostate Cancer Cells. *Cancer Res.* **1996**, *56*, 1253-1255.
- (37) Haldar, S.; Basu, A.; Croce, C. M. Bcl2 Is the Guardian of Microtubule Integrity. *Cancer Res.* **1997**, *57*, 229-233.

- (38) Haldar, S.; Basu, A.; Croce, C. M. Serine-70 Is One of the Critical Sites for Drug-Induced Bcl2 Phosphorylation in Cancer Cells. *Cancer Res.* **1998**, *58*, 1609-1615.
- (39) Makhija, S.; Taylor, D. D.; Gibb, R. K.; Gercel-Taylor, C. Taxol-Induced Bcl-2 Phosphorylation in Ovarian Cancer Cell Monolayer and Spheroids. *Int. J. Oncol.* **1999**, *14*, 515-521.
- (40) Rodi, D. J.; Janes, R. W.; Sanganee, H. J.; Holton, R. A.; Wallace, B. A.; Makowski, L. Screening of a Library of Phage-Displayed Peptides Identifies Human Bcl-2 as a Taxol Binding Protein. *J. Mol. Biol.* **1999**, *285*, 197-203.
- (41) Srivastava, R. K.; Mi, Q. S.; Hardwick, J. M.; Longo, D. L. Deletion of the Loop Region of Bcl-2 Completely Blocks Paclitaxel-Induced Apoptosis. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 3775-3780.
- (42) Sato, T.; Hanada, M.; Bodrug, S.; Irie, S. J.; Iwama, N.; Boise, L. H.; Thompson, C. B.; Golemis, E.; Fong, L.; Wang, H. G.; Reed, J. C. Interactions among Members of the Bcl-2 Protein Family Analyzed with a Yeast 2-Hybrid System. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 9238-9242.
- (43) Ding, A. H.; Porteu, F.; Sanchez, E.; Nathan, C. F. Shared Actions of Endotoxin and Taxol on TNF Receptors and TNF Release *Science* **1990**, *248*, 370-372.
- (44) Burkhart, C. A.; Berman, J. W.; Swindell, C. S.; Horwitz, S. B. Relationship between the Structure of Taxol and Other Taxanes on Induction of Tumor-Necrosis-Factor-Alpha Gene-Expression and Cytotoxicity. *Cancer Res.* **1994**, *54*, 5779-5782.
- (45) Byrd, C. A.; Bornmann, W.; Erdjument-Bromage, H.; Tempst, P.; Pavletich, N.; Rosen, N.; Nathan, C. F.; Ding, A. Heat Shock Protein 90 Mediates Macrophage Activation by Taxol and Bacterial Lipopolysaccharide. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 5645-5650.
- (46) Ding, A.; Sanchez, E.; Nathan, C. F. Taxol Shares the Ability of Bacterial Lipopolysaccharide to Induce Tyrosine Phosphorylation of Microtubule-Associated Protein-Kinase. *J. Immunol.* **1993**, *151*, 5596-5602.
- (47) Ball, E. H.; Singer, S. J. Mitochondria Are Associated with Microtubules and Not with Intermediate Filaments in Cultured Fibroblasts. *Proc. Natl. Acad. Sci. USA* **1982**, *79*, 123-126.
- (48) Cooper, M. S.; Cornellbell, A. H.; Chernjavsky, A.; Dani, J. W.; Smith, S. J. Tubulovesicular Processes Emerge from Trans-Golgi Cisternae, Extend Along

- Microtubules, and Interlink Adjacent Trans-Golgi Elements into a Reticulum. *Cell* **1990**, *61*, 135-145.
- (49) Scholey, J. M.; Porter, M. E.; Grissom, P. M.; McIntosh, J. R. Identification of Kinesin in Sea-Urchin Eggs, and Evidence for Its Localization in the Mitotic Spindle. *Nature* **1985**, *318*, 483-486.
- (50) Porter, M. E.; Johnson, K. A. Dynein Structure and Function. *Annu. Rev. Cell Biol.* **1989**, *5*, 119-151.
- (51) Welte, M. A. Bidirectional Transport Along Microtubules. *Curr. Biol.* **2004**, *14*, R525-R537.
- (52) Haimo, L. T.; Rosenbaum, J. L. Dynein Binding to Microtubules Containing Microtubule-Associated Proteins. *Cell Motil. Cytoskeleton* **1981**, *1*, 499-516.
- (53) Joshi, H. C. Gamma-Tubulin - the Hub of Cellular Microtubule Assemblies. *Bioessays* **1993**, *15*, 637-643.
- (54) Song, Y. H.; Mandelkow, E. The Anatomy of Flagellar Microtubules - Polarity, Seam, Junctions, and Lattice. *J. Cell Biol.* **1995**, *128*, 81-94.
- (55) McIntosh, J. R.; Pfarr, C. M. Mitotic Motors. *J. Cell Biol.* **1991**, *115*, 577-585.
- (56) Gorbsky, G. J. Chromosome Motion in Mitosis. *Bioessays* **1992**, *14*, 73-80.
- (57) Gadde, S.; Heald, R. Mechanisms and Molecules of the Mitotic Spindle. *Curr. Biol.* **2004**, *14*, R797-R805.
- (58) Hamel, E. Antimitotic Natural Products and Their Interactions with Tubulin. *Med. Res. Rev.* **1996**, *16*, 207-231.
- (59) Oakley, C. E.; Oakley, B. R. Identification of Gamma-Tubulin, a New Member of the Tubulin Superfamily Encoded by mipA Gene of *Aspergillus-Nidulans*. *Nature* **1989**, *338*, 662-664.
- (60) Schiebel, E. Gamma-Tubulin Complexes: Binding to the Centrosome, Regulation and Microtubule Nucleation. *Curr. Opin. Cell Biol.* **2000**, *12*, 113-118.
- (61) Mitchison, T.; Kirschner, M. Dynamic Instability of Microtubule Growth. *Nature* **1984**, *312*, 237-242.

- (62) Walker, R. A.; Inoue, S.; Salmon, E. D. Asymmetric Behavior of Severed Microtubule Ends after Ultraviolet Microbeam Irradiation of Individual Microtubules In Vitro. *J. Cell Biol.* **1989**, *108*, 931-937.
- (63) Weisenberg, R. C.; Deery, W. J. Role of Nucleotide Hydrolysis in Microtubule Assembly. *Nature* **1976**, *263*, 792-793.
- (64) David-Pfeuty, T.; Erickson, H. P.; Pantaloni, D. GTPase Activity of Tubulin Associated with Microtubule Assembly. *J. Cell Biol.* **1977**, *75*, A273-A273.
- (65) Spiegelman, B. M.; Penningroth, S. M.; Kirschner, M. W. Turnover of Tubulin and N Site GTP in Chinese-Hamster Ovary Cells. *Cell* **1977**, *12*, 587-600.
- (66) Caplow, M.; Ruhlen, R.; Shanks, J.; Walker, R. A.; Salmon, E. D. Stabilization of Microtubules by Tubulin GDP-Pi Subunits. *Biochemistry* **1989**, *28*, 8136-8141.
- (67) Mandelkow, E. M.; Mandelkow, E.; Milligan, R. A. Microtubule Dynamics and Microtubule Caps - a Time-Resolved Cryoelectron Microscopy Study. *J. Cell Biol.* **1991**, *114*, 977-991.
- (68) Wang, H. W.; Nogales, E. Nucleotide-Dependent Bending Flexibility of Tubulin Regulates Microtubule Assembly. *Nature* **2005**, *435*, 911-915.
- (69) Parysek, L. M.; Wolosewick, J. J.; Olmsted, J. B. MAP-4 - a Microtubule-Associated Protein Specific for a Subset of Tissue Microtubules. *J. Cell Biol.* **1984**, *99*, 2287-2296.
- (70) Panda, D.; Goode, B. L.; Feinstein, S. C.; Wilson, L. Kinetic Stabilization of Microtubule Dynamics at Steady-State by Tau and Microtubule-Binding Domains of Tau. *Biochemistry* **1995**, *34*, 11117-11127.
- (71) Belmont, L. D.; Mitchison, T. J. Identification of a Protein That Interacts with Tubulin Dimers and Increases the Catastrophe Rate of Microtubules. *Cell* **1996**, *84*, 623-631.
- (72) Walczak, C. E.; Mitchison, T. J.; Desai, A. XKCM1: A Xenopus Kinesin-Related Protein That Regulates Microtubule Dynamics During Mitotic Spindle Assembly. *Cell* **1996**, *84*, 37-47.
- (73) Venier, P.; Maggs, A. C.; Carrier, M. F.; Pantaloni, D. Analysis of Microtubule Rigidity Using Hydrodynamic Flow and Thermal Fluctuations. *J. Biol. Chem.* **1994**, *269*, 13353-13360.

- (74) Amos, L. A. Microtubule Structure and Its Stabilisation. *Org. Biomol. Chem.* **2004**, *2*, 2153-2160.
- (75) Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a New Class of Microtubule-Stabilizing Agents with a Taxol-Like Mechanism of Action. *Cancer Res.* **1995**, *55*, 2325-2333.
- (76) Haar, E.; Kowalski, R.; Hamel, E.; C., L.; Longley, R. E.; Gunnasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Discodermolide, a Cytotoxic Marine Agent That Stabilizes Microtubules More Potently Than Taxol. *Biochemistry* **1996**, *35*, 243-250.
- (77) Long, B. H.; Carboni, J. M.; Wasserman, A. J.; Cornell, L. A.; Casazza, A. M.; Jensen, P. R.; Lindel, T.; Fenical, W.; Fairchild, C. R. Eleutherobin, a Novel Cytotoxic Agent That Induces Tubulin Polymerization, Is Similar to Paclitaxel. *Cancer Res.* **1998**, *58*, 1111-1115.
- (78) Hamel, E.; Sackett, D. L.; Vourloumis, D.; Nicolaou, K. C. The Coral-Derived Natural Products Eleutherobin and Sarcodictyins a and B: Effects on the Assembly of Purified Tubulin with and without Microtubule-Associated Proteins and Binding at the Polymer Taxoid Site. *Biochemistry* **1999**, *38*, 3490-3498.
- (79) Altmann, K. H. Microtubule-Stabilizing Agents: A Growing Class of Important Anticancer Drugs. *Curr. Opin. Chem. Biol.* **2001**, *5*, 424-431.
- (80) Dhamodharan, R.; Jordan, M. A.; Thrower, D.; Wilson, L.; Wadsworth, P. Vinblastine Suppresses Dynamics of Individual Microtubules in Living Interphase Cells. *Mol. Biol. Cell* **1995**, *6*, 1215-1229.
- (81) Derry, W. B.; Wilson, L.; Jordan, M. A. Substoichiometric Binding of Taxol Suppresses Microtubule Dynamics. *Biochemistry* **1995**, *34*, 2203-2211.
- (82) Tilney, L. G.; Bryan, J.; Bush, D. J.; Fujiwara, K.; Mooseker, M. S.; Murphy, D. B.; Snyder, D. H. Microtubules - Evidence for 13 Protofilaments. *J. Cell Biol.* **1973**, *59*, 267-275.
- (83) Wade, R. H.; Hyman, A. A. Microtubule Structure and Dynamics. *Curr. Opin. Cell Biol.* **1997**, *9*, 12-17.
- (84) Andreu, J. M.; Diaz, J. F.; Gil, R.; Depereda, J. M.; Delacoba, M. G.; Peyrot, V.; Briand, C.; Townsandrews, E.; Bordas, J. Solution Structure of Taxotere-Induced

Microtubules to 3 nm Resolution - the Change in Protofilament Number Is Linked to the Binding of the Taxol Side-Chain. *J. Biol. Chem.* **1994**, *269*, 31785-31792.

- (85) Mandelkow, E. M.; Schultheiss, R.; Rapp, R.; Muller, M.; Mandelkow, E. On the Surface Lattice of Microtubules - Helix Starts, Protofilament Number, Seam, and Handedness. *J. Cell Biol.* **1986**, *102*, 1067-1073.
- (86) Burns, R. G. Alpha-Tubulin, Beta-Tubulin, and Gamma-Tubulins - Sequence Comparisons and Structural Constraints. *Cell Motil. Cytoskeleton* **1991**, *20*, 181-189.
- (87) Nogales, E.; Wolf, S. G.; Downing, K. H. Structure of the $\alpha\beta$ Tubulin Dimer by Electron Crystallography. *Nature* **1998**, *391*, 199-203.
- (88) Loewe, J.; Li, H.; Downing, K. H.; Nogales, E. Refined Structure of $\alpha\beta$ -Tubulin at 3.5 Å Resolution. *J. Mol. Biol.* **2001**, *313*, 1045-1057.
- (89) Nogales, E.; Whittaker, M.; Milligan, R. A.; Downing, K. H. High-Resolution Model of the Microtubule. *Cell* **1999**, *96*, 79-88.
- (90) Li, H. L.; De Rosier, D. J.; Nicholson, W. V.; Nogales, E.; Downing, K. H. Microtubule Structure at 8 Å Resolution. *Structure* **2002**, *10*, 1317-1328.
- (91) Sage, C. R.; Dougherty, C. A.; Davis, A. S.; Burns, R. G.; Wilson, L.; Farrell, K. W. Site-Directed Mutagenesis of Putative GTP-Binding Sites of Yeast Beta-Tubulin - Evidence That Alpha-Tubulins, Beta-Tubulins, and Gamma-Tubulins Are Atypical GTPases. *Biochemistry* **1995**, *34*, 7409-7419.
- (92) Hyman, A. A.; Chretien, D.; Arnal, I.; Wade, R. H. Structural-Changes Accompanying GTP Hydrolysis in Microtubules - Information from a Slowly Hydrolyzable Analog Guanylyl-(Alpha,Beta)-Methylene-Diphosphonate. *J. Cell Biol.* **1995**, *128*, 117-125.
- (93) Caplow, M.; Ruhlen, R. L.; Shanks, J. The Free-Energy for Hydrolysis of a Microtubule-Bound Nucleotide Triphosphate Is near Zero - All of the Free-Energy for Hydrolysis Is Stored in the Microtubule Lattice. *J. Cell Biol.* **1994**, *127*, 779-788.
- (94) Reijo, R. A.; Cooper, E. M.; Beagle, G. J.; Huffaker, T. C. Systematic Mutational Analysis of the Yeast Beta-Tubulin Gene. *Mol. Biol. Cell* **1994**, *5*, 29-43.

- (95) dePereda, J. M.; Andreu, J. M. Mapping Surface Sequences of the Tubulin Dimer and Taxol-Induced Microtubules with Limited Proteolysis. *Biochemistry* **1996**, *35*, 14184-14202.
- (96) Dai, K.; Mukherjee, A.; Xu, Y. F.; Lutkenhaus, J. Mutations in FtsZ That Confer Resistance to SulA Affect the Interaction of FtsZ with GTP. *J. Bacteriol.* **1994**, *176*, 130-136.
- (97) Kar, S.; Fan, J.; Smith, M. J.; Goedert, M.; Amos, L. A. Repeat Motifs of Tau Bind to the Insides of Microtubules in the Absence of Taxol. *Embo J.* **2003**, *22*, 70-77.
- (98) Bai, R. L.; Covell, D. G.; Pei, X. F.; Ewell, J. B.; Nguyen, N. Y.; Brossi, A.; Hamel, E. Mapping the Binding Site of Colchicinoids on Beta-Tubulin - 2-Chloroacetyl-2-Demethylthiocolchicine Covalently Reacts Predominantly with Cysteine 239 and Secondarily with Cysteine 354. *J. Biol. Chem.* **2000**, *275*, 40443-40452.
- (99) Ermer, O. Calculation of Molecular Properties Using Force Fields. Applications in Organic Chemistry. *Structure and Bonding* **1976**, *27*, 161-211.
- (100) Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A 2nd Generation Force-Field for the Simulation of Proteins, Nucleic-Acids, and Organic-Molecules. *J. Am. Chem. Soc.* **1995**, *117*, 5179-5197.
- (101) Dauber-Osguthorpe, P.; Roberts, V. A.; Osguthorpe, D. J.; Wolff, J.; Genest, M.; Hagler, A. T. Structure and Energetics of Ligand-Binding to Proteins - Escherichia-Coli Dihydrofolate Reductase Trimethoprim, a Drug-Receptor System. *Proteins* **1988**, *4*, 31-47.
- (102) Bayly, C. I.; Cieplak, P.; Cornell, W. D.; Kollman, P. A. A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges - the RESP Model. *J. Phys. Chem.* **1993**, *97*, 10269-10280.
- (103) Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Kollman, P. A. Application of RESP Charges to Calculate Conformational Energies, Hydrogen-Bond Energies, and Free-Energies of Solvation. *J. Am. Chem. Soc.* **1993**, *115*, 9620-9631.
- (104) Halgren, T. A.; Damm, W. Polarizable Force Fields. *Curr. Opin. Struct. Biol.* **2001**, *11*, 236-242.

- (105) Ponder, J. W.; Case, D. A. Force Fields for Protein Simulations. In *Advances in Protein Chemistry, Protein Simulations*, **2003**; Vol. 66, pp 27-85.
- (106) Mackerell, A. D. Empirical Force Fields for Biological Macromolecules: Overview and Issues. *J. Comput. Chem.* **2004**, *25*, 1584-1604.
- (107) Wang, J. M.; Cieplak, P.; Kollman, P. A. How Well Does a Restrained Electrostatic Potential (RESP) Model Perform in Calculating Conformational Energies of Organic and Biological Molecules? *J. Comput. Chem.* **2000**, *21*, 1049-1074.
- (108) Garcia, A. E.; Sanbonmatsu, K. Y. Alpha-Helical Stabilization by Side Chain Shielding of Backbone Hydrogen Bonds. *Proc. Natl. Acad. Sci. U. S. A.* **2002**, *99*, 2782-2787.
- (109) Okur, A.; Strockbine, B.; Hornak, V.; Simmerling, C. Using PC Clusters to Evaluate the Transferability of Molecular Mechanics Force Fields for Proteins. *J. Comput. Chem.* **2003**, *24*, 21-31.
- (110) Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G. M.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J. M.; Kollman, P. A Point-Charge Force Field for Molecular Mechanics Simulations of Proteins Based on Condensed-Phase Quantum Mechanical Calculations. *J. Comput. Chem.* **2003**, *24*, 1999-2012.
- (111) Yoda, T.; Sugita, Y.; Okamoto, Y. Secondary-Structure Preferences of Force Fields for Proteins Evaluated by Generalized-Ensemble Simulations. *Chem. Phys.* **2004**, *307*, 269-283.
- (112) Sakae, Y.; Okamoto, Y. Protein Force-Field Parameters Optimized with the Protein Data Bank. I. Force-Field Optimizations. *J. Theor. Comput. Chem.* **2004**, *3*, 339-358.
- (113) Sakae, Y.; Okamoto, Y. Protein Force-Field Parameters Optimized with the Protein Data Bank. II. Comparisons of Force Fields by Folding Simulations of Short Peptides. *J. Theor. Comput. Chem.* **2004**, *3*, 359-378.
- (114) Sorin, E. J.; Pande, V. S. Empirical Force-Field Assessment: The Interplay between Backbone Torsions and Noncovalent Term Scaling. *J. Comput. Chem.* **2005**, *26*, 682-690.
- (115) Beachy, M. D.; Chasman, D.; Murphy, R. B.; Halgren, T. A.; Friesner, R. A. Accurate Ab Initio Quantum Chemical Determination of the Relative Energetics

of Peptide Conformations and Assessment of Empirical Force Fields. *J. Am. Chem. Soc.* **1997**, *119*, 5908-5920.

- (116) Simmerling, C.; Strockbine, B.; Roitberg, A. E. All-Atom Structure Prediction and Folding Simulations of a Stable Protein. *J. Am. Chem. Soc.* **2002**, *124*, 11258-11259.
- (117) Chowdhury, S.; Lee, M. C.; Xiong, G. M.; Duan, Y. Ab Initio Folding Simulation of the Trp-Cage Mini-Protein Approaches NMR Resolution. *J. Mol. Biol.* **2003**, *327*, 711-717.
- (118) Jacobson, M. P.; Kaminski, G. A.; Friesner, R. A.; Rapp, C. S. Force Field Validation Using Protein Side Chain Prediction. *J. Phys. Chem. B* **2002**, *106*, 11673-11680.
- (119) Fletcher, R.; Reeves, C. M. Function Minimization by Conjugate Gradients. *Comput. J.* **1964**, *7*, 149-&.
- (120) Verlet, L. Computer Experiments on Classical Fluids .I. Thermodynamical Properties of Lennard-Jones Molecules. *Physical Review* **1967**, *159*, 98-103.
- (121) Hokney, R. W. The Potential Calculation and Some Applications. *Method. Comput. Phys.* **1970**, *9*, 136-211.
- (122) Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical-Integration of Cartesian Equations of Motion of a System with Constraints - Molecular-Dynamics of N-Alkanes. *J. Comput. Phys.* **1977**, *23*, 327-341.
- (123) Andersen, H. C. Rattle - a Velocity Version of the Shake Algorithm for Molecular-Dynamics Calculations. *J. Comput. Phys.* **1983**, *52*, 24-34.
- (124) Miyamoto, S.; Kollman, P. A. Settle - an Analytical Version of the Shake and Rattle Algorithm for Rigid Water Models. *J. Comput. Chem.* **1992**, *13*, 952-962.
- (125) Hess, B.; Bekker, H.; Berendsen, H. J. C.; Fraaije, J. Lincs: A Linear Constraint Solver for Molecular Simulations. *J. Comput. Chem.* **1997**, *18*, 1463-1472.
- (126) McCammon, J. A.; Gelin, B. R.; Karplus, M. Dynamics of Folded Proteins. *Nature* **1977**, *267*, 585-590.
- (127) Pitman, M. C.; Grossfield, A.; Suits, F.; Feller, S. E. Role of Cholesterol and Polyunsaturated Chains in Lipid-Protein Interactions: Molecular Dynamics

- Simulation of Rhodopsin in a Realistic Membrane Environment. *J. Am. Chem. Soc.* **2005**, *127*, 4576-4577.
- (128) Duan, Y.; Kollman, P. A. Pathways to a Protein Folding Intermediate Observed in a 1-Microsecond Simulation in Aqueous Solution. *Science* **1998**, *282*, 740-744.
- (129) Metropolis, N.; Rosenbluth, A. W.; Rosenbluth, M. N.; Teller, A. H.; Teller, E. Equation of State Calculations by Fast Computing Machines. *J. Chem. Phys.* **1953**, *21*, 1087-1092.
- (130) Straub, J. E.; Rashkin, A. B.; Thirumalai, D. Dynamics in Rugged Energy Landscapes with Applications to the S-Peptide and Ribonuclease-A. *J. Am. Chem. Soc.* **1994**, *116*, 2049-2063.
- (131) Wolynes, P. G.; Onuchic, J. N.; Thirumalai, D. Navigating the Folding Routes. *Science* **1995**, *267*, 1619-1620.
- (132) Berne, B. J.; Straub, J. E. Novel Methods of Sampling Phase Space in the Simulation of Biological Systems. *Curr. Opin. Struct. Biol.* **1997**, *7*, 181-189.
- (133) Okamoto, Y. Generalized-Ensemble Algorithms: Enhanced Sampling Techniques for Monte Carlo and Molecular Dynamics Simulations. *J. Mol. Graph.* **2004**, *22*, 425-439.
- (134) Sugita, Y.; Okamoto, Y. Replica-Exchange Molecular Dynamics Method for Protein Folding. *Chem. Phys. Lett.* **1999**, *314*, 141-151.
- (135) Hansmann, U. H. E. Parallel Tempering Algorithm for Conformational Studies of Biological Molecules. *Chem. Phys. Lett.* **1997**, *281*, 140-150.
- (136) Irback, A.; Sandelin, E. Monte Carlo Study of the Phase Structure of Compact Polymer Chains. *J. Chem. Phys.* **1999**, *110*, 12256-12262.
- (137) Garcia, A. E.; Sanbonmatsu, K. Y. Exploring the Energy Landscape of a Beta Hairpin in Explicit Solvent. *Proteins* **2001**, *42*, 345-354.
- (138) Zhou, R. H.; Berne, B. J.; Germain, R. The Free Energy Landscape for Beta Hairpin Folding in Explicit Water. *Proc. Natl. Acad. Sci. U. S. A.* **2001**, *98*, 14931-14936.
- (139) Sanbonmatsu, K. Y.; Garcia, A. E. Structure of Met-Enkephalin in Explicit Aqueous Solution Using Replica Exchange Molecular Dynamics. *Proteins* **2002**, *46*, 225-234.

- (140) Zhou, R. H.; Berne, B. J. Can a Continuum Solvent Model Reproduce the Free Energy Landscape of a Beta-Hairpin Folding in Water? *Proc. Natl. Acad. Sci. U. S. A.* **2002**, *99*, 12777-12782.
- (141) Bratko, D.; Blanch, H. W. Effect of Secondary Structure on Protein Aggregation: A Replica Exchange Simulation Study. *J. Chem. Phys.* **2003**, *118*, 5185-5194.
- (142) Pitera, J. W.; Swope, W. Understanding Folding and Design: Replica-Exchange Simulations of "Trp-Cage" Miniproteins. *Proc. Natl. Acad. Sci. U. S. A.* **2003**, *100*, 7587-7592.
- (143) Zhou, R. H. Trp-Cage: Folding Free Energy Landscape in Explicit Water. *Proc. Natl. Acad. Sci. U. S. A.* **2003**, *100*, 13280-13285.
- (144) Nymeyer, H.; Gnanakaran, S.; Garcia, A. E. Atomic Simulations of Protein Folding, Using the Replica Exchange Algorithm. In *Methods in Enzymology Numerical Computer Methods, Pt D*, **2004**; Vol. 383, pp 119-149.
- (145) Lin, S.; Ojima, I. Recent Strategies in the Development of Taxane Anticancer Drugs. *Expert Opin. Ther. Patents* **2000**, *10*, 869-889.
- (146) Gueritte, F. General and Recent Aspects of the Chemistry and Structure-Activity Relationships of Taxoids. *Curr. Pharm. Design* **2001**, *7*, 1229-1249.
- (147) Dubois, J.; Guenard, D.; Gueritte, F. Recent Developments in Antitumour Taxoids. *Expert Opin. Ther. Patents* **2003**, *13*, 1809-1823.
- (148) Ojima, I.; Kuduk, S. D.; Chakravarty, S.; Ourevitch, M.; Begue, J. P. A Novel Approach to the Study of Solution Structures and Dynamic Behavior of Paclitaxel and Docetaxel Using Fluorine-Containing Analogs as Probes. *J. Am. Chem. Soc.* **1997**, *119*, 5519-5527.
- (149) Ojima, I.; Inoue, T.; Chakravarty, S. Enantiopure Fluorine-Containing Taxoids: Potent Anticancer Agents and Versatile Probes for Biomedical Problems. *J. Fluor. Chem.* **1999**, *97*, 3-10.
- (150) Li, Y. K.; Poliks, B.; Cegelski, L.; Poliks, M.; Gryczynski, Z.; Piszczek, G.; Jagtap, P. G.; Studelska, D. R.; Kingston, D. G. I.; Schaefer, J.; Bane, S. Conformation of Microtubule-Bound Paclitaxel Determined by Fluorescence Spectroscopy and REDOR NMR. *Biochemistry* **2000**, *39*, 281-291.

- (151) Rao, S.; Krauss, N. E.; Heerding, J. M.; Swindell, C. S.; Ringel, I.; Orr, G. A.; Horwitz, S. B. 3'-(p-Azidobenzamido)Taxol Photolabels the N-Terminal 31 Amino- Acids of Beta-Tubulin. *J. Biol. Chem.* **1994**, *269*, 3132-3134.
- (152) Rao, S.; Orr, G. A.; Chaudhary, A. G.; Kingston, D. G. I.; Horwitz, S. B. Characterization of the Taxol Binding-Site on the Microtubule - 2-(m-Azidobenzoyl)Taxol Photolabels a Peptide (Amino-Acids 217- 231) of Beta-Tubulin. *J. Biol. Chem.* **1995**, *270*, 20235-20238.
- (153) Rao, S.; He, L. F.; Chakravarty, S.; Ojima, I.; Orr, G. A.; Horwitz, S. B. Characterization of the Taxol Binding Site on the Microtubule - Identification of Arg(282) in Beta-Tubulin as the Site of Photoincorporation of a 7-Benzophenone Analogue of Taxol. *J. Biol. Chem.* **1999**, *274*, 37990-37994.
- (154) Ojima, I.; Chakravarty, S.; Inoue, T.; Lin, S. N.; He, L. F.; Horwitz, S. B.; Kuduk, S. D.; Danishefsky, S. J. A Common Pharmacophore for Cytotoxic Natural Products That Stabilize Microtubules. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 4256-4261.
- (155) Snyder, J. P.; Nettles, J.; Cornett, B.; Downing, K. H.; Nogales, E. The Binding Conformation of Taxol in Beta-Tubulin: A Model Based on Electron Crystallographic Density. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 5312-5316.
- (156) Giannakakou, P.; Gussio, R.; Nogales, E.; Downing, K. H.; Zaharevitz, D.; Bollbuck, B.; Poy, G.; Sackett, D.; Nicolaou, K. C.; Fojo, T. A Common Pharmacophore for Epothilone and Taxanes: Molecular Basis for Drug Resistance Conferred by Tubulin Mutations in Human Cancer Cells. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 2904-2909.
- (157) Mastropaolo, D.; Camerman, A.; Luo, Y. G.; Brayer, G. D.; Camerman, N. Crystal and Molecular-Structure of Paclitaxel (Taxol). *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 6920-6924.
- (158) Chang, G.; Guida, W. C.; Still, W. C. An Internal Coordinate Monte-Carlo Method for Searching Conformational Space. *J. Am. Chem. Soc.* **1989**, *111*, 4379-4386.
- (159) Saunders, M.; Houk, K. N.; Wu, Y. D.; Still, W. C.; Lipton, M.; Chang, G.; Guida, W. C. Conformations of Cycloheptadecane - a Comparison of Methods for Conformational Searching. *J. Am. Chem. Soc.* **1990**, *112*, 1419-1427.
- (160) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel - an Integrated

Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. *J. Comput. Chem.* **1990**, *11*, 440-467.

- (161) Allinger, N. L.; Yuh, Y. H.; Lii, J. H. Molecular Mechanics - the MM3 Force-Field for Hydrocarbons .1. *J. Am. Chem. Soc.* **1989**, *111*, 8551-8566.
- (162) Lii, J. H.; Allinger, N. L. Molecular Mechanics - the MM3 Force-Field for Hydrocarbons .2. Vibrational Frequencies and Thermodynamics. *J. Am. Chem. Soc.* **1989**, *111*, 8566-8575.
- (163) Lii, J. H.; Allinger, N. L. Molecular Mechanics - the MM3 Force-Field for Hydrocarbons .3. The van der Waals Potentials and Crystal Data for Aliphatic and Aromatic-Hydrocarbons. *J. Am. Chem. Soc.* **1989**, *111*, 8576-8582.
- (164) Williams, H. J.; Scott, A. I.; Dieden, R. A.; Swindell, C. S.; Chirlian, L. E.; Francl, M. M.; Heerding, J. M.; Krauss, N. E. NMR and Molecular Modeling Study of the Conformations of Taxol and of Its Side-Chain Methylene in Aqueous and Nonaqueous Solution. *Tetrahedron* **1993**, *49*, 6545-6560.
- (165) Dubois, J.; Guenard, D.; Gueritte-Voegelein, F.; Guedira, N.; Potier, P.; Gillet, B.; Beloeil, J. C. Conformation of Taxotere(R) and Analogs Determined by NMR Spectroscopy and Molecular Modeling Studies. *Tetrahedron* **1993**, *49*, 6533-6544.
- (166) Vandervelde, D. G.; Georg, G. I.; Grunewald, G. L.; Gunn, G. W.; Mitscher, L. A. Hydrophobic Collapse of Taxol and Taxotere Solution Conformations in Mixtures of Water and Organic-Solvent. *J. Am. Chem. Soc.* **1993**, *115*, 11650-11651.
- (167) Nicklaus, M. C.; Wang, S. M.; Driscoll, J. S.; Milne, G. W. A. Conformational Changes of Small Molecules Binding to Proteins. *Bioorg. Med. Chem.* **1995**, *3*, 411-428.
- (168) Rao, S.; Horwitz, S. B.; Ringel, I. Direct Photoaffinity-Labeling of Tubulin with Taxol. *J. Natl Cancer Inst.* **1992**, *84*, 785-788.
- (169) Dorman, G.; Prestwich, G. D. Benzophenone Photophores in Biochemistry. *Biochemistry* **1994**, *33*, 5661-5673.
- (170) Geng, X.; Miller, M. L.; Lin, S.; Ojima, I. Synthesis of Novel C2-C3'N-Linked Macrocyclic Taxoids by Means of Highly Regioselective Heck Macrocyclization. *Org. Lett.* **2003**, *5*, 3733-3736.

- (171) Boge, T. C.; Himes, R. H.; Vandervelde, D. G.; Georg, G. I. The Effect of the Aromatic Rings of Taxol on Biological Activity and Solution Conformation Synthesis and Evaluation of Saturated Taxol and Taxotere Analogs. *J. Med. Chem.* **1994**, *37*, 3337-3343.
- (172) Georg, G. I.; Harriman, G. C. B.; Hepperle, M.; Clowers, J. S.; VanderVelde, D. G.; Himes, R. H. Synthesis, Conformational Analysis, and Biological Evaluation of Heteroaromatic Taxanes. *J. Org. Chem.* **1996**, *61*, 2664-2676.
- (173) Boge, T. C.; Wu, Z. J.; Himes, R. H.; Vander Velde, D. G.; Georg, G. I. Conformationally Restricted Paclitaxel Analogues: Macrocyclic Mimics of the "Hydrophobic Collapse" Conformation. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 3047-3052.
- (174) Ojima, I.; Lin, S.; Inoue, T.; Miller, M. L.; Borella, C. P.; Geng, X.; Walsh, J. J. Macrocyclic Formation by Ring-Closing Metathesis. Application to the Syntheses of Novel Macrocyclic Taxoids. *J. Am. Chem. Soc.* **2000**, *122*, 5343-5353.
- (175) Ojima, I.; Geng, X.; Lin, S.; Pera, P.; Bernacki, R. J. Design, Synthesis and Biological Activity of Novel C2-C3' N-Linked Macrocyclic Taxoids. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 349-352.
- (176) Ojima, I.; Slater, J. C.; Michaud, E.; Kuduk, S. D.; Bounaud, P. Y.; Vrignaud, P.; Bissery, M. C.; Veith, J. M.; Pera, P.; Bernacki, R. J. Syntheses and Structure-Activity Relationships of the Second-Generation Antitumor Taxoids: Exceptional Activity against Drug-Resistant Cancer Cells. *J. Med. Chem.* **1996**, *39*, 3889-3896.
- (177) Ojima, I.; Wang, T.; Miller, M. L.; Lin, S. N.; Borella, C. P.; Geng, X. D.; Pera, P.; Bernacki, R. J. Synthesis and Structure-Activity Relationships of New Second-Generation Taxoids. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 3423-3428.
- (178) Grubbs, R. H.; Chang, S. Recent Advances in Olefin Metathesis and Its Application in Organic Synthesis. *Tetrahedron* **1998**, *54*, 4413-4450.
- (179) Ojima, I.; Habus, I.; Zhao, M.; Zucco, M.; Park, Y. H.; Sun, C. M.; Brigaud, T. New and Efficient Approaches to the Semisynthesis of Taxol and Its C-13 Side-Chain Analogs by Means of Beta-Lactam Synthons Method. *Tetrahedron* **1992**, *48*, 6985-7012.
- (180) Ojima, I.; Kuduk, S. D.; Chakravarty, S. *Advances in Medicinal Chemistry*; Maryanoff, B. E., Reitz, A. B., Eds.; JAI Press: Greenwich, CT, **1998**; Vol. 4, pp 69-124.

- (181) Metaferia, B. B.; Hoch, J.; Glass, T. E.; Bane, S. L.; Chatterjee, S. K.; Snyder, J. P.; Lakdawala, A.; Cornett, B.; Kingston, D. G. I. Synthesis and Biological Evaluation of Novel Macrocyclic Paclitaxel Analogues. *Org. Lett.* **2001**, *3*, 2461-2464.
- (182) Ojima, I.; Wang, T.; Delaloge, F. Extremely Stereoselective Alkylation of 3-Siloxy-Beta-Lactams and Its Applications to the Asymmetric Syntheses of Novel 2-Alkylisoserines, Their Dipeptides, and Taxoids. *Tetrahedron Lett.* **1998**, *39*, 3663-3666.
- (183) Ojima, I.; Slater, J. C.; Kuduk, S. D.; Takeuchi, C. S.; Gimi, R. H.; Sun, C. M.; Park, Y. H.; Pera, P.; Veith, J. M.; Bernacki, R. J. Syntheses and Structure-Activity Relationships of Taxoids Derived from 14-Beta-Hydroxy-10-Deacetylbaaccatin III. *J. Med. Chem.* **1997**, *40*, 267-278.
- (184) Crich, D.; Yao, Q. Generation of Acyl Radicals from Thioesters by Intramolecular Homolytic Substitution at Sulfur. *J. Org. Chem.* **1996**, *61*, 3566-3570.
- (185) Appendino, G.; Gariboldi, P.; Gabetta, B.; Pace, R.; Bombardelli, E.; Viterbo, D. 14-Beta-Hydroxy-10-Deacetylbaaccatin-III, a New Taxane from Himalayan Yew (*Taxus-Wallichiana* Zucc). *J. Chem. Soc. Perkin Trans. 1* **1992**, 2925-2929.
- (186) Ford, J. M.; Hait, W. N. Pharmacology of Drugs That Alter Multidrug Resistance in Cancer. *Pharmacol. Rev.* **1990**, *42*, 155-199.
- (187) Gottesman, M. M.; Pastan, I. Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter. *Annu. Rev. Biochem.* **1993**, *62*, 385-427.
- (188) Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug Resistance in Cancer: Role of ATP-Dependent Transporters. *Nat. Rev. Cancer.* **2002**, *2*, 48-58.
- (189) Arbuck, S. G. Paclitaxel: Current Developmental Approaches of the National Cancer Institute. *Semin Oncol* **1995**, *22*, 55-63.
- (190) Huisman, C.; Ferreira, C. G.; Broker, L. E.; Rodriguez, J. A.; Smit, E. F.; Postmus, P. E.; Kruyt, F. A. E.; Giaccone, G. Paclitaxel Triggers Cell Death Primarily Via Caspase-Independent Routes in the Non-Small Cell Lung Cancer Cell Line NCI-H460. *Clin Cancer Res* **2002**, *8*, 596-606.
- (191) Ofir, R.; Seidman, R.; Rabinski, T.; Krup, M.; Yavelsky, V.; Weinstein, Y.; Wolfson, M. Taxol-Induced Apoptosis in Human SKOV3 Ovarian and MCF7

Breast Carcinoma Cells Is Caspase-3 and Caspase-9 Independent. *Cell Death Differ.* **2002**, *9*, 636-642.

- (192) Ganesh, T.; Guza, R. C.; Bane, S.; Ravindra, S.; Shanker, N.; Lakdawala, A. S.; Snyder, J. P.; Kingston, D. G. I. The Bioactive Taxol Conformation on Beta-Tubulin: Experimental Evidence from Highly Active Constrained Analogs. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 10006-10011.
- (193) Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical Treatment of Solvation for Molecular Mechanics and Dynamics. *J. Am. Chem. Soc.* **1990**, *112*, 6127-6129.
- (194) Diaz, J. F.; Barasoain, I.; Andreu, J. M. Fast Kinetics of Taxol Binding to Microtubules - Effects of Solution Variables and Microtubule-Associated Proteins. *J. Biol. Chem.* **2003**, *278*, 8407-8419.
- (195) Nettles, J. H.; Li, H. L.; Cornett, B.; Krahn, J. M.; Snyder, J. P.; Downing, K. H. The Binding Mode of Epothilone A on α,β -Tubulin by Electron Crystallography. *Science* **2004**, *305*, 866-869.
- (196) Perutz, M. F. Electrostatic Effects in Proteins. *Science* **1978**, *201*, 1187-1191.
- (197) Dill, K. A. Dominant Forces in Protein Folding. *Biochemistry* **1990**, *29*, 7133-7155.
- (198) Honig, B.; Yang, A. S. In *Advances in Protein Chemistry, Advances in Protein Chemistry*, **1995**; Vol. 46, pp 27-58.
- (199) Honig, B. H.; Hubbell, W. L. Stability of Salt Bridges in Membrane-Proteins. *Proc. Natl. Acad. Sci. U. S. A.* **1984**, *81*, 5412-5416.
- (200) Daopin, S.; Soderlind, E.; Baase, W. A.; Wozniak, J. A.; Sauer, U.; Matthews, B. W. Cumulative Site-Directed Charge-Change Replacements in Bacteriophage-T4 Lysozyme Suggest That Long-Range Electrostatic Interactions Contribute Little to Protein Stability. *J. Mol. Biol.* **1991**, *221*, 873-887.
- (201) Hendsch, Z. S.; Tidor, B. Do Salt Bridges Stabilize Proteins - a Continuum Electrostatic Analysis. *Protein Sci.* **1994**, *3*, 211-226.
- (202) Waldburger, C. D.; Schildbach, J. F.; Sauer, R. T. Are Buried Salt Bridges Important for Protein Stability and Conformational Specificity. *Nat. Struct. Biol.* **1995**, *2*, 122-128.

- (203) Waldburger, C. D.; Jonsson, T.; Sauer, R. T. Barriers to Protein Folding: Formation of Buried Polar Interactions Is a Slow Step in Acquisition of Structure. *Proc. Natl. Acad. Sci. U. S. A.* **1996**, *93*, 2629-2634.
- (204) Dong, F.; Zhou, H. X. Electrostatic Contributions to T4 Lysozyme Stability: Solvent-Exposed Charges Versus Semi-Buried Salt Bridges. *Biophys. J.* **2002**, *83*, 1341-1347.
- (205) Elcock, A. H. The Stability of Salt Bridges at High Temperatures: Implications for Hyperthermophilic Proteins. *J. Mol. Biol.* **1998**, *284*, 489-502.
- (206) Xiao, L.; Honig, B. Electrostatic Contributions to the Stability of Hyperthermophilic Proteins. *J. Mol. Biol.* **1999**, *289*, 1435-1444.
- (207) Vieille, C.; Zeikus, G. J. Hyperthermophilic Enzymes: Sources, Uses, and Molecular Mechanisms for Thermostability. *Microbiol. Mol. Biol. Rev.* **2001**, *65*, 1-43.
- (208) Zhou, H. X. Toward the Physical Basis of Thermophilic Proteins: Linking of Enriched Polar Interactions and Reduced Heat Capacity of Unfolding. *Biophys. J.* **2002**, *83*, 3126-3133.
- (209) Dominy, B. N.; Minoux, H.; Brooks, C. L. An Electrostatic Basis for the Stability of Thermophilic Proteins. *Proteins* **2004**, *57*, 128-141.
- (210) Thomas, A. S.; Elcock, A. H. Molecular Simulations Suggest Protein Salt Bridges Are Uniquely Suited to Life at High Temperatures. *J. Am. Chem. Soc.* **2004**, *126*, 2208-2214.
- (211) Karplus, M.; McCammon, J. A. Molecular Dynamics Simulations of Biomolecules. *Nat. Struct. Biol.* **2002**, *9*, 646-652.
- (212) Cramer, C. J.; Truhlar, D. G. Implicit Solvation Models: Equilibria, Structure, Spectra, and Dynamics. *Chem. Rev.* **1999**, *99*, 2161-2200.
- (213) Roux, B.; Simonson, T. Implicit Solvent Models. *Biophys. Chem.* **1999**, *78*, 1-20.
- (214) Simonson, T. Macromolecular Electrostatics: Continuum Models and Their Growing Pains. *Curr. Opin. Struct. Biol.* **2001**, *11*, 243-252.
- (215) Simonson, T. Electrostatics and Dynamics of Proteins. *Rep. Prog. Phys.* **2003**, *66*, 737-787.

- (216) Feig, M.; Brooks, C. L. Recent Advances in the Development and Application of Implicit Solvent Models in Biomolecule Simulations. *Curr. Opin. Struct. Biol.* **2004**, *14*, 217-224.
- (217) Baker, N. A. Improving Implicit Solvent Simulations: A Poisson-Centric View. *Curr. Opin. Struct. Biol.* **2005**, *15*, 137-143.
- (218) Kramers, H. A. Brownian Motion in a Field of Force and the Diffusion Model of Chemical Reactions. *Physica* **1940**, *7*, 284-304.
- (219) Weiner, J. H.; Pear, M. R. Computer Simulation of Conformational Transitions in an Idealized Polymer Model. *Macromolecules* **1977**, *10*, 317-325.
- (220) Chandler, D. Statistical Mechanics of Isomerization Dynamics in Liquids and Transition-State Approximation. *J. Chem. Phys.* **1978**, *68*, 2959-2970.
- (221) Helfand, E. Brownian Dynamics Simulation of Systems with Transitions, Particularly Conformational Transitions in Chain Molecules. *Physica A* **1983**, *118*, 123-135.
- (222) Ansari, A.; Jones, C. M.; Henry, E. R.; Hofrichter, J.; Eaton, W. A. The Role of Solvent Viscosity in the Dynamics of Protein Conformational Changes. *Science* **1992**, *256*, 1796-1798.
- (223) Haran, G.; Haas, E.; Rapaport, D. C. Molecular Dynamics Simulations of Simple Peptide Models - Solvent Effects and Comparison with Experiment. *J. Phys. Chem.* **1994**, *98*, 10294-10302.
- (224) Takano, M.; Yamato, T.; Higo, J.; Suyama, A.; Nagayama, K. Molecular Dynamics of a 15-Residue Poly(L-Alanine) in Water: Helix Formation and Energetics. *J. Am. Chem. Soc.* **1999**, *121*, 605-612.
- (225) Karplus, M. Aspects of Protein Reaction Dynamics: Deviations from Simple Behavior. *J. Phys. Chem. B* **2000**, *104*, 11-27.
- (226) Zagrovic, B.; Pande, V. Solvent Viscosity Dependence of the Folding Rate of a Small Protein: Distributed Computing Study. *J. Comput. Chem.* **2003**, *24*, 1432-1436.
- (227) Srinivasan, J.; Cheatham, T. E.; Cieplak, P.; Kollman, P. A.; Case, D. A. Continuum Solvent Studies of the Stability of DNA, RNA, and Phosphoramidate - DNA Helices. *J. Am. Chem. Soc.* **1998**, *120*, 9401-9409.

- (228) Guillot, B. A Reappraisal of What We Have Learnt During Three Decades of Computer Simulations on Water. *J. Mol. Liq.* **2002**, *101*, 219-260.
- (229) Constanciel, R.; Contreras, R. Self-Consistent Field-Theory of Solvent Effects Representation by Continuum Models - Introduction of Desolvation Contribution. *Theoretica Chimica Acta* **1984**, *65*, 1-11.
- (230) Qiu, D.; Shenkin, P. S.; Hollinger, F. P.; Still, W. C. The GB/SA Continuum Model for Solvation. A Fast Analytical Method for the Calculation of Approximate Born Radii. *J. Phys. Chem. A* **1997**, *101*, 3005-3014.
- (231) Cornell, W.; Abseher, R.; Nilges, M.; Case, D. A. Continuum Solvent Molecular Dynamics Study of Flexibility in Interleukin-8. *J. Mol. Graph.* **2001**, *19*, 136-145.
- (232) Zhou, R. H. Free Energy Landscape of Protein Folding in Water: Explicit vs. Implicit Solvent. *Proteins* **2003**, *53*, 148-161.
- (233) Felts, A. K.; Harano, Y.; Gallicchio, E.; Levy, R. M. Free Energy Surfaces of Beta-Hairpin and Alpha-Helical Peptides Generated by Replica Exchange Molecular Dynamics with the AGBNP Implicit Solvent Model. *Proteins* **2004**, *56*, 310-321.
- (234) Ghosh, A.; Rapp, C. S.; Friesner, R. A. Generalized Born Model Based on a Surface Integral Formulation. *J. Phys. Chem. B* **1998**, *102*, 10983-10990.
- (235) Masunov, A.; Lazaridis, T. Potentials of Mean Force Between Ionizable Amino Acid Side Chains in Water. *J. Am. Chem. Soc.* **2003**, *125*, 1722-1730.
- (236) Dominy, B. N.; Brooks, C. L. Development of a Generalized Born Model Parametrization for Proteins and Nucleic Acids. *J. Phys. Chem. B* **1999**, *103*, 3765-3773.
- (237) Hawkins, G. D.; Cramer, C. J.; Truhlar, D. G. Pairwise Solute Descreening of Solute Charges from a Dielectric Medium. *Chem. Phys. Lett.* **1995**, *246*, 122-129.
- (238) Hawkins, G. D.; Cramer, C. J.; Truhlar, D. G. Parametrized Models of Aqueous Free Energies of Solvation Based on Pairwise Descreening of Solute Atomic Charges from a Dielectric Medium. *J. Phys. Chem.* **1996**, *100*, 19824-19839.
- (239) Tsui, V.; Case, D. A. Molecular Dynamics Simulations of Nucleic Acids with a Generalized Born Solvation Model. *J. Am. Chem. Soc.* **2000**, *122*, 2489-2498.

- (240) Tsui, V.; Case, D. A. Theory and Applications of the Generalized Born Solvation Model in Macromolecular Simulations. *Biopolymers* **2001**, *56*, 275-291.
- (241) Onufriev, A.; Bashford, D.; Case, D. A. Modification of the Generalized Born Model Suitable for Macromolecules. *J. Phys. Chem. B* **2000**, *104*, 3712-3720.
- (242) Onufriev, A.; Bashford, D.; Case, D. A. Exploring Protein Native States and Large-Scale Conformational Changes with a Modified Generalized Born Model. *Proteins* **2004**, *55*, 383-394.
- (243) Case, D. A.; Darden, T. A.; Cheatham, T. E.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Wang, B.; Pearlman, D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J. W.; Ross, W. S.; Kollman, P. A. *Amber*; ver. 8; University of California: San Francisco, **2004**.
- (244) Hornak, V.; Roitberg, A. E.; Simmerling, C. *in preparation*.
- (245) Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of Simple Potential Functions for Simulating Liquid Water. *J. Chem. Phys.* **1983**, *79*, 926-935.
- (246) Essex, J. W. The Application of the Reaction-Field Method to the Calculation of Dielectric Constants. *Mol. Simul.* **1998**, *20*, 159-178.
- (247) Hocht, P.; Boresch, S.; Bitomsky, W.; Steinhauser, O. Rationalization of the Dielectric Properties of Common Three-Site Water Models in Terms of Their Force Field Parameters. *J. Chem. Phys.* **1998**, *109*, 4927-4937.
- (248) Richardi, J.; Fries, P. H.; Millot, C. Fast Hybrid Methods for the Simulation of Dielectric Constants of Liquids. *J. Mol. Liq.* **2005**, *117*, 3-16.
- (249) Rini, J. M.; Schulze-Gahmen, U.; Wilson, I. A. Structural Evidence for Induced Fit as a Mechanism for Antibody-Antigen Recognition. *Science* **1992**, *255*, 959-965.
- (250) Darden, T.; York, D.; Pedersen, L. Particle Mesh Ewald - an N.Log(N) Method for Ewald Sums in Large Systems. *J. Chem. Phys.* **1993**, *98*, 10089-10092.
- (251) Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A Smooth Particle Mesh Ewald Method. *J. Chem. Phys.* **1995**, *103*, 8577-8593.

- (252) Crowley, M. F.; Darden, T. A.; Cheatham, T. E.; Deerfield, D. W. Adventures in Improving the Scaling and Accuracy of a Parallel Molecular Dynamics Program. *J. Supercomput.* **1997**, *11*, 255-278.
- (253) Toukmaji, A.; Sagui, C.; Board, J.; Darden, T. Efficient Particle-Mesh Ewald Based Approach to Fixed and Induced Dipolar Interactions. *J. Chem. Phys.* **2000**, *113*, 10913-10927.
- (254) Bondi, A. Van der Waals Volumes and Radii. *J. Phys. Chem.* **1964**, *68*, 441-&.
- (255) Torrie, G. M.; Valleau, J. P. Non-Physical Sampling Distributions in Monte-Carlo Free-Energy Estimation - Umbrella Sampling. *J. Comput. Phys.* **1977**, *23*, 187-199.
- (256) Kumar, S.; Bouzida, D.; Swendsen, R. H.; Kollman, P. A.; Rosenberg, J. M. The Weighted Histogram Analysis Method for Free-Energy Calculations on Biomolecules .1. The Method. *J. Comput. Chem.* **1992**, *13*, 1011-1021.
- (257) Roux, B. The Calculation of the Potential of Mean Force Using Computer-Simulations. *Comput. Phys. Commun.* **1995**, *91*, 275-282.
- (258) Neidigh, J. W.; Fesinmeyer, R. M.; Andersen, N. H. Designing a 20-Residue Protein. *Nat. Struct. Biol.* **2002**, *9*, 425-430.
- (259) Berendsen, H. J. C.; Postma, J. P. M.; vanGunsteren, W. F.; Dinola, A.; Haak, J. R. Molecular-Dynamics with Coupling to an External Bath. *J. Chem. Phys.* **1984**, *81*, 3684-3690.
- (260) Hornak, V.; Simmerling, C. Development of Softcore Potential Functions for Overcoming Steric Barriers in Molecular Dynamics Simulations. *J. Mol. Graph.* **2004**, *22*, 405-413.
- (261) Hornak, V.; Simmerling, C. Generation of Accurate Protein Loop Conformations through Low-Barrier Molecular Dynamics. *Proteins* **2003**, *51*, 577-590.
- (262) Kabat, E. A.; Wu, T. T.; Perry, H. M.; Gottesman, K. S.; C., F. *Sequences of Proteins of Immunological Interest*; Diane Books Publishing Company, **1991**.
- (263) Bader, J. S.; Chandler, D. Computer-Simulation Study of the Mean Forces between Ferrous and Ferric Ions in Water. *J. Phys. Chem.* **1992**, *96*, 6423-6427.
- (264) Rey, R.; Guardia, E. Dynamic Aspects of the Na⁺-Cl⁻ Ion-Pair Association in Water. *J. Phys. Chem.* **1992**, *96*, 4712-4718.

- (265) Friedman, R. A.; Mezei, M. The Potentials of Mean Force of Sodium-Chloride and Sodium Dimethylphosphate in Water - an Application of Adaptive Umbrella Sampling. *J. Chem. Phys.* **1995**, *102*, 419-426.
- (266) Resat, H.; Mezei, M.; McCammon, J. A. Use of the Grand Canonical Ensemble in Potential of Mean Force Calculations. *J. Phys. Chem.* **1996**, *100*, 1426-1433.
- (267) Martorana, V.; La Fata, L.; Bulone, D.; San Biagio, P. L. Potential of Mean Force between Two Ions in a Sucrose Rich Aqueous Solution. *Chem. Phys. Lett.* **2000**, *329*, 221-227.
- (268) Rozanska, X.; Chipot, C. Modeling Ion-Ion Interaction in Proteins: A Molecular Dynamics Free Energy Calculation of the Guanidinium-Acetate Association. *J. Chem. Phys.* **2000**, *112*, 9691-9694.
- (269) Belch, A. C.; Berkowitz, M.; McCammon, J. A. Solvation Structure of a Sodium-Chloride Ion-Pair in Water. *J. Am. Chem. Soc.* **1986**, *108*, 1755-1761.
- (270) Gruia, A. D.; Fischer, S.; Smith, J. C. Molecular Dynamics Simulation Reveals a Surface Salt Bridge Forming a Kinetic Trap in Unfolding of Truncated Staphylococcal Nuclease. *Proteins* **2003**, *50*, 507-515.
- (271) Gruia, A. D.; Fischer, S.; Smith, J. C. Kinetics of Breaking a Salt-Bridge Critical in Protein Unfolding. *Chem. Phys. Lett.* **2004**, *385*, 337-340.
- (272) Born, M. *Z. Phys.* **1920**, *1*, 45-48.
- (273) Dudek, M. J.; Ponder, J. W. Accurate Modeling of the Intramolecular Electrostatic Energy of Proteins. *J. Comput. Chem.* **1995**, *16*, 791-816.
- (274) Schmidt, M. W.; Baldrige, K. K.; Boatz, J. A.; Elbert, S. T.; Gordon, M. S.; Jensen, J. H.; Koseki, S.; Matsunaga, N.; Nguyen, K. A.; Su, S. J.; Windus, T. L.; Dupuis, M.; Montgomery, J. A. General Atomic and Molecular Electronic-Structure System. *J. Comput. Chem.* **1993**, *14*, 1347-1363.
- (275) Barlow, D. J.; Thornton, J. M. Ion-Pairs in Proteins. *J. Mol. Biol.* **1983**, *168*, 867-885.
- (276) Kumar, S.; Nussinov, R. Salt Bridge Stability in Monomeric Proteins. *J. Mol. Biol.* **1999**, *293*, 1241-1255.
- (277) Zhu, J.; Alexov, E.; Honig, B. Comparative Study of Generalized Born Models: Born Radii and Peptide Folding. *J. Phys. Chem. B* **2005**, *109*, 3008-3022.

- (278) Chandler, D. Structures of Molecular Liquids. *Annu. Rev. Phys. Chem.* **1978**, *29*, 441-471.
- (279) Hirata, F.; Rossky, P. J. An Extended RISM Equation for Molecular Polar Fluids. *Chem. Phys. Lett.* **1981**, *83*, 329-334.
- (280) Hirata, F.; Rossky, P. J.; Pettitt, B. M. The Interionic Potential of Mean Force in a Molecular Polar-Solvent from an Extended RISM Equation. *J. Chem. Phys.* **1983**, *78*, 4133-4144.
- (281) Pettitt, B. M.; Rossky, P. J. Alkali-Halides in Water - Ion Solvent Correlations and Ion Ion Potentials of Mean Force at Infinite Dilution. *J. Chem. Phys.* **1986**, *84*, 5836-5844.
- (282) Fukunishi, Y.; Suzuki, M. Reproduction of the Potential of Mean Force by a Modified Solvent-Accessible Surface Method. *J. Phys. Chem.* **1996**, *100*, 5634-5636.
- (283) Fukunishi, Y.; Suzuki, M. Potential of Mean Force Calculation of Solute Molecules in Water by a Modified Solvent-Accessible Surface Method. *J. Comput. Chem.* **1997**, *18*, 1656-1663.
- (284) Rashin, A. A. Electrostatics of Ion Ion Interactions in Solution. *J. Phys. Chem.* **1989**, *93*, 4664-4669.
- (285) Pratt, L. R.; Hummer, G.; Garcia, A. E. Ion-Pair Potentials-of-Mean-Force in Water. *Biophys. Chem.* **1994**, *51*, 147-165.
- (286) Marqusee, S.; Baldwin, R. L. Helix Stabilization by Glu-...Lys+ Salt Bridges in Short Peptides of De Novo Design. *Proc. Natl. Acad. Sci. U. S. A.* **1987**, *84*, 8898-8902.
- (287) Perutz, M. F.; Fermi, G. Stereochemistry of Salt-Bridge Formation in Alpha-Helices and Beta-Strands. *Proteins* **1988**, *4*, 294-295.
- (288) Luo, R.; David, L.; Hung, H.; Devaney, J.; Gilson, M. K. Strength of Solvent-Exposed Salt-Bridges. *J. Phys. Chem. B* **1999**, *103*, 727-736.
- (289) Qiu, L. L.; Pabit, S. A.; Roitberg, A. E.; Hagen, S. J. Smaller and Faster: The 20-Residue Trp-Cage Protein Folds in 4 μ s. *J. Am. Chem. Soc.* **2002**, *124*, 12952-12953.

- (290) Snow, C. D.; Zagrovic, B.; Pande, V. S. The Trp Cage: Folding Kinetics and Unfolded State Topology Via Molecular Dynamics Simulations. *J. Am. Chem. Soc.* **2002**, *124*, 14548-14549.
- (291) Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. *J. Am. Chem. Soc.* **1996**, *118*, 11225-11236.
- (292) Kabsch, W.; Sander, C. Dictionary of Protein Secondary Structure - Pattern-Recognition of Hydrogen-Bonded and Geometrical Features. *Biopolymers* **1983**, *22*, 2577-2637.
- (293) Bosshard, H. R.; Marti, D. N.; Jelesarov, I. Protein Stabilization by Salt Bridges: Concepts, Experimental Approaches and Clarification of Some Misunderstandings. *J. Mol. Recognit.* **2004**, *17*, 1-16.
- (294) Pace, C. N.; Alston, R. W.; Shaw, K. L. Charge-Charge Interactions Influence the Denatured State Ensemble and Contribute to Protein Stability. *Protein Sci.* **2000**, *9*, 1395-1398.
- (295) Fernandez, D. P.; Goodwin, A. R. H.; Lemmon, E. W.; Sengers, J.; Williams, R. C. A Formulation for the Static Permittivity of Water and Steam at Temperatures from 238 K to 873 K at Pressures up to 1200 Mpa, Including Derivatives and Debye-Huckel Coefficients. *J. Phys. Chem. Ref. Data* **1997**, *26*, 1125-1166.
- (296) Elcock, A. H.; McCammon, J. A. Continuum Solvation Model for Studying Protein Hydration Thermodynamics at High Temperatures. *J. Phys. Chem. B* **1997**, *101*, 9624-9634.
- (297) Cornell, W. D.; Caldwell, J. W.; Kollman, P. A. Calculation of the Phi-Psi Maps for Alanine and Glycyl Dipeptides with Different Additive and Non-Additive Molecular Mechanical Models. *J. Chim. Phys.-Chim. Biol.* **1997**, *94*, 1417-1435.
- (298) Feig, M.; Onufriev, A.; Lee, M. S.; Im, W.; Case, D. A.; Brooks, C. L. Performance Comparison of Generalized Born and Poisson Methods in the Calculation of Electrostatic Solvation Energies for Protein Structures. *J. Comput. Chem.* **2004**, *25*, 265-284.
- (299) Beglov, D.; Roux, B. Finite Representation of an Infinite Bulk System - Solvent Boundary Potential for Computer-Simulations. *J. Chem. Phys.* **1994**, *100*, 9050-9063.

- (300) Lounnas, V.; Ludemann, S. K.; Wade, R. C. Towards Molecular Dynamics Simulation of Large Proteins with a Hydration Shell at Constant Pressure. *Biophys. Chem.* **1999**, *78*, 157-182.
- (301) Topol, I. A.; Tawa, G. J.; Burt, S. K.; Rashin, A. A. On the Structure and Thermodynamics of Solvated Monoatomic Ions Using a Hybrid Solvation Model. *J. Chem. Phys.* **1999**, *111*, 10998-11014.
- (302) Rosenhouse-Dantsker, A.; Osman, R. Application of the Primary Hydration Shell Approach to Locally Enhanced Sampling Simulated Annealing: Computer Simulation of Thyrotropin-Releasing Hormone in Water. *Biophys. J.* **2000**, *79*, 66-79.
- (303) Lee, M. S.; Salsbury, F. R.; Olson, M. A. An Efficient Hybrid Explicit/Implicit Solvent Method for Biomolecular Simulations. *J. Comput. Chem.* **2004**, *25*, 1967-1978.
- (304) Kentsis, A.; Mezei, M.; Osman, R. MC-PHS: A Monte Carlo Implementation of the Primary Hydration Shell for Protein Folding and Design. *Biophys. J.* **2003**, *84*, 805-815.
- (305) Yu, Z. Y.; Jacobson, M. P.; Josovitz, J.; Rapp, C. S.; Friesner, R. A. First-Shell Solvation of Ion Pairs: Correction of Systematic Errors in Implicit Solvent Models. *J. Phys. Chem. B* **2004**, *108*, 6643-6654.

Appendices

**Appendix A: REDOR-Taxol in β -Tubulin Binding Site
(PDB File Format, Version 2.0)**

REMARK	4									
REMARK	4	COMPLIES WITH FORMAT V. 2.0, 7-AUG-2005								
ATOM	1	O1	UNK	1	4.359	12.244	-7.211	0.00	0.00	O
ATOM	2	O2	UNK	1	5.767	10.182	-8.788	0.00	0.00	O
ATOM	3	O3	UNK	1	8.287	9.054	-9.342	0.00	0.00	O
ATOM	4	O4	UNK	1	7.687	6.456	-7.747	0.00	0.00	O
ATOM	5	O5	UNK	1	9.456	8.346	-3.972	0.00	0.00	O
ATOM	6	O6	UNK	1	8.138	10.577	-3.323	0.00	0.00	O
ATOM	7	O7	UNK	1	8.859	13.104	-3.877	0.00	0.00	O
ATOM	8	O8	UNK	1	8.241	13.348	-9.823	0.00	0.00	O
ATOM	9	O9	UNK	1	3.482	10.263	-8.543	0.00	0.00	O
ATOM	10	O10	UNK	1	10.346	9.940	-8.680	0.00	0.00	O
ATOM	11	O11	UNK	1	6.889	14.949	-10.866	0.00	0.00	O
ATOM	12	O12	UNK	1	8.890	12.263	-12.164	0.00	0.00	O
ATOM	13	O13	UNK	1	7.478	15.279	-14.878	0.00	0.00	O
ATOM	14	N14	UNK	1	8.797	15.901	-13.175	0.00	0.00	N
ATOM	15	C15	UNK	1	5.788	12.143	-7.235	0.00	0.00	C
ATOM	16	C16	UNK	1	6.099	10.563	-7.402	0.00	0.00	C
ATOM	17	C17	UNK	1	7.506	9.839	-7.034	0.00	0.00	C
ATOM	18	C18	UNK	1	7.871	8.614	-8.006	0.00	0.00	C
ATOM	19	C19	UNK	1	8.739	7.405	-7.533	0.00	0.00	C
ATOM	20	C20	UNK	1	9.217	7.336	-6.078	0.00	0.00	C
ATOM	21	C21	UNK	1	9.182	8.678	-5.339	0.00	0.00	C
ATOM	22	C22	UNK	1	7.854	9.533	-5.486	0.00	0.00	C
ATOM	23	C23	UNK	1	8.203	10.767	-4.547	0.00	0.00	C
ATOM	24	C24	UNK	1	8.745	12.157	-4.986	0.00	0.00	C
ATOM	25	C25	UNK	1	7.924	12.820	-6.109	0.00	0.00	C
ATOM	26	C26	UNK	1	8.509	13.207	-7.291	0.00	0.00	C
ATOM	27	C27	UNK	1	7.640	13.604	-8.515	0.00	0.00	C
ATOM	28	C28	UNK	1	6.201	12.976	-8.502	0.00	0.00	C
ATOM	29	C29	UNK	1	6.356	12.921	-5.957	0.00	0.00	C
ATOM	30	C30	UNK	1	5.987	14.446	-5.832	0.00	0.00	C
ATOM	31	C31	UNK	1	5.663	12.415	-4.647	0.00	0.00	C
ATOM	32	C32	UNK	1	6.815	7.498	-8.185	0.00	0.00	C
ATOM	33	C33	UNK	1	6.663	8.734	-4.858	0.00	0.00	C
ATOM	34	C34	UNK	1	10.008	13.272	-7.568	0.00	0.00	C
ATOM	35	C35	UNK	1	4.466	9.930	-9.217	0.00	0.00	C
ATOM	36	C36	UNK	1	9.563	9.571	-9.554	0.00	0.00	C
ATOM	37	C37	UNK	1	9.935	9.562	-11.020	0.00	0.00	C
ATOM	38	C38	UNK	1	7.733	14.050	-10.920	0.00	0.00	C
ATOM	39	C39	UNK	1	8.327	13.573	-12.262	0.00	0.00	C
ATOM	40	C40	UNK	1	9.357	14.534	-12.942	0.00	0.00	C
ATOM	41	C41	UNK	1	7.864	16.174	-14.119	0.00	0.00	C
ATOM	42	C75	UNK	1	10.000	13.079	-3.080	0.00	0.00	C
ATOM	43	O76	UNK	1	10.956	12.311	-3.210	0.00	0.00	O
ATOM	44	C77	UNK	1	9.954	14.141	-1.999	0.00	0.00	C
ATOM	45	C81	UNK	1	4.274	9.215	-10.531	0.00	0.00	C
ATOM	46	C82	UNK	1	5.381	8.889	-11.332	0.00	0.00	C
ATOM	47	C83	UNK	1	5.219	8.162	-12.508	0.00	0.00	C
ATOM	48	C84	UNK	1	3.947	7.781	-12.919	0.00	0.00	C
ATOM	49	C85	UNK	1	2.835	8.118	-12.154	0.00	0.00	C
ATOM	50	C86	UNK	1	2.996	8.832	-10.969	0.00	0.00	C
ATOM	51	C92	UNK	1	10.745	14.513	-12.232	0.00	0.00	C
ATOM	52	C93	UNK	1	11.809	13.795	-12.799	0.00	0.00	C
ATOM	53	C94	UNK	1	13.020	13.667	-12.121	0.00	0.00	C
ATOM	54	C95	UNK	1	13.172	14.237	-10.860	0.00	0.00	C

ATOM	55	C96	UNK	1	12.123	14.945	-10.283	0.00	0.00	C	
ATOM	56	C97	UNK	1	10.925	15.097	-10.969	0.00	0.00	C	
ATOM	57	C103	UNK	1	7.306	17.585	-14.234	0.00	0.00	C	
ATOM	58	C104	UNK	1	6.558	17.908	-15.382	0.00	0.00	C	
ATOM	59	C105	UNK	1	6.048	19.189	-15.572	0.00	0.00	C	
ATOM	60	C106	UNK	1	6.240	20.161	-14.599	0.00	0.00	C	
ATOM	61	C107	UNK	1	6.945	19.858	-13.441	0.00	0.00	C	
ATOM	62	C108	UNK	1	7.483	18.589	-13.262	0.00	0.00	C	
ATOM	63	H5	UNK	1	9.123	9.086	-3.444	1.00	0.00	H	
ATOM	64	H12	UNK	1	9.631	12.327	-11.552	0.00	0.00	H	
ATOM	65	H14	UNK	1	9.076	16.700	-12.598	0.00	0.00	H	
ATOM	66	H16	UNK	1	5.357	10.063	-6.756	0.00	0.00	H	
ATOM	67	H17	UNK	1	8.273	10.561	-7.343	0.00	0.00	H	
ATOM	68	H19	UNK	1	9.578	7.200	-8.224	0.00	0.00	H	
ATOM	69	1H20	UNK	1	10.240	6.919	-6.035	0.00	0.00	H	
ATOM	70	2H20	UNK	1	8.605	6.605	-5.530	0.00	0.00	H	
ATOM	71	H21	UNK	1	10.037	9.270	-5.729	0.00	0.00	H	
ATOM	72	H24	UNK	1	9.753	11.910	-5.364	0.00	0.00	H	
ATOM	73	H27	UNK	1	7.537	14.703	-8.411	0.00	0.00	H	
ATOM	74	1H28	UNK	1	5.496	13.823	-8.612	0.00	0.00	H	
ATOM	75	2H28	UNK	1	6.022	12.413	-9.433	0.00	0.00	H	
ATOM	76	1H30	UNK	1	6.383	15.076	-6.642	0.00	0.00	H	
ATOM	77	2H30	UNK	1	4.894	14.615	-5.842	0.00	0.00	H	
ATOM	78	3H30	UNK	1	6.384	14.898	-4.902	0.00	0.00	H	
ATOM	79	1H31	UNK	1	5.650	11.326	-4.555	0.00	0.00	H	
ATOM	80	2H31	UNK	1	6.144	12.806	-3.730	0.00	0.00	H	
ATOM	81	3H31	UNK	1	4.593	12.695	-4.593	0.00	0.00	H	
ATOM	82	1H32	UNK	1	5.925	7.593	-7.538	0.00	0.00	H	
ATOM	83	2H32	UNK	1	6.494	7.338	-9.231	0.00	0.00	H	
ATOM	84	1H33	UNK	1	5.700	9.264	-4.844	0.00	0.00	H	
ATOM	85	2H33	UNK	1	6.483	7.791	-5.397	0.00	0.00	H	
ATOM	86	3H33	UNK	1	6.852	8.470	-3.800	0.00	0.00	H	
ATOM	87	1H34	UNK	1	10.627	13.371	-6.659	0.00	0.00	H	
ATOM	88	2H34	UNK	1	10.363	12.380	-8.112	0.00	0.00	H	
ATOM	89	3H34	UNK	1	10.262	14.153	-8.184	0.00	0.00	H	
ATOM	90	1H37	UNK	1	9.053	9.748	-11.656	0.00	0.00	H	
ATOM	91	2H37	UNK	1	10.694	10.331	-11.241	0.00	0.00	H	
ATOM	92	3H37	UNK	1	10.355	8.580	-11.301	0.00	0.00	H	
ATOM	93	H39	UNK	1	7.460	13.491	-12.945	0.00	0.00	H	
ATOM	94	H40	UNK	1	9.517	14.094	-13.949	0.00	0.00	H	
ATOM	95	H1	UNK	1	4.019	11.538	-7.794	0.00	0.00	H	
ATOM	96	1H77	UNK	1	9.261	13.845	-1.193	0.00	0.00	H	
ATOM	97	2H77	UNK	1	10.955	14.291	-1.557	0.00	0.00	H	
ATOM	98	3H77	UNK	1	9.619	15.108	-2.414	0.00	0.00	H	
ATOM	99	H84	UNK	1	3.823	7.227	-13.839	1.00	0.00	H	
ATOM	100	H82	UNK	1	6.380	9.188	-11.051	0.00	0.00	H	
ATOM	101	H83	UNK	1	6.082	7.907	-13.109	0.00	0.00	H	
ATOM	102	H85	UNK	1	1.847	7.822	-12.478	0.00	0.00	H	
ATOM	103	H86	UNK	1	2.119	9.071	-10.383	0.00	0.00	H	
ATOM	104	H93	UNK	1	11.699	13.314	-13.762	0.00	0.00	H	
ATOM	105	H94	UNK	1	13.833	13.112	-12.569	0.00	0.00	H	
ATOM	106	H95	UNK	1	14.104	14.122	-10.326	0.00	0.00	H	
ATOM	107	H96	UNK	1	12.215	15.361	-9.291	0.00	0.00	H	
ATOM	108	H97	UNK	1	10.116	15.634	-10.496	0.00	0.00	H	
ATOM	109	H104	UNK	1	6.387	17.169	-16.153	0.00	0.00	H	
ATOM	110	H105	UNK	1	5.507	19.428	-16.475	0.00	0.00	H	
ATOM	111	H106	UNK	1	5.846	21.156	-14.743	0.00	0.00	H	
ATOM	112	H107	UNK	1	7.075	20.609	-12.680	0.00	0.00	H	
ATOM	113	H108	UNK	1	8.026	18.390	-12.350	0.00	0.00	H	
ATOM	114	N	ALA	B	18	9.659	12.580	-25.704	1.00	20.00	N
ATOM	115	CA	ALA	B	18	8.461	12.700	-24.999	1.00	20.00	C
ATOM	116	C	ALA	B	18	8.692	12.750	-23.534	1.00	20.00	C
ATOM	117	O	ALA	B	18	8.016	13.486	-22.831	1.00	20.00	O

ATOM	118	CB	ALA	B	18	7.513	11.565	-25.441	1.00	20.00	C
ATOM	119	1H	ALA	B	18	9.468	12.487	-26.708	1.00	0.00	H
ATOM	120	2H	ALA	B	18	10.220	13.434	-25.611	1.00	0.00	H
ATOM	121	HA	ALA	B	18	7.992	13.661	-25.288	1.00	0.00	H
ATOM	122	1HB	ALA	B	18	6.532	11.642	-24.936	1.00	0.00	H
ATOM	123	2HB	ALA	B	18	7.310	11.592	-26.528	1.00	0.00	H
ATOM	124	3HB	ALA	B	18	7.918	10.561	-25.209	1.00	0.00	H
ATOM	125	N	LYS	B	19	9.645	11.981	-23.045	1.00	20.00	N
ATOM	126	CA	LYS	B	19	9.807	11.922	-21.625	1.00	20.00	C
ATOM	127	C	LYS	B	19	10.918	12.800	-21.054	1.00	20.00	C
ATOM	128	O	LYS	B	19	10.976	13.058	-19.887	1.00	20.00	O
ATOM	129	CB	LYS	B	19	8.958	11.027	-20.650	1.00	20.00	C
ATOM	130	CG	LYS	B	19	7.679	10.343	-21.186	1.00	20.00	C
ATOM	131	CD	LYS	B	19	6.865	9.706	-20.040	1.00	20.00	C
ATOM	132	CE	LYS	B	19	5.594	8.996	-20.524	1.00	20.00	C
ATOM	133	NZ	LYS	B	19	4.885	8.425	-19.362	1.00	20.00	N
ATOM	134	H	LYS	B	19	10.071	11.343	-23.728	1.00	0.00	H
ATOM	135	HA	LYS	B	19	9.198	12.760	-21.237	1.00	0.00	H
ATOM	136	1HB	LYS	B	19	8.623	11.631	-19.773	1.00	0.00	H
ATOM	137	2HB	LYS	B	19	9.605	10.345	-20.092	1.00	0.00	H
ATOM	138	1HG	LYS	B	19	7.937	9.593	-21.957	1.00	0.00	H
ATOM	139	2HG	LYS	B	19	7.049	11.093	-21.701	1.00	0.00	H
ATOM	140	1HD	LYS	B	19	6.586	10.494	-19.311	1.00	0.00	H
ATOM	141	2HD	LYS	B	19	7.505	9.001	-19.475	1.00	0.00	H
ATOM	142	1HE	LYS	B	19	5.844	8.201	-21.253	1.00	0.00	H
ATOM	143	2HE	LYS	B	19	4.932	9.709	-21.054	1.00	0.00	H
ATOM	144	1HZ	LYS	B	19	4.053	7.894	-19.647	1.00	0.00	H
ATOM	145	2HZ	LYS	B	19	5.490	7.770	-18.854	1.00	0.00	H
ATOM	146	N	PHE	B	20	11.796	13.271	-21.836	1.00	20.00	N
ATOM	147	CA	PHE	B	20	12.844	14.192	-21.361	1.00	20.00	C
ATOM	148	C	PHE	B	20	12.181	15.530	-21.231	1.00	20.00	C
ATOM	149	O	PHE	B	20	11.968	16.072	-20.156	1.00	20.00	O
ATOM	150	CB	PHE	B	20	14.166	14.061	-22.196	1.00	20.00	C
ATOM	151	CG	PHE	B	20	15.173	15.232	-22.074	1.00	20.00	C
ATOM	152	CD1	PHE	B	20	15.660	15.846	-23.234	1.00	20.00	C
ATOM	153	CD2	PHE	B	20	15.543	15.748	-20.824	1.00	20.00	C
ATOM	154	CE1	PHE	B	20	16.493	16.959	-23.147	1.00	20.00	C
ATOM	155	CE2	PHE	B	20	16.371	16.865	-20.739	1.00	20.00	C
ATOM	156	CZ	PHE	B	20	16.846	17.467	-21.901	1.00	20.00	C
ATOM	157	H	PHE	B	20	11.673	12.980	-22.811	1.00	0.00	H
ATOM	158	HA	PHE	B	20	13.154	13.922	-20.329	1.00	0.00	H
ATOM	159	1HB	PHE	B	20	13.908	13.906	-23.262	1.00	0.00	H
ATOM	160	2HB	PHE	B	20	14.678	13.123	-21.911	1.00	0.00	H
ATOM	161	HD1	PHE	B	20	15.383	15.478	-24.211	1.00	0.00	H
ATOM	162	HD2	PHE	B	20	15.170	15.304	-19.913	1.00	0.00	H
ATOM	163	HE1	PHE	B	20	16.856	17.435	-24.047	1.00	0.00	H
ATOM	164	HE2	PHE	B	20	16.642	17.265	-19.773	1.00	0.00	H
ATOM	165	HZ	PHE	B	20	17.480	18.339	-21.835	1.00	0.00	H
ATOM	166	N	TRP	B	21	11.882	15.988	-22.347	1.00	20.00	N
ATOM	167	CA	TRP	B	21	11.152	17.168	-22.447	1.00	20.00	C
ATOM	168	C	TRP	B	21	9.935	17.009	-21.620	1.00	20.00	C
ATOM	169	O	TRP	B	21	9.246	17.936	-21.193	1.00	20.00	O
ATOM	170	CB	TRP	B	21	10.842	17.502	-23.935	1.00	20.00	C
ATOM	171	CG	TRP	B	21	11.996	18.220	-24.652	1.00	20.00	C
ATOM	172	CD1	TRP	B	21	13.073	17.604	-25.324	1.00	20.00	C
ATOM	173	CD2	TRP	B	21	12.269	19.578	-24.676	1.00	20.00	C
ATOM	174	NE1	TRP	B	21	14.025	18.547	-25.759	1.00	20.00	N
ATOM	175	CE2	TRP	B	21	13.510	19.762	-25.337	1.00	20.00	C
ATOM	176	CE3	TRP	B	21	11.580	20.688	-24.118	1.00	20.00	C
ATOM	177	CZ2	TRP	B	21	14.076	21.055	-25.435	1.00	20.00	C
ATOM	178	CZ3	TRP	B	21	12.155	21.955	-24.237	1.00	20.00	C
ATOM	179	CH2	TRP	B	21	13.385	22.136	-24.882	1.00	20.00	C
ATOM	180	H	TRP	B	21	12.162	15.416	-23.148	1.00	0.00	H

ATOM	181	HA	TRP	B	21	11.711	18.014	-22.019	1.00	0.00	H
ATOM	182	1HB	TRP	B	21	9.957	18.165	-23.994	1.00	0.00	H
ATOM	183	2HB	TRP	B	21	10.533	16.601	-24.502	1.00	0.00	H
ATOM	184	HD1	TRP	B	21	13.180	16.535	-25.448	1.00	0.00	H
ATOM	185	HE1	TRP	B	21	14.907	18.382	-26.257	1.00	0.00	H
ATOM	186	HE3	TRP	B	21	10.643	20.559	-23.596	1.00	0.00	H
ATOM	187	HZ2	TRP	B	21	15.028	21.202	-25.923	1.00	0.00	H
ATOM	188	HZ3	TRP	B	21	11.646	22.811	-23.816	1.00	0.00	H
ATOM	189	HH2	TRP	B	21	13.808	23.129	-24.950	1.00	0.00	H
ATOM	190	N	GLU	B	22	9.261	16.086	-21.084	1.00	20.00	N
ATOM	191	CA	GLU	B	22	8.173	16.812	-20.466	1.00	20.00	C
ATOM	192	C	GLU	B	22	8.510	17.150	-19.056	1.00	20.00	C
ATOM	193	O	GLU	B	22	7.758	17.709	-18.249	1.00	20.00	O
ATOM	194	CB	GLU	B	22	7.191	15.563	-20.214	1.00	20.00	C
ATOM	195	CG	GLU	B	22	6.188	15.181	-21.328	1.00	20.00	C
ATOM	196	CD	GLU	B	22	5.497	13.820	-21.188	1.00	20.00	C
ATOM	197	OE1	GLU	B	22	5.561	13.095	-20.199	1.00	20.00	O
ATOM	198	OE2	GLU	B	22	4.784	13.500	-22.302	1.00	20.00	O
ATOM	199	H	GLU	B	22	9.188	15.198	-21.594	1.00	0.00	H
ATOM	200	HA	GLU	B	22	7.318	17.391	-20.966	1.00	0.00	H
ATOM	201	1HB	GLU	B	22	6.514	15.755	-19.350	1.00	0.00	H
ATOM	202	2HB	GLU	B	22	7.726	14.648	-19.867	1.00	0.00	H
ATOM	203	1HG	GLU	B	22	6.637	15.282	-22.329	1.00	0.00	H
ATOM	204	2HG	GLU	B	22	5.397	15.927	-21.320	1.00	0.00	H
ATOM	205	HE2	GLU	B	22	4.375	12.646	-22.160	1.00	0.00	H
ATOM	206	N	VAL	B	23	9.488	16.848	-18.745	1.00	20.00	N
ATOM	207	CA	VAL	B	23	10.018	17.057	-17.427	1.00	20.00	C
ATOM	208	C	VAL	B	23	10.596	18.445	-17.290	1.00	20.00	C
ATOM	209	O	VAL	B	23	11.150	18.828	-16.336	1.00	20.00	O
ATOM	210	CB	VAL	B	23	10.947	15.844	-17.028	1.00	20.00	C
ATOM	211	CG1	VAL	B	23	11.685	15.997	-15.676	1.00	20.00	C
ATOM	212	CG2	VAL	B	23	10.161	14.506	-16.960	1.00	20.00	C
ATOM	213	H	VAL	B	23	9.980	16.323	-19.489	1.00	0.00	H
ATOM	214	HA	VAL	B	23	9.233	17.024	-16.638	1.00	0.00	H
ATOM	215	HB	VAL	B	23	11.735	15.733	-17.795	1.00	0.00	H
ATOM	216	1HG1	VAL	B	23	12.235	15.084	-15.381	1.00	0.00	H
ATOM	217	2HG1	VAL	B	23	12.441	16.802	-15.708	1.00	0.00	H
ATOM	218	3HG1	VAL	B	23	10.993	16.242	-14.851	1.00	0.00	H
ATOM	219	1HG2	VAL	B	23	10.769	13.653	-16.617	1.00	0.00	H
ATOM	220	2HG2	VAL	B	23	9.299	14.566	-16.276	1.00	0.00	H
ATOM	221	3HG2	VAL	B	23	9.755	14.219	-17.947	1.00	0.00	H
ATOM	222	N	ILE	B	24	10.259	19.080	-18.343	1.00	20.00	N
ATOM	223	CA	ILE	B	24	10.780	20.409	-18.505	1.00	20.00	C
ATOM	224	C	ILE	B	24	9.689	21.464	-18.400	1.00	20.00	C
ATOM	225	O	ILE	B	24	9.769	22.472	-17.749	1.00	20.00	O
ATOM	226	CB	ILE	B	24	11.526	20.442	-19.899	1.00	20.00	C
ATOM	227	CG1	ILE	B	24	12.738	19.451	-19.962	1.00	20.00	C
ATOM	228	CG2	ILE	B	24	11.966	21.865	-20.293	1.00	20.00	C
ATOM	229	CD1	ILE	B	24	13.756	19.568	-21.111	1.00	20.00	C
ATOM	230	H	ILE	B	24	9.876	18.462	-19.074	1.00	0.00	H
ATOM	231	HA	ILE	B	24	11.535	20.702	-17.746	1.00	0.00	H
ATOM	232	HB	ILE	B	24	10.810	20.127	-20.687	1.00	0.00	H
ATOM	233	1HG1	ILE	B	24	12.330	18.429	-19.977	1.00	0.00	H
ATOM	234	2HG1	ILE	B	24	13.278	19.452	-19.008	1.00	0.00	H
ATOM	235	1HG2	ILE	B	24	12.385	21.868	-21.312	1.00	0.00	H
ATOM	236	2HG2	ILE	B	24	11.137	22.596	-20.315	1.00	0.00	H
ATOM	237	3HG2	ILE	B	24	12.726	22.236	-19.587	1.00	0.00	H
ATOM	238	1HD1	ILE	B	24	14.395	18.673	-21.168	1.00	0.00	H
ATOM	239	2HD1	ILE	B	24	13.269	19.667	-22.094	1.00	0.00	H
ATOM	240	3HD1	ILE	B	24	14.421	20.442	-20.992	1.00	0.00	H
ATOM	241	N	SER	B	25	8.510	21.435	-19.019	1.00	20.00	N
ATOM	242	CA	SER	B	25	7.874	22.683	-18.628	1.00	20.00	C
ATOM	243	C	SER	B	25	8.120	22.749	-17.084	1.00	20.00	C

ATOM	244	O	SER	B	25	7.499	23.564	-16.387	1.00	20.00	O
ATOM	245	CB	SER	B	25	6.392	22.619	-19.070	1.00	20.00	C
ATOM	246	OG	SER	B	25	5.695	21.502	-18.513	1.00	20.00	O
ATOM	247	H	SER	B	25	8.069	20.534	-19.238	1.00	0.00	H
ATOM	248	HA	SER	B	25	8.311	23.573	-19.138	1.00	0.00	H
ATOM	249	1HB	SER	B	25	6.332	22.584	-20.176	1.00	0.00	H
ATOM	250	2HB	SER	B	25	5.880	23.552	-18.779	1.00	0.00	H
ATOM	251	HG	SER	B	25	4.923	21.343	-19.065	1.00	0.00	H
ATOM	252	N	ASP	B	26	9.025	21.766	-16.526	1.00	20.00	N
ATOM	253	CA	ASP	B	26	9.543	21.883	-15.222	1.00	20.00	C
ATOM	254	C	ASP	B	26	10.332	23.133	-15.032	1.00	20.00	C
ATOM	255	O	ASP	B	26	10.650	23.621	-13.995	1.00	20.00	O
ATOM	256	CB	ASP	B	26	10.315	20.683	-14.685	1.00	20.00	C
ATOM	257	CG	ASP	B	26	10.831	20.474	-13.270	1.00	20.00	C
ATOM	258	OD1	ASP	B	26	11.377	21.334	-12.591	1.00	20.00	O
ATOM	259	OD2	ASP	B	26	10.732	19.168	-12.889	1.00	20.00	O
ATOM	260	H	ASP	B	26	9.002	20.871	-17.022	1.00	0.00	H
ATOM	261	HA	ASP	B	26	8.673	21.995	-14.547	1.00	0.00	H
ATOM	262	1HB	ASP	B	26	11.260	20.693	-15.252	1.00	0.00	H
ATOM	263	2HB	ASP	B	26	9.703	19.795	-14.921	1.00	0.00	H
ATOM	264	HD2	ASP	B	26	11.192	19.048	-12.058	1.00	0.00	H
ATOM	265	N	GLU	B	27	10.676	23.595	-16.313	1.00	20.00	N
ATOM	266	CA	GLU	B	27	10.979	24.872	-16.843	1.00	20.00	C
ATOM	267	C	GLU	B	27	12.457	25.146	-16.723	1.00	20.00	C
ATOM	268	O	GLU	B	27	12.940	25.839	-15.845	1.00	20.00	O
ATOM	269	CB	GLU	B	27	10.206	26.082	-16.188	1.00	20.00	C
ATOM	270	CG	GLU	B	27	8.684	26.034	-16.015	1.00	20.00	C
ATOM	271	CD	GLU	B	27	7.877	27.232	-15.535	1.00	20.00	C
ATOM	272	OE1	GLU	B	27	8.110	28.394	-15.840	1.00	20.00	O
ATOM	273	OE2	GLU	B	27	6.766	26.846	-14.844	1.00	20.00	O
ATOM	274	H	GLU	B	27	10.168	22.932	-17.043	1.00	0.00	H
ATOM	275	HA	GLU	B	27	10.682	24.869	-17.911	1.00	0.00	H
ATOM	276	1HB	GLU	B	27	10.478	27.014	-16.720	1.00	0.00	H
ATOM	277	2HB	GLU	B	27	10.600	26.182	-15.166	1.00	0.00	H
ATOM	278	1HG	GLU	B	27	8.494	25.247	-15.267	1.00	0.00	H
ATOM	279	2HG	GLU	B	27	8.246	25.716	-16.973	1.00	0.00	H
ATOM	280	HE2	GLU	B	27	6.111	27.564	-14.861	1.00	0.00	H
ATOM	281	N	HIS	B	28	13.173	24.815	-17.644	1.00	20.00	N
ATOM	282	CA	HIS	B	28	14.477	25.353	-17.845	1.00	20.00	C
ATOM	283	C	HIS	B	28	15.130	25.132	-19.137	1.00	20.00	C
ATOM	284	O	HIS	B	28	16.054	25.682	-19.477	1.00	20.00	O
ATOM	285	CB	HIS	B	28	15.382	24.433	-16.880	1.00	20.00	C
ATOM	286	CG	HIS	B	28	15.257	22.879	-17.013	1.00	20.00	C
ATOM	287	ND1	HIS	B	28	14.277	22.146	-16.346	1.00	20.00	N
ATOM	288	CD2	HIS	B	28	15.839	22.107	-18.034	1.00	20.00	C
ATOM	289	CE1	HIS	B	28	14.340	20.984	-17.057	1.00	20.00	C
ATOM	290	NE2	HIS	B	28	15.234	20.869	-18.093	1.00	20.00	N
ATOM	291	H	HIS	B	28	13.059	23.795	-17.700	1.00	0.00	H
ATOM	292	HA	HIS	B	28	14.564	26.429	-17.582	1.00	0.00	H
ATOM	293	1HB	HIS	B	28	15.117	24.644	-15.838	1.00	0.00	H
ATOM	294	2HB	HIS	B	28	16.449	24.727	-16.929	1.00	0.00	H
ATOM	295	HD2	HIS	B	28	16.562	22.479	-18.749	1.00	0.00	H
ATOM	296	HE1	HIS	B	28	13.703	20.154	-16.777	1.00	0.00	H
ATOM	297	HE2	HIS	B	28	15.342	20.112	-18.781	1.00	0.00	H
ATOM	298	N	GLY	B	29	14.405	24.262	-19.730	1.00	20.00	N
ATOM	299	CA	GLY	B	29	14.678	23.692	-20.978	1.00	20.00	C
ATOM	300	C	GLY	B	29	15.439	24.657	-21.892	1.00	20.00	C
ATOM	301	O	GLY	B	29	14.869	25.646	-22.384	1.00	20.00	O
ATOM	302	H	GLY	B	29	13.489	24.219	-19.268	1.00	0.00	H
ATOM	303	1HA	GLY	B	29	13.739	23.468	-21.505	1.00	0.00	H
ATOM	304	2HA	GLY	B	29	15.225	22.736	-20.874	1.00	0.00	H
ATOM	305	HC	GLY	B	29	16.514	24.432	-22.015	1.00	0.00	H
ATOM	306	N	SER	B	35	11.672	31.987	-16.117	1.00	20.00	N

ATOM	307	CA	SER	B	35	10.540	31.156	-16.015	1.00	20.00	C
ATOM	308	C	SER	B	35	10.769	30.449	-14.744	1.00	20.00	C
ATOM	309	O	SER	B	35	11.006	31.054	-13.733	1.00	20.00	O
ATOM	310	CB	SER	B	35	10.306	30.429	-17.376	1.00	20.00	C
ATOM	311	OG	SER	B	35	11.315	29.457	-17.661	1.00	20.00	O
ATOM	312	1H	SER	B	35	12.536	31.435	-16.139	1.00	0.00	H
ATOM	313	2H	SER	B	35	11.651	32.529	-16.988	1.00	0.00	H
ATOM	314	HA	SER	B	35	9.663	31.807	-15.843	1.00	0.00	H
ATOM	315	1HB	SER	B	35	10.233	31.155	-18.211	1.00	0.00	H
ATOM	316	2HB	SER	B	35	9.322	29.927	-17.363	1.00	0.00	H
ATOM	317	HG	SER	B	35	12.132	29.941	-17.815	1.00	0.00	H
ATOM	318	N	TYR	B	36	10.770	29.221	-14.740	1.00	20.00	N
ATOM	319	CA	TYR	B	36	10.873	28.327	-13.657	1.00	20.00	C
ATOM	320	C	TYR	B	36	11.072	29.084	-12.383	1.00	20.00	C
ATOM	321	O	TYR	B	36	11.146	28.417	-11.310	1.00	20.00	O
ATOM	322	CB	TYR	B	36	12.352	27.799	-13.859	1.00	20.00	C
ATOM	323	CG	TYR	B	36	13.674	28.654	-13.689	1.00	20.00	C
ATOM	324	CD1	TYR	B	36	14.308	28.734	-12.440	1.00	20.00	C
ATOM	325	CD2	TYR	B	36	14.248	29.314	-14.784	1.00	20.00	C
ATOM	326	CE1	TYR	B	36	15.490	29.456	-12.292	1.00	20.00	C
ATOM	327	CE2	TYR	B	36	15.432	30.032	-14.634	1.00	20.00	C
ATOM	328	CZ	TYR	B	36	16.051	30.101	-13.390	1.00	20.00	C
ATOM	329	OH	TYR	B	36	17.217	30.804	-13.252	1.00	20.00	O
ATOM	330	H	TYR	B	36	10.596	28.874	-15.692	1.00	0.00	H
ATOM	331	HA	TYR	B	36	10.077	27.562	-13.596	1.00	0.00	H
ATOM	332	HC	TYR	B	36	11.849	29.862	-12.341	1.00	0.00	H
ATOM	333	1HB	TYR	B	36	12.391	27.575	-14.910	1.00	0.00	H
ATOM	334	2HB	TYR	B	36	12.465	26.825	-13.348	1.00	0.00	H
ATOM	335	HD1	TYR	B	36	13.892	28.218	-11.586	1.00	0.00	H
ATOM	336	HD2	TYR	B	36	13.781	29.260	-15.756	1.00	0.00	H
ATOM	337	HE1	TYR	B	36	15.969	29.502	-11.326	1.00	0.00	H
ATOM	338	HE2	TYR	B	36	15.874	30.535	-15.481	1.00	0.00	H
ATOM	339	HH	TYR	B	36	17.472	30.801	-12.327	1.00	0.00	H
ATOM	340	N	ASP	B	39	6.766	29.564	-10.458	1.00	20.00	N
ATOM	341	CA	ASP	B	39	5.865	28.673	-11.126	1.00	20.00	C
ATOM	342	C	ASP	B	39	5.089	29.250	-12.211	1.00	20.00	C
ATOM	343	O	ASP	B	39	5.222	30.345	-12.635	1.00	20.00	O
ATOM	344	CB	ASP	B	39	5.087	27.997	-9.925	1.00	20.00	C
ATOM	345	CG	ASP	B	39	5.861	26.944	-9.123	1.00	20.00	C
ATOM	346	OD1	ASP	B	39	6.101	27.031	-7.924	1.00	20.00	O
ATOM	347	OD2	ASP	B	39	6.229	25.886	-9.895	1.00	20.00	O
ATOM	348	1H	ASP	B	39	7.376	30.032	-11.139	1.00	0.00	H
ATOM	349	2H	ASP	B	39	6.245	30.321	-10.001	1.00	0.00	H
ATOM	350	HA	ASP	B	39	6.515	27.902	-11.594	1.00	0.00	H
ATOM	351	1HB	ASP	B	39	4.184	27.471	-10.279	1.00	0.00	H
ATOM	352	2HB	ASP	B	39	4.683	28.754	-9.225	1.00	0.00	H
ATOM	353	HD2	ASP	B	39	6.698	25.240	-9.362	1.00	0.00	H
ATOM	354	N	SER	B	40	4.320	28.432	-12.701	1.00	20.00	N
ATOM	355	CA	SER	B	40	3.414	28.862	-13.590	1.00	20.00	C
ATOM	356	C	SER	B	40	3.597	28.379	-14.983	1.00	20.00	C
ATOM	357	O	SER	B	40	4.725	28.244	-15.463	1.00	20.00	O
ATOM	358	CB	SER	B	40	2.648	30.257	-13.499	1.00	20.00	C
ATOM	359	OG	SER	B	40	3.433	31.301	-14.069	1.00	20.00	O
ATOM	360	H	SER	B	40	4.330	27.494	-12.285	1.00	0.00	H
ATOM	361	HA	SER	B	40	2.596	28.251	-13.136	1.00	0.00	H
ATOM	362	1HB	SER	B	40	2.416	30.506	-12.444	1.00	0.00	H
ATOM	363	2HB	SER	B	40	1.666	30.228	-14.011	1.00	0.00	H
ATOM	364	HG	SER	B	40	4.299	31.191	-13.630	1.00	0.00	H
ATOM	365	N	ASP	B	41	2.496	28.040	-15.450	1.00	20.00	N
ATOM	366	CA	ASP	B	41	2.171	27.935	-16.838	1.00	20.00	C
ATOM	367	C	ASP	B	41	1.619	26.569	-17.167	1.00	20.00	C
ATOM	368	O	ASP	B	41	0.707	26.127	-16.500	1.00	20.00	O
ATOM	369	CB	ASP	B	41	2.941	28.889	-17.854	1.00	20.00	C

ATOM	370	CG	ASP	B	41	2.915	30.387	-17.539	1.00	20.00	C
ATOM	371	OD1	ASP	B	41	1.901	31.074	-17.591	1.00	20.00	O
ATOM	372	OD2	ASP	B	41	4.138	30.868	-17.182	1.00	20.00	O
ATOM	373	H	ASP	B	41	1.729	28.114	-14.774	1.00	0.00	H
ATOM	374	HA	ASP	B	41	1.195	28.465	-16.853	1.00	0.00	H
ATOM	375	1HB	ASP	B	41	2.501	28.798	-18.863	1.00	0.00	H
ATOM	376	2HB	ASP	B	41	3.987	28.555	-17.956	1.00	0.00	H
ATOM	377	HD2	ASP	B	41	4.039	31.781	-16.906	1.00	0.00	H
ATOM	378	N	LEU	B	42	2.062	26.226	-18.304	1.00	20.00	N
ATOM	379	CA	LEU	B	42	2.243	24.814	-18.624	1.00	20.00	C
ATOM	380	C	LEU	B	42	1.778	24.530	-20.019	1.00	20.00	C
ATOM	381	O	LEU	B	42	0.890	25.205	-20.556	1.00	20.00	O
ATOM	382	CB	LEU	B	42	1.755	23.667	-17.620	1.00	20.00	C
ATOM	383	CG	LEU	B	42	2.439	23.521	-16.226	1.00	20.00	C
ATOM	384	CD1	LEU	B	42	1.677	22.491	-15.373	1.00	20.00	C
ATOM	385	CD2	LEU	B	42	3.917	23.108	-16.292	1.00	20.00	C
ATOM	386	H	LEU	B	42	2.672	26.931	-18.730	1.00	0.00	H
ATOM	387	HA	LEU	B	42	3.353	24.748	-18.579	1.00	0.00	H
ATOM	388	1HB	LEU	B	42	1.828	22.676	-18.108	1.00	0.00	H
ATOM	389	2HB	LEU	B	42	0.665	23.800	-17.475	1.00	0.00	H
ATOM	390	HG	LEU	B	42	2.392	24.483	-15.683	1.00	0.00	H
ATOM	391	1HD1	LEU	B	42	2.111	22.392	-14.360	1.00	0.00	H
ATOM	392	2HD1	LEU	B	42	0.619	22.783	-15.233	1.00	0.00	H
ATOM	393	3HD1	LEU	B	42	1.681	21.483	-15.828	1.00	0.00	H
ATOM	394	1HD2	LEU	B	42	4.366	23.043	-15.284	1.00	0.00	H
ATOM	395	2HD2	LEU	B	42	4.048	22.117	-16.761	1.00	0.00	H
ATOM	396	3HD2	LEU	B	42	4.534	23.833	-16.850	1.00	0.00	H
ATOM	397	N	GLN	B	43	2.517	23.637	-20.497	1.00	20.00	N
ATOM	398	CA	GLN	B	43	2.167	22.789	-21.619	1.00	20.00	C
ATOM	399	C	GLN	B	43	3.242	22.844	-22.643	1.00	20.00	C
ATOM	400	O	GLN	B	43	4.438	22.678	-22.315	1.00	20.00	O
ATOM	401	CB	GLN	B	43	0.631	22.496	-21.919	1.00	20.00	C
ATOM	402	CG	GLN	B	43	-0.178	21.837	-20.769	1.00	20.00	C
ATOM	403	CD	GLN	B	43	-1.648	21.585	-21.107	1.00	20.00	C
ATOM	404	OE1	GLN	B	43	-2.038	20.512	-21.553	1.00	20.00	O
ATOM	405	NE2	GLN	B	43	-2.510	22.553	-20.907	1.00	20.00	N
ATOM	406	H	GLN	B	43	3.281	23.363	-19.874	1.00	0.00	H
ATOM	407	HA	GLN	B	43	2.433	21.790	-21.217	1.00	0.00	H
ATOM	408	1HB	GLN	B	43	0.555	21.824	-22.797	1.00	0.00	H
ATOM	409	2HB	GLN	B	43	0.138	23.437	-22.235	1.00	0.00	H
ATOM	410	1HG	GLN	B	43	-0.113	22.440	-19.844	1.00	0.00	H
ATOM	411	2HG	GLN	B	43	0.276	20.864	-20.505	1.00	0.00	H
ATOM	412	1HE2	GLN	B	43	-2.130	23.454	-20.602	1.00	0.00	H
ATOM	413	2HE2	GLN	B	43	-3.468	22.326	-21.187	1.00	0.00	H
ATOM	414	N	LEU	B	44	2.723	23.162	-23.717	1.00	20.00	N
ATOM	415	CA	LEU	B	44	3.497	23.213	-24.909	1.00	20.00	C
ATOM	416	C	LEU	B	44	3.616	24.654	-25.280	1.00	20.00	C
ATOM	417	O	LEU	B	44	3.428	24.979	-26.392	1.00	20.00	O
ATOM	418	CB	LEU	B	44	2.813	22.271	-25.956	1.00	20.00	C
ATOM	419	CG	LEU	B	44	3.659	21.889	-27.202	1.00	20.00	C
ATOM	420	CD1	LEU	B	44	4.826	20.943	-26.859	1.00	20.00	C
ATOM	421	CD2	LEU	B	44	2.768	21.218	-28.263	1.00	20.00	C
ATOM	422	H	LEU	B	44	1.706	23.290	-23.703	1.00	0.00	H
ATOM	423	HA	LEU	B	44	4.539	22.856	-24.765	1.00	0.00	H
ATOM	424	1HB	LEU	B	44	1.869	22.747	-26.287	1.00	0.00	H
ATOM	425	2HB	LEU	B	44	2.484	21.331	-25.475	1.00	0.00	H
ATOM	426	HG	LEU	B	44	4.075	22.813	-27.653	1.00	0.00	H
ATOM	427	1HD1	LEU	B	44	4.478	20.012	-26.375	1.00	0.00	H
ATOM	428	2HD1	LEU	B	44	5.396	20.651	-27.761	1.00	0.00	H
ATOM	429	3HD1	LEU	B	44	5.554	21.411	-26.172	1.00	0.00	H
ATOM	430	1HD2	LEU	B	44	1.947	21.885	-28.585	1.00	0.00	H
ATOM	431	2HD2	LEU	B	44	3.339	20.962	-29.175	1.00	0.00	H
ATOM	432	3HD2	LEU	B	44	2.306	20.285	-27.892	1.00	0.00	H

ATOM	433	N	GLU	B	47	3.551	25.573	-24.187	1.00	20.00	N
ATOM	434	CA	GLU	B	47	3.785	26.990	-24.318	1.00	20.00	C
ATOM	435	C	GLU	B	47	2.950	27.789	-23.342	1.00	20.00	C
ATOM	436	O	GLU	B	47	1.989	27.354	-22.763	1.00	20.00	O
ATOM	437	CB	GLU	B	47	3.981	27.659	-25.739	1.00	20.00	C
ATOM	438	CG	GLU	B	47	5.360	27.407	-26.406	1.00	20.00	C
ATOM	439	CD	GLU	B	47	5.500	28.057	-27.779	1.00	20.00	C
ATOM	440	OE1	GLU	B	47	5.893	29.206	-27.953	1.00	20.00	O
ATOM	441	OE2	GLU	B	47	5.142	27.219	-28.791	1.00	20.00	O
ATOM	442	H	GLU	B	47	3.445	25.108	-23.278	1.00	0.00	H
ATOM	443	HA	GLU	B	47	4.781	27.103	-23.856	1.00	0.00	H
ATOM	444	1HB	GLU	B	47	3.878	28.759	-25.678	1.00	0.00	H
ATOM	445	2HB	GLU	B	47	3.151	27.364	-26.409	1.00	0.00	H
ATOM	446	1HG	GLU	B	47	5.565	26.326	-26.505	1.00	0.00	H
ATOM	447	2HG	GLU	B	47	6.169	27.797	-25.761	1.00	0.00	H
ATOM	448	HE2	GLU	B	47	5.243	27.683	-29.623	1.00	0.00	H
ATOM	449	N	ARG	B	48	2.874	29.140	-23.382	1.00	20.00	N
ATOM	450	CA	ARG	B	48	3.028	30.420	-22.705	1.00	20.00	C
ATOM	451	C	ARG	B	48	2.591	31.544	-23.593	1.00	20.00	C
ATOM	452	O	ARG	B	48	1.580	31.416	-24.308	1.00	20.00	O
ATOM	453	CB	ARG	B	48	4.467	30.618	-22.151	1.00	20.00	C
ATOM	454	CG	ARG	B	48	4.827	29.682	-20.972	1.00	20.00	C
ATOM	455	CD	ARG	B	48	5.936	28.656	-21.279	1.00	20.00	C
ATOM	456	NE	ARG	B	48	5.899	27.545	-20.273	1.00	20.00	N
ATOM	457	CZ	ARG	B	48	6.285	27.487	-19.073	1.00	20.00	C
ATOM	458	NH1	ARG	B	48	6.868	28.486	-18.470	1.00	20.00	N
ATOM	459	NH2	ARG	B	48	6.054	26.396	-18.422	1.00	20.00	N
ATOM	460	H	ARG	B	48	2.096	29.247	-24.044	1.00	0.00	H
ATOM	461	HA	ARG	B	48	2.323	30.430	-21.850	1.00	0.00	H
ATOM	462	HC	ARG	B	48	3.214	32.457	-23.563	1.00	0.00	H
ATOM	463	1HB	ARG	B	48	4.580	31.656	-21.783	1.00	0.00	H
ATOM	464	2HB	ARG	B	48	5.209	30.537	-22.971	1.00	0.00	H
ATOM	465	1HG	ARG	B	48	3.918	29.142	-20.642	1.00	0.00	H
ATOM	466	2HG	ARG	B	48	5.118	30.281	-20.087	1.00	0.00	H
ATOM	467	1HD	ARG	B	48	6.934	29.136	-21.298	1.00	0.00	H
ATOM	468	2HD	ARG	B	48	5.802	28.227	-22.286	1.00	0.00	H
ATOM	469	1HH1	ARG	B	48	7.148	28.373	-17.489	1.00	0.00	H
ATOM	470	2HH1	ARG	B	48	6.984	29.305	-19.068	1.00	0.00	H
ATOM	471	1HH2	ARG	B	48	6.311	26.366	-17.433	1.00	0.00	H
ATOM	472	2HH2	ARG	B	48	5.592	25.695	-19.000	1.00	0.00	H
ATOM	473	N	PHE	B	83	1.262	15.881	-24.607	1.00	20.00	N
ATOM	474	CA	PHE	B	83	2.001	17.004	-23.893	1.00	20.00	C
ATOM	475	C	PHE	B	83	2.395	18.200	-24.738	1.00	20.00	C
ATOM	476	O	PHE	B	83	2.770	19.264	-24.235	1.00	20.00	O
ATOM	477	CB	PHE	B	83	3.118	16.479	-22.964	1.00	20.00	C
ATOM	478	CG	PHE	B	83	3.374	17.372	-21.725	1.00	20.00	C
ATOM	479	CD1	PHE	B	83	2.694	17.116	-20.529	1.00	20.00	C
ATOM	480	CD2	PHE	B	83	4.357	18.370	-21.752	1.00	20.00	C
ATOM	481	CE1	PHE	B	83	3.000	17.838	-19.377	1.00	20.00	C
ATOM	482	CE2	PHE	B	83	4.664	19.088	-20.599	1.00	20.00	C
ATOM	483	CZ	PHE	B	83	3.988	18.817	-19.412	1.00	20.00	C
ATOM	484	1H	PHE	B	83	0.465	16.244	-25.143	1.00	0.00	H
ATOM	485	2H	PHE	B	83	1.875	15.413	-25.285	1.00	0.00	H
ATOM	486	HA	PHE	B	83	1.227	17.425	-23.220	1.00	0.00	H
ATOM	487	HC	PHE	B	83	2.325	18.029	-25.828	1.00	0.00	H
ATOM	488	1HB	PHE	B	83	4.052	16.326	-23.540	1.00	0.00	H
ATOM	489	2HB	PHE	B	83	2.863	15.459	-22.613	1.00	0.00	H
ATOM	490	HD1	PHE	B	83	1.943	16.340	-20.482	1.00	0.00	H
ATOM	491	HD2	PHE	B	83	4.901	18.575	-22.663	1.00	0.00	H
ATOM	492	HE1	PHE	B	83	2.483	17.624	-18.453	1.00	0.00	H
ATOM	493	HE2	PHE	B	83	5.443	19.836	-20.630	1.00	0.00	H
ATOM	494	HZ	PHE	B	83	4.236	19.350	-18.507	1.00	0.00	H
ATOM	495	N	LEU	B	209	18.035	-0.588	-17.442	1.00	20.00	N

ATOM	496	CA	LEU	B	209	17.039	0.374	-16.979	1.00	20.00	C
ATOM	497	C	LEU	B	209	16.036	-0.299	-16.122	1.00	20.00	C
ATOM	498	O	LEU	B	209	15.469	0.322	-15.241	1.00	20.00	O
ATOM	499	CB	LEU	B	209	16.400	1.129	-18.183	1.00	20.00	C
ATOM	500	CG	LEU	B	209	17.104	2.435	-18.641	1.00	20.00	C
ATOM	501	CD1	LEU	B	209	18.499	2.207	-19.252	1.00	20.00	C
ATOM	502	CD2	LEU	B	209	16.238	3.207	-19.653	1.00	20.00	C
ATOM	503	1H	LEU	B	209	17.614	-1.253	-18.101	1.00	0.00	H
ATOM	504	2H	LEU	B	209	18.760	-0.104	-17.985	1.00	0.00	H
ATOM	505	HA	LEU	B	209	17.553	1.110	-16.329	1.00	0.00	H
ATOM	506	HC	LEU	B	209	15.843	-1.364	-16.354	1.00	0.00	H
ATOM	507	1HB	LEU	B	209	15.372	1.422	-17.897	1.00	0.00	H
ATOM	508	2HB	LEU	B	209	16.250	0.449	-19.045	1.00	0.00	H
ATOM	509	HG	LEU	B	209	17.210	3.087	-17.755	1.00	0.00	H
ATOM	510	1HD1	LEU	B	209	18.974	3.158	-19.561	1.00	0.00	H
ATOM	511	2HD1	LEU	B	209	19.196	1.743	-18.530	1.00	0.00	H
ATOM	512	3HD1	LEU	B	209	18.463	1.553	-20.143	1.00	0.00	H
ATOM	513	1HD2	LEU	B	209	16.706	4.166	-19.943	1.00	0.00	H
ATOM	514	2HD2	LEU	B	209	16.070	2.632	-20.583	1.00	0.00	H
ATOM	515	3HD2	LEU	B	209	15.244	3.460	-19.238	1.00	0.00	H
ATOM	516	N	ILE	B	212	16.889	-0.953	-12.423	1.00	20.00	N
ATOM	517	CA	ILE	B	212	16.587	0.279	-11.711	1.00	20.00	C
ATOM	518	C	ILE	B	212	15.114	0.467	-11.449	1.00	20.00	C
ATOM	519	O	ILE	B	212	14.707	0.759	-10.358	1.00	20.00	O
ATOM	520	CB	ILE	B	212	17.502	1.459	-12.215	1.00	20.00	C
ATOM	521	CG1	ILE	B	212	18.886	1.397	-11.490	1.00	20.00	C
ATOM	522	CG2	ILE	B	212	16.895	2.865	-12.018	1.00	20.00	C
ATOM	523	CD1	ILE	B	212	20.026	2.205	-12.118	1.00	20.00	C
ATOM	524	1H	ILE	B	212	16.676	-0.847	-13.422	1.00	0.00	H
ATOM	525	2H	ILE	B	212	17.896	-1.148	-12.384	1.00	0.00	H
ATOM	526	HA	ILE	B	212	16.934	0.071	-10.680	1.00	0.00	H
ATOM	527	HB	ILE	B	212	17.663	1.339	-13.306	1.00	0.00	H
ATOM	528	1HG1	ILE	B	212	19.235	0.347	-11.437	1.00	0.00	H
ATOM	529	2HG1	ILE	B	212	18.769	1.699	-10.430	1.00	0.00	H
ATOM	530	1HG2	ILE	B	212	17.545	3.673	-12.400	1.00	0.00	H
ATOM	531	2HG2	ILE	B	212	15.923	2.978	-12.523	1.00	0.00	H
ATOM	532	3HG2	ILE	B	212	16.707	3.062	-10.951	1.00	0.00	H
ATOM	533	1HD1	ILE	B	212	20.953	2.123	-11.520	1.00	0.00	H
ATOM	534	2HD1	ILE	B	212	20.260	1.822	-13.125	1.00	0.00	H
ATOM	535	3HD1	ILE	B	212	19.791	3.281	-12.204	1.00	0.00	H
ATOM	536	N	CYS	B	213	14.322	0.307	-12.443	1.00	20.00	N
ATOM	537	CA	CYS	B	213	12.899	0.530	-12.319	1.00	20.00	C
ATOM	538	C	CYS	B	213	12.272	-0.616	-11.670	1.00	20.00	C
ATOM	539	O	CYS	B	213	11.083	-0.856	-11.813	1.00	20.00	O
ATOM	540	CB	CYS	B	213	12.371	0.813	-13.758	1.00	20.00	C
ATOM	541	SG	CYS	B	213	11.581	2.450	-13.781	1.00	20.00	S
ATOM	542	H	CYS	B	213	14.786	0.151	-13.350	1.00	0.00	H
ATOM	543	HA	CYS	B	213	12.695	1.446	-11.743	1.00	0.00	H
ATOM	544	HC	CYS	B	213	12.925	-1.224	-11.013	1.00	0.00	H
ATOM	545	1HB	CYS	B	213	11.628	0.065	-14.097	1.00	0.00	H
ATOM	546	2HB	CYS	B	213	13.142	0.811	-14.551	1.00	0.00	H
ATOM	547	HG	CYS	B	213	11.209	2.447	-15.055	1.00	0.00	H
ATOM	548	N	THR	B	216	15.553	-0.661	-7.257	1.00	20.00	N
ATOM	549	CA	THR	B	216	15.416	0.629	-6.590	1.00	20.00	C
ATOM	550	C	THR	B	216	13.989	1.019	-6.484	1.00	20.00	C
ATOM	551	O	THR	B	216	13.526	1.419	-5.438	1.00	20.00	O
ATOM	552	CB	THR	B	216	16.403	1.697	-7.137	1.00	20.00	C
ATOM	553	OG1	THR	B	216	16.176	1.992	-8.514	1.00	20.00	O
ATOM	554	CG2	THR	B	216	17.895	1.357	-6.971	1.00	20.00	C
ATOM	555	1H	THR	B	216	15.571	-0.554	-8.277	1.00	0.00	H
ATOM	556	2H	THR	B	216	16.460	-1.081	-7.024	1.00	0.00	H
ATOM	557	HA	THR	B	216	15.725	0.453	-5.541	1.00	0.00	H
ATOM	558	HB	THR	B	216	16.228	2.616	-6.548	1.00	0.00	H

ATOM	559	HG1	THR	B	216	15.516	1.381	-8.871	1.00	0.00	H
ATOM	560	1HG2	THR	B	216	18.153	1.128	-5.920	1.00	0.00	H
ATOM	561	2HG2	THR	B	216	18.190	0.486	-7.584	1.00	0.00	H
ATOM	562	3HG2	THR	B	216	18.538	2.201	-7.280	1.00	0.00	H
ATOM	563	N	LEU	B	217	13.355	0.883	-7.557	1.00	20.00	N
ATOM	564	CA	LEU	B	217	11.961	1.134	-7.652	1.00	20.00	C
ATOM	565	C	LEU	B	217	11.294	-0.133	-7.434	1.00	20.00	C
ATOM	566	O	LEU	B	217	11.893	-1.207	-7.546	1.00	20.00	O
ATOM	567	CB	LEU	B	217	11.650	1.864	-8.995	1.00	20.00	C
ATOM	568	CG	LEU	B	217	11.770	3.409	-8.955	1.00	20.00	C
ATOM	569	CD1	LEU	B	217	11.926	3.992	-10.366	1.00	20.00	C
ATOM	570	CD2	LEU	B	217	10.556	4.067	-8.272	1.00	20.00	C
ATOM	571	H	LEU	B	217	13.820	0.223	-8.191	1.00	0.00	H
ATOM	572	HA	LEU	B	217	11.651	1.842	-6.848	1.00	0.00	H
ATOM	573	1HB	LEU	B	217	10.645	1.595	-9.371	1.00	0.00	H
ATOM	574	2HB	LEU	B	217	12.326	1.460	-9.756	1.00	0.00	H
ATOM	575	HG	LEU	B	217	12.686	3.674	-8.390	1.00	0.00	H
ATOM	576	1HD1	LEU	B	217	12.010	5.095	-10.349	1.00	0.00	H
ATOM	577	2HD1	LEU	B	217	12.848	3.616	-10.844	1.00	0.00	H
ATOM	578	3HD1	LEU	B	217	11.076	3.734	-11.026	1.00	0.00	H
ATOM	579	1HD2	LEU	B	217	10.689	5.161	-8.197	1.00	0.00	H
ATOM	580	2HD2	LEU	B	217	9.614	3.891	-8.825	1.00	0.00	H
ATOM	581	3HD2	LEU	B	217	10.404	3.706	-7.241	1.00	0.00	H
ATOM	582	N	LYS	B	218	10.088	0.003	-7.128	1.00	20.00	N
ATOM	583	CA	LYS	B	218	9.298	-1.191	-7.004	1.00	20.00	C
ATOM	584	C	LYS	B	218	8.448	-1.430	-8.225	1.00	20.00	C
ATOM	585	O	LYS	B	218	8.305	-2.587	-8.724	1.00	20.00	O
ATOM	586	CB	LYS	B	218	8.452	-1.017	-5.705	1.00	20.00	C
ATOM	587	CG	LYS	B	218	7.630	-2.257	-5.278	1.00	20.00	C
ATOM	588	CD	LYS	B	218	6.839	-2.015	-3.978	1.00	20.00	C
ATOM	589	CE	LYS	B	218	6.001	-3.238	-3.574	1.00	20.00	C
ATOM	590	NZ	LYS	B	218	5.260	-2.951	-2.330	1.00	20.00	N
ATOM	591	H	LYS	B	218	9.771	0.946	-6.885	1.00	0.00	H
ATOM	592	HA	LYS	B	218	9.889	-2.121	-6.850	1.00	0.00	H
ATOM	593	1HB	LYS	B	218	7.770	-0.149	-5.805	1.00	0.00	H
ATOM	594	2HB	LYS	B	218	9.126	-0.757	-4.863	1.00	0.00	H
ATOM	595	1HG	LYS	B	218	8.304	-3.127	-5.149	1.00	0.00	H
ATOM	596	2HG	LYS	B	218	6.931	-2.543	-6.088	1.00	0.00	H
ATOM	597	1HD	LYS	B	218	6.175	-1.137	-4.104	1.00	0.00	H
ATOM	598	2HD	LYS	B	218	7.539	-1.748	-3.162	1.00	0.00	H
ATOM	599	1HE	LYS	B	218	6.649	-4.126	-3.433	1.00	0.00	H
ATOM	600	2HE	LYS	B	218	5.287	-3.501	-4.379	1.00	0.00	H
ATOM	601	1HZ	LYS	B	218	4.724	-3.769	-2.017	1.00	0.00	H
ATOM	602	2HZ	LYS	B	218	5.906	-2.734	-1.562	1.00	0.00	H
ATOM	603	N	LEU	B	219	7.704	-0.297	-8.881	1.00	20.00	N
ATOM	604	CA	LEU	B	219	6.813	-0.377	-10.142	1.00	20.00	C
ATOM	605	C	LEU	B	219	6.267	-1.705	-10.183	1.00	20.00	C
ATOM	606	O	LEU	B	219	6.936	-2.679	-10.172	1.00	20.00	O
ATOM	607	CB	LEU	B	219	7.546	0.025	-11.446	1.00	20.00	C
ATOM	608	CG	LEU	B	219	8.027	1.492	-11.563	1.00	20.00	C
ATOM	609	CD1	LEU	B	219	8.689	1.677	-12.932	1.00	20.00	C
ATOM	610	CD2	LEU	B	219	6.913	2.544	-11.403	1.00	20.00	C
ATOM	611	H	LEU	B	219	7.927	0.607	-8.456	1.00	0.00	H
ATOM	612	HA	LEU	B	219	5.972	0.326	-9.993	1.00	0.00	H
ATOM	613	1HB	LEU	B	219	6.884	-0.197	-12.307	1.00	0.00	H
ATOM	614	2HB	LEU	B	219	8.414	-0.652	-11.580	1.00	0.00	H
ATOM	615	HG	LEU	B	219	8.794	1.674	-10.785	1.00	0.00	H
ATOM	616	1HD1	LEU	B	219	9.125	2.686	-13.034	1.00	0.00	H
ATOM	617	2HD1	LEU	B	219	9.510	0.953	-13.083	1.00	0.00	H
ATOM	618	3HD1	LEU	B	219	7.976	1.541	-13.766	1.00	0.00	H
ATOM	619	1HD2	LEU	B	219	7.303	3.570	-11.543	1.00	0.00	H
ATOM	620	2HD2	LEU	B	219	6.096	2.399	-12.135	1.00	0.00	H
ATOM	621	3HD2	LEU	B	219	6.463	2.523	-10.395	1.00	0.00	H

ATOM	622	N	THR	B	220	5.097	-2.067	-10.215	1.00	20.00	N
ATOM	623	CA	THR	B	220	5.087	-3.527	-10.126	1.00	20.00	C
ATOM	624	C	THR	B	220	5.446	-4.241	-11.471	1.00	20.00	C
ATOM	625	O	THR	B	220	6.064	-5.348	-11.440	1.00	20.00	O
ATOM	626	CB	THR	B	220	3.613	-3.961	-9.760	1.00	20.00	C
ATOM	627	OG1	THR	B	220	2.633	-3.458	-10.675	1.00	20.00	O
ATOM	628	CG2	THR	B	220	3.140	-3.579	-8.344	1.00	20.00	C
ATOM	629	H	THR	B	220	4.364	-1.437	-9.877	1.00	0.00	H
ATOM	630	HA	THR	B	220	5.599	-4.021	-9.255	1.00	0.00	H
ATOM	631	HB	THR	B	220	3.565	-5.070	-9.798	1.00	0.00	H
ATOM	632	HG1	THR	B	220	2.898	-3.737	-11.558	1.00	0.00	H
ATOM	633	1HG2	THR	B	220	2.128	-3.977	-8.142	1.00	0.00	H
ATOM	634	2HG2	THR	B	220	3.811	-3.980	-7.562	1.00	0.00	H
ATOM	635	3HG2	THR	B	220	3.087	-2.484	-8.207	1.00	0.00	H
ATOM	636	N	THR	B	221	5.010	-3.504	-12.571	1.00	20.00	N
ATOM	637	CA	THR	B	221	5.039	-3.827	-14.104	1.00	20.00	C
ATOM	638	C	THR	B	221	5.545	-2.539	-14.789	1.00	20.00	C
ATOM	639	O	THR	B	221	4.789	-1.588	-15.024	1.00	20.00	O
ATOM	640	CB	THR	B	221	3.636	-4.248	-14.638	1.00	20.00	C
ATOM	641	OG1	THR	B	221	2.676	-3.223	-14.391	1.00	20.00	O
ATOM	642	CG2	THR	B	221	3.087	-5.563	-14.063	1.00	20.00	C
ATOM	643	H	THR	B	221	4.700	-2.580	-12.246	1.00	0.00	H
ATOM	644	HA	THR	B	221	5.719	-4.680	-14.276	1.00	0.00	H
ATOM	645	HB	THR	B	221	3.715	-4.384	-15.736	1.00	0.00	H
ATOM	646	HG1	THR	B	221	3.100	-2.401	-14.678	1.00	0.00	H
ATOM	647	1HG2	THR	B	221	2.107	-5.813	-14.509	1.00	0.00	H
ATOM	648	2HG2	THR	B	221	3.764	-6.414	-14.260	1.00	0.00	H
ATOM	649	3HG2	THR	B	221	2.938	-5.507	-12.969	1.00	0.00	H
ATOM	650	N	PRO	B	222	6.819	-2.397	-15.191	1.00	20.00	N
ATOM	651	CA	PRO	B	222	7.323	-1.169	-15.718	1.00	20.00	C
ATOM	652	C	PRO	B	222	6.695	-0.873	-16.949	1.00	20.00	C
ATOM	653	O	PRO	B	222	5.648	-1.439	-17.289	1.00	20.00	O
ATOM	654	CB	PRO	B	222	8.867	-1.379	-15.534	1.00	20.00	C
ATOM	655	CG	PRO	B	222	9.098	-2.876	-15.669	1.00	20.00	C
ATOM	656	CD	PRO	B	222	7.856	-3.445	-14.997	1.00	20.00	C
ATOM	657	HA	PRO	B	222	7.037	-0.345	-15.030	1.00	0.00	H
ATOM	658	1HB	PRO	B	222	9.171	-1.052	-14.519	1.00	0.00	H
ATOM	659	2HB	PRO	B	222	9.499	-0.800	-16.234	1.00	0.00	H
ATOM	660	1HG	PRO	B	222	10.038	-3.216	-15.194	1.00	0.00	H
ATOM	661	2HG	PRO	B	222	9.134	-3.171	-16.736	1.00	0.00	H
ATOM	662	1HD	PRO	B	222	7.580	-4.413	-15.459	1.00	0.00	H
ATOM	663	2HD	PRO	B	222	8.035	-3.623	-13.917	1.00	0.00	H
ATOM	664	N	THR	B	223	7.343	-0.088	-17.621	1.00	20.00	N
ATOM	665	CA	THR	B	223	6.769	0.339	-18.786	1.00	20.00	C
ATOM	666	C	THR	B	223	7.753	1.099	-19.511	1.00	20.00	C
ATOM	667	O	THR	B	223	8.689	1.648	-18.930	1.00	20.00	O
ATOM	668	CB	THR	B	223	5.419	1.223	-18.634	1.00	20.00	C
ATOM	669	OG1	THR	B	223	4.647	0.937	-17.471	1.00	20.00	O
ATOM	670	CG2	THR	B	223	4.408	1.030	-19.781	1.00	20.00	C
ATOM	671	H	THR	B	223	8.199	0.306	-17.217	1.00	0.00	H
ATOM	672	HA	THR	B	223	6.507	-0.576	-19.380	1.00	0.00	H
ATOM	673	HB	THR	B	223	5.667	2.299	-18.564	1.00	0.00	H
ATOM	674	HG1	THR	B	223	4.768	-0.016	-17.313	1.00	0.00	H
ATOM	675	1HG2	THR	B	223	3.500	1.639	-19.614	1.00	0.00	H
ATOM	676	2HG2	THR	B	223	4.802	1.317	-20.770	1.00	0.00	H
ATOM	677	3HG2	THR	B	223	4.073	-0.022	-19.852	1.00	0.00	H
ATOM	678	N	TYR	B	224	7.510	1.084	-20.758	1.00	20.00	N
ATOM	679	CA	TYR	B	224	8.246	1.904	-21.594	1.00	20.00	C
ATOM	680	C	TYR	B	224	7.786	3.322	-21.200	1.00	20.00	C
ATOM	681	O	TYR	B	224	8.460	4.256	-21.106	1.00	20.00	O
ATOM	682	CB	TYR	B	224	7.998	1.581	-23.094	1.00	20.00	C
ATOM	683	CG	TYR	B	224	8.634	0.268	-23.588	1.00	20.00	C
ATOM	684	CD1	TYR	B	224	10.000	0.213	-23.887	1.00	20.00	C

ATOM	685	CD2	TYR	B	224	7.855	-0.886	-23.729	1.00	20.00	C
ATOM	686	CE1	TYR	B	224	10.579	-0.980	-24.315	1.00	20.00	C
ATOM	687	CE2	TYR	B	224	8.436	-2.078	-24.157	1.00	20.00	C
ATOM	688	CZ	TYR	B	224	9.796	-2.124	-24.449	1.00	20.00	C
ATOM	689	OH	TYR	B	224	10.358	-3.299	-24.870	1.00	20.00	O
ATOM	690	H	TYR	B	224	6.759	0.467	-21.082	1.00	0.00	H
ATOM	691	HA	TYR	B	224	9.338	1.830	-21.400	1.00	0.00	H
ATOM	692	1HB	TYR	B	224	8.404	2.407	-23.709	1.00	0.00	H
ATOM	693	2HB	TYR	B	224	6.914	1.599	-23.324	1.00	0.00	H
ATOM	694	HD1	TYR	B	224	10.619	1.094	-23.783	1.00	0.00	H
ATOM	695	HD2	TYR	B	224	6.798	-0.867	-23.505	1.00	0.00	H
ATOM	696	HE1	TYR	B	224	11.635	-1.011	-24.541	1.00	0.00	H
ATOM	697	HE2	TYR	B	224	7.835	-2.969	-24.264	1.00	0.00	H
ATOM	698	HH	TYR	B	224	11.291	-3.157	-25.038	1.00	0.00	H
ATOM	699	N	GLY	B	225	6.606	3.740	-20.847	1.00	20.00	N
ATOM	700	CA	GLY	B	225	6.574	5.207	-20.510	1.00	20.00	C
ATOM	701	C	GLY	B	225	7.283	5.461	-19.203	1.00	20.00	C
ATOM	702	O	GLY	B	225	7.881	6.509	-19.054	1.00	20.00	O
ATOM	703	H	GLY	B	225	5.809	3.109	-20.979	1.00	0.00	H
ATOM	704	1HA	GLY	B	225	5.520	5.499	-20.359	1.00	0.00	H
ATOM	705	2HA	GLY	B	225	6.908	5.891	-21.321	1.00	0.00	H
ATOM	706	N	ASP	B	226	7.352	4.615	-18.320	1.00	20.00	N
ATOM	707	CA	ASP	B	226	7.911	4.852	-17.047	1.00	20.00	C
ATOM	708	C	ASP	B	226	9.410	4.927	-17.088	1.00	20.00	C
ATOM	709	O	ASP	B	226	10.053	5.601	-16.316	1.00	20.00	O
ATOM	710	CB	ASP	B	226	7.334	3.838	-16.016	1.00	20.00	C
ATOM	711	CG	ASP	B	226	7.202	4.435	-14.609	1.00	20.00	C
ATOM	712	OD1	ASP	B	226	8.145	4.860	-13.952	1.00	20.00	O
ATOM	713	OD2	ASP	B	226	5.911	4.467	-14.177	1.00	20.00	O
ATOM	714	H	ASP	B	226	6.941	3.719	-18.600	1.00	0.00	H
ATOM	715	HA	ASP	B	226	7.579	5.855	-16.706	1.00	0.00	H
ATOM	716	1HB	ASP	B	226	7.956	2.925	-15.964	1.00	0.00	H
ATOM	717	2HB	ASP	B	226	6.331	3.473	-16.316	1.00	0.00	H
ATOM	718	HD2	ASP	B	226	5.886	4.862	-13.304	1.00	0.00	H
ATOM	719	N	LEU	B	227	9.936	4.229	-18.065	1.00	20.00	N
ATOM	720	CA	LEU	B	227	11.354	4.291	-18.306	1.00	20.00	C
ATOM	721	C	LEU	B	227	11.749	5.668	-18.727	1.00	20.00	C
ATOM	722	O	LEU	B	227	12.917	6.031	-18.605	1.00	20.00	O
ATOM	723	CB	LEU	B	227	11.767	3.176	-19.326	1.00	20.00	C
ATOM	724	CG	LEU	B	227	12.461	1.924	-18.723	1.00	20.00	C
ATOM	725	CD1	LEU	B	227	11.549	1.051	-17.843	1.00	20.00	C
ATOM	726	CD2	LEU	B	227	13.042	1.040	-19.841	1.00	20.00	C
ATOM	727	H	LEU	B	227	9.290	3.609	-18.574	1.00	0.00	H
ATOM	728	HA	LEU	B	227	11.899	4.105	-17.356	1.00	0.00	H
ATOM	729	1HB	LEU	B	227	12.475	3.610	-20.061	1.00	0.00	H
ATOM	730	2HB	LEU	B	227	10.915	2.864	-19.960	1.00	0.00	H
ATOM	731	HG	LEU	B	227	13.300	2.278	-18.093	1.00	0.00	H
ATOM	732	1HD1	LEU	B	227	12.131	0.311	-17.262	1.00	0.00	H
ATOM	733	2HD1	LEU	B	227	10.971	1.648	-17.118	1.00	0.00	H
ATOM	734	3HD1	LEU	B	227	10.816	0.480	-18.442	1.00	0.00	H
ATOM	735	1HD2	LEU	B	227	13.579	0.162	-19.437	1.00	0.00	H
ATOM	736	2HD2	LEU	B	227	12.254	0.656	-20.518	1.00	0.00	H
ATOM	737	3HD2	LEU	B	227	13.766	1.592	-20.469	1.00	0.00	H
ATOM	738	N	ASN	B	228	10.772	6.420	-19.188	1.00	20.00	N
ATOM	739	CA	ASN	B	228	10.987	7.782	-19.597	1.00	20.00	C
ATOM	740	C	ASN	B	228	11.062	8.714	-18.350	1.00	20.00	C
ATOM	741	O	ASN	B	228	11.707	9.754	-18.362	1.00	20.00	O
ATOM	742	CB	ASN	B	228	10.264	8.024	-20.947	1.00	20.00	C
ATOM	743	CG	ASN	B	228	10.745	7.209	-22.161	1.00	20.00	C
ATOM	744	OD1	ASN	B	228	11.731	7.547	-22.807	1.00	20.00	O
ATOM	745	ND2	ASN	B	228	10.092	6.139	-22.535	1.00	20.00	N
ATOM	746	H	ASN	B	228	9.846	5.969	-19.182	1.00	0.00	H
ATOM	747	HA	ASN	B	228	12.044	7.875	-19.930	1.00	0.00	H

ATOM	748	1HB	ASN	B	228	10.502	9.040	-21.285	1.00	0.00	H
ATOM	749	2HB	ASN	B	228	9.168	7.960	-20.834	1.00	0.00	H
ATOM	750	1HD2	ASN	B	228	9.424	5.734	-21.865	1.00	0.00	H
ATOM	751	2HD2	ASN	B	228	10.548	5.658	-23.314	1.00	0.00	H
ATOM	752	N	HIS	B	229	10.350	8.392	-17.246	1.00	20.00	N
ATOM	753	CA	HIS	B	229	10.717	9.020	-15.962	1.00	20.00	C
ATOM	754	C	HIS	B	229	12.252	8.701	-15.921	1.00	20.00	C
ATOM	755	O	HIS	B	229	13.088	9.463	-16.144	1.00	20.00	O
ATOM	756	CB	HIS	B	229	9.786	8.550	-14.814	1.00	20.00	C
ATOM	757	CG	HIS	B	229	8.362	9.123	-14.913	1.00	20.00	C
ATOM	758	ND1	HIS	B	229	7.930	10.194	-14.150	1.00	20.00	N
ATOM	759	CD2	HIS	B	229	7.391	8.797	-15.884	1.00	20.00	C
ATOM	760	CE1	HIS	B	229	6.723	10.436	-14.751	1.00	20.00	C
ATOM	761	NE2	HIS	B	229	6.301	9.641	-15.782	1.00	20.00	N
ATOM	762	H	HIS	B	229	9.973	7.436	-17.287	1.00	0.00	H
ATOM	763	HA	HIS	B	229	10.623	10.123	-16.045	1.00	0.00	H
ATOM	764	1HB	HIS	B	229	10.230	8.869	-13.854	1.00	0.00	H
ATOM	765	2HB	HIS	B	229	9.743	7.449	-14.744	1.00	0.00	H
ATOM	766	HD2	HIS	B	229	7.539	8.088	-16.684	1.00	0.00	H
ATOM	767	HE1	HIS	B	229	6.120	11.272	-14.418	1.00	0.00	H
ATOM	768	HE2	HIS	B	229	5.507	9.773	-16.421	1.00	0.00	H
ATOM	769	N	LEU	B	230	12.789	7.501	-15.745	1.00	20.00	N
ATOM	770	CA	LEU	B	230	14.305	7.338	-15.562	1.00	20.00	C
ATOM	771	C	LEU	B	230	15.245	8.344	-16.242	1.00	20.00	C
ATOM	772	O	LEU	B	230	16.032	9.049	-15.605	1.00	20.00	O
ATOM	773	CB	LEU	B	230	14.680	5.843	-15.824	1.00	20.00	C
ATOM	774	CG	LEU	B	230	14.672	4.864	-14.626	1.00	20.00	C
ATOM	775	CD1	LEU	B	230	13.419	4.951	-13.742	1.00	20.00	C
ATOM	776	CD2	LEU	B	230	14.813	3.429	-15.165	1.00	20.00	C
ATOM	777	H	LEU	B	230	12.118	6.729	-15.658	1.00	0.00	H
ATOM	778	HA	LEU	B	230	14.498	7.524	-14.488	1.00	0.00	H
ATOM	779	1HB	LEU	B	230	15.691	5.785	-16.272	1.00	0.00	H
ATOM	780	2HB	LEU	B	230	14.037	5.439	-16.624	1.00	0.00	H
ATOM	781	HG	LEU	B	230	15.551	5.087	-13.989	1.00	0.00	H
ATOM	782	1HD1	LEU	B	230	13.431	4.179	-12.954	1.00	0.00	H
ATOM	783	2HD1	LEU	B	230	13.344	5.923	-13.220	1.00	0.00	H
ATOM	784	3HD1	LEU	B	230	12.489	4.825	-14.325	1.00	0.00	H
ATOM	785	1HD2	LEU	B	230	14.799	2.676	-14.359	1.00	0.00	H
ATOM	786	2HD2	LEU	B	230	13.992	3.156	-15.853	1.00	0.00	H
ATOM	787	3HD2	LEU	B	230	15.761	3.284	-15.715	1.00	0.00	H
ATOM	788	N	VAL	B	231	15.193	8.383	-17.523	1.00	20.00	N
ATOM	789	CA	VAL	B	231	16.102	9.185	-18.298	1.00	20.00	C
ATOM	790	C	VAL	B	231	15.992	10.655	-18.038	1.00	20.00	C
ATOM	791	O	VAL	B	231	16.975	11.356	-17.997	1.00	20.00	O
ATOM	792	CB	VAL	B	231	15.949	8.825	-19.833	1.00	20.00	C
ATOM	793	CG1	VAL	B	231	16.956	9.563	-20.751	1.00	20.00	C
ATOM	794	CG2	VAL	B	231	16.082	7.319	-20.188	1.00	20.00	C
ATOM	795	H	VAL	B	231	14.470	7.779	-17.935	1.00	0.00	H
ATOM	796	HA	VAL	B	231	17.136	8.900	-18.015	1.00	0.00	H
ATOM	797	HB	VAL	B	231	14.932	9.136	-20.149	1.00	0.00	H
ATOM	798	1HG1	VAL	B	231	16.821	9.303	-21.818	1.00	0.00	H
ATOM	799	2HG1	VAL	B	231	16.844	10.662	-20.691	1.00	0.00	H
ATOM	800	3HG1	VAL	B	231	18.006	9.332	-20.488	1.00	0.00	H
ATOM	801	1HG2	VAL	B	231	15.922	7.130	-21.266	1.00	0.00	H
ATOM	802	2HG2	VAL	B	231	17.077	6.916	-19.930	1.00	0.00	H
ATOM	803	3HG2	VAL	B	231	15.335	6.697	-19.660	1.00	0.00	H
ATOM	804	N	SER	B	232	14.822	11.162	-17.885	1.00	20.00	N
ATOM	805	CA	SER	B	232	14.721	12.569	-17.652	1.00	20.00	C
ATOM	806	C	SER	B	232	15.729	12.938	-16.591	1.00	20.00	C
ATOM	807	O	SER	B	232	16.343	13.982	-16.629	1.00	20.00	O
ATOM	808	CB	SER	B	232	13.252	12.862	-17.279	1.00	20.00	C
ATOM	809	OG	SER	B	232	12.813	12.185	-16.090	1.00	20.00	O
ATOM	810	H	SER	B	232	14.036	10.496	-17.889	1.00	0.00	H

ATOM	811	HA	SER	B	232	14.970	13.124	-18.579	1.00	0.00	H
ATOM	812	1HB	SER	B	232	12.581	12.595	-18.116	1.00	0.00	H
ATOM	813	2HB	SER	B	232	13.132	13.951	-17.148	1.00	0.00	H
ATOM	814	HG	SER	B	232	12.929	11.231	-16.234	1.00	0.00	H
ATOM	815	N	ALA	B	233	15.869	12.048	-15.683	1.00	20.00	N
ATOM	816	CA	ALA	B	233	16.776	12.208	-14.570	1.00	20.00	C
ATOM	817	C	ALA	B	233	18.178	12.446	-15.024	1.00	20.00	C
ATOM	818	O	ALA	B	233	18.726	13.513	-14.735	1.00	20.00	O
ATOM	819	CB	ALA	B	233	16.404	11.057	-13.615	1.00	20.00	C
ATOM	820	H	ALA	B	233	15.380	11.166	-15.881	1.00	0.00	H
ATOM	821	HA	ALA	B	233	16.471	13.131	-14.032	1.00	0.00	H
ATOM	822	1HB	ALA	B	233	16.322	11.435	-12.595	1.00	0.00	H
ATOM	823	2HB	ALA	B	233	15.405	10.602	-13.773	1.00	0.00	H
ATOM	824	3HB	ALA	B	233	17.136	10.232	-13.640	1.00	0.00	H
ATOM	825	N	THR	B	234	18.644	11.552	-15.861	1.00	20.00	N
ATOM	826	CA	THR	B	234	19.968	11.533	-16.398	1.00	20.00	C
ATOM	827	C	THR	B	234	20.147	12.695	-17.277	1.00	20.00	C
ATOM	828	O	THR	B	234	21.363	13.017	-17.339	1.00	20.00	O
ATOM	829	CB	THR	B	234	20.222	10.139	-17.064	1.00	20.00	C
ATOM	830	OG1	THR	B	234	20.014	9.092	-16.119	1.00	20.00	O
ATOM	831	CG2	THR	B	234	21.648	9.908	-17.591	1.00	20.00	C
ATOM	832	H	THR	B	234	17.958	10.822	-16.092	1.00	0.00	H
ATOM	833	HA	THR	B	234	20.682	11.624	-15.552	1.00	0.00	H
ATOM	834	HB	THR	B	234	19.513	10.004	-17.906	1.00	0.00	H
ATOM	835	HG1	THR	B	234	20.492	8.332	-16.459	1.00	0.00	H
ATOM	836	1HG2	THR	B	234	21.773	8.901	-18.030	1.00	0.00	H
ATOM	837	2HG2	THR	B	234	21.912	10.632	-18.385	1.00	0.00	H
ATOM	838	3HG2	THR	B	234	22.404	10.017	-16.790	1.00	0.00	H
ATOM	839	N	MET	B	235	19.348	13.310	-17.913	1.00	20.00	N
ATOM	840	CA	MET	B	235	19.501	14.454	-18.724	1.00	20.00	C
ATOM	841	C	MET	B	235	19.355	15.738	-17.938	1.00	20.00	C
ATOM	842	O	MET	B	235	20.116	16.692	-18.086	1.00	20.00	O
ATOM	843	CB	MET	B	235	18.599	14.334	-19.979	1.00	20.00	C
ATOM	844	CG	MET	B	235	19.003	13.239	-20.990	1.00	20.00	C
ATOM	845	SD	MET	B	235	17.903	13.292	-22.415	1.00	20.00	S
ATOM	846	CE	MET	B	235	18.649	12.004	-23.426	1.00	20.00	C
ATOM	847	H	MET	B	235	18.426	12.856	-17.832	1.00	0.00	H
ATOM	848	HA	MET	B	235	20.539	14.491	-19.118	1.00	0.00	H
ATOM	849	1HB	MET	B	235	18.620	15.297	-20.524	1.00	0.00	H
ATOM	850	2HB	MET	B	235	17.545	14.187	-19.677	1.00	0.00	H
ATOM	851	1HG	MET	B	235	18.952	12.235	-20.528	1.00	0.00	H
ATOM	852	2HG	MET	B	235	20.046	13.381	-21.330	1.00	0.00	H
ATOM	853	1HE	MET	B	235	19.686	12.270	-23.698	1.00	0.00	H
ATOM	854	2HE	MET	B	235	18.668	11.039	-22.888	1.00	0.00	H
ATOM	855	3HE	MET	B	235	18.075	11.865	-24.360	1.00	0.00	H
ATOM	856	N	SER	B	236	18.388	15.880	-17.087	1.00	20.00	N
ATOM	857	CA	SER	B	236	18.152	17.136	-16.350	1.00	20.00	C
ATOM	858	C	SER	B	236	19.395	17.550	-15.569	1.00	20.00	C
ATOM	859	O	SER	B	236	19.707	18.721	-15.450	1.00	20.00	O
ATOM	860	CB	SER	B	236	16.875	16.995	-15.481	1.00	20.00	C
ATOM	861	OG	SER	B	236	16.958	15.922	-14.537	1.00	20.00	O
ATOM	862	H	SER	B	236	17.749	15.071	-17.024	1.00	0.00	H
ATOM	863	HA	SER	B	236	17.953	17.940	-17.085	1.00	0.00	H
ATOM	864	1HB	SER	B	236	15.988	16.847	-16.128	1.00	0.00	H
ATOM	865	2HB	SER	B	236	16.683	17.941	-14.940	1.00	0.00	H
ATOM	866	HG	SER	B	236	17.064	15.106	-15.045	1.00	0.00	H
ATOM	867	N	GLY	B	237	20.103	16.593	-15.036	1.00	20.00	N
ATOM	868	CA	GLY	B	237	21.326	16.874	-14.290	1.00	20.00	C
ATOM	869	C	GLY	B	237	22.346	17.446	-15.183	1.00	20.00	C
ATOM	870	O	GLY	B	237	22.950	18.457	-14.874	1.00	20.00	O
ATOM	871	H	GLY	B	237	19.671	15.662	-15.114	1.00	0.00	H
ATOM	872	1HA	GLY	B	237	21.722	15.902	-13.961	1.00	0.00	H
ATOM	873	2HA	GLY	B	237	21.209	17.376	-13.335	1.00	0.00	H

ATOM	874	N	VAL	B	238	22.405	16.895	-16.350	1.00	20.00	N
ATOM	875	CA	VAL	B	238	23.422	17.332	-17.237	1.00	20.00	C
ATOM	876	C	VAL	B	238	22.978	18.644	-17.837	1.00	20.00	C
ATOM	877	O	VAL	B	238	23.806	19.539	-17.984	1.00	20.00	O
ATOM	878	CB	VAL	B	238	23.787	16.189	-18.264	1.00	20.00	C
ATOM	879	CG1	VAL	B	238	24.827	16.622	-19.325	1.00	20.00	C
ATOM	880	CG2	VAL	B	238	24.340	14.901	-17.603	1.00	20.00	C
ATOM	881	H	VAL	B	238	21.698	16.177	-16.543	1.00	0.00	H
ATOM	882	HA	VAL	B	238	24.368	17.543	-16.691	1.00	0.00	H
ATOM	883	HB	VAL	B	238	22.864	15.907	-18.811	1.00	0.00	H
ATOM	884	1HG1	VAL	B	238	25.052	15.812	-20.045	1.00	0.00	H
ATOM	885	2HG1	VAL	B	238	24.469	17.479	-19.926	1.00	0.00	H
ATOM	886	3HG1	VAL	B	238	25.786	16.930	-18.867	1.00	0.00	H
ATOM	887	1HG2	VAL	B	238	24.558	14.111	-18.347	1.00	0.00	H
ATOM	888	2HG2	VAL	B	238	25.272	15.089	-17.037	1.00	0.00	H
ATOM	889	3HG2	VAL	B	238	23.615	14.459	-16.895	1.00	0.00	H
ATOM	890	N	THR	B	239	21.710	18.535	-18.522	1.00	20.00	N
ATOM	891	CA	THR	B	239	21.194	19.638	-19.295	1.00	20.00	C
ATOM	892	C	THR	B	239	20.688	20.756	-18.399	1.00	20.00	C
ATOM	893	O	THR	B	239	20.921	21.925	-18.767	1.00	20.00	O
ATOM	894	CB	THR	B	239	20.145	19.150	-20.351	1.00	20.00	C
ATOM	895	OG1	THR	B	239	19.068	18.455	-19.727	1.00	20.00	O
ATOM	896	CG2	THR	B	239	20.704	18.229	-21.448	1.00	20.00	C
ATOM	897	H	THR	B	239	21.149	17.700	-18.252	1.00	0.00	H
ATOM	898	HA	THR	B	239	22.032	20.074	-19.875	1.00	0.00	H
ATOM	899	HB	THR	B	239	19.725	20.043	-20.857	1.00	0.00	H
ATOM	900	HG1	THR	B	239	19.480	17.744	-19.211	1.00	0.00	H
ATOM	901	1HG2	THR	B	239	19.922	17.945	-22.175	1.00	0.00	H
ATOM	902	2HG2	THR	B	239	21.516	18.718	-22.017	1.00	0.00	H
ATOM	903	3HG2	THR	B	239	21.116	17.291	-21.031	1.00	0.00	H
ATOM	904	N	THR	B	240	19.646	20.585	-17.595	1.00	20.00	N
ATOM	905	CA	THR	B	240	19.240	21.576	-16.634	1.00	20.00	C
ATOM	906	C	THR	B	240	20.356	21.847	-15.666	1.00	20.00	C
ATOM	907	O	THR	B	240	20.574	23.022	-15.249	1.00	20.00	O
ATOM	908	CB	THR	B	240	18.057	21.093	-15.671	1.00	20.00	C
ATOM	909	OG1	THR	B	240	17.130	20.219	-16.278	1.00	20.00	O
ATOM	910	CG2	THR	B	240	17.364	22.148	-14.796	1.00	20.00	C
ATOM	911	H	THR	B	240	19.465	19.595	-17.398	1.00	0.00	H
ATOM	912	HA	THR	B	240	18.950	22.513	-17.148	1.00	0.00	H
ATOM	913	HB	THR	B	240	18.433	20.441	-14.871	1.00	0.00	H
ATOM	914	HG1	THR	B	240	16.556	20.755	-16.847	1.00	0.00	H
ATOM	915	1HG2	THR	B	240	16.371	21.816	-14.444	1.00	0.00	H
ATOM	916	2HG2	THR	B	240	17.955	22.357	-13.884	1.00	0.00	H
ATOM	917	3HG2	THR	B	240	17.248	23.116	-15.306	1.00	0.00	H
ATOM	918	N	CYS	B	241	20.959	20.855	-15.074	1.00	20.00	N
ATOM	919	CA	CYS	B	241	21.805	21.126	-13.931	1.00	20.00	C
ATOM	920	C	CYS	B	241	23.078	21.787	-14.339	1.00	20.00	C
ATOM	921	O	CYS	B	241	23.748	21.301	-15.205	1.00	20.00	O
ATOM	922	CB	CYS	B	241	21.872	20.106	-12.793	1.00	20.00	C
ATOM	923	SG	CYS	B	241	20.264	19.261	-12.721	1.00	20.00	S
ATOM	924	H	CYS	B	241	20.576	19.911	-15.287	1.00	0.00	H
ATOM	925	HA	CYS	B	241	21.301	21.931	-13.352	1.00	0.00	H
ATOM	926	HC	CYS	B	241	23.309	22.737	-13.824	1.00	0.00	H
ATOM	927	1HB	CYS	B	241	22.086	20.607	-11.832	1.00	0.00	H
ATOM	928	2HB	CYS	B	241	22.694	19.381	-12.869	1.00	0.00	H
ATOM	929	HG	CYS	B	241	19.477	20.296	-12.996	1.00	0.00	H
ATOM	930	N	PHE	B	244	20.974	25.498	-14.954	1.00	20.00	N
ATOM	931	CA	PHE	B	244	20.179	26.180	-14.130	1.00	20.00	C
ATOM	932	C	PHE	B	244	21.144	26.663	-13.125	1.00	20.00	C
ATOM	933	O	PHE	B	244	22.193	26.109	-12.909	1.00	20.00	O
ATOM	934	CB	PHE	B	244	19.202	25.109	-13.562	1.00	20.00	C
ATOM	935	CG	PHE	B	244	17.807	25.472	-13.080	1.00	20.00	C
ATOM	936	CD1	PHE	B	244	16.946	26.134	-13.955	1.00	20.00	C

ATOM	937	CD2	PHE	B	244	17.274	24.746	-12.011	1.00	20.00	C
ATOM	938	CE1	PHE	B	244	15.574	26.035	-13.781	1.00	20.00	C
ATOM	939	CE2	PHE	B	244	15.893	24.664	-11.837	1.00	20.00	C
ATOM	940	CZ	PHE	B	244	15.043	25.300	-12.728	1.00	20.00	C
ATOM	941	1H	PHE	B	244	21.896	25.417	-14.506	1.00	0.00	H
ATOM	942	2H	PHE	B	244	20.657	24.519	-15.058	1.00	0.00	H
ATOM	943	HA	PHE	B	244	19.677	27.005	-14.671	1.00	0.00	H
ATOM	944	HC	PHE	B	244	20.809	27.569	-12.590	1.00	0.00	H
ATOM	945	1HB	PHE	B	244	19.729	24.465	-12.826	1.00	0.00	H
ATOM	946	2HB	PHE	B	244	18.933	24.392	-14.359	1.00	0.00	H
ATOM	947	HD1	PHE	B	244	17.321	26.628	-14.840	1.00	0.00	H
ATOM	948	HD2	PHE	B	244	17.921	24.160	-11.374	1.00	0.00	H
ATOM	949	HE1	PHE	B	244	14.924	26.482	-14.512	1.00	0.00	H
ATOM	950	HE2	PHE	B	244	15.475	24.064	-11.045	1.00	0.00	H
ATOM	951	HZ	PHE	B	244	13.972	25.199	-12.621	1.00	0.00	H
ATOM	952	N	GLY	B	271	23.751	7.696	-13.507	1.00	20.00	N
ATOM	953	CA	GLY	B	271	22.776	7.315	-12.576	1.00	20.00	C
ATOM	954	C	GLY	B	271	22.022	8.494	-11.964	1.00	20.00	C
ATOM	955	O	GLY	B	271	22.569	9.593	-11.928	1.00	20.00	O
ATOM	956	1H	GLY	B	271	24.345	8.439	-13.118	1.00	0.00	H
ATOM	957	2H	GLY	B	271	24.384	6.918	-13.729	1.00	0.00	H
ATOM	958	1HA	GLY	B	271	23.259	6.751	-11.755	1.00	0.00	H
ATOM	959	2HA	GLY	B	271	22.091	6.600	-13.074	1.00	0.00	H
ATOM	960	N	PHE	B	272	20.883	8.121	-11.481	1.00	20.00	N
ATOM	961	CA	PHE	B	272	20.090	9.099	-10.736	1.00	20.00	C
ATOM	962	C	PHE	B	272	19.751	8.505	-9.445	1.00	20.00	C
ATOM	963	O	PHE	B	272	19.238	7.392	-9.582	1.00	20.00	O
ATOM	964	CB	PHE	B	272	18.937	9.736	-11.559	1.00	20.00	C
ATOM	965	CG	PHE	B	272	18.684	11.233	-11.243	1.00	20.00	C
ATOM	966	CD1	PHE	B	272	17.584	11.623	-10.477	1.00	20.00	C
ATOM	967	CD2	PHE	B	272	19.481	12.223	-11.830	1.00	20.00	C
ATOM	968	CE1	PHE	B	272	17.274	12.972	-10.305	1.00	20.00	C
ATOM	969	CE2	PHE	B	272	19.163	13.572	-11.669	1.00	20.00	C
ATOM	970	CZ	PHE	B	272	18.062	13.944	-10.907	1.00	20.00	C
ATOM	971	H	PHE	B	272	20.666	7.120	-11.503	1.00	0.00	H
ATOM	972	HA	PHE	B	272	20.746	9.962	-10.502	1.00	0.00	H
ATOM	973	1HB	PHE	B	272	18.013	9.135	-11.457	1.00	0.00	H
ATOM	974	2HB	PHE	B	272	19.175	9.662	-12.639	1.00	0.00	H
ATOM	975	HD1	PHE	B	272	16.895	10.877	-10.116	1.00	0.00	H
ATOM	976	HD2	PHE	B	272	20.317	11.948	-12.457	1.00	0.00	H
ATOM	977	HE1	PHE	B	272	16.396	13.260	-9.745	1.00	0.00	H
ATOM	978	HE2	PHE	B	272	19.726	14.330	-12.190	1.00	0.00	H
ATOM	979	HZ	PHE	B	272	17.803	14.989	-10.814	1.00	0.00	H
ATOM	980	N	ALA	B	273	20.081	9.081	-8.354	1.00	20.00	N
ATOM	981	CA	ALA	B	273	19.730	8.491	-7.122	1.00	20.00	C
ATOM	982	C	ALA	B	273	18.767	9.413	-6.387	1.00	20.00	C
ATOM	983	O	ALA	B	273	19.039	10.590	-6.202	1.00	20.00	O
ATOM	984	CB	ALA	B	273	21.050	8.299	-6.352	1.00	20.00	C
ATOM	985	H	ALA	B	273	20.567	9.983	-8.436	1.00	0.00	H
ATOM	986	HA	ALA	B	273	19.286	7.473	-7.221	1.00	0.00	H
ATOM	987	1HB	ALA	B	273	20.824	8.045	-5.303	1.00	0.00	H
ATOM	988	2HB	ALA	B	273	21.659	7.481	-6.780	1.00	0.00	H
ATOM	989	3HB	ALA	B	273	21.694	9.192	-6.314	1.00	0.00	H
ATOM	990	N	PRO	B	274	17.927	8.962	-5.794	1.00	20.00	N
ATOM	991	CA	PRO	B	274	16.599	9.444	-5.515	1.00	20.00	C
ATOM	992	C	PRO	B	274	15.625	8.598	-6.226	1.00	20.00	C
ATOM	993	O	PRO	B	274	14.513	9.039	-6.615	1.00	20.00	O
ATOM	994	CB	PRO	B	274	16.314	10.890	-5.938	1.00	20.00	C
ATOM	995	CG	PRO	B	274	16.584	10.975	-7.425	1.00	20.00	C
ATOM	996	CD	PRO	B	274	17.389	9.645	-7.521	1.00	20.00	C
ATOM	997	HA	PRO	B	274	16.415	9.349	-4.429	1.00	0.00	H
ATOM	998	1HB	PRO	B	274	16.913	11.585	-5.321	1.00	0.00	H
ATOM	999	2HB	PRO	B	274	15.260	11.086	-5.823	1.00	0.00	H

ATOM	1000	1HG	PRO	B	274	17.197	11.862	-7.672	1.00	0.00	H
ATOM	1001	2HG	PRO	B	274	15.668	10.965	-8.048	1.00	0.00	H
ATOM	1002	1HD	PRO	B	274	16.925	8.894	-8.208	1.00	0.00	H
ATOM	1003	2HD	PRO	B	274	17.993	10.066	-8.377	1.00	0.00	H
ATOM	1004	N	LEU	B	275	16.035	7.352	-6.418	1.00	20.00	N
ATOM	1005	CA	LEU	B	275	15.231	6.341	-7.082	1.00	20.00	C
ATOM	1006	C	LEU	B	275	14.075	5.971	-6.229	1.00	20.00	C
ATOM	1007	O	LEU	B	275	13.042	5.505	-6.703	1.00	20.00	O
ATOM	1008	CB	LEU	B	275	16.094	5.174	-7.604	1.00	20.00	C
ATOM	1009	CG	LEU	B	275	16.980	5.553	-8.811	1.00	20.00	C
ATOM	1010	CD1	LEU	B	275	18.167	4.592	-8.983	1.00	20.00	C
ATOM	1011	CD2	LEU	B	275	16.182	5.724	-10.119	1.00	20.00	C
ATOM	1012	H	LEU	B	275	16.993	7.183	-6.079	1.00	0.00	H
ATOM	1013	HA	LEU	B	275	14.756	6.807	-7.969	1.00	0.00	H
ATOM	1014	1HB	LEU	B	275	15.440	4.331	-7.896	1.00	0.00	H
ATOM	1015	2HB	LEU	B	275	16.716	4.789	-6.773	1.00	0.00	H
ATOM	1016	HG	LEU	B	275	17.412	6.534	-8.567	1.00	0.00	H
ATOM	1017	1HD1	LEU	B	275	18.814	4.592	-8.086	1.00	0.00	H
ATOM	1018	2HD1	LEU	B	275	17.857	3.553	-9.156	1.00	0.00	H
ATOM	1019	3HD1	LEU	B	275	18.810	4.881	-9.834	1.00	0.00	H
ATOM	1020	1HD2	LEU	B	275	16.848	5.890	-10.986	1.00	0.00	H
ATOM	1021	2HD2	LEU	B	275	15.549	4.847	-10.341	1.00	0.00	H
ATOM	1022	3HD2	LEU	B	275	15.509	6.599	-10.079	1.00	0.00	H
ATOM	1023	N	THR	B	276	13.588	5.684	-5.379	1.00	20.00	N
ATOM	1024	CA	THR	B	276	13.275	6.043	-4.031	1.00	20.00	C
ATOM	1025	C	THR	B	276	12.404	4.990	-3.460	1.00	20.00	C
ATOM	1026	O	THR	B	276	12.517	4.841	-2.147	1.00	20.00	O
ATOM	1027	CB	THR	B	276	12.685	7.496	-3.808	1.00	20.00	C
ATOM	1028	OG1	THR	B	276	12.443	8.229	-5.013	1.00	20.00	O
ATOM	1029	CG2	THR	B	276	13.567	8.387	-2.924	1.00	20.00	C
ATOM	1030	H	THR	B	276	12.872	5.427	-6.095	1.00	0.00	H
ATOM	1031	HA	THR	B	276	14.225	5.965	-3.464	1.00	0.00	H
ATOM	1032	HB	THR	B	276	11.707	7.425	-3.288	1.00	0.00	H
ATOM	1033	HG1	THR	B	276	13.297	8.429	-5.422	1.00	0.00	H
ATOM	1034	1HG2	THR	B	276	13.127	9.395	-2.806	1.00	0.00	H
ATOM	1035	2HG2	THR	B	276	13.678	7.965	-1.907	1.00	0.00	H
ATOM	1036	3HG2	THR	B	276	14.580	8.515	-3.341	1.00	0.00	H
ATOM	1037	N	SER	B	277	11.357	4.383	-4.126	1.00	20.00	N
ATOM	1038	CA	SER	B	277	10.194	3.623	-3.828	1.00	20.00	C
ATOM	1039	C	SER	B	277	9.075	4.519	-3.324	1.00	20.00	C
ATOM	1040	O	SER	B	277	9.346	5.312	-2.400	1.00	20.00	O
ATOM	1041	CB	SER	B	277	10.518	2.257	-3.188	1.00	20.00	C
ATOM	1042	OG	SER	B	277	10.990	1.325	-4.169	1.00	20.00	O
ATOM	1043	H	SER	B	277	11.454	4.681	-5.102	1.00	0.00	H
ATOM	1044	HA	SER	B	277	9.871	3.309	-4.842	1.00	0.00	H
ATOM	1045	1HB	SER	B	277	9.627	1.836	-2.684	1.00	0.00	H
ATOM	1046	2HB	SER	B	277	11.297	2.361	-2.422	1.00	0.00	H
ATOM	1047	HG	SER	B	277	11.905	1.559	-4.396	1.00	0.00	H
ATOM	1048	N	ARG	B	278	7.948	4.488	-3.969	1.00	20.00	N
ATOM	1049	CA	ARG	B	278	6.813	5.326	-3.630	1.00	20.00	C
ATOM	1050	C	ARG	B	278	6.601	5.351	-2.180	1.00	20.00	C
ATOM	1051	O	ARG	B	278	6.681	6.394	-1.519	1.00	20.00	O
ATOM	1052	CB	ARG	B	278	5.611	4.947	-4.551	1.00	20.00	C
ATOM	1053	CG	ARG	B	278	4.341	5.811	-4.371	1.00	20.00	C
ATOM	1054	CD	ARG	B	278	3.202	5.411	-5.327	1.00	20.00	C
ATOM	1055	NE	ARG	B	278	2.118	6.429	-5.297	1.00	20.00	N
ATOM	1056	CZ	ARG	B	278	2.068	7.531	-6.049	1.00	20.00	C
ATOM	1057	NH1	ARG	B	278	2.977	7.856	-6.928	1.00	20.00	N
ATOM	1058	NH2	ARG	B	278	1.060	8.325	-5.888	1.00	20.00	N
ATOM	1059	H	ARG	B	278	7.921	3.840	-4.762	1.00	0.00	H
ATOM	1060	HA	ARG	B	278	7.113	6.349	-3.887	1.00	0.00	H
ATOM	1061	1HB	ARG	B	278	5.342	3.882	-4.406	1.00	0.00	H
ATOM	1062	2HB	ARG	B	278	5.934	5.020	-5.609	1.00	0.00	H

ATOM	1063	1HG	ARG	B	278	4.589	6.878	-4.515	1.00	0.00	H
ATOM	1064	2HG	ARG	B	278	3.969	5.750	-3.329	1.00	0.00	H
ATOM	1065	1HD	ARG	B	278	2.779	4.435	-5.020	1.00	0.00	H
ATOM	1066	2HD	ARG	B	278	3.568	5.244	-6.360	1.00	0.00	H
ATOM	1067	1HH1	ARG	B	278	2.857	8.736	-7.444	1.00	0.00	H
ATOM	1068	2HH1	ARG	B	278	3.729	7.171	-6.991	1.00	0.00	H
ATOM	1069	1HH2	ARG	B	278	1.024	9.170	-6.459	1.00	0.00	H
ATOM	1070	2HH2	ARG	B	278	0.406	7.989	-5.178	1.00	0.00	H
ATOM	1071	N	GLY	B	279	6.421	4.075	-1.727	1.00	20.00	N
ATOM	1072	CA	GLY	B	279	6.187	3.904	-0.342	1.00	20.00	C
ATOM	1073	C	GLY	B	279	7.453	4.053	0.477	1.00	20.00	C
ATOM	1074	O	GLY	B	279	7.498	4.854	1.401	1.00	20.00	O
ATOM	1075	H	GLY	B	279	6.459	3.336	-2.436	1.00	0.00	H
ATOM	1076	1HA	GLY	B	279	5.760	2.900	-0.158	1.00	0.00	H
ATOM	1077	2HA	GLY	B	279	5.417	4.608	0.035	1.00	0.00	H
ATOM	1078	N	SER	B	280	8.456	3.258	0.127	1.00	20.00	N
ATOM	1079	CA	SER	B	280	9.717	3.343	0.828	1.00	20.00	C
ATOM	1080	C	SER	B	280	10.155	4.772	0.968	1.00	20.00	C
ATOM	1081	O	SER	B	280	11.147	5.091	1.567	1.00	20.00	O
ATOM	1082	CB	SER	B	280	10.843	2.421	0.308	1.00	20.00	C
ATOM	1083	OG	SER	B	280	10.373	1.134	-0.100	1.00	20.00	O
ATOM	1084	H	SER	B	280	8.325	2.708	-0.726	1.00	0.00	H
ATOM	1085	HA	SER	B	280	9.524	2.993	1.862	1.00	0.00	H
ATOM	1086	1HB	SER	B	280	11.601	2.289	1.102	1.00	0.00	H
ATOM	1087	2HB	SER	B	280	11.396	2.928	-0.500	1.00	0.00	H
ATOM	1088	HG	SER	B	280	11.139	0.624	-0.384	1.00	0.00	H
ATOM	1089	N	GLN	B	281	9.252	5.561	0.533	1.00	20.00	N
ATOM	1090	CA	GLN	B	281	9.557	6.943	0.357	1.00	20.00	C
ATOM	1091	C	GLN	B	281	10.331	7.502	1.512	1.00	20.00	C
ATOM	1092	O	GLN	B	281	11.224	8.284	1.394	1.00	20.00	O
ATOM	1093	CB	GLN	B	281	8.489	8.017	-0.007	1.00	20.00	C
ATOM	1094	CG	GLN	B	281	7.226	8.127	0.891	1.00	20.00	C
ATOM	1095	CD	GLN	B	281	6.214	9.183	0.443	1.00	20.00	C
ATOM	1096	OE1	GLN	B	281	6.087	10.258	1.019	1.00	20.00	O
ATOM	1097	NE2	GLN	B	281	5.452	8.902	-0.586	1.00	20.00	N
ATOM	1098	H	GLN	B	281	8.307	5.251	0.968	1.00	0.00	H
ATOM	1099	HA	GLN	B	281	10.266	6.980	-0.497	1.00	0.00	H
ATOM	1100	1HB	GLN	B	281	8.240	7.911	-1.073	1.00	0.00	H
ATOM	1101	2HB	GLN	B	281	8.968	9.019	-0.027	1.00	0.00	H
ATOM	1102	1HG	GLN	B	281	7.534	8.368	1.924	1.00	0.00	H
ATOM	1103	2HG	GLN	B	281	6.714	7.152	0.965	1.00	0.00	H
ATOM	1104	1HE2	GLN	B	281	5.708	8.035	-1.080	1.00	0.00	H
ATOM	1105	2HE2	GLN	B	281	4.864	9.677	-0.903	1.00	0.00	H
ATOM	1106	N	GLN	B	282	10.384	6.881	2.618	1.00	20.00	N
ATOM	1107	CA	GLN	B	282	10.631	7.299	3.955	1.00	20.00	C
ATOM	1108	C	GLN	B	282	12.093	7.130	4.324	1.00	20.00	C
ATOM	1109	O	GLN	B	282	12.487	7.553	5.442	1.00	20.00	O
ATOM	1110	CB	GLN	B	282	9.684	6.521	4.921	1.00	20.00	C
ATOM	1111	CG	GLN	B	282	8.154	6.753	4.763	1.00	20.00	C
ATOM	1112	CD	GLN	B	282	7.639	8.177	5.030	1.00	20.00	C
ATOM	1113	OE1	GLN	B	282	8.288	9.032	5.624	1.00	20.00	O
ATOM	1114	NE2	GLN	B	282	6.436	8.477	4.606	1.00	20.00	N
ATOM	1115	H	GLN	B	282	10.669	5.917	2.299	1.00	0.00	H
ATOM	1116	HA	GLN	B	282	10.414	8.382	4.052	1.00	0.00	H
ATOM	1117	1HB	GLN	B	282	9.956	6.772	5.966	1.00	0.00	H
ATOM	1118	2HB	GLN	B	282	9.889	5.435	4.839	1.00	0.00	H
ATOM	1119	1HG	GLN	B	282	7.620	6.073	5.452	1.00	0.00	H
ATOM	1120	2HG	GLN	B	282	7.848	6.431	3.748	1.00	0.00	H
ATOM	1121	1HE2	GLN	B	282	5.931	7.759	4.080	1.00	0.00	H
ATOM	1122	2HE2	GLN	B	282	6.173	9.454	4.762	1.00	0.00	H
ATOM	1123	N	TYR	B	283	12.904	6.499	3.548	1.00	20.00	N
ATOM	1124	CA	TYR	B	283	14.312	6.278	3.881	1.00	20.00	C
ATOM	1125	C	TYR	B	283	15.129	7.428	3.421	1.00	20.00	C

ATOM	1126	O	TYR	B	283	14.898	7.896	2.356	1.00	20.00	O
ATOM	1127	CB	TYR	B	283	14.772	4.977	3.140	1.00	20.00	C
ATOM	1128	CG	TYR	B	283	14.390	3.650	3.829	1.00	20.00	C
ATOM	1129	CD1	TYR	B	283	13.149	3.053	3.587	1.00	20.00	C
ATOM	1130	CD2	TYR	B	283	15.281	3.035	4.717	1.00	20.00	C
ATOM	1131	CE1	TYR	B	283	12.801	1.862	4.219	1.00	20.00	C
ATOM	1132	CE2	TYR	B	283	14.933	1.843	5.349	1.00	20.00	C
ATOM	1133	CZ	TYR	B	283	13.696	1.257	5.099	1.00	20.00	C
ATOM	1134	OH	TYR	B	283	13.361	0.087	5.726	1.00	20.00	O
ATOM	1135	H	TYR	B	283	12.518	6.323	2.612	1.00	0.00	H
ATOM	1136	HA	TYR	B	283	14.419	5.995	4.961	1.00	0.00	H
ATOM	1137	1HB	TYR	B	283	15.874	4.982	3.020	1.00	0.00	H
ATOM	1138	2HB	TYR	B	283	14.415	4.975	2.089	1.00	0.00	H
ATOM	1139	HD1	TYR	B	283	12.446	3.521	2.918	1.00	0.00	H
ATOM	1140	HD2	TYR	B	283	16.244	3.481	4.923	1.00	0.00	H
ATOM	1141	HE1	TYR	B	283	11.837	1.415	4.025	1.00	0.00	H
ATOM	1142	HE2	TYR	B	283	15.621	1.370	6.035	1.00	0.00	H
ATOM	1143	HH	TYR	B	283	12.479	-0.171	5.454	1.00	0.00	H
ATOM	1144	N	ARG	B	284	15.063	8.189	4.527	1.00	20.00	N
ATOM	1145	CA	ARG	B	284	14.774	9.629	4.646	1.00	20.00	C
ATOM	1146	C	ARG	B	284	15.990	10.067	3.754	1.00	20.00	C
ATOM	1147	O	ARG	B	284	16.607	9.647	2.762	1.00	20.00	O
ATOM	1148	CB	ARG	B	284	14.555	9.929	6.178	1.00	20.00	C
ATOM	1149	CG	ARG	B	284	15.521	9.405	7.282	1.00	20.00	C
ATOM	1150	CD	ARG	B	284	16.965	9.940	7.265	1.00	20.00	C
ATOM	1151	NE	ARG	B	284	17.720	9.433	8.440	1.00	20.00	N
ATOM	1152	CZ	ARG	B	284	18.465	8.327	8.475	1.00	20.00	C
ATOM	1153	NH1	ARG	B	284	18.631	7.511	7.465	1.00	20.00	N
ATOM	1154	NH2	ARG	B	284	19.059	8.047	9.590	1.00	20.00	N
ATOM	1155	H	ARG	B	284	14.809	7.624	5.343	1.00	0.00	H
ATOM	1156	HA	ARG	B	284	13.845	9.868	4.090	1.00	0.00	H
ATOM	1157	1HB	ARG	B	284	13.555	9.530	6.434	1.00	0.00	H
ATOM	1158	2HB	ARG	B	284	14.402	11.006	6.323	1.00	0.00	H
ATOM	1159	1HG	ARG	B	284	15.543	8.299	7.268	1.00	0.00	H
ATOM	1160	2HG	ARG	B	284	15.076	9.646	8.268	1.00	0.00	H
ATOM	1161	1HD	ARG	B	284	16.959	11.047	7.315	1.00	0.00	H
ATOM	1162	2HD	ARG	B	284	17.488	9.686	6.324	1.00	0.00	H
ATOM	1163	1HH1	ARG	B	284	19.230	6.699	7.617	1.00	0.00	H
ATOM	1164	2HH1	ARG	B	284	18.132	7.792	6.619	1.00	0.00	H
ATOM	1165	1HH2	ARG	B	284	19.632	7.204	9.630	1.00	0.00	H
ATOM	1166	2HH2	ARG	B	284	18.867	8.741	10.316	1.00	0.00	H
ATOM	1167	N	ALA	B	285	16.473	11.028	4.173	1.00	20.00	N
ATOM	1168	CA	ALA	B	285	15.898	12.314	3.805	1.00	20.00	C
ATOM	1169	C	ALA	B	285	16.719	12.905	2.736	1.00	20.00	C
ATOM	1170	O	ALA	B	285	17.484	13.834	2.968	1.00	20.00	O
ATOM	1171	CB	ALA	B	285	15.835	13.206	5.077	1.00	20.00	C
ATOM	1172	H	ALA	B	285	16.623	10.905	5.178	1.00	0.00	H
ATOM	1173	HA	ALA	B	285	14.848	12.253	3.433	1.00	0.00	H
ATOM	1174	1HB	ALA	B	285	15.524	14.237	4.820	1.00	0.00	H
ATOM	1175	2HB	ALA	B	285	15.109	12.868	5.830	1.00	0.00	H
ATOM	1176	3HB	ALA	B	285	16.818	13.300	5.579	1.00	0.00	H
ATOM	1177	N	LEU	B	286	16.623	12.302	1.563	1.00	20.00	N
ATOM	1178	CA	LEU	B	286	17.376	12.730	0.447	1.00	20.00	C
ATOM	1179	C	LEU	B	286	18.847	12.824	0.815	1.00	20.00	C
ATOM	1180	O	LEU	B	286	19.401	13.909	0.872	1.00	20.00	O
ATOM	1181	CB	LEU	B	286	16.649	14.010	-0.085	1.00	20.00	C
ATOM	1182	CG	LEU	B	286	15.082	14.036	0.000	1.00	20.00	C
ATOM	1183	CD1	LEU	B	286	14.574	15.457	0.018	1.00	20.00	C
ATOM	1184	CD2	LEU	B	286	14.478	13.067	-1.015	1.00	20.00	C
ATOM	1185	H	LEU	B	286	16.186	11.372	1.620	1.00	0.00	H
ATOM	1186	HA	LEU	B	286	17.283	11.958	-0.341	1.00	0.00	H
ATOM	1187	1HB	LEU	B	286	16.980	14.204	-1.122	1.00	0.00	H
ATOM	1188	2HB	LEU	B	286	17.040	14.865	0.501	1.00	0.00	H

ATOM	1189	HG	LEU	B	286	14.711	13.681	0.979	1.00	0.00	H
ATOM	1190	1HD1	LEU	B	286	13.469	15.485	-0.014	1.00	0.00	H
ATOM	1191	2HD1	LEU	B	286	14.893	15.999	0.928	1.00	0.00	H
ATOM	1192	3HD1	LEU	B	286	14.967	16.014	-0.840	1.00	0.00	H
ATOM	1193	1HD2	LEU	B	286	13.377	13.152	-1.081	1.00	0.00	H
ATOM	1194	2HD2	LEU	B	286	14.904	13.265	-2.007	1.00	0.00	H
ATOM	1195	3HD2	LEU	B	286	14.705	12.014	-0.770	1.00	0.00	H
ATOM	1196	N	THR	B	287	19.513	11.749	1.141	1.00	20.00	N
ATOM	1197	CA	THR	B	287	20.844	11.801	1.701	1.00	20.00	C
ATOM	1198	C	THR	B	287	21.851	12.126	0.685	1.00	20.00	C
ATOM	1199	O	THR	B	287	21.716	11.836	-0.453	1.00	20.00	O
ATOM	1200	CB	THR	B	287	20.902	10.894	2.990	1.00	20.00	C
ATOM	1201	OG1	THR	B	287	19.972	11.396	3.954	1.00	20.00	O
ATOM	1202	CG2	THR	B	287	22.222	10.793	3.766	1.00	20.00	C
ATOM	1203	H	THR	B	287	18.958	10.887	1.103	1.00	0.00	H
ATOM	1204	HA	THR	B	287	20.888	12.766	2.254	1.00	0.00	H
ATOM	1205	HB	THR	B	287	20.555	9.877	2.770	1.00	0.00	H
ATOM	1206	HG1	THR	B	287	19.177	11.644	3.469	1.00	0.00	H
ATOM	1207	1HG2	THR	B	287	22.108	10.140	4.652	1.00	0.00	H
ATOM	1208	2HG2	THR	B	287	23.039	10.365	3.163	1.00	0.00	H
ATOM	1209	3HG2	THR	B	287	22.555	11.777	4.142	1.00	0.00	H
ATOM	1210	N	VAL	B	288	23.184	12.577	1.370	1.00	20.00	N
ATOM	1211	CA	VAL	B	288	24.233	12.654	0.406	1.00	20.00	C
ATOM	1212	C	VAL	B	288	24.912	11.294	0.221	1.00	20.00	C
ATOM	1213	O	VAL	B	288	25.130	10.852	-0.892	1.00	20.00	O
ATOM	1214	CB	VAL	B	288	25.279	13.753	0.833	1.00	20.00	C
ATOM	1215	CG1	VAL	B	288	26.488	13.894	-0.130	1.00	20.00	C
ATOM	1216	CG2	VAL	B	288	24.679	15.177	0.943	1.00	20.00	C
ATOM	1217	H	VAL	B	288	23.190	12.877	2.350	1.00	0.00	H
ATOM	1218	HA	VAL	B	288	23.859	13.025	-0.561	1.00	0.00	H
ATOM	1219	HC	VAL	B	288	25.408	10.940	1.147	1.00	0.00	H
ATOM	1220	HB	VAL	B	288	25.684	13.487	1.831	1.00	0.00	H
ATOM	1221	1HG1	VAL	B	288	27.204	14.669	0.205	1.00	0.00	H
ATOM	1222	2HG1	VAL	B	288	27.071	12.958	-0.211	1.00	0.00	H
ATOM	1223	3HG1	VAL	B	288	26.173	14.163	-1.156	1.00	0.00	H
ATOM	1224	1HG2	VAL	B	288	25.421	15.921	1.289	1.00	0.00	H
ATOM	1225	2HG2	VAL	B	288	24.274	15.538	-0.022	1.00	0.00	H
ATOM	1226	3HG2	VAL	B	288	23.848	15.207	1.668	1.00	0.00	H
ATOM	1227	N	GLU	B	290	23.798	9.088	0.934	1.00	20.00	N
ATOM	1228	CA	GLU	B	290	22.723	8.413	0.256	1.00	20.00	C
ATOM	1229	C	GLU	B	290	22.821	8.555	-1.203	1.00	20.00	C
ATOM	1230	O	GLU	B	290	22.800	7.655	-1.891	1.00	20.00	O
ATOM	1231	CB	GLU	B	290	21.294	8.361	0.845	1.00	20.00	C
ATOM	1232	CG	GLU	B	290	20.269	7.366	0.227	1.00	20.00	C
ATOM	1233	CD	GLU	B	290	20.624	5.879	0.288	1.00	20.00	C
ATOM	1234	OE1	GLU	B	290	20.850	5.189	-0.702	1.00	20.00	O
ATOM	1235	OE2	GLU	B	290	20.645	5.402	1.563	1.00	20.00	O
ATOM	1236	1H	GLU	B	290	24.565	9.231	0.263	1.00	0.00	H
ATOM	1237	2H	GLU	B	290	23.492	10.029	1.204	1.00	0.00	H
ATOM	1238	HA	GLU	B	290	23.037	7.360	0.402	1.00	0.00	H
ATOM	1239	1HB	GLU	B	290	20.855	9.360	0.725	1.00	0.00	H
ATOM	1240	2HB	GLU	B	290	21.375	8.148	1.927	1.00	0.00	H
ATOM	1241	1HG	GLU	B	290	20.084	7.629	-0.831	1.00	0.00	H
ATOM	1242	2HG	GLU	B	290	19.290	7.496	0.724	1.00	0.00	H
ATOM	1243	HE2	GLU	B	290	20.871	4.471	1.537	1.00	0.00	H
ATOM	1244	N	LEU	B	291	23.133	9.745	-1.350	1.00	20.00	N
ATOM	1245	CA	LEU	B	291	23.173	10.049	-2.620	1.00	20.00	C
ATOM	1246	C	LEU	B	291	24.464	9.605	-3.275	1.00	20.00	C
ATOM	1247	O	LEU	B	291	24.443	9.400	-4.498	1.00	20.00	O
ATOM	1248	CB	LEU	B	291	22.922	11.546	-3.004	1.00	20.00	C
ATOM	1249	CG	LEU	B	291	21.458	12.094	-3.130	1.00	20.00	C
ATOM	1250	CD1	LEU	B	291	21.453	13.628	-3.056	1.00	20.00	C
ATOM	1251	CD2	LEU	B	291	20.602	11.607	-4.264	1.00	20.00	C

ATOM	1252	H	LEU	B	291	22.795	10.411	-0.643	1.00	0.00	H
ATOM	1253	HA	LEU	B	291	22.370	9.579	-3.250	1.00	0.00	H
ATOM	1254	HC	LEU	B	291	25.340	9.408	-2.632	1.00	0.00	H
ATOM	1255	1HB	LEU	B	291	23.431	11.766	-3.951	1.00	0.00	H
ATOM	1256	2HB	LEU	B	291	23.503	12.184	-2.332	1.00	0.00	H
ATOM	1257	HG	LEU	B	291	20.813	11.700	-2.339	1.00	0.00	H
ATOM	1258	1HD1	LEU	B	291	20.458	14.048	-3.287	1.00	0.00	H
ATOM	1259	2HD1	LEU	B	291	21.733	13.986	-2.049	1.00	0.00	H
ATOM	1260	3HD1	LEU	B	291	22.164	14.078	-3.771	1.00	0.00	H
ATOM	1261	1HD2	LEU	B	291	20.636	12.256	-5.146	1.00	0.00	H
ATOM	1262	2HD2	LEU	B	291	20.860	10.579	-4.565	1.00	0.00	H
ATOM	1263	3HD2	LEU	B	291	19.529	11.598	-3.986	1.00	0.00	H
ATOM	1264	N	GLN	B	294	24.427	5.745	-3.793	1.00	20.00	N
ATOM	1265	CA	GLN	B	294	23.616	5.182	-4.857	1.00	20.00	C
ATOM	1266	C	GLN	B	294	24.181	5.505	-6.175	1.00	20.00	C
ATOM	1267	O	GLN	B	294	23.737	4.994	-7.184	1.00	20.00	O
ATOM	1268	CB	GLN	B	294	22.147	5.508	-4.492	1.00	20.00	C
ATOM	1269	CG	GLN	B	294	21.047	4.814	-5.340	1.00	20.00	C
ATOM	1270	CD	GLN	B	294	19.603	5.064	-4.876	1.00	20.00	C
ATOM	1271	OE1	GLN	B	294	18.805	5.724	-5.532	1.00	20.00	O
ATOM	1272	NE2	GLN	B	294	19.197	4.534	-3.746	1.00	20.00	N
ATOM	1273	1H	GLN	B	294	24.283	6.761	-3.745	1.00	0.00	H
ATOM	1274	2H	GLN	B	294	24.099	5.401	-2.883	1.00	0.00	H
ATOM	1275	HA	GLN	B	294	23.717	4.082	-4.776	1.00	0.00	H
ATOM	1276	HC	GLN	B	294	24.999	6.252	-6.180	1.00	0.00	H
ATOM	1277	1HB	GLN	B	294	22.016	6.600	-4.473	1.00	0.00	H
ATOM	1278	2HB	GLN	B	294	21.973	5.215	-3.435	1.00	0.00	H
ATOM	1279	1HG	GLN	B	294	21.222	3.723	-5.373	1.00	0.00	H
ATOM	1280	2HG	GLN	B	294	21.127	5.141	-6.394	1.00	0.00	H
ATOM	1281	1HE2	GLN	B	294	19.926	4.142	-3.142	1.00	0.00	H
ATOM	1282	2HE2	GLN	B	294	18.251	4.818	-3.479	1.00	0.00	H
ATOM	1283	N	MET	B	302	22.249	3.365	-14.461	1.00	20.00	N
ATOM	1284	CA	MET	B	302	21.185	3.289	-15.469	1.00	20.00	C
ATOM	1285	C	MET	B	302	21.790	3.003	-16.815	1.00	20.00	C
ATOM	1286	O	MET	B	302	21.478	3.673	-17.759	1.00	20.00	O
ATOM	1287	CB	MET	B	302	20.371	4.610	-15.324	1.00	20.00	C
ATOM	1288	CG	MET	B	302	18.999	4.604	-16.024	1.00	20.00	C
ATOM	1289	SD	MET	B	302	18.471	6.294	-16.374	1.00	20.00	S
ATOM	1290	CE	MET	B	302	19.252	6.530	-17.985	1.00	20.00	C
ATOM	1291	1H	MET	B	302	22.839	4.187	-14.633	1.00	0.00	H
ATOM	1292	2H	MET	B	302	21.846	3.509	-13.528	1.00	0.00	H
ATOM	1293	HA	MET	B	302	20.526	2.435	-15.228	1.00	0.00	H
ATOM	1294	HC	MET	B	302	22.510	2.165	-16.843	1.00	0.00	H
ATOM	1295	1HB	MET	B	302	20.977	5.448	-15.719	1.00	0.00	H
ATOM	1296	2HB	MET	B	302	20.196	4.867	-14.260	1.00	0.00	H
ATOM	1297	1HG	MET	B	302	18.238	4.097	-15.402	1.00	0.00	H
ATOM	1298	2HG	MET	B	302	19.043	4.047	-16.976	1.00	0.00	H
ATOM	1299	1HE	MET	B	302	19.060	7.545	-18.374	1.00	0.00	H
ATOM	1300	2HE	MET	B	302	20.346	6.382	-17.924	1.00	0.00	H
ATOM	1301	3HE	MET	B	302	18.857	5.803	-18.718	1.00	0.00	H
ATOM	1302	N	ARG	B	320	22.309	18.342	-6.951	1.00	20.00	N
ATOM	1303	CA	ARG	B	320	21.581	19.593	-6.911	1.00	20.00	C
ATOM	1304	C	ARG	B	320	20.461	19.561	-5.948	1.00	20.00	C
ATOM	1305	O	ARG	B	320	19.269	19.816	-6.278	1.00	20.00	O
ATOM	1306	CB	ARG	B	320	21.270	20.218	-8.317	1.00	20.00	C
ATOM	1307	CG	ARG	B	320	20.122	19.614	-9.166	1.00	20.00	C
ATOM	1308	CD	ARG	B	320	19.451	20.534	-10.190	1.00	20.00	C
ATOM	1309	NE	ARG	B	320	18.304	19.769	-10.782	1.00	20.00	N
ATOM	1310	CZ	ARG	B	320	17.164	20.260	-11.251	1.00	20.00	C
ATOM	1311	NH1	ARG	B	320	16.769	21.482	-11.076	1.00	20.00	N
ATOM	1312	NH2	ARG	B	320	16.407	19.462	-11.932	1.00	20.00	N
ATOM	1313	1H	ARG	B	320	21.721	17.598	-7.347	1.00	0.00	H
ATOM	1314	2H	ARG	B	320	23.112	18.416	-7.586	1.00	0.00	H

ATOM	1315	HA	ARG	B	320	22.307	20.321	-6.493	1.00	0.00	H
ATOM	1316	1HB	ARG	B	320	22.193	20.251	-8.928	1.00	0.00	H
ATOM	1317	2HB	ARG	B	320	21.027	21.285	-8.143	1.00	0.00	H
ATOM	1318	1HG	ARG	B	320	19.292	19.317	-8.510	1.00	0.00	H
ATOM	1319	2HG	ARG	B	320	20.461	18.678	-9.651	1.00	0.00	H
ATOM	1320	1HD	ARG	B	320	20.166	20.841	-10.955	1.00	0.00	H
ATOM	1321	2HD	ARG	B	320	19.193	21.514	-9.776	1.00	0.00	H
ATOM	1322	1HH1	ARG	B	320	15.851	21.733	-11.443	1.00	0.00	H
ATOM	1323	2HH1	ARG	B	320	17.333	21.955	-10.363	1.00	0.00	H
ATOM	1324	1HH2	ARG	B	320	15.563	19.851	-12.352	1.00	0.00	H
ATOM	1325	2HH2	ARG	B	320	16.828	18.537	-12.050	1.00	0.00	H
ATOM	1326	N	GLY	B	321	20.796	19.432	-4.693	1.00	20.00	N
ATOM	1327	CA	GLY	B	321	19.776	19.437	-3.670	1.00	20.00	C
ATOM	1328	C	GLY	B	321	19.782	20.627	-2.795	1.00	20.00	C
ATOM	1329	O	GLY	B	321	19.039	20.753	-1.814	1.00	20.00	O
ATOM	1330	H	GLY	B	321	21.762	19.110	-4.551	1.00	0.00	H
ATOM	1331	1HA	GLY	B	321	19.960	18.579	-3.012	1.00	0.00	H
ATOM	1332	2HA	GLY	B	321	18.775	19.290	-4.048	1.00	0.00	H
ATOM	1333	HC	GLY	B	321	20.504	21.413	-3.092	1.00	0.00	H
ATOM	1334	N	MET	B	323	22.260	21.160	-0.702	1.00	20.00	N
ATOM	1335	CA	MET	B	323	23.111	20.730	0.379	1.00	20.00	C
ATOM	1336	C	MET	B	323	24.443	21.390	0.258	1.00	20.00	C
ATOM	1337	O	MET	B	323	24.806	22.066	-0.642	1.00	20.00	O
ATOM	1338	CB	MET	B	323	23.157	19.190	0.500	1.00	20.00	C
ATOM	1339	CG	MET	B	323	23.622	18.672	1.881	1.00	20.00	C
ATOM	1340	SD	MET	B	323	22.553	17.321	2.417	1.00	20.00	S
ATOM	1341	CE	MET	B	323	23.261	16.983	4.038	1.00	20.00	C
ATOM	1342	1H	MET	B	323	22.222	22.186	-0.723	1.00	0.00	H
ATOM	1343	2H	MET	B	323	22.697	20.898	-1.593	1.00	0.00	H
ATOM	1344	HA	MET	B	323	22.646	21.129	1.302	1.00	0.00	H
ATOM	1345	HC	MET	B	323	25.094	21.181	1.125	1.00	0.00	H
ATOM	1346	1HB	MET	B	323	23.766	18.743	-0.310	1.00	0.00	H
ATOM	1347	2HB	MET	B	323	22.143	18.788	0.321	1.00	0.00	H
ATOM	1348	1HG	MET	B	323	23.577	19.457	2.660	1.00	0.00	H
ATOM	1349	2HG	MET	B	323	24.673	18.329	1.846	1.00	0.00	H
ATOM	1350	1HE	MET	B	323	22.706	16.169	4.537	1.00	0.00	H
ATOM	1351	2HE	MET	B	323	24.319	16.674	3.952	1.00	0.00	H
ATOM	1352	3HE	MET	B	323	23.211	17.876	4.686	1.00	0.00	H
ATOM	1353	N	ILE	B	358	18.835	24.056	-7.329	1.00	20.00	N
ATOM	1354	CA	ILE	B	358	17.416	23.836	-7.269	1.00	20.00	C
ATOM	1355	C	ILE	B	358	17.145	22.351	-7.364	1.00	20.00	C
ATOM	1356	O	ILE	B	358	17.607	21.728	-8.306	1.00	20.00	O
ATOM	1357	CB	ILE	B	358	16.624	24.739	-8.287	1.00	20.00	C
ATOM	1358	CG1	ILE	B	358	16.849	26.274	-8.073	1.00	20.00	C
ATOM	1359	CG2	ILE	B	358	15.093	24.461	-8.263	1.00	20.00	C
ATOM	1360	CD1	ILE	B	358	16.425	27.194	-9.233	1.00	20.00	C
ATOM	1361	1H	ILE	B	358	19.312	23.490	-6.617	1.00	0.00	H
ATOM	1362	2H	ILE	B	358	19.200	23.719	-8.227	1.00	0.00	H
ATOM	1363	HA	ILE	B	358	17.152	24.285	-6.300	1.00	0.00	H
ATOM	1364	HB	ILE	B	358	17.006	24.478	-9.287	1.00	0.00	H
ATOM	1365	1HG1	ILE	B	358	17.923	26.470	-7.891	1.00	0.00	H
ATOM	1366	2HG1	ILE	B	358	16.350	26.603	-7.141	1.00	0.00	H
ATOM	1367	1HG2	ILE	B	358	14.545	25.050	-9.021	1.00	0.00	H
ATOM	1368	2HG2	ILE	B	358	14.855	23.402	-8.476	1.00	0.00	H
ATOM	1369	3HG2	ILE	B	358	14.640	24.702	-7.284	1.00	0.00	H
ATOM	1370	1HD1	ILE	B	358	16.643	28.253	-9.002	1.00	0.00	H
ATOM	1371	2HD1	ILE	B	358	16.963	26.952	-10.168	1.00	0.00	H
ATOM	1372	3HD1	ILE	B	358	15.344	27.132	-9.451	1.00	0.00	H
ATOM	1373	N	PRO	B	359	16.577	21.810	-6.385	1.00	20.00	N
ATOM	1374	CA	PRO	B	359	16.368	20.384	-6.464	1.00	20.00	C
ATOM	1375	C	PRO	B	359	15.041	20.034	-7.119	1.00	20.00	C
ATOM	1376	O	PRO	B	359	14.059	20.757	-6.897	1.00	20.00	O
ATOM	1377	CB	PRO	B	359	16.127	20.226	-5.014	1.00	20.00	C

ATOM	1378	CG	PRO	B	359	15.438	21.408	-4.342	1.00	20.00	C
ATOM	1379	CD	PRO	B	359	16.074	22.501	-5.147	1.00	20.00	C
ATOM	1380	HA	PRO	B	359	17.279	19.890	-6.771	1.00	0.00	H
ATOM	1381	1HB	PRO	B	359	17.084	20.073	-4.517	1.00	0.00	H
ATOM	1382	2HB	PRO	B	359	15.524	19.312	-4.931	1.00	0.00	H
ATOM	1383	1HG	PRO	B	359	15.645	21.475	-3.257	1.00	0.00	H
ATOM	1384	2HG	PRO	B	359	14.341	21.379	-4.484	1.00	0.00	H
ATOM	1385	1HD	PRO	B	359	15.336	23.297	-5.369	1.00	0.00	H
ATOM	1386	2HD	PRO	B	359	16.910	22.948	-4.571	1.00	0.00	H
ATOM	1387	N	PRO	B	360	15.535	19.068	-7.903	1.00	20.00	N
ATOM	1388	CA	PRO	B	360	14.468	18.708	-8.821	1.00	20.00	C
ATOM	1389	C	PRO	B	360	13.088	18.891	-8.237	1.00	20.00	C
ATOM	1390	O	PRO	B	360	12.854	18.503	-7.128	1.00	20.00	O
ATOM	1391	CB	PRO	B	360	14.674	17.288	-9.343	1.00	20.00	C
ATOM	1392	CG	PRO	B	360	16.063	17.011	-8.866	1.00	20.00	C
ATOM	1393	CD	PRO	B	360	16.124	17.763	-7.515	1.00	20.00	C
ATOM	1394	HA	PRO	B	360	14.602	19.380	-9.697	1.00	0.00	H
ATOM	1395	1HB	PRO	B	360	14.567	17.201	-10.441	1.00	0.00	H
ATOM	1396	2HB	PRO	B	360	13.984	16.561	-8.878	1.00	0.00	H
ATOM	1397	1HG	PRO	B	360	16.822	17.411	-9.571	1.00	0.00	H
ATOM	1398	2HG	PRO	B	360	16.208	15.920	-8.829	1.00	0.00	H
ATOM	1399	1HD	PRO	B	360	15.542	17.272	-6.711	1.00	0.00	H
ATOM	1400	2HD	PRO	B	360	17.154	17.874	-7.145	1.00	0.00	H
ATOM	1401	N	ARG	B	369	12.205	19.481	-9.015	1.00	20.00	N
ATOM	1402	CA	ARG	B	369	10.833	19.718	-8.654	1.00	20.00	C
ATOM	1403	C	ARG	B	369	10.259	18.496	-8.074	1.00	20.00	C
ATOM	1404	O	ARG	B	369	10.023	17.494	-8.765	1.00	20.00	O
ATOM	1405	CB	ARG	B	369	10.100	20.356	-9.857	1.00	20.00	C
ATOM	1406	CG	ARG	B	369	8.757	21.093	-9.618	1.00	20.00	C
ATOM	1407	CD	ARG	B	369	8.526	22.167	-10.705	1.00	20.00	C
ATOM	1408	NE	ARG	B	369	7.104	22.582	-10.806	1.00	20.00	N
ATOM	1409	CZ	ARG	B	369	6.599	23.323	-11.797	1.00	20.00	C
ATOM	1410	NH1	ARG	B	369	7.310	23.861	-12.759	1.00	20.00	N
ATOM	1411	NH2	ARG	B	369	5.320	23.514	-11.807	1.00	20.00	N
ATOM	1412	H	ARG	B	369	12.606	19.860	-9.877	1.00	0.00	H
ATOM	1413	HA	ARG	B	369	10.877	20.550	-7.914	1.00	0.00	H
ATOM	1414	1HB	ARG	B	369	9.938	19.593	-10.636	1.00	0.00	H
ATOM	1415	2HB	ARG	B	369	10.793	21.103	-10.293	1.00	0.00	H
ATOM	1416	1HG	ARG	B	369	8.729	21.580	-8.624	1.00	0.00	H
ATOM	1417	2HG	ARG	B	369	7.927	20.358	-9.609	1.00	0.00	H
ATOM	1418	1HD	ARG	B	369	8.855	21.777	-11.688	1.00	0.00	H
ATOM	1419	2HD	ARG	B	369	9.169	23.048	-10.510	1.00	0.00	H
ATOM	1420	1HH1	ARG	B	369	6.812	24.410	-13.463	1.00	0.00	H
ATOM	1421	2HH1	ARG	B	369	8.317	23.703	-12.678	1.00	0.00	H
ATOM	1422	1HH2	ARG	B	369	4.929	24.068	-12.570	1.00	0.00	H
ATOM	1423	2HH2	ARG	B	369	4.848	23.048	-11.029	1.00	0.00	H
ATOM	1424	N	GLY	B	370	10.068	18.588	-6.813	1.00	20.00	N
ATOM	1425	CA	GLY	B	370	9.526	17.518	-6.061	1.00	20.00	C
ATOM	1426	C	GLY	B	370	10.394	16.328	-5.676	1.00	20.00	C
ATOM	1427	O	GLY	B	370	9.891	15.314	-5.243	1.00	20.00	O
ATOM	1428	H	GLY	B	370	10.569	19.373	-6.381	1.00	0.00	H
ATOM	1429	1HA	GLY	B	370	8.620	17.114	-6.557	1.00	0.00	H
ATOM	1430	2HA	GLY	B	370	9.137	17.929	-5.113	1.00	0.00	H
ATOM	1431	N	LEU	B	371	11.711	16.039	-5.590	1.00	20.00	N
ATOM	1432	CA	LEU	B	371	12.639	15.159	-4.904	1.00	20.00	C
ATOM	1433	C	LEU	B	371	13.169	15.823	-3.665	1.00	20.00	C
ATOM	1434	O	LEU	B	371	13.374	15.180	-2.571	1.00	20.00	O
ATOM	1435	CB	LEU	B	371	13.647	14.780	-5.980	1.00	20.00	C
ATOM	1436	CG	LEU	B	371	14.831	14.035	-5.379	1.00	20.00	C
ATOM	1437	CD1	LEU	B	371	14.338	12.814	-4.562	1.00	20.00	C
ATOM	1438	CD2	LEU	B	371	15.796	13.882	-6.541	1.00	20.00	C
ATOM	1439	H	LEU	B	371	12.153	16.724	-6.221	1.00	0.00	H
ATOM	1440	HA	LEU	B	371	12.078	14.261	-4.587	1.00	0.00	H

ATOM	1441	1HB	LEU	B	371	14.003	15.686	-6.511	1.00	0.00	H
ATOM	1442	2HB	LEU	B	371	13.151	14.157	-6.753	1.00	0.00	H
ATOM	1443	HG	LEU	B	371	15.357	14.682	-4.664	1.00	0.00	H
ATOM	1444	1HD1	LEU	B	371	15.162	12.271	-4.071	1.00	0.00	H
ATOM	1445	2HD1	LEU	B	371	13.678	13.076	-3.723	1.00	0.00	H
ATOM	1446	3HD1	LEU	B	371	13.703	12.133	-5.158	1.00	0.00	H
ATOM	1447	1HD2	LEU	B	371	16.746	13.456	-6.206	1.00	0.00	H
ATOM	1448	2HD2	LEU	B	371	15.375	13.284	-7.367	1.00	0.00	H
ATOM	1449	3HD2	LEU	B	371	16.066	14.860	-6.958	1.00	0.00	H
ATOM	1450	N	LYS	B	372	13.241	16.924	-3.692	1.00	20.00	N
ATOM	1451	CA	LYS	B	372	13.897	17.782	-2.745	1.00	20.00	C
ATOM	1452	C	LYS	B	372	15.388	17.778	-2.947	1.00	20.00	C
ATOM	1453	O	LYS	B	372	15.994	18.810	-2.942	1.00	20.00	O
ATOM	1454	CB	LYS	B	372	13.211	18.238	-1.416	1.00	20.00	C
ATOM	1455	CG	LYS	B	372	11.663	18.299	-1.384	1.00	20.00	C
ATOM	1456	CD	LYS	B	372	11.041	19.374	-2.300	1.00	20.00	C
ATOM	1457	CE	LYS	B	372	9.507	19.393	-2.208	1.00	20.00	C
ATOM	1458	NZ	LYS	B	372	8.960	20.467	-3.060	1.00	20.00	N
ATOM	1459	H	LYS	B	372	12.797	17.293	-4.539	1.00	0.00	H
ATOM	1460	HA	LYS	B	372	13.698	18.730	-3.286	1.00	0.00	H
ATOM	1461	1HB	LYS	B	372	13.608	19.235	-1.139	1.00	0.00	H
ATOM	1462	2HB	LYS	B	372	13.531	17.620	-0.576	1.00	0.00	H
ATOM	1463	1HG	LYS	B	372	11.340	18.485	-0.341	1.00	0.00	H
ATOM	1464	2HG	LYS	B	372	11.253	17.301	-1.636	1.00	0.00	H
ATOM	1465	1HD	LYS	B	372	11.348	19.200	-3.349	1.00	0.00	H
ATOM	1466	2HD	LYS	B	372	11.446	20.369	-2.030	1.00	0.00	H
ATOM	1467	1HE	LYS	B	372	9.187	19.557	-1.159	1.00	0.00	H
ATOM	1468	2HE	LYS	B	372	9.086	18.413	-2.508	1.00	0.00	H
ATOM	1469	1HZ	LYS	B	372	9.213	20.331	-4.045	1.00	0.00	H
ATOM	1470	2HZ	LYS	B	372	7.933	20.484	-3.031	1.00	0.00	H
ATOM	1471	N	MET	B	373	16.108	16.628	-3.169	1.00	20.00	N
ATOM	1472	CA	MET	B	373	17.542	16.681	-3.298	1.00	20.00	C
ATOM	1473	C	MET	B	373	18.051	15.610	-4.233	1.00	20.00	C
ATOM	1474	O	MET	B	373	17.899	14.417	-4.032	1.00	20.00	O
ATOM	1475	CB	MET	B	373	18.147	16.817	-1.856	1.00	20.00	C
ATOM	1476	CG	MET	B	373	19.550	16.280	-1.511	1.00	20.00	C
ATOM	1477	SD	MET	B	373	20.012	16.568	0.225	1.00	20.00	S
ATOM	1478	CE	MET	B	373	19.484	18.249	0.627	1.00	20.00	C
ATOM	1479	H	MET	B	373	15.577	15.763	-3.006	1.00	0.00	H
ATOM	1480	HA	MET	B	373	17.780	17.599	-3.844	1.00	0.00	H
ATOM	1481	1HB	MET	B	373	17.467	16.393	-1.099	1.00	0.00	H
ATOM	1482	2HB	MET	B	373	18.120	17.896	-1.617	1.00	0.00	H
ATOM	1483	1HG	MET	B	373	20.342	16.665	-2.174	1.00	0.00	H
ATOM	1484	2HG	MET	B	373	19.548	15.185	-1.646	1.00	0.00	H
ATOM	1485	1HE	MET	B	373	19.893	18.558	1.605	1.00	0.00	H
ATOM	1486	2HE	MET	B	373	19.833	18.969	-0.134	1.00	0.00	H
ATOM	1487	3HE	MET	B	373	18.383	18.313	0.687	1.00	0.00	H
ATOM	1488	N	SER	B	374	19.024	15.932	-5.190	1.00	20.00	N
ATOM	1489	CA	SER	B	374	19.258	15.184	-6.387	1.00	20.00	C
ATOM	1490	C	SER	B	374	20.708	14.742	-6.485	1.00	20.00	C
ATOM	1491	O	SER	B	374	21.628	15.246	-5.893	1.00	20.00	O
ATOM	1492	CB	SER	B	374	18.863	15.864	-7.678	1.00	20.00	C
ATOM	1493	OG	SER	B	374	19.514	17.104	-7.866	1.00	20.00	O
ATOM	1494	H	SER	B	374	19.480	16.837	-5.038	1.00	0.00	H
ATOM	1495	HA	SER	B	374	18.681	14.242	-6.335	1.00	0.00	H
ATOM	1496	1HB	SER	B	374	17.801	15.946	-7.590	1.00	0.00	H
ATOM	1497	2HB	SER	B	374	19.027	15.224	-8.566	1.00	0.00	H
ATOM	1498	HG	SER	B	374	19.282	17.681	-7.130	1.00	0.00	H
ATOM	1499	N	ALA	B	375	20.968	13.822	-7.310	1.00	20.00	N
ATOM	1500	CA	ALA	B	375	22.239	13.187	-7.590	1.00	20.00	C
ATOM	1501	C	ALA	B	375	22.297	12.703	-8.994	1.00	20.00	C
ATOM	1502	O	ALA	B	375	21.492	11.895	-9.439	1.00	20.00	O
ATOM	1503	CB	ALA	B	375	22.698	12.085	-6.652	1.00	20.00	C

ATOM	1504	H	ALA	B	375	20.126	13.439	-7.752	1.00	0.00	H
ATOM	1505	HA	ALA	B	375	23.015	13.975	-7.459	1.00	0.00	H
ATOM	1506	1HB	ALA	B	375	23.691	11.669	-6.910	1.00	0.00	H
ATOM	1507	2HB	ALA	B	375	22.792	12.535	-5.660	1.00	0.00	H
ATOM	1508	3HB	ALA	B	375	21.980	11.253	-6.614	1.00	0.00	H
ATOM	1509	N	THR	B	376	23.191	13.233	-9.763	1.00	20.00	N
ATOM	1510	CA	THR	B	376	23.403	12.743	-11.121	1.00	20.00	C
ATOM	1511	C	THR	B	376	24.837	12.220	-11.199	1.00	20.00	C
ATOM	1512	O	THR	B	376	25.726	12.699	-10.506	1.00	20.00	O
ATOM	1513	CB	THR	B	376	23.252	13.891	-12.168	1.00	20.00	C
ATOM	1514	OG1	THR	B	376	22.091	14.661	-11.895	1.00	20.00	O
ATOM	1515	CG2	THR	B	376	23.125	13.394	-13.621	1.00	20.00	C
ATOM	1516	H	THR	B	376	23.931	13.755	-9.280	1.00	0.00	H
ATOM	1517	HA	THR	B	376	22.713	11.927	-11.409	1.00	0.00	H
ATOM	1518	HC	THR	B	376	24.975	11.376	-11.900	1.00	0.00	H
ATOM	1519	HB	THR	B	376	24.122	14.579	-12.101	1.00	0.00	H
ATOM	1520	HG1	THR	B	376	21.957	14.572	-10.944	1.00	0.00	H
ATOM	1521	1HG2	THR	B	376	23.117	14.232	-14.339	1.00	0.00	H
ATOM	1522	2HG2	THR	B	376	23.966	12.742	-13.920	1.00	0.00	H
ATOM	1523	3HG2	THR	B	376	22.191	12.824	-13.780	1.00	0.00	H
END											

Appendix B: SB-T-2053 in β -Tubulin Binding Site (PDB File Format, Version 2.0)

REMARK	4									
REMARK	4	COMPLIES WITH FORMAT V. 2.0, 10-JAN-2005								
ATOM	1	CC	METH	1D	3.390	0.436	-3.807	0.00	0.00	C
ATOM	2	CC3	METH	1D	1.916	0.651	-4.114	1.00	0.00	C
ATOM	3	1O16	METH	1D	-1.318	-0.010	-2.411	0.00	0.00	O
ATOM	4	C161	METH	1D	-0.548	0.439	-3.558	1.00	0.00	C
ATOM	5	C161	METH	1D	0.924	0.163	-3.362	1.00	0.00	C
ATOM	6	H1	METH	1D	3.570	0.603	-2.731	1.00	0.00	H
ATOM	7	H2	METH	1D	3.935	1.286	-4.253	1.00	0.00	H
ATOM	8	H3	METH	1D	1.673	1.250	-4.994	1.00	0.00	H
ATOM	9	H4	METH	1D	1.177	-0.493	-2.534	1.00	0.00	H
ATOM	10	H5	METH	1D	-0.901	-0.105	-4.453	1.00	0.00	H
ATOM	11	H6	METH	1D	-0.733	1.505	-3.778	1.00	0.00	H
ATOM	12	O1	UNK	1	-3.361	1.580	-3.108	0.00	0.00	O
ATOM	13	O2	UNK	1	-4.454	-0.089	-1.109	0.00	0.00	O
ATOM	14	O3	UNK	1	-3.700	-0.769	1.469	0.00	0.00	O
ATOM	15	O4	UNK	1	-6.534	-0.165	2.650	0.00	0.00	O
ATOM	16	O5	UNK	1	-5.558	4.132	3.435	0.00	0.00	O
ATOM	17	O6	UNK	1	-4.988	5.374	1.000	0.00	0.00	O
ATOM	18	O7	UNK	1	-2.468	5.965	0.240	0.00	0.00	O
ATOM	19	O8	UNK	1	-0.032	0.533	0.252	0.00	0.00	O
ATOM	20	O9	UNK	1	-5.499	0.087	-3.143	0.00	0.00	O
ATOM	21	O10	UNK	1	-2.085	0.254	2.807	0.00	0.00	O
ATOM	22	O11	UNK	1	2.189	1.106	-0.084	0.00	0.00	O
ATOM	23	O12	UNK	1	1.036	-1.776	1.487	0.00	0.00	O
ATOM	24	O13	UNK	1	2.658	-3.480	-2.021	0.00	0.00	O
ATOM	25	N14	UNK	1	3.505	-1.538	-1.293	0.00	0.00	N
ATOM	26	C15	UNK	1	-3.019	1.828	-1.734	0.00	0.00	C
ATOM	27	C16	UNK	1	-4.291	1.354	-0.867	0.00	0.00	C
ATOM	28	C17	UNK	1	-4.327	1.596	0.734	0.00	0.00	C
ATOM	29	C18	UNK	1	-4.702	0.289	1.579	0.00	0.00	C
ATOM	30	C19	UNK	1	-5.270	0.401	3.024	0.00	0.00	C
ATOM	31	C20	UNK	1	-5.452	1.785	3.666	0.00	0.00	C
ATOM	32	C21	UNK	1	-4.895	2.987	2.886	0.00	0.00	C
ATOM	33	C22	UNK	1	-4.976	2.961	1.304	0.00	0.00	C
ATOM	34	C23	UNK	1	-4.282	4.356	0.953	0.00	0.00	C
ATOM	35	C24	UNK	1	-2.766	4.622	0.736	0.00	0.00	C
ATOM	36	C25	UNK	1	-2.083	3.612	-0.200	0.00	0.00	C
ATOM	37	C26	UNK	1	-1.049	2.833	0.246	0.00	0.00	C
ATOM	38	C27	UNK	1	-0.593	1.597	-0.569	0.00	0.00	C
ATOM	39	C28	UNK	1	-1.765	0.912	-1.357	0.00	0.00	C
ATOM	40	C29	UNK	1	-2.665	3.384	-1.645	0.00	0.00	C
ATOM	41	C30	UNK	1	-1.595	3.904	-2.668	0.00	0.00	C
ATOM	42	C31	UNK	1	-3.887	4.257	-2.106	0.00	0.00	C
ATOM	43	C32	UNK	1	-6.071	-0.374	1.314	0.00	0.00	C
ATOM	44	C33	UNK	1	-6.461	3.034	0.824	0.00	0.00	C
ATOM	45	C34	UNK	1	-0.290	3.063	1.553	0.00	0.00	C
ATOM	46	C35	UNK	1	-5.043	-0.630	-2.244	0.00	0.00	C
ATOM	47	C36	UNK	1	-2.533	-0.729	2.217	0.00	0.00	C
ATOM	48	C37	UNK	1	-1.887	-2.090	2.271	0.00	0.00	C
ATOM	49	C38	UNK	1	1.317	0.263	0.146	0.00	0.00	C
ATOM	50	C39	UNK	1	1.584	-1.251	0.275	0.00	0.00	C
ATOM	51	C40	UNK	1	3.071	-1.701	0.131	0.00	0.00	C
ATOM	52	C41	UNK	1	3.279	-2.439	-2.266	0.00	0.00	C
ATOM	53	C75	UNK	1	-2.191	6.982	1.144	0.00	0.00	C
ATOM	54	O76	UNK	1	-2.199	6.882	2.373	0.00	0.00	O
ATOM	55	C77	UNK	1	-1.844	8.277	0.437	0.00	0.00	C

ATOM	56	C81	UNK	1	-5.080	-2.130	-2.366	0.00	0.00	C
ATOM	57	C82	UNK	1	-4.477	-2.936	-1.384	0.00	0.00	C
ATOM	58	C83	UNK	1	-4.500	-4.323	-1.490	0.00	0.00	C
ATOM	59	C84	UNK	1	-5.127	-4.926	-2.576	0.00	0.00	C
ATOM	60	C85	UNK	1	-5.729	-4.145	-3.558	0.00	0.00	C
ATOM	61	C86	UNK	1	-5.705	-2.756	-3.456	0.00	0.00	C
ATOM	62	C92	UNK	1	4.007	-1.071	1.220	0.00	0.00	C
ATOM	63	C93	UNK	1	3.857	-1.487	2.551	0.00	0.00	C
ATOM	64	C94	UNK	1	4.693	-0.999	3.545	0.00	0.00	C
ATOM	65	C95	UNK	1	5.729	-0.130	3.223	0.00	0.00	C
ATOM	66	C96	UNK	1	5.912	0.273	1.906	0.00	0.00	C
ATOM	67	C97	UNK	1	5.028	-0.150	0.920	0.00	0.00	C
ATOM	68	C103	UNK	1	3.874	-2.164	-3.640	0.00	0.00	C
ATOM	69	C104	UNK	1	4.371	-3.311	-4.288	0.00	0.00	C
ATOM	70	C105	UNK	1	5.046	-3.216	-5.497	0.00	0.00	C
ATOM	71	C106	UNK	1	5.200	-1.985	-6.113	0.00	0.00	C
ATOM	72	C107	UNK	1	4.668	-0.843	-5.531	0.00	0.00	C
ATOM	73	C108	UNK	1	3.999	-0.907	-4.301	0.00	0.00	C
ATOM	74	H5	UNK	1	-5.464	4.843	2.787	1.00	0.00	H
ATOM	75	H12	UNK	1	0.895	-2.729	1.353	0.00	0.00	H
ATOM	76	H14	UNK	1	4.041	-0.717	-1.587	0.00	0.00	H
ATOM	77	H16	UNK	1	-5.179	1.852	-1.291	0.00	0.00	H
ATOM	78	H17	UNK	1	-3.274	1.682	1.030	0.00	0.00	H
ATOM	79	H19	UNK	1	-4.762	-0.284	3.731	0.00	0.00	H
ATOM	80	1H20	UNK	1	-5.000	1.785	4.676	0.00	0.00	H
ATOM	81	2H20	UNK	1	-6.518	1.934	3.869	0.00	0.00	H
ATOM	82	H21	UNK	1	-3.823	3.043	3.177	0.00	0.00	H
ATOM	83	H24	UNK	1	-2.369	4.511	1.761	0.00	0.00	H
ATOM	84	H27	UNK	1	0.153	1.961	-1.300	0.00	0.00	H
ATOM	85	H28	UNK	1	-2.143	0.200	-0.602	0.00	0.00	H
ATOM	86	1H30	UNK	1	-0.602	3.450	-2.554	0.00	0.00	H
ATOM	87	2H30	UNK	1	-1.888	3.719	-3.718	0.00	0.00	H
ATOM	88	3H30	UNK	1	-1.419	4.993	-2.565	0.00	0.00	H
ATOM	89	1H31	UNK	1	-4.824	4.033	-1.575	0.00	0.00	H
ATOM	90	2H31	UNK	1	-3.711	5.342	-1.973	0.00	0.00	H
ATOM	91	3H31	UNK	1	-4.133	4.105	-3.174	0.00	0.00	H
ATOM	92	1H32	UNK	1	-6.698	0.130	0.561	0.00	0.00	H
ATOM	93	2H32	UNK	1	-6.012	-1.452	1.070	0.00	0.00	H
ATOM	94	1H33	UNK	1	-6.570	3.130	-0.270	0.00	0.00	H
ATOM	95	2H33	UNK	1	-7.034	2.151	1.132	0.00	0.00	H
ATOM	96	3H33	UNK	1	-6.997	3.906	1.245	0.00	0.00	H
ATOM	97	1H34	UNK	1	-0.213	4.133	1.812	0.00	0.00	H
ATOM	98	2H34	UNK	1	-0.774	2.544	2.400	0.00	0.00	H
ATOM	99	3H34	UNK	1	0.754	2.707	1.503	0.00	0.00	H
ATOM	100	1H37	UNK	1	-1.024	-2.084	2.959	0.00	0.00	H
ATOM	101	2H37	UNK	1	-2.598	-2.856	2.625	0.00	0.00	H
ATOM	102	3H37	UNK	1	-1.534	-2.384	1.268	0.00	0.00	H
ATOM	103	H39	UNK	1	1.008	-1.716	-0.548	0.00	0.00	H
ATOM	104	H40	UNK	1	3.081	-2.790	0.344	0.00	0.00	H
ATOM	105	H1	UNK	1	-4.124	0.977	-3.111	0.00	0.00	H
ATOM	106	1H77	UNK	1	-2.723	8.681	-0.094	0.00	0.00	H
ATOM	107	2H77	UNK	1	-1.495	9.037	1.159	0.00	0.00	H
ATOM	108	3H77	UNK	1	-1.035	8.113	-0.297	0.00	0.00	H
ATOM	109	H84	UNK	1	-5.144	-6.003	-2.659	1.00	0.00	H
ATOM	110	H82	UNK	1	-3.973	-2.496	-0.536	0.00	0.00	H
ATOM	111	H83	UNK	1	-4.027	-4.931	-0.732	0.00	0.00	H
ATOM	112	H85	UNK	1	-6.213	-4.618	-4.402	0.00	0.00	H
ATOM	113	H86	UNK	1	-6.176	-2.168	-4.231	0.00	0.00	H
ATOM	114	H93	UNK	1	3.099	-2.205	2.827	0.00	0.00	H
ATOM	115	H94	UNK	1	4.535	-1.321	4.557	0.00	0.00	H
ATOM	116	H95	UNK	1	6.401	0.220	3.994	0.00	0.00	H
ATOM	117	H96	UNK	1	6.759	0.880	1.636	0.00	0.00	H
ATOM	118	H97	UNK	1	5.184	0.191	-0.091	0.00	0.00	H

ATOM	119	H104	UNK	1	4.288	-4.291	-3.834	0.00	0.00	H
ATOM	120	H105	UNK	1	5.459	-4.106	-5.953	0.00	0.00	H
ATOM	121	H106	UNK	1	5.722	-1.916	-7.057	0.00	0.00	H
ATOM	122	H107	UNK	1	4.763	0.092	-6.064	0.00	0.00	H
ATOM	123	N	ILE B	16	6.333	-15.273	4.338	1.00	20.00	N
ATOM	124	CA	ILE B	16	6.625	-13.911	4.728	1.00	20.00	C
ATOM	125	C	ILE B	16	7.567	-13.238	3.754	1.00	20.00	C
ATOM	126	O	ILE B	16	7.636	-12.084	3.584	1.00	20.00	O
ATOM	127	CB	ILE B	16	7.112	-13.829	6.230	1.00	20.00	C
ATOM	128	CG1	ILE B	16	6.252	-14.591	7.291	1.00	20.00	C
ATOM	129	CG2	ILE B	16	7.329	-12.375	6.736	1.00	20.00	C
ATOM	130	CD1	ILE B	16	4.767	-14.196	7.399	1.00	20.00	C
ATOM	131	1H	ILE B	16	5.775	-15.728	5.071	1.00	0.00	H
ATOM	132	2H	ILE B	16	5.738	-15.288	3.502	1.00	0.00	H
ATOM	133	HA	ILE B	16	5.675	-13.347	4.669	1.00	0.00	H
ATOM	134	HB	ILE B	16	8.109	-14.314	6.263	1.00	0.00	H
ATOM	135	1HG1	ILE B	16	6.720	-14.489	8.289	1.00	0.00	H
ATOM	136	2HG1	ILE B	16	6.309	-15.677	7.088	1.00	0.00	H
ATOM	137	1HG2	ILE B	16	7.682	-12.346	7.785	1.00	0.00	H
ATOM	138	2HG2	ILE B	16	8.091	-11.834	6.145	1.00	0.00	H
ATOM	139	3HG2	ILE B	16	6.401	-11.775	6.689	1.00	0.00	H
ATOM	140	1HD1	ILE B	16	4.253	-14.772	8.191	1.00	0.00	H
ATOM	141	2HD1	ILE B	16	4.634	-13.126	7.644	1.00	0.00	H
ATOM	142	3HD1	ILE B	16	4.219	-14.385	6.458	1.00	0.00	H
ATOM	143	N	GLY B	17	8.193	-14.226	3.031	1.00	20.00	N
ATOM	144	CA	GLY B	17	9.085	-13.731	2.010	1.00	20.00	C
ATOM	145	C	GLY B	17	8.404	-13.138	0.858	1.00	20.00	C
ATOM	146	O	GLY B	17	8.913	-12.188	0.241	1.00	20.00	O
ATOM	147	H	GLY B	17	8.002	-15.190	3.345	1.00	0.00	H
ATOM	148	1HA	GLY B	17	9.720	-14.561	1.646	1.00	0.00	H
ATOM	149	2HA	GLY B	17	9.811	-13.001	2.424	1.00	0.00	H
ATOM	150	N	ALA B	18	7.326	-13.755	0.641	1.00	20.00	N
ATOM	151	CA	ALA B	18	6.441	-13.382	-0.370	1.00	20.00	C
ATOM	152	C	ALA B	18	5.953	-11.993	-0.186	1.00	20.00	C
ATOM	153	O	ALA B	18	5.791	-11.265	-1.154	1.00	20.00	O
ATOM	154	CB	ALA B	18	5.309	-14.431	-0.426	1.00	20.00	C
ATOM	155	H	ALA B	18	7.132	-14.476	1.345	1.00	0.00	H
ATOM	156	HA	ALA B	18	6.966	-13.417	-1.348	1.00	0.00	H
ATOM	157	1HB	ALA B	18	4.597	-14.206	-1.243	1.00	0.00	H
ATOM	158	2HB	ALA B	18	5.695	-15.450	-0.623	1.00	0.00	H
ATOM	159	3HB	ALA B	18	4.718	-14.475	0.509	1.00	0.00	H
ATOM	160	N	LYS B	19	5.715	-11.595	1.049	1.00	20.00	N
ATOM	161	CA	LYS B	19	5.132	-10.302	1.245	1.00	20.00	C
ATOM	162	C	LYS B	19	6.111	-9.190	1.610	1.00	20.00	C
ATOM	163	O	LYS B	19	5.808	-8.035	1.526	1.00	20.00	O
ATOM	164	CB	LYS B	19	3.600	-9.982	1.111	1.00	20.00	C
ATOM	165	CG	LYS B	19	2.677	-11.049	0.474	1.00	20.00	C
ATOM	166	CD	LYS B	19	1.263	-10.499	0.193	1.00	20.00	C
ATOM	167	CE	LYS B	19	0.310	-11.567	-0.359	1.00	20.00	C
ATOM	168	NZ	LYS B	19	-1.012	-10.960	-0.608	1.00	20.00	N
ATOM	169	H	LYS B	19	5.930	-12.272	1.788	1.00	0.00	H
ATOM	170	HA	LYS B	19	5.226	-9.802	0.262	1.00	0.00	H
ATOM	171	1HB	LYS B	19	3.450	-9.059	0.502	1.00	0.00	H
ATOM	172	2HB	LYS B	19	3.215	-9.582	2.052	1.00	0.00	H
ATOM	173	1HG	LYS B	19	2.636	-11.948	1.116	1.00	0.00	H
ATOM	174	2HG	LYS B	19	3.117	-11.392	-0.482	1.00	0.00	H
ATOM	175	1HD	LYS B	19	1.338	-9.663	-0.532	1.00	0.00	H
ATOM	176	2HD	LYS B	19	0.839	-10.048	1.111	1.00	0.00	H
ATOM	177	1HE	LYS B	19	0.215	-12.412	0.351	1.00	0.00	H
ATOM	178	2HE	LYS B	19	0.709	-11.993	-1.301	1.00	0.00	H
ATOM	179	1HZ	LYS B	19	-1.705	-11.659	-0.903	1.00	0.00	H
ATOM	180	2HZ	LYS B	19	-1.380	-10.528	0.248	1.00	0.00	H
ATOM	181	N	PHE B	20	7.274	-9.496	2.008	1.00	20.00	N

ATOM	182	CA	PHE	B	20	8.291	-8.469	2.297	1.00	20.00	C
ATOM	183	C	PHE	B	20	8.816	-8.032	0.963	1.00	20.00	C
ATOM	184	O	PHE	B	20	8.607	-6.925	0.489	1.00	20.00	O
ATOM	185	CB	PHE	B	20	9.290	-8.957	3.404	1.00	20.00	C
ATOM	186	CG	PHE	B	20	10.625	-8.182	3.508	1.00	20.00	C
ATOM	187	CD1	PHE	B	20	11.836	-8.884	3.473	1.00	20.00	C
ATOM	188	CD2	PHE	B	20	10.652	-6.781	3.547	1.00	20.00	C
ATOM	189	CE1	PHE	B	20	13.049	-8.199	3.472	1.00	20.00	C
ATOM	190	CE2	PHE	B	20	11.865	-6.098	3.542	1.00	20.00	C
ATOM	191	CZ	PHE	B	20	13.062	-6.808	3.507	1.00	20.00	C
ATOM	192	H	PHE	B	20	7.402	-10.497	2.209	1.00	0.00	H
ATOM	193	HA	PHE	B	20	7.816	-7.566	2.735	1.00	0.00	H
ATOM	194	1HB	PHE	B	20	9.501	-10.034	3.252	1.00	0.00	H
ATOM	195	2HB	PHE	B	20	8.781	-8.926	4.387	1.00	0.00	H
ATOM	196	HD1	PHE	B	20	11.845	-9.963	3.423	1.00	0.00	H
ATOM	197	HD2	PHE	B	20	9.732	-6.214	3.556	1.00	0.00	H
ATOM	198	HE1	PHE	B	20	13.979	-8.747	3.429	1.00	0.00	H
ATOM	199	HE2	PHE	B	20	11.877	-5.018	3.560	1.00	0.00	H
ATOM	200	HZ	PHE	B	20	14.002	-6.277	3.493	1.00	0.00	H
ATOM	201	N	TRP	B	21	9.471	-8.940	0.424	1.00	20.00	N
ATOM	202	CA	TRP	B	21	9.951	-8.783	-0.872	1.00	20.00	C
ATOM	203	C	TRP	B	21	8.803	-8.409	-1.728	1.00	20.00	C
ATOM	204	O	TRP	B	21	8.891	-7.862	-2.827	1.00	20.00	O
ATOM	205	CB	TRP	B	21	10.725	-10.019	-1.411	1.00	20.00	C
ATOM	206	CG	TRP	B	21	12.085	-10.263	-0.741	1.00	20.00	C
ATOM	207	CD1	TRP	B	21	12.306	-11.002	0.441	1.00	20.00	C
ATOM	208	CD2	TRP	B	21	13.322	-9.753	-1.098	1.00	20.00	C
ATOM	209	NE1	TRP	B	21	13.655	-10.951	0.844	1.00	20.00	N
ATOM	210	CE2	TRP	B	21	14.263	-10.162	-0.120	1.00	20.00	C
ATOM	211	CE3	TRP	B	21	13.724	-8.922	-2.179	1.00	20.00	C
ATOM	212	CZ2	TRP	B	21	15.607	-9.731	-0.205	1.00	20.00	C
ATOM	213	CZ3	TRP	B	21	15.056	-8.511	-2.242	1.00	20.00	C
ATOM	214	CH2	TRP	B	21	15.984	-8.908	-1.269	1.00	20.00	C
ATOM	215	H	TRP	B	21	9.414	-9.852	0.890	1.00	0.00	H
ATOM	216	HA	TRP	B	21	10.654	-7.937	-0.913	1.00	0.00	H
ATOM	217	1HB	TRP	B	21	10.908	-9.886	-2.496	1.00	0.00	H
ATOM	218	2HB	TRP	B	21	10.106	-10.930	-1.369	1.00	0.00	H
ATOM	219	HD1	TRP	B	21	11.526	-11.510	0.991	1.00	0.00	H
ATOM	220	HE1	TRP	B	21	14.096	-11.386	1.663	1.00	0.00	H
ATOM	221	HE3	TRP	B	21	13.014	-8.597	-2.926	1.00	0.00	H
ATOM	222	HZ2	TRP	B	21	16.328	-10.030	0.542	1.00	0.00	H
ATOM	223	HZ3	TRP	B	21	15.379	-7.875	-3.054	1.00	0.00	H
ATOM	224	HH2	TRP	B	21	17.009	-8.573	-1.345	1.00	0.00	H
ATOM	225	N	GLU	B	22	7.541	-8.436	-1.695	1.00	20.00	N
ATOM	226	CA	GLU	B	22	7.184	-7.892	-2.988	1.00	20.00	C
ATOM	227	C	GLU	B	22	6.983	-6.420	-2.893	1.00	20.00	C
ATOM	228	O	GLU	B	22	6.607	-5.684	-3.812	1.00	20.00	O
ATOM	229	CB	GLU	B	22	5.649	-8.373	-3.011	1.00	20.00	C
ATOM	230	CG	GLU	B	22	5.328	-9.766	-3.601	1.00	20.00	C
ATOM	231	CD	GLU	B	22	3.921	-10.311	-3.339	1.00	20.00	C
ATOM	232	OE1	GLU	B	22	2.993	-9.665	-2.860	1.00	20.00	O
ATOM	233	OE2	GLU	B	22	3.806	-11.615	-3.712	1.00	20.00	O
ATOM	234	H	GLU	B	22	7.107	-9.245	-1.235	1.00	0.00	H
ATOM	235	HA	GLU	B	22	7.347	-8.345	-4.030	1.00	0.00	H
ATOM	236	1HB	GLU	B	22	5.030	-7.702	-3.649	1.00	0.00	H
ATOM	237	2HB	GLU	B	22	5.140	-8.263	-2.025	1.00	0.00	H
ATOM	238	1HG	GLU	B	22	6.089	-10.512	-3.319	1.00	0.00	H
ATOM	239	2HG	GLU	B	22	5.430	-9.689	-4.681	1.00	0.00	H
ATOM	240	HE2	GLU	B	22	2.911	-11.901	-3.526	1.00	0.00	H
ATOM	241	N	VAL	B	23	7.168	-6.005	-1.925	1.00	20.00	N
ATOM	242	CA	VAL	B	23	7.022	-4.614	-1.601	1.00	20.00	C
ATOM	243	C	VAL	B	23	8.262	-3.838	-1.977	1.00	20.00	C
ATOM	244	O	VAL	B	23	8.414	-2.703	-1.746	1.00	20.00	O

ATOM	245	CB	VAL	B	23	6.520	-4.508	-0.110	1.00	20.00	C
ATOM	246	CG1	VAL	B	23	6.576	-3.088	0.477	1.00	20.00	C
ATOM	247	CG2	VAL	B	23	5.071	-5.039	0.048	1.00	20.00	C
ATOM	248	H	VAL	B	23	7.397	-6.739	-1.233	1.00	0.00	H
ATOM	249	HA	VAL	B	23	6.215	-4.111	-2.179	1.00	0.00	H
ATOM	250	HB	VAL	B	23	7.165	-5.113	0.547	1.00	0.00	H
ATOM	251	1HG1	VAL	B	23	6.064	-2.998	1.452	1.00	0.00	H
ATOM	252	2HG1	VAL	B	23	7.614	-2.752	0.650	1.00	0.00	H
ATOM	253	3HG1	VAL	B	23	6.116	-2.361	-0.215	1.00	0.00	H
ATOM	254	1HG2	VAL	B	23	4.652	-4.880	1.056	1.00	0.00	H
ATOM	255	2HG2	VAL	B	23	4.377	-4.558	-0.659	1.00	0.00	H
ATOM	256	3HG2	VAL	B	23	5.012	-6.126	-0.143	1.00	0.00	H
ATOM	257	N	ILE	B	24	8.994	-4.635	-2.651	1.00	20.00	N
ATOM	258	CA	ILE	B	24	10.293	-4.163	-3.043	1.00	20.00	C
ATOM	259	C	ILE	B	24	10.394	-3.960	-4.547	1.00	20.00	C
ATOM	260	O	ILE	B	24	10.863	-2.988	-5.078	1.00	20.00	O
ATOM	261	CB	ILE	B	24	11.336	-5.218	-2.490	1.00	20.00	C
ATOM	262	CG1	ILE	B	24	11.330	-5.295	-0.925	1.00	20.00	C
ATOM	263	CG2	ILE	B	24	12.762	-4.979	-3.025	1.00	20.00	C
ATOM	264	CD1	ILE	B	24	12.484	-5.993	-0.184	1.00	20.00	C
ATOM	265	H	ILE	B	24	8.672	-5.613	-2.594	1.00	0.00	H
ATOM	266	HA	ILE	B	24	10.580	-3.184	-2.603	1.00	0.00	H
ATOM	267	HB	ILE	B	24	11.051	-6.223	-2.864	1.00	0.00	H
ATOM	268	1HG1	ILE	B	24	10.393	-5.785	-0.618	1.00	0.00	H
ATOM	269	2HG1	ILE	B	24	11.195	-4.293	-0.502	1.00	0.00	H
ATOM	270	1HG2	ILE	B	24	13.438	-5.789	-2.702	1.00	0.00	H
ATOM	271	2HG2	ILE	B	24	12.822	-4.968	-4.129	1.00	0.00	H
ATOM	272	3HG2	ILE	B	24	13.149	-4.016	-2.657	1.00	0.00	H
ATOM	273	1HD1	ILE	B	24	12.261	-6.086	0.889	1.00	0.00	H
ATOM	274	2HD1	ILE	B	24	12.664	-7.013	-0.554	1.00	0.00	H
ATOM	275	3HD1	ILE	B	24	13.435	-5.439	-0.273	1.00	0.00	H
ATOM	276	N	SER	B	25	10.000	-4.822	-5.482	1.00	20.00	N
ATOM	277	CA	SER	B	25	10.362	-4.177	-6.734	1.00	20.00	C
ATOM	278	C	SER	B	25	9.859	-2.708	-6.545	1.00	20.00	C
ATOM	279	O	SER	B	25	9.785	-1.943	-7.517	1.00	20.00	O
ATOM	280	CB	SER	B	25	9.717	-4.968	-7.896	1.00	20.00	C
ATOM	281	OG	SER	B	25	8.295	-5.056	-7.782	1.00	20.00	O
ATOM	282	H	SER	B	25	9.226	-5.468	-5.292	1.00	0.00	H
ATOM	283	HA	SER	B	25	11.459	-4.196	-6.929	1.00	0.00	H
ATOM	284	1HB	SER	B	25	10.151	-5.988	-7.942	1.00	0.00	H
ATOM	285	2HB	SER	B	25	9.986	-4.493	-8.858	1.00	0.00	H
ATOM	286	HG	SER	B	25	8.008	-5.796	-8.325	1.00	0.00	H
ATOM	287	N	ASP	B	26	9.412	-2.338	-5.218	1.00	20.00	N
ATOM	288	CA	ASP	B	26	9.201	-0.996	-4.849	1.00	20.00	C
ATOM	289	C	ASP	B	26	10.435	-0.170	-4.971	1.00	20.00	C
ATOM	290	O	ASP	B	26	10.495	1.017	-4.991	1.00	20.00	O
ATOM	291	CB	ASP	B	26	8.502	-0.767	-3.516	1.00	20.00	C
ATOM	292	CG	ASP	B	26	7.969	0.552	-2.989	1.00	20.00	C
ATOM	293	OD1	ASP	B	26	8.571	1.616	-3.039	1.00	20.00	O
ATOM	294	OD2	ASP	B	26	6.787	0.387	-2.328	1.00	20.00	O
ATOM	295	H	ASP	B	26	8.996	-3.116	-4.700	1.00	0.00	H
ATOM	296	HA	ASP	B	26	8.508	-0.575	-5.603	1.00	0.00	H
ATOM	297	1HB	ASP	B	26	9.270	-1.000	-2.763	1.00	0.00	H
ATOM	298	2HB	ASP	B	26	7.656	-1.477	-3.477	1.00	0.00	H
ATOM	299	HD2	ASP	B	26	6.558	1.211	-1.900	1.00	0.00	H
ATOM	300	N	GLU	B	27	11.520	-1.062	-5.004	1.00	20.00	N
ATOM	301	CA	GLU	B	27	12.825	-0.994	-5.545	1.00	20.00	C
ATOM	302	C	GLU	B	27	13.778	-0.413	-4.531	1.00	20.00	C
ATOM	303	O	GLU	B	27	14.144	0.749	-4.547	1.00	20.00	O
ATOM	304	CB	GLU	B	27	12.971	-0.171	-6.883	1.00	20.00	C
ATOM	305	CG	GLU	B	27	12.054	-0.452	-8.084	1.00	20.00	C
ATOM	306	CD	GLU	B	27	12.304	0.181	-9.448	1.00	20.00	C
ATOM	307	OE1	GLU	B	27	13.410	0.321	-9.956	1.00	20.00	O

ATOM	308	OE2	GLU	B	27	11.135	0.467	-10.088	1.00	20.00	O
ATOM	309	H	GLU	B	27	11.095	-2.086	-5.023	1.00	0.00	H
ATOM	310	HA	GLU	B	27	13.133	-2.029	-5.798	1.00	0.00	H
ATOM	311	1HB	GLU	B	27	14.026	-0.207	-7.219	1.00	0.00	H
ATOM	312	2HB	GLU	B	27	12.784	0.880	-6.615	1.00	0.00	H
ATOM	313	1HG	GLU	B	27	11.054	-0.101	-7.781	1.00	0.00	H
ATOM	314	2HG	GLU	B	27	11.997	-1.541	-8.253	1.00	0.00	H
ATOM	315	HE2	GLU	B	27	11.283	0.477	-11.050	1.00	0.00	H
ATOM	316	N	HIS	B	28	14.345	-1.177	-3.781	1.00	20.00	N
ATOM	317	CA	HIS	B	28	15.531	-0.832	-3.071	1.00	20.00	C
ATOM	318	C	HIS	B	28	16.307	-1.905	-2.446	1.00	20.00	C
ATOM	319	O	HIS	B	28	17.355	-1.775	-2.050	1.00	20.00	O
ATOM	320	CB	HIS	B	28	14.958	-0.058	-1.781	1.00	20.00	C
ATOM	321	CG	HIS	B	28	13.838	-0.762	-0.947	1.00	20.00	C
ATOM	322	ND1	HIS	B	28	12.487	-0.662	-1.272	1.00	20.00	N
ATOM	323	CD2	HIS	B	28	14.051	-1.822	-0.047	1.00	20.00	C
ATOM	324	CE1	HIS	B	28	12.001	-1.709	-0.547	1.00	20.00	C
ATOM	325	NE2	HIS	B	28	12.861	-2.468	0.209	1.00	20.00	N
ATOM	326	H	HIS	B	28	13.584	-1.626	-3.255	1.00	0.00	H
ATOM	327	HA	HIS	B	28	16.227	-0.190	-3.654	1.00	0.00	H
ATOM	328	1HB	HIS	B	28	14.518	0.895	-2.103	1.00	0.00	H
ATOM	329	2HB	HIS	B	28	15.777	0.266	-1.108	1.00	0.00	H
ATOM	330	HD2	HIS	B	28	15.024	-2.159	0.285	1.00	0.00	H
ATOM	331	HE1	HIS	B	28	10.938	-1.918	-0.558	1.00	0.00	H
ATOM	332	HE2	HIS	B	28	12.681	-3.343	0.719	1.00	0.00	H
ATOM	333	N	GLY	B	29	15.556	-2.936	-2.510	1.00	20.00	N
ATOM	334	CA	GLY	B	29	15.856	-4.194	-1.974	1.00	20.00	C
ATOM	335	C	GLY	B	29	17.363	-4.467	-1.971	1.00	20.00	C
ATOM	336	O	GLY	B	29	17.968	-4.692	-3.033	1.00	20.00	O
ATOM	337	H	GLY	B	29	14.817	-2.770	-3.203	1.00	0.00	H
ATOM	338	1HA	GLY	B	29	15.409	-4.986	-2.595	1.00	0.00	H
ATOM	339	2HA	GLY	B	29	15.437	-4.307	-0.957	1.00	0.00	H
ATOM	340	HC	GLY	B	29	17.848	-4.388	-0.981	1.00	0.00	H
ATOM	341	N	TYR	B	36	14.857	2.425	-8.295	1.00	20.00	N
ATOM	342	CA	TYR	B	36	13.800	3.095	-7.650	1.00	20.00	C
ATOM	343	C	TYR	B	36	13.881	4.564	-7.921	1.00	20.00	C
ATOM	344	O	TYR	B	36	12.973	5.299	-7.437	1.00	20.00	O
ATOM	345	CB	TYR	B	36	14.405	3.112	-6.189	1.00	20.00	C
ATOM	346	CG	TYR	B	36	15.669	3.943	-5.715	1.00	20.00	C
ATOM	347	CD1	TYR	B	36	15.515	5.251	-5.235	1.00	20.00	C
ATOM	348	CD2	TYR	B	36	16.946	3.366	-5.713	1.00	20.00	C
ATOM	349	CE1	TYR	B	36	16.613	5.963	-4.756	1.00	20.00	C
ATOM	350	CE2	TYR	B	36	18.042	4.078	-5.232	1.00	20.00	C
ATOM	351	CZ	TYR	B	36	17.874	5.374	-4.754	1.00	20.00	C
ATOM	352	OH	TYR	B	36	18.954	6.065	-4.275	1.00	20.00	O
ATOM	353	1H	TYR	B	36	14.724	2.410	-9.313	1.00	0.00	H
ATOM	354	2H	TYR	B	36	15.753	2.893	-8.118	1.00	0.00	H
ATOM	355	HA	TYR	B	36	12.798	2.651	-7.787	1.00	0.00	H
ATOM	356	HC	TYR	B	36	14.735	4.930	-8.524	1.00	0.00	H
ATOM	357	1HB	TYR	B	36	14.734	2.099	-5.999	1.00	0.00	H
ATOM	358	2HB	TYR	B	36	13.576	3.267	-5.474	1.00	0.00	H
ATOM	359	HD1	TYR	B	36	14.536	5.708	-5.209	1.00	0.00	H
ATOM	360	HD2	TYR	B	36	17.087	2.354	-6.068	1.00	0.00	H
ATOM	361	HE1	TYR	B	36	16.474	6.965	-4.378	1.00	0.00	H
ATOM	362	HE2	TYR	B	36	19.023	3.626	-5.224	1.00	0.00	H
ATOM	363	HH	TYR	B	36	18.672	6.946	-4.025	1.00	0.00	H
ATOM	364	N	ASP	B	39	11.002	5.374	-11.600	1.00	20.00	N
ATOM	365	CA	ASP	B	39	10.173	4.223	-11.793	1.00	20.00	C
ATOM	366	C	ASP	B	39	10.636	3.265	-12.783	1.00	20.00	C
ATOM	367	O	ASP	B	39	11.672	3.318	-13.348	1.00	20.00	O
ATOM	368	CB	ASP	B	39	8.721	4.836	-11.937	1.00	20.00	C
ATOM	369	CG	ASP	B	39	8.023	5.179	-10.617	1.00	20.00	C
ATOM	370	OD1	ASP	B	39	7.690	6.313	-10.288	1.00	20.00	O

ATOM	371	OD2	ASP	B	39	7.794	4.071	-9.859	1.00	20.00	O
ATOM	372	1H	ASP	B	39	11.978	5.089	-11.460	1.00	0.00	H
ATOM	373	2H	ASP	B	39	11.010	5.952	-12.448	1.00	0.00	H
ATOM	374	HA	ASP	B	39	10.221	3.678	-10.825	1.00	0.00	H
ATOM	375	1HB	ASP	B	39	8.036	4.138	-12.449	1.00	0.00	H
ATOM	376	2HB	ASP	B	39	8.707	5.727	-12.595	1.00	0.00	H
ATOM	377	HD2	ASP	B	39	7.341	4.318	-9.050	1.00	0.00	H
ATOM	378	N	SER	B	40	9.851	2.332	-12.911	1.00	20.00	N
ATOM	379	CA	SER	B	40	10.053	1.464	-13.912	1.00	20.00	C
ATOM	380	C	SER	B	40	10.429	0.085	-13.504	1.00	20.00	C
ATOM	381	O	SER	B	40	11.166	-0.109	-12.534	1.00	20.00	O
ATOM	382	CB	SER	B	40	10.580	1.861	-15.364	1.00	20.00	C
ATOM	383	OG	SER	B	40	12.002	1.928	-15.381	1.00	20.00	O
ATOM	384	H	SER	B	40	9.024	2.346	-12.306	1.00	0.00	H
ATOM	385	HA	SER	B	40	8.969	1.441	-14.184	1.00	0.00	H
ATOM	386	1HB	SER	B	40	10.161	2.838	-15.675	1.00	0.00	H
ATOM	387	2HB	SER	B	40	10.246	1.144	-16.139	1.00	0.00	H
ATOM	388	HG	SER	B	40	12.207	2.500	-14.615	1.00	0.00	H
ATOM	389	N	ASP	B	41	9.792	-0.735	-14.187	1.00	20.00	N
ATOM	390	CA	ASP	B	41	10.154	-2.100	-14.412	1.00	20.00	C
ATOM	391	C	ASP	B	41	9.030	-3.032	-14.033	1.00	20.00	C
ATOM	392	O	ASP	B	41	7.920	-2.826	-14.478	1.00	20.00	O
ATOM	393	CB	ASP	B	41	11.710	-2.468	-14.334	1.00	20.00	C
ATOM	394	CG	ASP	B	41	12.643	-1.666	-15.247	1.00	20.00	C
ATOM	395	OD1	ASP	B	41	12.613	-1.729	-16.471	1.00	20.00	O
ATOM	396	OD2	ASP	B	41	13.501	-0.870	-14.552	1.00	20.00	O
ATOM	397	H	ASP	B	41	9.121	-0.297	-14.825	1.00	0.00	H
ATOM	398	HA	ASP	B	41	10.024	-2.172	-15.512	1.00	0.00	H
ATOM	399	1HB	ASP	B	41	11.872	-3.522	-14.625	1.00	0.00	H
ATOM	400	2HB	ASP	B	41	12.066	-2.399	-13.289	1.00	0.00	H
ATOM	401	HD2	ASP	B	41	13.988	-0.329	-15.176	1.00	0.00	H
ATOM	402	N	LEU	B	42	9.535	-4.064	-13.497	1.00	20.00	N
ATOM	403	CA	LEU	B	42	8.776	-4.821	-12.506	1.00	20.00	C
ATOM	404	C	LEU	B	42	8.939	-6.291	-12.735	1.00	20.00	C
ATOM	405	O	LEU	B	42	9.167	-6.751	-13.862	1.00	20.00	O
ATOM	406	CB	LEU	B	42	7.242	-4.477	-12.205	1.00	20.00	C
ATOM	407	CG	LEU	B	42	6.879	-3.120	-11.527	1.00	20.00	C
ATOM	408	CD1	LEU	B	42	5.359	-2.889	-11.593	1.00	20.00	C
ATOM	409	CD2	LEU	B	42	7.329	-3.023	-10.061	1.00	20.00	C
ATOM	410	H	LEU	B	42	10.557	-4.035	-13.450	1.00	0.00	H
ATOM	411	HA	LEU	B	42	9.307	-4.519	-11.575	1.00	0.00	H
ATOM	412	1HB	LEU	B	42	6.783	-5.268	-11.580	1.00	0.00	H
ATOM	413	2HB	LEU	B	42	6.693	-4.564	-13.163	1.00	0.00	H
ATOM	414	HG	LEU	B	42	7.357	-2.287	-12.075	1.00	0.00	H
ATOM	415	1HD1	LEU	B	42	5.070	-1.916	-11.152	1.00	0.00	H
ATOM	416	2HD1	LEU	B	42	4.996	-2.879	-12.638	1.00	0.00	H
ATOM	417	3HD1	LEU	B	42	4.791	-3.672	-11.056	1.00	0.00	H
ATOM	418	1HD2	LEU	B	42	7.057	-2.050	-9.611	1.00	0.00	H
ATOM	419	2HD2	LEU	B	42	6.863	-3.804	-9.433	1.00	0.00	H
ATOM	420	3HD2	LEU	B	42	8.424	-3.111	-9.952	1.00	0.00	H
ATOM	421	N	GLN	B	43	8.924	-6.859	-11.617	1.00	20.00	N
ATOM	422	CA	GLN	B	43	8.629	-8.262	-11.408	1.00	20.00	C
ATOM	423	C	GLN	B	43	9.713	-8.887	-10.606	1.00	20.00	C
ATOM	424	O	GLN	B	43	10.106	-8.352	-9.547	1.00	20.00	O
ATOM	425	CB	GLN	B	43	7.711	-9.027	-12.460	1.00	20.00	C
ATOM	426	CG	GLN	B	43	6.289	-8.442	-12.681	1.00	20.00	C
ATOM	427	CD	GLN	B	43	5.447	-9.220	-13.693	1.00	20.00	C
ATOM	428	OE1	GLN	B	43	4.674	-10.108	-13.351	1.00	20.00	O
ATOM	429	NE2	GLN	B	43	5.561	-8.917	-14.965	1.00	20.00	N
ATOM	430	H	GLN	B	43	8.885	-6.207	-10.829	1.00	0.00	H
ATOM	431	HA	GLN	B	43	7.890	-8.200	-10.583	1.00	0.00	H
ATOM	432	1HB	GLN	B	43	7.583	-10.078	-12.131	1.00	0.00	H
ATOM	433	2HB	GLN	B	43	8.246	-9.093	-13.427	1.00	0.00	H

ATOM	434	1HG	GLN	B	43	6.342	-7.381	-12.986	1.00	0.00	H
ATOM	435	2HG	GLN	B	43	5.737	-8.434	-11.723	1.00	0.00	H
ATOM	436	1HE2	GLN	B	43	6.268	-8.219	-15.212	1.00	0.00	H
ATOM	437	2HE2	GLN	B	43	4.994	-9.499	-15.587	1.00	0.00	H
ATOM	438	N	LEU	B	44	10.129	-9.866	-11.235	1.00	20.00	N
ATOM	439	CA	LEU	B	44	11.120	-10.718	-10.675	1.00	20.00	C
ATOM	440	C	LEU	B	44	12.370	-10.495	-11.458	1.00	20.00	C
ATOM	441	O	LEU	B	44	12.990	-11.420	-11.828	1.00	20.00	O
ATOM	442	CB	LEU	B	44	10.538	-12.173	-10.675	1.00	20.00	C
ATOM	443	CG	LEU	B	44	11.283	-13.222	-9.805	1.00	20.00	C
ATOM	444	CD1	LEU	B	44	11.119	-12.966	-8.294	1.00	20.00	C
ATOM	445	CD2	LEU	B	44	10.771	-14.637	-10.129	1.00	20.00	C
ATOM	446	H	LEU	B	44	9.651	-10.067	-12.119	1.00	0.00	H
ATOM	447	HA	LEU	B	44	11.374	-10.458	-9.625	1.00	0.00	H
ATOM	448	1HB	LEU	B	44	10.498	-12.531	-11.723	1.00	0.00	H
ATOM	449	2HB	LEU	B	44	9.480	-12.165	-10.354	1.00	0.00	H
ATOM	450	HG	LEU	B	44	12.364	-13.194	-10.051	1.00	0.00	H
ATOM	451	1HD1	LEU	B	44	10.056	-12.948	-7.989	1.00	0.00	H
ATOM	452	2HD1	LEU	B	44	11.620	-13.744	-7.689	1.00	0.00	H
ATOM	453	3HD1	LEU	B	44	11.561	-12.002	-7.985	1.00	0.00	H
ATOM	454	1HD2	LEU	B	44	11.307	-15.411	-9.549	1.00	0.00	H
ATOM	455	2HD2	LEU	B	44	9.693	-14.752	-9.910	1.00	0.00	H
ATOM	456	3HD2	LEU	B	44	10.916	-14.888	-11.196	1.00	0.00	H
ATOM	457	N	GLU	B	47	12.500	-9.196	-12.042	1.00	20.00	N
ATOM	458	CA	GLU	B	47	13.690	-8.737	-12.715	1.00	20.00	C
ATOM	459	C	GLU	B	47	13.365	-7.783	-13.842	1.00	20.00	C
ATOM	460	O	GLU	B	47	12.272	-7.666	-14.332	1.00	20.00	O
ATOM	461	CB	GLU	B	47	14.902	-9.717	-12.993	1.00	20.00	C
ATOM	462	CG	GLU	B	47	15.779	-10.055	-11.758	1.00	20.00	C
ATOM	463	CD	GLU	B	47	16.928	-11.008	-12.070	1.00	20.00	C
ATOM	464	OE1	GLU	B	47	18.029	-10.643	-12.471	1.00	20.00	O
ATOM	465	OE2	GLU	B	47	16.598	-12.312	-11.854	1.00	20.00	O
ATOM	466	H	GLU	B	47	11.705	-8.583	-11.832	1.00	0.00	H
ATOM	467	HA	GLU	B	47	14.116	-8.020	-11.987	1.00	0.00	H
ATOM	468	1HB	GLU	B	47	15.596	-9.288	-13.741	1.00	0.00	H
ATOM	469	2HB	GLU	B	47	14.535	-10.637	-13.488	1.00	0.00	H
ATOM	470	1HG	GLU	B	47	15.172	-10.488	-10.943	1.00	0.00	H
ATOM	471	2HG	GLU	B	47	16.211	-9.129	-11.335	1.00	0.00	H
ATOM	472	HE2	GLU	B	47	17.353	-12.859	-12.073	1.00	0.00	H
ATOM	473	N	ARG	B	48	14.298	-7.344	-14.720	1.00	20.00	N
ATOM	474	CA	ARG	B	48	14.988	-6.232	-15.356	1.00	20.00	C
ATOM	475	C	ARG	B	48	15.938	-6.727	-16.402	1.00	20.00	C
ATOM	476	O	ARG	B	48	15.609	-7.670	-17.145	1.00	20.00	O
ATOM	477	CB	ARG	B	48	15.834	-5.462	-14.295	1.00	20.00	C
ATOM	478	CG	ARG	B	48	15.123	-4.804	-13.091	1.00	20.00	C
ATOM	479	CD	ARG	B	48	16.165	-4.266	-12.091	1.00	20.00	C
ATOM	480	NE	ARG	B	48	15.517	-3.770	-10.839	1.00	20.00	N
ATOM	481	CZ	ARG	B	48	15.003	-2.658	-10.536	1.00	20.00	C
ATOM	482	NH1	ARG	B	48	14.903	-1.661	-11.371	1.00	20.00	N
ATOM	483	NH2	ARG	B	48	14.561	-2.507	-9.332	1.00	20.00	N
ATOM	484	H	ARG	B	48	14.238	-8.094	-15.420	1.00	0.00	H
ATOM	485	HA	ARG	B	48	14.249	-5.556	-15.828	1.00	0.00	H
ATOM	486	HC	ARG	B	48	16.907	-6.199	-16.486	1.00	0.00	H
ATOM	487	1HB	ARG	B	48	16.410	-4.659	-14.799	1.00	0.00	H
ATOM	488	2HB	ARG	B	48	16.604	-6.155	-13.895	1.00	0.00	H
ATOM	489	1HG	ARG	B	48	14.475	-5.536	-12.575	1.00	0.00	H
ATOM	490	2HG	ARG	B	48	14.451	-3.993	-13.429	1.00	0.00	H
ATOM	491	1HD	ARG	B	48	16.784	-3.468	-12.546	1.00	0.00	H
ATOM	492	2HD	ARG	B	48	16.880	-5.066	-11.815	1.00	0.00	H
ATOM	493	1HH1	ARG	B	48	14.444	-0.813	-11.011	1.00	0.00	H
ATOM	494	2HH1	ARG	B	48	15.254	-1.855	-12.309	1.00	0.00	H
ATOM	495	1HH2	ARG	B	48	14.187	-1.583	-9.101	1.00	0.00	H
ATOM	496	2HH2	ARG	B	48	14.713	-3.326	-8.742	1.00	0.00	H

ATOM	497	N	PHE	B	83	4.566	-13.690	-8.018	1.00	20.00	N
ATOM	498	CA	PHE	B	83	5.450	-12.454	-8.093	1.00	20.00	C
ATOM	499	C	PHE	B	83	6.888	-12.675	-8.519	1.00	20.00	C
ATOM	500	O	PHE	B	83	7.624	-11.740	-8.853	1.00	20.00	O
ATOM	501	CB	PHE	B	83	5.284	-11.530	-6.865	1.00	20.00	C
ATOM	502	CG	PHE	B	83	5.508	-10.027	-7.169	1.00	20.00	C
ATOM	503	CD1	PHE	B	83	4.420	-9.212	-7.501	1.00	20.00	C
ATOM	504	CD2	PHE	B	83	6.770	-9.443	-6.996	1.00	20.00	C
ATOM	505	CE1	PHE	B	83	4.587	-7.836	-7.642	1.00	20.00	C
ATOM	506	CE2	PHE	B	83	6.935	-8.067	-7.134	1.00	20.00	C
ATOM	507	CZ	PHE	B	83	5.842	-7.264	-7.450	1.00	20.00	C
ATOM	508	1H	PHE	B	83	3.598	-13.423	-7.802	1.00	0.00	H
ATOM	509	2H	PHE	B	83	4.521	-14.160	-8.929	1.00	0.00	H
ATOM	510	HA	PHE	B	83	5.026	-11.890	-8.948	1.00	0.00	H
ATOM	511	HC	PHE	B	83	7.211	-13.732	-8.490	1.00	0.00	H
ATOM	512	1HB	PHE	B	83	5.946	-11.868	-6.045	1.00	0.00	H
ATOM	513	2HB	PHE	B	83	4.269	-11.652	-6.438	1.00	0.00	H
ATOM	514	HD1	PHE	B	83	3.434	-9.639	-7.622	1.00	0.00	H
ATOM	515	HD2	PHE	B	83	7.620	-10.052	-6.725	1.00	0.00	H
ATOM	516	HE1	PHE	B	83	3.739	-7.210	-7.878	1.00	0.00	H
ATOM	517	HE2	PHE	B	83	7.908	-7.627	-6.968	1.00	0.00	H
ATOM	518	HZ	PHE	B	83	5.954	-6.193	-7.527	1.00	0.00	H
ATOM	519	N	LEU	B	209	-1.064	-9.042	15.447	1.00	20.00	N
ATOM	520	CA	LEU	B	209	-1.135	-8.527	14.081	1.00	20.00	C
ATOM	521	C	LEU	B	209	-2.543	-8.259	13.708	1.00	20.00	C
ATOM	522	O	LEU	B	209	-2.805	-7.386	12.900	1.00	20.00	O
ATOM	523	CB	LEU	B	209	-0.421	-9.495	13.090	1.00	20.00	C
ATOM	524	CG	LEU	B	209	1.101	-9.277	12.866	1.00	20.00	C
ATOM	525	CD1	LEU	B	209	1.958	-9.575	14.110	1.00	20.00	C
ATOM	526	CD2	LEU	B	209	1.618	-10.129	11.693	1.00	20.00	C
ATOM	527	1H	LEU	B	209	-1.558	-8.426	16.103	1.00	0.00	H
ATOM	528	2H	LEU	B	209	-1.511	-9.962	15.521	1.00	0.00	H
ATOM	529	HA	LEU	B	209	-0.614	-7.549	14.058	1.00	0.00	H
ATOM	530	HC	LEU	B	209	-3.300	-8.915	14.180	1.00	0.00	H
ATOM	531	1HB	LEU	B	209	-0.894	-9.379	12.098	1.00	0.00	H
ATOM	532	2HB	LEU	B	209	-0.619	-10.552	13.357	1.00	0.00	H
ATOM	533	HG	LEU	B	209	1.252	-8.220	12.580	1.00	0.00	H
ATOM	534	1HD1	LEU	B	209	3.036	-9.418	13.919	1.00	0.00	H
ATOM	535	2HD1	LEU	B	209	1.697	-8.912	14.955	1.00	0.00	H
ATOM	536	3HD1	LEU	B	209	1.833	-10.616	14.462	1.00	0.00	H
ATOM	537	1HD2	LEU	B	209	2.690	-9.942	11.492	1.00	0.00	H
ATOM	538	2HD2	LEU	B	209	1.509	-11.213	11.886	1.00	0.00	H
ATOM	539	3HD2	LEU	B	209	1.083	-9.905	10.752	1.00	0.00	H
ATOM	540	N	ILE	B	212	-4.178	-4.968	14.862	1.00	20.00	N
ATOM	541	CA	ILE	B	212	-3.787	-3.957	13.892	1.00	20.00	C
ATOM	542	C	ILE	B	212	-4.580	-4.025	12.611	1.00	20.00	C
ATOM	543	O	ILE	B	212	-5.080	-3.045	12.134	1.00	20.00	O
ATOM	544	CB	ILE	B	212	-2.227	-3.740	13.893	1.00	20.00	C
ATOM	545	CG1	ILE	B	212	-1.836	-2.780	15.063	1.00	20.00	C
ATOM	546	CG2	ILE	B	212	-1.667	-3.179	12.567	1.00	20.00	C
ATOM	547	CD1	ILE	B	212	-0.353	-2.724	15.444	1.00	20.00	C
ATOM	548	1H	ILE	B	212	-5.201	-5.049	14.913	1.00	0.00	H
ATOM	549	2H	ILE	B	212	-3.836	-5.893	14.576	1.00	0.00	H
ATOM	550	HA	ILE	B	212	-4.202	-3.022	14.319	1.00	0.00	H
ATOM	551	HB	ILE	B	212	-1.735	-4.721	14.054	1.00	0.00	H
ATOM	552	1HG1	ILE	B	212	-2.388	-3.071	15.979	1.00	0.00	H
ATOM	553	2HG1	ILE	B	212	-2.191	-1.754	14.843	1.00	0.00	H
ATOM	554	1HG2	ILE	B	212	-0.570	-3.046	12.583	1.00	0.00	H
ATOM	555	2HG2	ILE	B	212	-1.892	-3.829	11.708	1.00	0.00	H
ATOM	556	3HG2	ILE	B	212	-2.120	-2.202	12.337	1.00	0.00	H
ATOM	557	1HD1	ILE	B	212	-0.174	-1.989	16.251	1.00	0.00	H
ATOM	558	2HD1	ILE	B	212	-0.018	-3.703	15.823	1.00	0.00	H
ATOM	559	3HD1	ILE	B	212	0.297	-2.439	14.597	1.00	0.00	H

ATOM	560	N	CYS	B	213	-4.687	-5.174	12.055	1.00	20.00	N
ATOM	561	CA	CYS	B	213	-5.366	-5.342	10.790	1.00	20.00	C
ATOM	562	C	CYS	B	213	-6.810	-5.338	10.997	1.00	20.00	C
ATOM	563	O	CYS	B	213	-7.569	-5.855	10.192	1.00	20.00	O
ATOM	564	CB	CYS	B	213	-4.815	-6.663	10.168	1.00	20.00	C
ATOM	565	SG	CYS	B	213	-4.035	-6.280	8.570	1.00	20.00	S
ATOM	566	H	CYS	B	213	-4.115	-5.920	12.480	1.00	0.00	H
ATOM	567	HA	CYS	B	213	-5.086	-4.543	10.086	1.00	0.00	H
ATOM	568	HC	CYS	B	213	-7.173	-4.800	11.894	1.00	0.00	H
ATOM	569	1HB	CYS	B	213	-5.607	-7.416	9.993	1.00	0.00	H
ATOM	570	2HB	CYS	B	213	-4.065	-7.195	10.782	1.00	0.00	H
ATOM	571	HG	CYS	B	213	-3.593	-7.500	8.292	1.00	0.00	H
ATOM	572	N	THR	B	216	-6.997	-0.571	13.732	1.00	20.00	N
ATOM	573	CA	THR	B	216	-6.454	0.463	12.857	1.00	20.00	C
ATOM	574	C	THR	B	216	-7.009	0.340	11.487	1.00	20.00	C
ATOM	575	O	THR	B	216	-7.445	1.305	10.899	1.00	20.00	O
ATOM	576	CB	THR	B	216	-4.916	0.615	12.991	1.00	20.00	C
ATOM	577	OG1	THR	B	216	-4.238	-0.563	12.567	1.00	20.00	O
ATOM	578	CG2	THR	B	216	-4.408	0.977	14.398	1.00	20.00	C
ATOM	579	1H	THR	B	216	-6.736	-0.383	14.707	1.00	0.00	H
ATOM	580	2H	THR	B	216	-8.025	-0.556	13.715	1.00	0.00	H
ATOM	581	HA	THR	B	216	-6.869	1.418	13.235	1.00	0.00	H
ATOM	582	HB	THR	B	216	-4.620	1.448	12.327	1.00	0.00	H
ATOM	583	HG1	THR	B	216	-4.847	-1.309	12.655	1.00	0.00	H
ATOM	584	1HG2	THR	B	216	-4.901	1.883	14.795	1.00	0.00	H
ATOM	585	2HG2	THR	B	216	-4.581	0.159	15.122	1.00	0.00	H
ATOM	586	3HG2	THR	B	216	-3.323	1.180	14.397	1.00	0.00	H
ATOM	587	N	LEU	B	217	-6.978	-0.832	11.042	1.00	20.00	N
ATOM	588	CA	LEU	B	217	-7.524	-1.178	9.778	1.00	20.00	C
ATOM	589	C	LEU	B	217	-8.884	-1.614	10.017	1.00	20.00	C
ATOM	590	O	LEU	B	217	-9.266	-1.955	11.140	1.00	20.00	O
ATOM	591	CB	LEU	B	217	-6.584	-2.192	9.055	1.00	20.00	C
ATOM	592	CG	LEU	B	217	-5.442	-1.568	8.210	1.00	20.00	C
ATOM	593	CD1	LEU	B	217	-4.336	-2.597	7.936	1.00	20.00	C
ATOM	594	CD2	LEU	B	217	-5.946	-1.006	6.867	1.00	20.00	C
ATOM	595	H	LEU	B	217	-6.791	-1.530	11.773	1.00	0.00	H
ATOM	596	HA	LEU	B	217	-7.550	-0.277	9.121	1.00	0.00	H
ATOM	597	1HB	LEU	B	217	-7.164	-2.880	8.412	1.00	0.00	H
ATOM	598	2HB	LEU	B	217	-6.160	-2.851	9.820	1.00	0.00	H
ATOM	599	HG	LEU	B	217	-4.984	-0.745	8.795	1.00	0.00	H
ATOM	600	1HD1	LEU	B	217	-3.514	-2.169	7.333	1.00	0.00	H
ATOM	601	2HD1	LEU	B	217	-3.882	-2.943	8.882	1.00	0.00	H
ATOM	602	3HD1	LEU	B	217	-4.711	-3.489	7.399	1.00	0.00	H
ATOM	603	1HD2	LEU	B	217	-5.124	-0.541	6.291	1.00	0.00	H
ATOM	604	2HD2	LEU	B	217	-6.390	-1.790	6.224	1.00	0.00	H
ATOM	605	3HD2	LEU	B	217	-6.709	-0.221	7.002	1.00	0.00	H
ATOM	606	N	LYS	B	218	-9.585	-1.595	8.981	1.00	20.00	N
ATOM	607	CA	LYS	B	218	-10.920	-2.120	9.075	1.00	20.00	C
ATOM	608	C	LYS	B	218	-11.015	-3.516	8.517	1.00	20.00	C
ATOM	609	O	LYS	B	218	-11.691	-4.422	9.092	1.00	20.00	O
ATOM	610	CB	LYS	B	218	-11.838	-1.107	8.325	1.00	20.00	C
ATOM	611	CG	LYS	B	218	-13.357	-1.384	8.429	1.00	20.00	C
ATOM	612	CD	LYS	B	218	-14.198	-0.332	7.680	1.00	20.00	C
ATOM	613	CE	LYS	B	218	-15.703	-0.628	7.761	1.00	20.00	C
ATOM	614	NZ	LYS	B	218	-16.458	0.404	7.024	1.00	20.00	N
ATOM	615	H	LYS	B	218	-9.199	-1.116	8.163	1.00	0.00	H
ATOM	616	HA	LYS	B	218	-11.323	-2.172	10.111	1.00	0.00	H
ATOM	617	1HB	LYS	B	218	-11.554	-1.052	7.255	1.00	0.00	H
ATOM	618	2HB	LYS	B	218	-11.657	-0.086	8.722	1.00	0.00	H
ATOM	619	1HG	LYS	B	218	-13.660	-1.416	9.494	1.00	0.00	H
ATOM	620	2HG	LYS	B	218	-13.585	-2.392	8.028	1.00	0.00	H
ATOM	621	1HD	LYS	B	218	-13.885	-0.293	6.618	1.00	0.00	H
ATOM	622	2HD	LYS	B	218	-13.986	0.674	8.093	1.00	0.00	H

ATOM	623	1HE	LYS	B	218	-16.038	-0.662	8.817	1.00	0.00	H
ATOM	624	2HE	LYS	B	218	-15.924	-1.626	7.335	1.00	0.00	H
ATOM	625	1HZ	LYS	B	218	-17.471	0.249	7.099	1.00	0.00	H
ATOM	626	2HZ	LYS	B	218	-16.291	1.334	7.424	1.00	0.00	H
ATOM	627	N	LEU	B	219	-10.329	-3.878	7.226	1.00	20.00	N
ATOM	628	CA	LEU	B	219	-10.316	-5.262	6.538	1.00	20.00	C
ATOM	629	C	LEU	B	219	-11.539	-5.922	6.904	1.00	20.00	C
ATOM	630	O	LEU	B	219	-11.866	-6.099	8.026	1.00	20.00	O
ATOM	631	CB	LEU	B	219	-9.042	-6.085	6.852	1.00	20.00	C
ATOM	632	CG	LEU	B	219	-7.697	-5.514	6.339	1.00	20.00	C
ATOM	633	CD1	LEU	B	219	-6.571	-6.467	6.751	1.00	20.00	C
ATOM	634	CD2	LEU	B	219	-7.638	-5.300	4.815	1.00	20.00	C
ATOM	635	H	LEU	B	219	-9.757	-3.111	6.865	1.00	0.00	H
ATOM	636	HA	LEU	B	219	-10.348	-5.085	5.446	1.00	0.00	H
ATOM	637	1HB	LEU	B	219	-9.169	-7.109	6.446	1.00	0.00	H
ATOM	638	2HB	LEU	B	219	-8.982	-6.226	7.951	1.00	0.00	H
ATOM	639	HG	LEU	B	219	-7.516	-4.540	6.834	1.00	0.00	H
ATOM	640	1HD1	LEU	B	219	-5.580	-6.059	6.481	1.00	0.00	H
ATOM	641	2HD1	LEU	B	219	-6.566	-6.631	7.844	1.00	0.00	H
ATOM	642	3HD1	LEU	B	219	-6.662	-7.459	6.273	1.00	0.00	H
ATOM	643	1HD2	LEU	B	219	-6.640	-4.946	4.495	1.00	0.00	H
ATOM	644	2HD2	LEU	B	219	-7.856	-6.230	4.257	1.00	0.00	H
ATOM	645	3HD2	LEU	B	219	-8.358	-4.534	4.475	1.00	0.00	H
ATOM	646	N	THR	B	220	-12.423	-6.379	6.190	1.00	20.00	N
ATOM	647	CA	THR	B	220	-13.502	-6.835	7.066	1.00	20.00	C
ATOM	648	C	THR	B	220	-13.213	-8.209	7.755	1.00	20.00	C
ATOM	649	O	THR	B	220	-13.672	-8.430	8.917	1.00	20.00	O
ATOM	650	CB	THR	B	220	-14.781	-7.039	6.162	1.00	20.00	C
ATOM	651	OG1	THR	B	220	-14.558	-7.922	5.059	1.00	20.00	O
ATOM	652	CG2	THR	B	220	-15.399	-5.750	5.586	1.00	20.00	C
ATOM	653	H	THR	B	220	-12.529	-6.033	5.232	1.00	0.00	H
ATOM	654	HA	THR	B	220	-13.957	-6.105	7.792	1.00	0.00	H
ATOM	655	HB	THR	B	220	-15.576	-7.489	6.794	1.00	0.00	H
ATOM	656	HG1	THR	B	220	-14.216	-8.748	5.419	1.00	0.00	H
ATOM	657	1HG2	THR	B	220	-16.326	-5.970	5.024	1.00	0.00	H
ATOM	658	2HG2	THR	B	220	-15.662	-5.026	6.379	1.00	0.00	H
ATOM	659	3HG2	THR	B	220	-14.714	-5.241	4.885	1.00	0.00	H
ATOM	660	N	THR	B	221	-12.443	-9.036	6.939	1.00	20.00	N
ATOM	661	CA	THR	B	221	-11.976	-10.521	7.124	1.00	20.00	C
ATOM	662	C	THR	B	221	-10.482	-10.536	6.734	1.00	20.00	C
ATOM	663	O	THR	B	221	-10.119	-10.590	5.553	1.00	20.00	O
ATOM	664	CB	THR	B	221	-12.808	-11.508	6.250	1.00	20.00	C
ATOM	665	OG1	THR	B	221	-12.718	-11.155	4.871	1.00	20.00	O
ATOM	666	CG2	THR	B	221	-14.296	-11.611	6.618	1.00	20.00	C
ATOM	667	H	THR	B	221	-12.103	-8.487	6.141	1.00	0.00	H
ATOM	668	HA	THR	B	221	-12.130	-10.815	8.177	1.00	0.00	H
ATOM	669	HB	THR	B	221	-12.374	-12.521	6.372	1.00	0.00	H
ATOM	670	HG1	THR	B	221	-11.775	-11.008	4.706	1.00	0.00	H
ATOM	671	1HG2	THR	B	221	-14.813	-12.350	5.980	1.00	0.00	H
ATOM	672	2HG2	THR	B	221	-14.440	-11.926	7.668	1.00	0.00	H
ATOM	673	3HG2	THR	B	221	-14.823	-10.648	6.489	1.00	0.00	H
ATOM	674	N	PRO	B	222	-9.504	-10.522	7.655	1.00	20.00	N
ATOM	675	CA	PRO	B	222	-8.124	-10.418	7.303	1.00	20.00	C
ATOM	676	C	PRO	B	222	-7.713	-11.572	6.598	1.00	20.00	C
ATOM	677	O	PRO	B	222	-8.538	-12.349	6.099	1.00	20.00	O
ATOM	678	CB	PRO	B	222	-7.503	-9.933	8.660	1.00	20.00	C
ATOM	679	CG	PRO	B	222	-8.380	-10.531	9.750	1.00	20.00	C
ATOM	680	CD	PRO	B	222	-9.762	-10.456	9.117	1.00	20.00	C
ATOM	681	HA	PRO	B	222	-8.003	-9.575	6.590	1.00	0.00	H
ATOM	682	1HB	PRO	B	222	-7.551	-8.827	8.718	1.00	0.00	H
ATOM	683	2HB	PRO	B	222	-6.438	-10.192	8.800	1.00	0.00	H
ATOM	684	1HG	PRO	B	222	-8.315	-9.984	10.709	1.00	0.00	H
ATOM	685	2HG	PRO	B	222	-8.097	-11.584	9.943	1.00	0.00	H

ATOM	686	1HD	PRO	B	222	-10.396	-11.289	9.480	1.00	0.00	H
ATOM	687	2HD	PRO	B	222	-10.268	-9.504	9.382	1.00	0.00	H
ATOM	688	N	THR	B	223	-6.503	-11.723	6.625	1.00	20.00	N
ATOM	689	CA	THR	B	223	-5.998	-12.756	5.885	1.00	20.00	C
ATOM	690	C	THR	B	223	-4.598	-12.880	6.193	1.00	20.00	C
ATOM	691	O	THR	B	223	-3.953	-11.922	6.620	1.00	20.00	O
ATOM	692	CB	THR	B	223	-6.149	-12.744	4.298	1.00	20.00	C
ATOM	693	OG1	THR	B	223	-7.384	-12.192	3.850	1.00	20.00	O
ATOM	694	CG2	THR	B	223	-6.128	-14.149	3.669	1.00	20.00	C
ATOM	695	H	THR	B	223	-5.926	-11.005	7.074	1.00	0.00	H
ATOM	696	HA	THR	B	223	-6.442	-13.710	6.255	1.00	0.00	H
ATOM	697	HC	THR	B	223	-4.183	-13.895	6.056	1.00	0.00	H
ATOM	698	HB	THR	B	223	-5.355	-12.129	3.832	1.00	0.00	H
ATOM	699	HG1	THR	B	223	-7.998	-12.284	4.605	1.00	0.00	H
ATOM	700	1HG2	THR	B	223	-6.200	-14.091	2.567	1.00	0.00	H
ATOM	701	2HG2	THR	B	223	-5.208	-14.713	3.902	1.00	0.00	H
ATOM	702	3HG2	THR	B	223	-6.983	-14.762	4.012	1.00	0.00	H
ATOM	703	N	GLY	B	225	-2.765	-13.403	3.656	1.00	20.00	N
ATOM	704	CA	GLY	B	225	-1.893	-12.573	2.751	1.00	20.00	C
ATOM	705	C	GLY	B	225	-1.904	-11.130	3.190	1.00	20.00	C
ATOM	706	O	GLY	B	225	-0.900	-10.463	3.036	1.00	20.00	O
ATOM	707	1H	GLY	B	225	-2.844	-14.360	3.290	1.00	0.00	H
ATOM	708	2H	GLY	B	225	-2.311	-13.507	4.572	1.00	0.00	H
ATOM	709	1HA	GLY	B	225	-2.257	-12.635	1.709	1.00	0.00	H
ATOM	710	2HA	GLY	B	225	-0.858	-12.961	2.749	1.00	0.00	H
ATOM	711	N	ASP	B	226	-2.857	-10.631	3.775	1.00	20.00	N
ATOM	712	CA	ASP	B	226	-2.947	-9.262	4.104	1.00	20.00	C
ATOM	713	C	ASP	B	226	-2.053	-8.892	5.252	1.00	20.00	C
ATOM	714	O	ASP	B	226	-1.565	-7.792	5.373	1.00	20.00	O
ATOM	715	CB	ASP	B	226	-4.440	-8.854	4.278	1.00	20.00	C
ATOM	716	CG	ASP	B	226	-4.715	-7.399	3.877	1.00	20.00	C
ATOM	717	OD1	ASP	B	226	-4.137	-6.430	4.359	1.00	20.00	O
ATOM	718	OD2	ASP	B	226	-5.662	-7.300	2.904	1.00	20.00	O
ATOM	719	H	ASP	B	226	-3.613	-11.307	3.924	1.00	0.00	H
ATOM	720	HA	ASP	B	226	-2.564	-8.673	3.241	1.00	0.00	H
ATOM	721	1HB	ASP	B	226	-4.777	-9.011	5.319	1.00	0.00	H
ATOM	722	2HB	ASP	B	226	-5.108	-9.495	3.669	1.00	0.00	H
ATOM	723	HD2	ASP	B	226	-5.787	-6.375	2.687	1.00	0.00	H
ATOM	724	N	LEU	B	227	-1.824	-9.889	6.072	1.00	20.00	N
ATOM	725	CA	LEU	B	227	-0.895	-9.724	7.159	1.00	20.00	C
ATOM	726	C	LEU	B	227	0.484	-9.499	6.632	1.00	20.00	C
ATOM	727	O	LEU	B	227	1.329	-8.962	7.346	1.00	20.00	O
ATOM	728	CB	LEU	B	227	-0.992	-10.953	8.128	1.00	20.00	C
ATOM	729	CG	LEU	B	227	-1.731	-10.705	9.471	1.00	20.00	C
ATOM	730	CD1	LEU	B	227	-3.243	-10.466	9.326	1.00	20.00	C
ATOM	731	CD2	LEU	B	227	-1.519	-11.892	10.428	1.00	20.00	C
ATOM	732	H	LEU	B	227	-2.446	-10.704	5.965	1.00	0.00	H
ATOM	733	HA	LEU	B	227	-1.150	-8.808	7.732	1.00	0.00	H
ATOM	734	1HB	LEU	B	227	0.033	-11.287	8.386	1.00	0.00	H
ATOM	735	2HB	LEU	B	227	-1.418	-11.844	7.625	1.00	0.00	H
ATOM	736	HG	LEU	B	227	-1.286	-9.804	9.935	1.00	0.00	H
ATOM	737	1HD1	LEU	B	227	-3.693	-10.116	10.274	1.00	0.00	H
ATOM	738	2HD1	LEU	B	227	-3.474	-9.708	8.559	1.00	0.00	H
ATOM	739	3HD1	LEU	B	227	-3.783	-11.387	9.037	1.00	0.00	H
ATOM	740	1HD2	LEU	B	227	-1.993	-11.719	11.412	1.00	0.00	H
ATOM	741	2HD2	LEU	B	227	-1.942	-12.832	10.025	1.00	0.00	H
ATOM	742	3HD2	LEU	B	227	-0.447	-12.080	10.623	1.00	0.00	H
ATOM	743	N	ASN	B	228	0.685	-9.884	5.390	1.00	20.00	N
ATOM	744	CA	ASN	B	228	1.949	-9.699	4.729	1.00	20.00	C
ATOM	745	C	ASN	B	228	2.097	-8.223	4.252	1.00	20.00	C
ATOM	746	O	ASN	B	228	3.193	-7.690	4.138	1.00	20.00	O
ATOM	747	CB	ASN	B	228	2.268	-10.975	3.908	1.00	20.00	C
ATOM	748	CG	ASN	B	228	2.237	-12.345	4.612	1.00	20.00	C

ATOM	749	OD1	ASN	B	228	2.507	-12.486	5.799	1.00	20.00	O
ATOM	750	ND2	ASN	B	228	1.943	-13.404	3.898	1.00	20.00	N
ATOM	751	H	ASN	B	228	-0.148	-10.269	4.921	1.00	0.00	H
ATOM	752	HA	ASN	B	228	2.748	-9.742	5.500	1.00	0.00	H
ATOM	753	1HB	ASN	B	228	3.314	-10.910	3.575	1.00	0.00	H
ATOM	754	2HB	ASN	B	228	1.621	-10.994	3.016	1.00	0.00	H
ATOM	755	1HD2	ASN	B	228	1.748	-13.261	2.904	1.00	0.00	H
ATOM	756	2HD2	ASN	B	228	1.954	-14.279	4.428	1.00	0.00	H
ATOM	757	N	HIS	B	229	0.988	-7.531	3.904	1.00	20.00	N
ATOM	758	CA	HIS	B	229	1.064	-6.058	3.844	1.00	20.00	C
ATOM	759	C	HIS	B	229	1.663	-5.750	5.261	1.00	20.00	C
ATOM	760	O	HIS	B	229	2.762	-5.460	5.461	1.00	20.00	O
ATOM	761	CB	HIS	B	229	-0.246	-5.353	3.420	1.00	20.00	C
ATOM	762	CG	HIS	B	229	-0.424	-5.330	1.900	1.00	20.00	C
ATOM	763	ND1	HIS	B	229	0.338	-4.523	1.057	1.00	20.00	N
ATOM	764	CD2	HIS	B	229	-1.268	-6.170	1.154	1.00	20.00	C
ATOM	765	CE1	HIS	B	229	-0.123	-4.973	-0.155	1.00	20.00	C
ATOM	766	NE2	HIS	B	229	-1.095	-5.939	-0.200	1.00	20.00	N
ATOM	767	H	HIS	B	229	0.118	-8.018	4.154	1.00	0.00	H
ATOM	768	HA	HIS	B	229	1.857	-5.765	3.124	1.00	0.00	H
ATOM	769	1HB	HIS	B	229	-0.222	-4.306	3.774	1.00	0.00	H
ATOM	770	2HB	HIS	B	229	-1.127	-5.797	3.917	1.00	0.00	H
ATOM	771	HD2	HIS	B	229	-1.913	-6.926	1.579	1.00	0.00	H
ATOM	772	HE1	HIS	B	229	0.311	-4.586	-1.070	1.00	0.00	H
ATOM	773	HE2	HIS	B	229	-1.458	-6.453	-1.011	1.00	0.00	H
ATOM	774	N	LEU	B	230	1.030	-5.894	6.417	1.00	20.00	N
ATOM	775	CA	LEU	B	230	1.667	-5.407	7.727	1.00	20.00	C
ATOM	776	C	LEU	B	230	3.197	-5.411	7.853	1.00	20.00	C
ATOM	777	O	LEU	B	230	3.846	-4.383	8.067	1.00	20.00	O
ATOM	778	CB	LEU	B	230	0.932	-6.091	8.926	1.00	20.00	C
ATOM	779	CG	LEU	B	230	-0.273	-5.363	9.568	1.00	20.00	C
ATOM	780	CD1	LEU	B	230	-1.291	-4.809	8.559	1.00	20.00	C
ATOM	781	CD2	LEU	B	230	-0.981	-6.342	10.523	1.00	20.00	C
ATOM	782	H	LEU	B	230	0.081	-6.278	6.350	1.00	0.00	H
ATOM	783	HA	LEU	B	230	1.429	-4.327	7.787	1.00	0.00	H
ATOM	784	1HB	LEU	B	230	1.653	-6.282	9.745	1.00	0.00	H
ATOM	785	2HB	LEU	B	230	0.625	-7.109	8.634	1.00	0.00	H
ATOM	786	HG	LEU	B	230	0.109	-4.509	10.162	1.00	0.00	H
ATOM	787	1HD1	LEU	B	230	-2.173	-4.387	9.070	1.00	0.00	H
ATOM	788	2HD1	LEU	B	230	-0.868	-3.992	7.947	1.00	0.00	H
ATOM	789	3HD1	LEU	B	230	-1.646	-5.587	7.858	1.00	0.00	H
ATOM	790	1HD2	LEU	B	230	-1.863	-5.891	11.009	1.00	0.00	H
ATOM	791	2HD2	LEU	B	230	-1.345	-7.247	10.003	1.00	0.00	H
ATOM	792	3HD2	LEU	B	230	-0.314	-6.681	11.337	1.00	0.00	H
ATOM	793	N	VAL	B	231	3.764	-6.558	7.760	1.00	20.00	N
ATOM	794	CA	VAL	B	231	5.175	-6.729	7.983	1.00	20.00	C
ATOM	795	C	VAL	B	231	6.041	-5.987	7.013	1.00	20.00	C
ATOM	796	O	VAL	B	231	7.059	-5.447	7.373	1.00	20.00	O
ATOM	797	CB	VAL	B	231	5.519	-8.273	8.055	1.00	20.00	C
ATOM	798	CG1	VAL	B	231	7.002	-8.566	8.403	1.00	20.00	C
ATOM	799	CG2	VAL	B	231	4.683	-9.104	9.066	1.00	20.00	C
ATOM	800	H	VAL	B	231	3.121	-7.331	7.544	1.00	0.00	H
ATOM	801	HA	VAL	B	231	5.415	-6.314	8.983	1.00	0.00	H
ATOM	802	HB	VAL	B	231	5.328	-8.707	7.052	1.00	0.00	H
ATOM	803	1HG1	VAL	B	231	7.222	-9.650	8.425	1.00	0.00	H
ATOM	804	2HG1	VAL	B	231	7.696	-8.130	7.660	1.00	0.00	H
ATOM	805	3HG1	VAL	B	231	7.287	-8.153	9.389	1.00	0.00	H
ATOM	806	1HG2	VAL	B	231	4.943	-10.179	9.040	1.00	0.00	H
ATOM	807	2HG2	VAL	B	231	4.824	-8.760	10.106	1.00	0.00	H
ATOM	808	3HG2	VAL	B	231	3.598	-9.051	8.854	1.00	0.00	H
ATOM	809	N	SER	B	232	5.689	-5.961	5.778	1.00	20.00	N
ATOM	810	CA	SER	B	232	6.527	-5.265	4.852	1.00	20.00	C
ATOM	811	C	SER	B	232	6.871	-3.924	5.455	1.00	20.00	C

ATOM	812	O	SER	B	232	7.964	-3.421	5.312	1.00	20.00	O
ATOM	813	CB	SER	B	232	5.760	-5.216	3.515	1.00	20.00	C
ATOM	814	OG	SER	B	232	4.507	-4.520	3.594	1.00	20.00	O
ATOM	815	H	SER	B	232	4.788	-6.408	5.554	1.00	0.00	H
ATOM	816	HA	SER	B	232	7.469	-5.828	4.699	1.00	0.00	H
ATOM	817	1HB	SER	B	232	5.580	-6.239	3.136	1.00	0.00	H
ATOM	818	2HB	SER	B	232	6.404	-4.740	2.759	1.00	0.00	H
ATOM	819	HG	SER	B	232	3.964	-4.962	4.269	1.00	0.00	H
ATOM	820	N	ALA	B	233	5.915	-3.400	6.124	1.00	20.00	N
ATOM	821	CA	ALA	B	233	6.032	-2.115	6.772	1.00	20.00	C
ATOM	822	C	ALA	B	233	7.172	-2.080	7.735	1.00	20.00	C
ATOM	823	O	ALA	B	233	8.101	-1.293	7.533	1.00	20.00	O
ATOM	824	CB	ALA	B	233	4.595	-1.784	7.223	1.00	20.00	C
ATOM	825	H	ALA	B	233	5.110	-4.024	6.263	1.00	0.00	H
ATOM	826	HA	ALA	B	233	6.282	-1.366	5.994	1.00	0.00	H
ATOM	827	1HB	ALA	B	233	4.356	-0.754	6.966	1.00	0.00	H
ATOM	828	2HB	ALA	B	233	3.789	-2.341	6.704	1.00	0.00	H
ATOM	829	3HB	ALA	B	233	4.441	-1.935	8.305	1.00	0.00	H
ATOM	830	N	THR	B	234	7.166	-3.039	8.629	1.00	20.00	N
ATOM	831	CA	THR	B	234	8.119	-3.191	9.684	1.00	20.00	C
ATOM	832	C	THR	B	234	9.430	-3.510	9.105	1.00	20.00	C
ATOM	833	O	THR	B	234	10.353	-3.140	9.878	1.00	20.00	O
ATOM	834	CB	THR	B	234	7.567	-4.237	10.710	1.00	20.00	C
ATOM	835	OG1	THR	B	234	6.285	-3.844	11.192	1.00	20.00	O
ATOM	836	CG2	THR	B	234	8.419	-4.428	11.975	1.00	20.00	C
ATOM	837	H	THR	B	234	6.386	-3.698	8.506	1.00	0.00	H
ATOM	838	HA	THR	B	234	8.202	-2.220	10.214	1.00	0.00	H
ATOM	839	HB	THR	B	234	7.463	-5.220	10.206	1.00	0.00	H
ATOM	840	HG1	THR	B	234	6.450	-3.166	11.851	1.00	0.00	H
ATOM	841	1HG2	THR	B	234	7.946	-5.139	12.679	1.00	0.00	H
ATOM	842	2HG2	THR	B	234	9.418	-4.837	11.735	1.00	0.00	H
ATOM	843	3HG2	THR	B	234	8.581	-3.479	12.520	1.00	0.00	H
ATOM	844	N	MET	B	235	9.709	-4.057	8.084	1.00	20.00	N
ATOM	845	CA	MET	B	235	10.962	-4.327	7.497	1.00	20.00	C
ATOM	846	C	MET	B	235	11.443	-3.192	6.622	1.00	20.00	C
ATOM	847	O	MET	B	235	12.602	-2.783	6.648	1.00	20.00	O
ATOM	848	CB	MET	B	235	10.935	-5.725	6.827	1.00	20.00	C
ATOM	849	CG	MET	B	235	10.813	-6.930	7.786	1.00	20.00	C
ATOM	850	SD	MET	B	235	10.845	-8.464	6.842	1.00	20.00	S
ATOM	851	CE	MET	B	235	10.761	-9.658	8.186	1.00	20.00	C
ATOM	852	H	MET	B	235	8.846	-4.386	7.626	1.00	0.00	H
ATOM	853	HA	MET	B	235	11.733	-4.405	8.293	1.00	0.00	H
ATOM	854	1HB	MET	B	235	11.874	-5.862	6.259	1.00	0.00	H
ATOM	855	2HB	MET	B	235	10.123	-5.769	6.077	1.00	0.00	H
ATOM	856	1HG	MET	B	235	9.872	-6.881	8.366	1.00	0.00	H
ATOM	857	2HG	MET	B	235	11.640	-6.936	8.521	1.00	0.00	H
ATOM	858	1HE	MET	B	235	11.652	-9.582	8.834	1.00	0.00	H
ATOM	859	2HE	MET	B	235	9.865	-9.491	8.810	1.00	0.00	H
ATOM	860	3HE	MET	B	235	10.714	-10.687	7.786	1.00	0.00	H
ATOM	861	N	SER	B	236	10.635	-2.621	5.784	1.00	20.00	N
ATOM	862	CA	SER	B	236	11.068	-1.563	4.852	1.00	20.00	C
ATOM	863	C	SER	B	236	11.697	-0.397	5.609	1.00	20.00	C
ATOM	864	O	SER	B	236	12.645	0.216	5.153	1.00	20.00	O
ATOM	865	CB	SER	B	236	9.891	-1.169	3.924	1.00	20.00	C
ATOM	866	OG	SER	B	236	8.716	-0.787	4.644	1.00	20.00	O
ATOM	867	H	SER	B	236	9.680	-3.014	5.777	1.00	0.00	H
ATOM	868	HA	SER	B	236	11.860	-1.976	4.199	1.00	0.00	H
ATOM	869	1HB	SER	B	236	9.644	-2.010	3.247	1.00	0.00	H
ATOM	870	2HB	SER	B	236	10.196	-0.341	3.255	1.00	0.00	H
ATOM	871	HG	SER	B	236	8.391	-1.584	5.088	1.00	0.00	H
ATOM	872	N	GLY	B	237	11.172	-0.090	6.763	1.00	20.00	N
ATOM	873	CA	GLY	B	237	11.711	0.990	7.583	1.00	20.00	C
ATOM	874	C	GLY	B	237	13.073	0.658	8.031	1.00	20.00	C

ATOM	875	O	GLY	B	237	13.983	1.456	7.907	1.00	20.00	O
ATOM	876	H	GLY	B	237	10.303	-0.602	6.973	1.00	0.00	H
ATOM	877	1HA	GLY	B	237	11.090	1.042	8.488	1.00	0.00	H
ATOM	878	2HA	GLY	B	237	11.586	1.998	7.199	1.00	0.00	H
ATOM	879	N	VAL	B	238	13.233	-0.574	8.385	1.00	20.00	N
ATOM	880	CA	VAL	B	238	14.494	-0.952	8.912	1.00	20.00	C
ATOM	881	C	VAL	B	238	15.446	-1.124	7.754	1.00	20.00	C
ATOM	882	O	VAL	B	238	16.600	-0.719	7.868	1.00	20.00	O
ATOM	883	CB	VAL	B	238	14.342	-2.195	9.875	1.00	20.00	C
ATOM	884	CG1	VAL	B	238	15.691	-2.719	10.425	1.00	20.00	C
ATOM	885	CG2	VAL	B	238	13.436	-1.933	11.106	1.00	20.00	C
ATOM	886	H	VAL	B	238	12.421	-1.188	8.254	1.00	0.00	H
ATOM	887	HA	VAL	B	238	14.921	-0.146	9.549	1.00	0.00	H
ATOM	888	HB	VAL	B	238	13.882	-3.024	9.300	1.00	0.00	H
ATOM	889	1HG1	VAL	B	238	15.562	-3.603	11.076	1.00	0.00	H
ATOM	890	2HG1	VAL	B	238	16.373	-3.030	9.612	1.00	0.00	H
ATOM	891	3HG1	VAL	B	238	16.225	-1.950	11.015	1.00	0.00	H
ATOM	892	1HG2	VAL	B	238	13.326	-2.831	11.742	1.00	0.00	H
ATOM	893	2HG2	VAL	B	238	13.827	-1.119	11.746	1.00	0.00	H
ATOM	894	3HG2	VAL	B	238	12.411	-1.644	10.807	1.00	0.00	H
ATOM	895	N	THR	B	239	14.976	-2.098	6.794	1.00	20.00	N
ATOM	896	CA	THR	B	239	15.816	-2.518	5.701	1.00	20.00	C
ATOM	897	C	THR	B	239	15.933	-1.435	4.641	1.00	20.00	C
ATOM	898	O	THR	B	239	17.053	-1.279	4.113	1.00	20.00	O
ATOM	899	CB	THR	B	239	15.367	-3.909	5.138	1.00	20.00	C
ATOM	900	OG1	THR	B	239	14.006	-3.882	4.714	1.00	20.00	O
ATOM	901	CG2	THR	B	239	15.512	-5.085	6.118	1.00	20.00	C
ATOM	902	H	THR	B	239	13.957	-2.303	6.858	1.00	0.00	H
ATOM	903	HA	THR	B	239	16.843	-2.665	6.092	1.00	0.00	H
ATOM	904	HB	THR	B	239	15.994	-4.142	4.254	1.00	0.00	H
ATOM	905	HG1	THR	B	239	13.500	-3.573	5.482	1.00	0.00	H
ATOM	906	1HG2	THR	B	239	15.207	-6.040	5.652	1.00	0.00	H
ATOM	907	2HG2	THR	B	239	16.557	-5.207	6.458	1.00	0.00	H
ATOM	908	3HG2	THR	B	239	14.887	-4.951	7.021	1.00	0.00	H
ATOM	909	N	THR	B	240	14.883	-1.041	3.932	1.00	20.00	N
ATOM	910	CA	THR	B	240	14.936	0.080	3.030	1.00	20.00	C
ATOM	911	C	THR	B	240	15.311	1.328	3.776	1.00	20.00	C
ATOM	912	O	THR	B	240	16.078	2.185	3.249	1.00	20.00	O
ATOM	913	CB	THR	B	240	13.516	0.468	2.402	1.00	20.00	C
ATOM	914	OG1	THR	B	240	12.657	-0.629	2.177	1.00	20.00	O
ATOM	915	CG2	THR	B	240	13.495	1.468	1.236	1.00	20.00	C
ATOM	916	H	THR	B	240	13.995	-1.272	4.390	1.00	0.00	H
ATOM	917	HA	THR	B	240	15.667	-0.112	2.221	1.00	0.00	H
ATOM	918	HB	THR	B	240	12.906	1.040	3.113	1.00	0.00	H
ATOM	919	HG1	THR	B	240	12.966	-1.081	1.377	1.00	0.00	H
ATOM	920	1HG2	THR	B	240	12.555	1.417	0.656	1.00	0.00	H
ATOM	921	2HG2	THR	B	240	13.567	2.509	1.604	1.00	0.00	H
ATOM	922	3HG2	THR	B	240	14.340	1.336	0.544	1.00	0.00	H
ATOM	923	N	CYS	B	241	14.677	1.649	4.868	1.00	20.00	N
ATOM	924	CA	CYS	B	241	14.826	2.986	5.403	1.00	20.00	C
ATOM	925	C	CYS	B	241	16.175	3.184	6.009	1.00	20.00	C
ATOM	926	O	CYS	B	241	16.582	2.399	6.817	1.00	20.00	O
ATOM	927	CB	CYS	B	241	13.636	3.650	6.097	1.00	20.00	C
ATOM	928	SG	CYS	B	241	12.120	3.009	5.324	1.00	20.00	S
ATOM	929	H	CYS	B	241	13.892	1.016	5.129	1.00	0.00	H
ATOM	930	HA	CYS	B	241	14.862	3.671	4.527	1.00	0.00	H
ATOM	931	HC	CYS	B	241	16.746	4.049	5.628	1.00	0.00	H
ATOM	932	1HB	CYS	B	241	13.684	4.749	5.989	1.00	0.00	H
ATOM	933	2HB	CYS	B	241	13.604	3.522	7.186	1.00	0.00	H
ATOM	934	HG	CYS	B	241	12.546	2.933	4.068	1.00	0.00	H
ATOM	935	N	PHE	B	244	17.920	3.455	2.077	1.00	20.00	N
ATOM	936	CA	PHE	B	244	17.601	4.242	1.050	1.00	20.00	C
ATOM	937	C	PHE	B	244	18.027	5.562	1.548	1.00	20.00	C

ATOM	938	O	PHE	B	244	18.115	5.819	2.723	1.00	20.00	O
ATOM	939	CB	PHE	B	244	16.058	4.103	0.912	1.00	20.00	C
ATOM	940	CG	PHE	B	244	15.357	4.316	-0.421	1.00	20.00	C
ATOM	941	CD1	PHE	B	244	15.768	3.577	-1.532	1.00	20.00	C
ATOM	942	CD2	PHE	B	244	14.074	4.869	-0.401	1.00	20.00	C
ATOM	943	CE1	PHE	B	244	14.891	3.369	-2.587	1.00	20.00	C
ATOM	944	CE2	PHE	B	244	13.203	4.660	-1.468	1.00	20.00	C
ATOM	945	CZ	PHE	B	244	13.608	3.902	-2.556	1.00	20.00	C
ATOM	946	1H	PHE	B	244	18.157	4.061	2.874	1.00	0.00	H
ATOM	947	2H	PHE	B	244	17.101	2.914	2.406	1.00	0.00	H
ATOM	948	HA	PHE	B	244	18.158	3.933	0.145	1.00	0.00	H
ATOM	949	HC	PHE	B	244	18.247	6.288	0.745	1.00	0.00	H
ATOM	950	1HB	PHE	B	244	15.553	4.659	1.729	1.00	0.00	H
ATOM	951	2HB	PHE	B	244	15.760	3.057	1.110	1.00	0.00	H
ATOM	952	HD1	PHE	B	244	16.718	3.063	-1.540	1.00	0.00	H
ATOM	953	HD2	PHE	B	244	13.714	5.377	0.482	1.00	0.00	H
ATOM	954	HE1	PHE	B	244	15.193	2.727	-3.396	1.00	0.00	H
ATOM	955	HE2	PHE	B	244	12.194	5.038	-1.431	1.00	0.00	H
ATOM	956	HZ	PHE	B	244	12.913	3.700	-3.358	1.00	0.00	H
ATOM	957	N	GLY	B	271	6.197	-1.045	15.077	1.00	20.00	N
ATOM	958	CA	GLY	B	271	4.978	-0.597	14.551	1.00	20.00	C
ATOM	959	C	GLY	B	271	5.128	0.191	13.251	1.00	20.00	C
ATOM	960	O	GLY	B	271	6.189	0.763	13.023	1.00	20.00	O
ATOM	961	1H	GLY	B	271	6.064	-1.700	15.858	1.00	0.00	H
ATOM	962	2H	GLY	B	271	6.765	-1.539	14.379	1.00	0.00	H
ATOM	963	1HA	GLY	B	271	4.480	0.049	15.299	1.00	0.00	H
ATOM	964	2HA	GLY	B	271	4.315	-1.477	14.422	1.00	0.00	H
ATOM	965	N	PHE	B	272	4.023	0.200	12.579	1.00	20.00	N
ATOM	966	CA	PHE	B	272	3.950	1.023	11.373	1.00	20.00	C
ATOM	967	C	PHE	B	272	2.770	1.877	11.490	1.00	20.00	C
ATOM	968	O	PHE	B	272	1.761	1.218	11.751	1.00	20.00	O
ATOM	969	CB	PHE	B	272	4.131	0.235	10.047	1.00	20.00	C
ATOM	970	CG	PHE	B	272	4.906	1.006	8.946	1.00	20.00	C
ATOM	971	CD1	PHE	B	272	4.236	1.545	7.844	1.00	20.00	C
ATOM	972	CD2	PHE	B	272	6.304	1.050	8.970	1.00	20.00	C
ATOM	973	CE1	PHE	B	272	4.943	2.104	6.781	1.00	20.00	C
ATOM	974	CE2	PHE	B	272	7.012	1.602	7.903	1.00	20.00	C
ATOM	975	CZ	PHE	B	272	6.332	2.128	6.811	1.00	20.00	C
ATOM	976	H	PHE	B	272	3.199	-0.217	13.024	1.00	0.00	H
ATOM	977	HA	PHE	B	272	4.817	1.714	11.379	1.00	0.00	H
ATOM	978	1HB	PHE	B	272	3.152	-0.129	9.679	1.00	0.00	H
ATOM	979	2HB	PHE	B	272	4.691	-0.699	10.254	1.00	0.00	H
ATOM	980	HD1	PHE	B	272	3.170	1.417	7.755	1.00	0.00	H
ATOM	981	HD2	PHE	B	272	6.847	0.611	9.794	1.00	0.00	H
ATOM	982	HE1	PHE	B	272	4.417	2.473	5.912	1.00	0.00	H
ATOM	983	HE2	PHE	B	272	8.090	1.565	7.888	1.00	0.00	H
ATOM	984	HZ	PHE	B	272	6.887	2.524	5.972	1.00	0.00	H
ATOM	985	N	ALA	B	273	2.875	3.149	11.428	1.00	20.00	N
ATOM	986	CA	ALA	B	273	1.718	3.948	11.531	1.00	20.00	C
ATOM	987	C	ALA	B	273	1.516	4.700	10.223	1.00	20.00	C
ATOM	988	O	ALA	B	273	2.417	5.364	9.732	1.00	20.00	O
ATOM	989	CB	ALA	B	273	1.968	4.901	12.715	1.00	20.00	C
ATOM	990	H	ALA	B	273	3.818	3.527	11.270	1.00	0.00	H
ATOM	991	HA	ALA	B	273	0.798	3.376	11.792	1.00	0.00	H
ATOM	992	1HB	ALA	B	273	1.203	5.695	12.710	1.00	0.00	H
ATOM	993	2HB	ALA	B	273	1.910	4.374	13.685	1.00	0.00	H
ATOM	994	3HB	ALA	B	273	2.939	5.420	12.692	1.00	0.00	H
ATOM	995	N	PRO	B	274	0.473	4.854	9.839	1.00	20.00	N
ATOM	996	CA	PRO	B	274	-0.040	4.944	8.496	1.00	20.00	C
ATOM	997	C	PRO	B	274	-0.858	3.752	8.216	1.00	20.00	C
ATOM	998	O	PRO	B	274	-0.984	3.283	7.056	1.00	20.00	O
ATOM	999	CB	PRO	B	274	1.008	5.031	7.385	1.00	20.00	C
ATOM	1000	CG	PRO	B	274	1.885	3.803	7.512	1.00	20.00	C

ATOM	1001	CD	PRO	B	274	1.429	3.424	8.955	1.00	20.00	C
ATOM	1002	HA	PRO	B	274	-0.693	5.833	8.434	1.00	0.00	H
ATOM	1003	1HB	PRO	B	274	1.539	5.996	7.472	1.00	0.00	H
ATOM	1004	2HB	PRO	B	274	0.520	4.945	6.428	1.00	0.00	H
ATOM	1005	1HG	PRO	B	274	2.957	4.068	7.459	1.00	0.00	H
ATOM	1006	2HG	PRO	B	274	1.656	3.013	6.770	1.00	0.00	H
ATOM	1007	1HD	PRO	B	274	0.949	2.416	9.020	1.00	0.00	H
ATOM	1008	2HD	PRO	B	274	2.440	2.964	9.164	1.00	0.00	H
ATOM	1009	N	LEU	B	275	-1.430	3.228	9.291	1.00	20.00	N
ATOM	1010	CA	LEU	B	275	-2.292	2.061	9.248	1.00	20.00	C
ATOM	1011	C	LEU	B	275	-3.569	2.398	8.569	1.00	20.00	C
ATOM	1012	O	LEU	B	275	-4.255	1.542	8.018	1.00	20.00	O
ATOM	1013	CB	LEU	B	275	-2.420	1.400	10.637	1.00	20.00	C
ATOM	1014	CG	LEU	B	275	-1.126	0.706	11.116	1.00	20.00	C
ATOM	1015	CD1	LEU	B	275	-1.097	0.508	12.640	1.00	20.00	C
ATOM	1016	CD2	LEU	B	275	-0.827	-0.604	10.361	1.00	20.00	C
ATOM	1017	H	LEU	B	275	-1.176	3.714	10.164	1.00	0.00	H
ATOM	1018	HA	LEU	B	275	-1.829	1.311	8.577	1.00	0.00	H
ATOM	1019	1HB	LEU	B	275	-3.236	0.653	10.617	1.00	0.00	H
ATOM	1020	2HB	LEU	B	275	-2.739	2.166	11.369	1.00	0.00	H
ATOM	1021	HG	LEU	B	275	-0.313	1.407	10.884	1.00	0.00	H
ATOM	1022	1HD1	LEU	B	275	-1.169	1.476	13.171	1.00	0.00	H
ATOM	1023	2HD1	LEU	B	275	-1.917	-0.124	13.007	1.00	0.00	H
ATOM	1024	3HD1	LEU	B	275	-0.155	0.038	12.977	1.00	0.00	H
ATOM	1025	1HD2	LEU	B	275	0.041	-1.137	10.792	1.00	0.00	H
ATOM	1026	2HD2	LEU	B	275	-1.687	-1.296	10.368	1.00	0.00	H
ATOM	1027	3HD2	LEU	B	275	-0.577	-0.420	9.301	1.00	0.00	H
ATOM	1028	N	THR	B	276	-4.416	2.932	8.373	1.00	20.00	N
ATOM	1029	CA	THR	B	276	-4.932	4.191	7.936	1.00	20.00	C
ATOM	1030	C	THR	B	276	-6.409	4.097	7.890	1.00	20.00	C
ATOM	1031	O	THR	B	276	-7.035	5.248	8.099	1.00	20.00	O
ATOM	1032	CB	THR	B	276	-4.340	4.751	6.575	1.00	20.00	C
ATOM	1033	OG1	THR	B	276	-3.438	3.863	5.908	1.00	20.00	O
ATOM	1034	CG2	THR	B	276	-3.601	6.086	6.735	1.00	20.00	C
ATOM	1035	H	THR	B	276	-4.673	2.014	7.943	1.00	0.00	H
ATOM	1036	HA	THR	B	276	-4.710	4.918	8.742	1.00	0.00	H
ATOM	1037	HB	THR	B	276	-5.164	4.945	5.857	1.00	0.00	H
ATOM	1038	HG1	THR	B	276	-2.638	3.789	6.448	1.00	0.00	H
ATOM	1039	1HG2	THR	B	276	-3.193	6.438	5.768	1.00	0.00	H
ATOM	1040	2HG2	THR	B	276	-4.275	6.880	7.107	1.00	0.00	H
ATOM	1041	3HG2	THR	B	276	-2.757	6.012	7.441	1.00	0.00	H
ATOM	1042	N	SER	B	277	-7.119	3.014	7.409	1.00	20.00	N
ATOM	1043	CA	SER	B	277	-8.428	2.710	6.948	1.00	20.00	C
ATOM	1044	C	SER	B	277	-8.632	3.206	5.526	1.00	20.00	C
ATOM	1045	O	SER	B	277	-8.331	4.391	5.283	1.00	20.00	O
ATOM	1046	CB	SER	B	277	-9.501	2.868	8.045	1.00	20.00	C
ATOM	1047	OG	SER	B	277	-9.466	1.770	8.965	1.00	20.00	O
ATOM	1048	H	SER	B	277	-6.420	2.276	7.280	1.00	0.00	H
ATOM	1049	HA	SER	B	277	-8.379	1.605	6.859	1.00	0.00	H
ATOM	1050	1HB	SER	B	277	-10.512	2.940	7.602	1.00	0.00	H
ATOM	1051	2HB	SER	B	277	-9.339	3.790	8.618	1.00	0.00	H
ATOM	1052	HG	SER	B	277	-8.693	1.882	9.543	1.00	0.00	H
ATOM	1053	N	ARG	B	278	-8.987	2.332	4.634	1.00	20.00	N
ATOM	1054	CA	ARG	B	278	-9.166	2.654	3.231	1.00	20.00	C
ATOM	1055	C	ARG	B	278	-9.908	3.909	3.078	1.00	20.00	C
ATOM	1056	O	ARG	B	278	-9.419	4.902	2.525	1.00	20.00	O
ATOM	1057	CB	ARG	B	278	-9.697	1.391	2.478	1.00	20.00	C
ATOM	1058	CG	ARG	B	278	-9.994	1.579	0.969	1.00	20.00	C
ATOM	1059	CD	ARG	B	278	-10.319	0.257	0.249	1.00	20.00	C
ATOM	1060	NE	ARG	B	278	-10.529	0.486	-1.205	1.00	20.00	N
ATOM	1061	CZ	ARG	B	278	-9.575	0.515	-2.138	1.00	20.00	C
ATOM	1062	NH1	ARG	B	278	-8.304	0.355	-1.889	1.00	20.00	N
ATOM	1063	NH2	ARG	B	278	-9.938	0.720	-3.362	1.00	20.00	N

ATOM	1064	H	ARG	B	278	-9.103	1.376	4.984	1.00	0.00	H
ATOM	1065	HA	ARG	B	278	-8.166	2.872	2.833	1.00	0.00	H
ATOM	1066	1HB	ARG	B	278	-10.616	1.012	2.967	1.00	0.00	H
ATOM	1067	2HB	ARG	B	278	-8.959	0.575	2.598	1.00	0.00	H
ATOM	1068	1HG	ARG	B	278	-9.144	2.072	0.465	1.00	0.00	H
ATOM	1069	2HG	ARG	B	278	-10.841	2.280	0.833	1.00	0.00	H
ATOM	1070	1HD	ARG	B	278	-11.247	-0.179	0.669	1.00	0.00	H
ATOM	1071	2HD	ARG	B	278	-9.541	-0.511	0.429	1.00	0.00	H
ATOM	1072	1HH1	ARG	B	278	-7.646	0.389	-2.673	1.00	0.00	H
ATOM	1073	2HH1	ARG	B	278	-8.115	0.198	-0.900	1.00	0.00	H
ATOM	1074	1HH2	ARG	B	278	-9.210	0.746	-4.077	1.00	0.00	H
ATOM	1075	2HH2	ARG	B	278	-10.950	0.835	-3.456	1.00	0.00	H
ATOM	1076	N	GLY	B	279	-11.112	3.803	3.715	1.00	20.00	N
ATOM	1077	CA	GLY	B	279	-11.976	4.922	3.661	1.00	20.00	C
ATOM	1078	C	GLY	B	279	-11.538	6.030	4.597	1.00	20.00	C
ATOM	1079	O	GLY	B	279	-11.357	7.162	4.169	1.00	20.00	O
ATOM	1080	H	GLY	B	279	-11.303	2.905	4.170	1.00	0.00	H
ATOM	1081	1HA	GLY	B	279	-13.003	4.613	3.932	1.00	0.00	H
ATOM	1082	2HA	GLY	B	279	-12.068	5.322	2.631	1.00	0.00	H
ATOM	1083	N	SER	B	280	-11.396	5.680	5.869	1.00	20.00	N
ATOM	1084	CA	SER	B	280	-10.953	6.658	6.837	1.00	20.00	C
ATOM	1085	C	SER	B	280	-9.764	7.417	6.325	1.00	20.00	C
ATOM	1086	O	SER	B	280	-9.259	8.321	6.936	1.00	20.00	O
ATOM	1087	CB	SER	B	280	-10.759	6.142	8.280	1.00	20.00	C
ATOM	1088	OG	SER	B	280	-11.747	5.186	8.675	1.00	20.00	O
ATOM	1089	H	SER	B	280	-11.476	4.682	6.078	1.00	0.00	H
ATOM	1090	HA	SER	B	280	-11.766	7.408	6.916	1.00	0.00	H
ATOM	1091	1HB	SER	B	280	-10.790	6.997	8.981	1.00	0.00	H
ATOM	1092	2HB	SER	B	280	-9.737	5.744	8.400	1.00	0.00	H
ATOM	1093	HG	SER	B	280	-11.562	4.939	9.587	1.00	0.00	H
ATOM	1094	N	GLN	B	281	-9.508	7.086	5.120	1.00	20.00	N
ATOM	1095	CA	GLN	B	281	-8.283	7.511	4.524	1.00	20.00	C
ATOM	1096	C	GLN	B	281	-7.974	8.945	4.828	1.00	20.00	C
ATOM	1097	O	GLN	B	281	-6.878	9.351	5.064	1.00	20.00	O
ATOM	1098	CB	GLN	B	281	-7.949	7.308	3.016	1.00	20.00	C
ATOM	1099	CG	GLN	B	281	-8.965	7.835	1.965	1.00	20.00	C
ATOM	1100	CD	GLN	B	281	-8.577	7.563	0.510	1.00	20.00	C
ATOM	1101	OE1	GLN	B	281	-8.130	8.436	-0.225	1.00	20.00	O
ATOM	1102	NE2	GLN	B	281	-8.753	6.350	0.047	1.00	20.00	N
ATOM	1103	H	GLN	B	281	-10.439	7.124	4.565	1.00	0.00	H
ATOM	1104	HA	GLN	B	281	-7.488	6.938	5.047	1.00	0.00	H
ATOM	1105	1HB	GLN	B	281	-7.689	6.252	2.857	1.00	0.00	H
ATOM	1106	2HB	GLN	B	281	-6.969	7.778	2.790	1.00	0.00	H
ATOM	1107	1HG	GLN	B	281	-9.082	8.926	2.087	1.00	0.00	H
ATOM	1108	2HG	GLN	B	281	-9.969	7.417	2.150	1.00	0.00	H
ATOM	1109	1HE2	GLN	B	281	-9.015	5.657	0.763	1.00	0.00	H
ATOM	1110	2HE2	GLN	B	281	-8.387	6.199	-0.896	1.00	0.00	H
ATOM	1111	N	GLN	B	282	-8.876	9.723	5.268	1.00	20.00	N
ATOM	1112	CA	GLN	B	282	-9.038	11.136	5.241	1.00	20.00	C
ATOM	1113	C	GLN	B	282	-8.518	11.775	6.516	1.00	20.00	C
ATOM	1114	O	GLN	B	282	-8.498	13.030	6.598	1.00	20.00	O
ATOM	1115	CB	GLN	B	282	-10.537	11.478	4.979	1.00	20.00	C
ATOM	1116	CG	GLN	B	282	-11.143	11.034	3.616	1.00	20.00	C
ATOM	1117	CD	GLN	B	282	-10.537	11.664	2.352	1.00	20.00	C
ATOM	1118	OE1	GLN	B	282	-9.838	12.673	2.365	1.00	20.00	O
ATOM	1119	NE2	GLN	B	282	-10.799	11.092	1.202	1.00	20.00	N
ATOM	1120	H	GLN	B	282	-9.260	9.157	6.072	1.00	0.00	H
ATOM	1121	HA	GLN	B	282	-8.433	11.563	4.416	1.00	0.00	H
ATOM	1122	1HB	GLN	B	282	-10.674	12.574	5.066	1.00	0.00	H
ATOM	1123	2HB	GLN	B	282	-11.157	11.059	5.796	1.00	0.00	H
ATOM	1124	1HG	GLN	B	282	-12.224	11.268	3.617	1.00	0.00	H
ATOM	1125	2HG	GLN	B	282	-11.089	9.930	3.545	1.00	0.00	H
ATOM	1126	1HE2	GLN	B	282	-11.352	10.232	1.222	1.00	0.00	H

ATOM	1127	2HE2	GLN	B	282	-10.322	11.523	0.406	1.00	0.00	H
ATOM	1128	N	TYR	B	283	-8.175	11.054	7.526	1.00	20.00	N
ATOM	1129	CA	TYR	B	283	-7.706	11.628	8.789	1.00	20.00	C
ATOM	1130	C	TYR	B	283	-6.238	11.842	8.735	1.00	20.00	C
ATOM	1131	O	TYR	B	283	-5.562	11.000	8.245	1.00	20.00	O
ATOM	1132	CB	TYR	B	283	-8.048	10.607	9.927	1.00	20.00	C
ATOM	1133	CG	TYR	B	283	-9.504	10.645	10.437	1.00	20.00	C
ATOM	1134	CD1	TYR	B	283	-10.499	9.894	9.804	1.00	20.00	C
ATOM	1135	CD2	TYR	B	283	-9.845	11.445	11.533	1.00	20.00	C
ATOM	1136	CE1	TYR	B	283	-11.815	9.939	10.259	1.00	20.00	C
ATOM	1137	CE2	TYR	B	283	-11.162	11.488	11.989	1.00	20.00	C
ATOM	1138	CZ	TYR	B	283	-12.144	10.736	11.352	1.00	20.00	C
ATOM	1139	OH	TYR	B	283	-13.435	10.787	11.804	1.00	20.00	O
ATOM	1140	H	TYR	B	283	-8.096	10.053	7.305	1.00	0.00	H
ATOM	1141	HA	TYR	B	283	-8.323	12.522	9.066	1.00	0.00	H
ATOM	1142	1HB	TYR	B	283	-7.387	10.782	10.799	1.00	0.00	H
ATOM	1143	2HB	TYR	B	283	-7.778	9.574	9.623	1.00	0.00	H
ATOM	1144	HD1	TYR	B	283	-10.256	9.286	8.949	1.00	0.00	H
ATOM	1145	HD2	TYR	B	283	-9.094	12.037	12.035	1.00	0.00	H
ATOM	1146	HE1	TYR	B	283	-12.574	9.357	9.757	1.00	0.00	H
ATOM	1147	HE2	TYR	B	283	-11.425	12.106	12.835	1.00	0.00	H
ATOM	1148	HH	TYR	B	283	-13.982	10.225	11.252	1.00	0.00	H
ATOM	1149	N	ARG	B	284	-6.221	13.091	8.237	1.00	20.00	N
ATOM	1150	CA	ARG	B	284	-5.416	13.643	7.130	1.00	20.00	C
ATOM	1151	C	ARG	B	284	-4.041	13.305	7.806	1.00	20.00	C
ATOM	1152	O	ARG	B	284	-3.542	12.378	8.464	1.00	20.00	O
ATOM	1153	CB	ARG	B	284	-6.001	15.067	6.792	1.00	20.00	C
ATOM	1154	CG	ARG	B	284	-6.338	16.119	7.890	1.00	20.00	C
ATOM	1155	CD	ARG	B	284	-5.165	16.666	8.726	1.00	20.00	C
ATOM	1156	NE	ARG	B	284	-5.637	17.728	9.651	1.00	20.00	N
ATOM	1157	CZ	ARG	B	284	-6.059	17.546	10.903	1.00	20.00	C
ATOM	1158	NH1	ARG	B	284	-6.130	16.384	11.500	1.00	20.00	N
ATOM	1159	NH2	ARG	B	284	-6.424	18.596	11.564	1.00	20.00	N
ATOM	1160	H	ARG	B	284	-7.121	13.554	8.392	1.00	0.00	H
ATOM	1161	HA	ARG	B	284	-5.516	12.990	6.240	1.00	0.00	H
ATOM	1162	1HB	ARG	B	284	-6.944	14.893	6.241	1.00	0.00	H
ATOM	1163	2HB	ARG	B	284	-5.386	15.543	6.018	1.00	0.00	H
ATOM	1164	1HG	ARG	B	284	-7.112	15.716	8.570	1.00	0.00	H
ATOM	1165	2HG	ARG	B	284	-6.840	16.977	7.400	1.00	0.00	H
ATOM	1166	1HD	ARG	B	284	-4.399	17.108	8.060	1.00	0.00	H
ATOM	1167	2HD	ARG	B	284	-4.648	15.863	9.286	1.00	0.00	H
ATOM	1168	1HH1	ARG	B	284	-6.467	16.376	12.463	1.00	0.00	H
ATOM	1169	2HH1	ARG	B	284	-5.828	15.601	10.919	1.00	0.00	H
ATOM	1170	1HH2	ARG	B	284	-6.749	18.472	12.523	1.00	0.00	H
ATOM	1171	2HH2	ARG	B	284	-6.332	19.453	11.013	1.00	0.00	H
ATOM	1172	N	ALA	B	285	-3.284	14.170	7.646	1.00	20.00	N
ATOM	1173	CA	ALA	B	285	-2.527	14.165	6.403	1.00	20.00	C
ATOM	1174	C	ALA	B	285	-1.184	13.630	6.677	1.00	20.00	C
ATOM	1175	O	ALA	B	285	-0.208	14.370	6.729	1.00	20.00	O
ATOM	1176	CB	ALA	B	285	-2.488	15.620	5.853	1.00	20.00	C
ATOM	1177	H	ALA	B	285	-3.753	15.057	7.850	1.00	0.00	H
ATOM	1178	HA	ALA	B	285	-2.977	13.550	5.588	1.00	0.00	H
ATOM	1179	1HB	ALA	B	285	-1.815	15.692	4.977	1.00	0.00	H
ATOM	1180	2HB	ALA	B	285	-3.458	15.997	5.500	1.00	0.00	H
ATOM	1181	3HB	ALA	B	285	-2.100	16.343	6.596	1.00	0.00	H
ATOM	1182	N	LEU	B	286	-1.142	12.335	6.939	1.00	20.00	N
ATOM	1183	CA	LEU	B	286	0.069	11.682	7.257	1.00	20.00	C
ATOM	1184	C	LEU	B	286	0.781	12.417	8.380	1.00	20.00	C
ATOM	1185	O	LEU	B	286	1.828	13.005	8.166	1.00	20.00	O
ATOM	1186	CB	LEU	B	286	0.825	11.504	5.891	1.00	20.00	C
ATOM	1187	CG	LEU	B	286	-0.029	11.293	4.591	1.00	20.00	C
ATOM	1188	CD1	LEU	B	286	0.742	11.698	3.356	1.00	20.00	C
ATOM	1189	CD2	LEU	B	286	-0.698	9.917	4.597	1.00	20.00	C

ATOM	1190	H	LEU	B	286	-2.066	11.950	7.184	1.00	0.00	H
ATOM	1191	HA	LEU	B	286	-0.177	10.667	7.625	1.00	0.00	H
ATOM	1192	1HB	LEU	B	286	1.570	10.693	5.996	1.00	0.00	H
ATOM	1193	2HB	LEU	B	286	1.428	12.422	5.745	1.00	0.00	H
ATOM	1194	HG	LEU	B	286	-0.868	12.009	4.536	1.00	0.00	H
ATOM	1195	1HD1	LEU	B	286	0.132	11.540	2.449	1.00	0.00	H
ATOM	1196	2HD1	LEU	B	286	1.028	12.766	3.376	1.00	0.00	H
ATOM	1197	3HD1	LEU	B	286	1.666	11.119	3.276	1.00	0.00	H
ATOM	1198	1HD2	LEU	B	286	-1.187	9.677	3.635	1.00	0.00	H
ATOM	1199	2HD2	LEU	B	286	0.046	9.138	4.812	1.00	0.00	H
ATOM	1200	3HD2	LEU	B	286	-1.474	9.838	5.380	1.00	0.00	H
ATOM	1201	N	THR	B	287	0.240	12.486	9.567	1.00	20.00	N
ATOM	1202	CA	THR	B	287	0.760	13.343	10.607	1.00	20.00	C
ATOM	1203	C	THR	B	287	1.994	12.807	11.190	1.00	20.00	C
ATOM	1204	O	THR	B	287	2.220	11.646	11.234	1.00	20.00	O
ATOM	1205	CB	THR	B	287	-0.422	14.183	11.229	1.00	20.00	C
ATOM	1206	OG1	THR	B	287	-1.006	14.993	10.206	1.00	20.00	O
ATOM	1207	CG2	THR	B	287	-0.111	15.177	12.356	1.00	20.00	C
ATOM	1208	H	THR	B	287	-0.655	11.992	9.646	1.00	0.00	H
ATOM	1209	HA	THR	B	287	1.222	14.202	10.071	1.00	0.00	H
ATOM	1210	HB	THR	B	287	-1.234	13.527	11.565	1.00	0.00	H
ATOM	1211	HG1	THR	B	287	-1.044	14.449	9.410	1.00	0.00	H
ATOM	1212	1HG2	THR	B	287	-1.028	15.705	12.679	1.00	0.00	H
ATOM	1213	2HG2	THR	B	287	0.304	14.689	13.253	1.00	0.00	H
ATOM	1214	3HG2	THR	B	287	0.602	15.957	12.032	1.00	0.00	H
ATOM	1215	N	VAL	B	288	2.742	13.921	11.994	1.00	20.00	N
ATOM	1216	CA	VAL	B	288	3.800	13.352	12.763	1.00	20.00	C
ATOM	1217	C	VAL	B	288	3.292	12.861	14.122	1.00	20.00	C
ATOM	1218	O	VAL	B	288	3.593	11.758	14.538	1.00	20.00	O
ATOM	1219	CB	VAL	B	288	4.964	14.399	12.943	1.00	20.00	C
ATOM	1220	CG1	VAL	B	288	6.156	13.890	13.797	1.00	20.00	C
ATOM	1221	CG2	VAL	B	288	5.592	14.870	11.609	1.00	20.00	C
ATOM	1222	H	VAL	B	288	2.518	14.911	11.843	1.00	0.00	H
ATOM	1223	HA	VAL	B	288	4.287	12.526	12.220	1.00	0.00	H
ATOM	1224	HC	VAL	B	288	2.902	13.687	14.750	1.00	0.00	H
ATOM	1225	HB	VAL	B	288	4.556	15.296	13.452	1.00	0.00	H
ATOM	1226	1HG1	VAL	B	288	6.951	14.653	13.907	1.00	0.00	H
ATOM	1227	2HG1	VAL	B	288	5.851	13.620	14.825	1.00	0.00	H
ATOM	1228	3HG1	VAL	B	288	6.628	12.990	13.358	1.00	0.00	H
ATOM	1229	1HG2	VAL	B	288	6.375	15.637	11.758	1.00	0.00	H
ATOM	1230	2HG2	VAL	B	288	6.049	14.036	11.041	1.00	0.00	H
ATOM	1231	3HG2	VAL	B	288	4.834	15.325	10.949	1.00	0.00	H
ATOM	1232	N	GLU	B	290	0.802	12.412	14.583	1.00	20.00	N
ATOM	1233	CA	GLU	B	290	0.034	11.287	14.120	1.00	20.00	C
ATOM	1234	C	GLU	B	290	0.835	10.056	14.081	1.00	20.00	C
ATOM	1235	O	GLU	B	290	0.491	9.106	14.593	1.00	20.00	O
ATOM	1236	CB	GLU	B	290	-1.049	11.433	13.025	1.00	20.00	C
ATOM	1237	CG	GLU	B	290	-2.039	10.255	12.794	1.00	20.00	C
ATOM	1238	CD	GLU	B	290	-2.920	9.846	13.975	1.00	20.00	C
ATOM	1239	OE1	GLU	B	290	-2.851	8.755	14.536	1.00	20.00	O
ATOM	1240	OE2	GLU	B	290	-3.804	10.821	14.327	1.00	20.00	O
ATOM	1241	1H	GLU	B	290	1.618	12.058	15.098	1.00	0.00	H
ATOM	1242	2H	GLU	B	290	1.185	12.916	13.776	1.00	0.00	H
ATOM	1243	HA	GLU	B	290	-0.605	11.112	15.009	1.00	0.00	H
ATOM	1244	1HB	GLU	B	290	-0.529	11.582	12.070	1.00	0.00	H
ATOM	1245	2HB	GLU	B	290	-1.638	12.343	13.243	1.00	0.00	H
ATOM	1246	1HG	GLU	B	290	-1.483	9.360	12.459	1.00	0.00	H
ATOM	1247	2HG	GLU	B	290	-2.708	10.502	11.949	1.00	0.00	H
ATOM	1248	HE2	GLU	B	290	-4.325	10.508	15.067	1.00	0.00	H
ATOM	1249	N	LEU	B	291	1.914	10.438	13.607	1.00	20.00	N
ATOM	1250	CA	LEU	B	291	2.715	9.421	13.429	1.00	20.00	C
ATOM	1251	C	LEU	B	291	3.401	8.999	14.710	1.00	20.00	C
ATOM	1252	O	LEU	B	291	3.786	7.823	14.792	1.00	20.00	O

ATOM	1253	CB	LEU	B	291	3.811	9.562	12.318	1.00	20.00	C
ATOM	1254	CG	LEU	B	291	3.461	9.279	10.815	1.00	20.00	C
ATOM	1255	CD1	LEU	B	291	4.526	9.896	9.897	1.00	20.00	C
ATOM	1256	CD2	LEU	B	291	3.139	7.870	10.404	1.00	20.00	C
ATOM	1257	H	LEU	B	291	1.886	11.228	12.950	1.00	0.00	H
ATOM	1258	HA	LEU	B	291	2.222	8.482	13.058	1.00	0.00	H
ATOM	1259	HC	LEU	B	291	3.458	9.724	15.541	1.00	0.00	H
ATOM	1260	1HB	LEU	B	291	4.668	8.926	12.573	1.00	0.00	H
ATOM	1261	2HB	LEU	B	291	4.281	10.545	12.411	1.00	0.00	H
ATOM	1262	HG	LEU	B	291	2.485	9.689	10.543	1.00	0.00	H
ATOM	1263	1HD1	LEU	B	291	4.394	9.586	8.846	1.00	0.00	H
ATOM	1264	2HD1	LEU	B	291	4.489	11.001	9.920	1.00	0.00	H
ATOM	1265	3HD1	LEU	B	291	5.548	9.599	10.193	1.00	0.00	H
ATOM	1266	1HD2	LEU	B	291	4.003	7.322	10.011	1.00	0.00	H
ATOM	1267	2HD2	LEU	B	291	2.690	7.290	11.226	1.00	0.00	H
ATOM	1268	3HD2	LEU	B	291	2.413	7.848	9.566	1.00	0.00	H
ATOM	1269	N	GLN	B	294	0.876	7.116	17.003	1.00	20.00	N
ATOM	1270	CA	GLN	B	294	0.504	5.752	16.674	1.00	20.00	C
ATOM	1271	C	GLN	B	294	1.628	4.832	16.900	1.00	20.00	C
ATOM	1272	O	GLN	B	294	1.470	3.629	16.835	1.00	20.00	O
ATOM	1273	CB	GLN	B	294	-0.228	5.835	15.312	1.00	20.00	C
ATOM	1274	CG	GLN	B	294	-0.954	4.550	14.828	1.00	20.00	C
ATOM	1275	CD	GLN	B	294	-1.767	4.702	13.532	1.00	20.00	C
ATOM	1276	OE1	GLN	B	294	-1.452	4.143	12.488	1.00	20.00	O
ATOM	1277	NE2	GLN	B	294	-2.852	5.441	13.543	1.00	20.00	N
ATOM	1278	1H	GLN	B	294	1.487	7.498	16.270	1.00	0.00	H
ATOM	1279	2H	GLN	B	294	0.047	7.721	16.982	1.00	0.00	H
ATOM	1280	HA	GLN	B	294	-0.257	5.448	17.419	1.00	0.00	H
ATOM	1281	HC	GLN	B	294	2.609	5.307	17.100	1.00	0.00	H
ATOM	1282	1HB	GLN	B	294	0.469	6.217	14.553	1.00	0.00	H
ATOM	1283	2HB	GLN	B	294	-0.996	6.634	15.373	1.00	0.00	H
ATOM	1284	1HG	GLN	B	294	-1.625	4.169	15.620	1.00	0.00	H
ATOM	1285	2HG	GLN	B	294	-0.216	3.741	14.675	1.00	0.00	H
ATOM	1286	1HE2	GLN	B	294	-2.987	6.034	14.367	1.00	0.00	H
ATOM	1287	2HE2	GLN	B	294	-3.278	5.550	12.619	1.00	0.00	H
ATOM	1288	N	MET	B	302	2.727	-3.861	16.477	1.00	20.00	N
ATOM	1289	CA	MET	B	302	2.536	-5.062	15.654	1.00	20.00	C
ATOM	1290	C	MET	B	302	3.263	-6.219	16.280	1.00	20.00	C
ATOM	1291	O	MET	B	302	3.985	-6.899	15.606	1.00	20.00	O
ATOM	1292	CB	MET	B	302	2.946	-4.658	14.207	1.00	20.00	C
ATOM	1293	CG	MET	B	302	2.497	-5.647	13.115	1.00	20.00	C
ATOM	1294	SD	MET	B	302	3.542	-5.480	11.654	1.00	20.00	S
ATOM	1295	CE	MET	B	302	4.869	-6.621	12.096	1.00	20.00	C
ATOM	1296	1H	MET	B	302	3.712	-3.571	16.454	1.00	0.00	H
ATOM	1297	2H	MET	B	302	2.201	-3.073	16.085	1.00	0.00	H
ATOM	1298	HA	MET	B	302	1.463	-5.326	15.657	1.00	0.00	H
ATOM	1299	HC	MET	B	302	3.075	-6.370	17.359	1.00	0.00	H
ATOM	1300	1HB	MET	B	302	4.047	-4.543	14.163	1.00	0.00	H
ATOM	1301	2HB	MET	B	302	2.546	-3.662	13.934	1.00	0.00	H
ATOM	1302	1HG	MET	B	302	1.440	-5.481	12.838	1.00	0.00	H
ATOM	1303	2HG	MET	B	302	2.564	-6.689	13.474	1.00	0.00	H
ATOM	1304	1HE	MET	B	302	5.641	-6.647	11.309	1.00	0.00	H
ATOM	1305	2HE	MET	B	302	5.357	-6.309	13.037	1.00	0.00	H
ATOM	1306	3HE	MET	B	302	4.480	-7.645	12.237	1.00	0.00	H
ATOM	1307	N	VAL	B	318	11.629	5.351	13.514	1.00	20.00	N
ATOM	1308	CA	VAL	B	318	12.037	5.823	12.187	1.00	20.00	C
ATOM	1309	C	VAL	B	318	10.880	6.331	11.353	1.00	20.00	C
ATOM	1310	O	VAL	B	318	9.887	5.625	11.185	1.00	20.00	O
ATOM	1311	CB	VAL	B	318	12.972	4.779	11.470	1.00	20.00	C
ATOM	1312	CG1	VAL	B	318	13.339	5.110	10.001	1.00	20.00	C
ATOM	1313	CG2	VAL	B	318	14.312	4.546	12.211	1.00	20.00	C
ATOM	1314	1H	VAL	B	318	11.229	6.122	14.060	1.00	0.00	H
ATOM	1315	2H	VAL	B	318	10.851	4.673	13.434	1.00	0.00	H

ATOM	1316	HA	VAL	B	318	12.669	6.715	12.364	1.00	0.00	H
ATOM	1317	HC	VAL	B	318	11.015	7.339	10.919	1.00	0.00	H
ATOM	1318	HB	VAL	B	318	12.446	3.809	11.455	1.00	0.00	H
ATOM	1319	1HG1	VAL	B	318	13.984	4.331	9.551	1.00	0.00	H
ATOM	1320	2HG1	VAL	B	318	12.444	5.168	9.353	1.00	0.00	H
ATOM	1321	3HG1	VAL	B	318	13.876	6.072	9.908	1.00	0.00	H
ATOM	1322	1HG2	VAL	B	318	14.923	3.759	11.729	1.00	0.00	H
ATOM	1323	2HG2	VAL	B	318	14.931	5.462	12.255	1.00	0.00	H
ATOM	1324	3HG2	VAL	B	318	14.150	4.216	13.254	1.00	0.00	H
ATOM	1325	N	ARG	B	320	10.035	8.351	7.636	1.00	20.00	N
ATOM	1326	CA	ARG	B	320	10.503	8.659	6.301	1.00	20.00	C
ATOM	1327	C	ARG	B	320	9.439	9.226	5.448	1.00	20.00	C
ATOM	1328	O	ARG	B	320	9.111	8.722	4.338	1.00	20.00	O
ATOM	1329	CB	ARG	B	320	11.409	7.555	5.648	1.00	20.00	C
ATOM	1330	CG	ARG	B	320	10.737	6.282	5.070	1.00	20.00	C
ATOM	1331	CD	ARG	B	320	11.480	5.540	3.954	1.00	20.00	C
ATOM	1332	NE	ARG	B	320	10.571	4.446	3.479	1.00	20.00	N
ATOM	1333	CZ	ARG	B	320	10.510	3.919	2.262	1.00	20.00	C
ATOM	1334	NH1	ARG	B	320	11.100	4.416	1.221	1.00	20.00	N
ATOM	1335	NH2	ARG	B	320	9.820	2.834	2.119	1.00	20.00	N
ATOM	1336	1H	ARG	B	320	9.421	9.086	8.003	1.00	0.00	H
ATOM	1337	2H	ARG	B	320	9.451	7.504	7.615	1.00	0.00	H
ATOM	1338	HA	ARG	B	320	11.230	9.484	6.450	1.00	0.00	H
ATOM	1339	1HB	ARG	B	320	12.203	7.254	6.357	1.00	0.00	H
ATOM	1340	2HB	ARG	B	320	11.958	8.044	4.818	1.00	0.00	H
ATOM	1341	1HG	ARG	B	320	9.781	6.551	4.599	1.00	0.00	H
ATOM	1342	2HG	ARG	B	320	10.473	5.587	5.891	1.00	0.00	H
ATOM	1343	1HD	ARG	B	320	12.430	5.143	4.321	1.00	0.00	H
ATOM	1344	2HD	ARG	B	320	11.849	6.214	3.173	1.00	0.00	H
ATOM	1345	1HH1	ARG	B	320	10.940	3.952	0.327	1.00	0.00	H
ATOM	1346	2HH1	ARG	B	320	11.438	5.366	1.407	1.00	0.00	H
ATOM	1347	1HH2	ARG	B	320	9.828	2.385	1.203	1.00	0.00	H
ATOM	1348	2HH2	ARG	B	320	9.437	2.503	3.007	1.00	0.00	H
ATOM	1349	N	GLY	B	321	8.974	10.388	5.821	1.00	20.00	N
ATOM	1350	CA	GLY	B	321	7.964	11.049	5.027	1.00	20.00	C
ATOM	1351	C	GLY	B	321	8.422	12.269	4.331	1.00	20.00	C
ATOM	1352	O	GLY	B	321	7.668	13.006	3.684	1.00	20.00	O
ATOM	1353	H	GLY	B	321	9.294	10.718	6.739	1.00	0.00	H
ATOM	1354	1HA	GLY	B	321	7.165	11.370	5.706	1.00	0.00	H
ATOM	1355	2HA	GLY	B	321	7.478	10.403	4.309	1.00	0.00	H
ATOM	1356	HC	GLY	B	321	9.506	12.474	4.429	1.00	0.00	H
ATOM	1357	N	MET	B	323	9.231	14.966	6.028	1.00	20.00	N
ATOM	1358	CA	MET	B	323	8.915	15.992	6.988	1.00	20.00	C
ATOM	1359	C	MET	B	323	10.168	16.461	7.648	1.00	20.00	C
ATOM	1360	O	MET	B	323	11.244	15.994	7.509	1.00	20.00	O
ATOM	1361	CB	MET	B	323	7.787	15.556	7.951	1.00	20.00	C
ATOM	1362	CG	MET	B	323	7.065	16.727	8.658	1.00	20.00	C
ATOM	1363	SD	MET	B	323	5.286	16.429	8.666	1.00	20.00	S
ATOM	1364	CE	MET	B	323	4.718	17.941	9.463	1.00	20.00	C
ATOM	1365	1H	MET	B	323	8.452	14.833	5.372	1.00	0.00	H
ATOM	1366	2H	MET	B	323	10.035	15.256	5.458	1.00	0.00	H
ATOM	1367	HA	MET	B	323	8.543	16.851	6.397	1.00	0.00	H
ATOM	1368	HC	MET	B	323	9.992	17.325	8.314	1.00	0.00	H
ATOM	1369	1HB	MET	B	323	8.159	14.822	8.692	1.00	0.00	H
ATOM	1370	2HB	MET	B	323	7.027	14.994	7.381	1.00	0.00	H
ATOM	1371	1HG	MET	B	323	7.234	17.694	8.146	1.00	0.00	H
ATOM	1372	2HG	MET	B	323	7.431	16.856	9.694	1.00	0.00	H
ATOM	1373	1HE	MET	B	323	3.617	17.934	9.560	1.00	0.00	H
ATOM	1374	2HE	MET	B	323	5.151	18.043	10.474	1.00	0.00	H
ATOM	1375	3HE	MET	B	323	5.001	18.830	8.871	1.00	0.00	H
ATOM	1376	N	ILE	B	358	12.341	9.219	1.408	1.00	20.00	N
ATOM	1377	CA	ILE	B	358	11.380	8.834	0.412	1.00	20.00	C
ATOM	1378	C	ILE	B	358	10.221	8.138	1.091	1.00	20.00	C

ATOM	1379	O	ILE	B	358	10.452	7.183	1.816	1.00	20.00	O
ATOM	1380	CB	ILE	B	358	12.039	8.050	-0.785	1.00	20.00	C
ATOM	1381	CG1	ILE	B	358	13.151	8.860	-1.533	1.00	20.00	C
ATOM	1382	CG2	ILE	B	358	10.989	7.580	-1.834	1.00	20.00	C
ATOM	1383	CD1	ILE	B	358	14.081	8.054	-2.460	1.00	20.00	C
ATOM	1384	1H	ILE	B	358	13.083	9.794	0.993	1.00	0.00	H
ATOM	1385	2H	ILE	B	358	11.900	9.803	2.129	1.00	0.00	H
ATOM	1386	HA	ILE	B	358	11.121	9.798	-0.051	1.00	0.00	H
ATOM	1387	HB	ILE	B	358	12.507	7.155	-0.344	1.00	0.00	H
ATOM	1388	1HG1	ILE	B	358	13.807	9.362	-0.797	1.00	0.00	H
ATOM	1389	2HG1	ILE	B	358	12.693	9.690	-2.105	1.00	0.00	H
ATOM	1390	1HG2	ILE	B	358	11.439	6.978	-2.644	1.00	0.00	H
ATOM	1391	2HG2	ILE	B	358	10.205	6.941	-1.386	1.00	0.00	H
ATOM	1392	3HG2	ILE	B	358	10.473	8.430	-2.318	1.00	0.00	H
ATOM	1393	1HD1	ILE	B	358	14.841	8.706	-2.929	1.00	0.00	H
ATOM	1394	2HD1	ILE	B	358	14.630	7.267	-1.910	1.00	0.00	H
ATOM	1395	3HD1	ILE	B	358	13.535	7.559	-3.284	1.00	0.00	H
ATOM	1396	N	PRO	B	359	9.091	8.674	0.987	1.00	20.00	N
ATOM	1397	CA	PRO	B	359	8.003	8.029	1.681	1.00	20.00	C
ATOM	1398	C	PRO	B	359	7.316	6.979	0.821	1.00	20.00	C
ATOM	1399	O	PRO	B	359	7.190	7.194	-0.393	1.00	20.00	O
ATOM	1400	CB	PRO	B	359	7.115	9.211	1.611	1.00	20.00	C
ATOM	1401	CG	PRO	B	359	7.278	10.070	0.363	1.00	20.00	C
ATOM	1402	CD	PRO	B	359	8.758	9.909	0.196	1.00	20.00	C
ATOM	1403	HA	PRO	B	359	8.276	7.803	2.704	1.00	0.00	H
ATOM	1404	1HB	PRO	B	359	7.308	9.842	2.477	1.00	0.00	H
ATOM	1405	2HB	PRO	B	359	6.098	8.802	1.677	1.00	0.00	H
ATOM	1406	1HG	PRO	B	359	6.958	11.119	0.511	1.00	0.00	H
ATOM	1407	2HG	PRO	B	359	6.721	9.653	-0.497	1.00	0.00	H
ATOM	1408	1HD	PRO	B	359	9.017	9.815	-0.877	1.00	0.00	H
ATOM	1409	2HD	PRO	B	359	9.277	10.799	0.607	1.00	0.00	H
ATOM	1410	N	PRO	B	360	7.251	6.048	1.782	1.00	20.00	N
ATOM	1411	CA	PRO	B	360	6.818	4.825	1.130	1.00	20.00	C
ATOM	1412	C	PRO	B	360	5.930	5.066	-0.067	1.00	20.00	C
ATOM	1413	O	PRO	B	360	5.035	5.859	0.005	1.00	20.00	O
ATOM	1414	CB	PRO	B	360	6.176	3.866	2.129	1.00	20.00	C
ATOM	1415	CG	PRO	B	360	6.348	4.614	3.407	1.00	20.00	C
ATOM	1416	CD	PRO	B	360	6.382	6.096	2.989	1.00	20.00	C
ATOM	1417	HA	PRO	B	360	7.758	4.332	0.800	1.00	0.00	H
ATOM	1418	1HB	PRO	B	360	6.710	2.907	2.177	1.00	0.00	H
ATOM	1419	2HB	PRO	B	360	5.106	3.650	1.927	1.00	0.00	H
ATOM	1420	1HG	PRO	B	360	7.307	4.334	3.891	1.00	0.00	H
ATOM	1421	2HG	PRO	B	360	5.542	4.328	4.102	1.00	0.00	H
ATOM	1422	1HD	PRO	B	360	5.378	6.500	2.752	1.00	0.00	H
ATOM	1423	2HD	PRO	B	360	6.803	6.748	3.770	1.00	0.00	H
ATOM	1424	N	ARG	B	369	6.208	4.361	-1.143	1.00	20.00	N
ATOM	1425	CA	ARG	B	369	5.462	4.424	-2.372	1.00	20.00	C
ATOM	1426	C	ARG	B	369	4.025	4.353	-2.078	1.00	20.00	C
ATOM	1427	O	ARG	B	369	3.492	3.307	-1.675	1.00	20.00	O
ATOM	1428	CB	ARG	B	369	6.017	3.407	-3.389	1.00	20.00	C
ATOM	1429	CG	ARG	B	369	5.630	3.568	-4.878	1.00	20.00	C
ATOM	1430	CD	ARG	B	369	6.473	2.611	-5.746	1.00	20.00	C
ATOM	1431	NE	ARG	B	369	5.928	2.488	-7.120	1.00	20.00	N
ATOM	1432	CZ	ARG	B	369	6.434	1.697	-8.068	1.00	20.00	C
ATOM	1433	NH1	ARG	B	369	7.528	0.989	-7.936	1.00	20.00	N
ATOM	1434	NH2	ARG	B	369	5.795	1.631	-9.191	1.00	20.00	N
ATOM	1435	H	ARG	B	369	7.073	3.819	-1.069	1.00	0.00	H
ATOM	1436	HA	ARG	B	369	5.747	5.404	-2.819	1.00	0.00	H
ATOM	1437	1HB	ARG	B	369	5.729	2.395	-3.065	1.00	0.00	H
ATOM	1438	2HB	ARG	B	369	7.122	3.460	-3.344	1.00	0.00	H
ATOM	1439	1HG	ARG	B	369	5.789	4.608	-5.224	1.00	0.00	H
ATOM	1440	2HG	ARG	B	369	4.548	3.374	-5.017	1.00	0.00	H
ATOM	1441	1HD	ARG	B	369	6.501	1.606	-5.281	1.00	0.00	H

ATOM	1442	2HD	ARG	B	369	7.527	2.958	-5.773	1.00	0.00	H
ATOM	1443	1HH1	ARG	B	369	7.835	0.434	-8.737	1.00	0.00	H
ATOM	1444	2HH1	ARG	B	369	8.005	1.129	-7.044	1.00	0.00	H
ATOM	1445	1HH2	ARG	B	369	6.171	1.021	-9.917	1.00	0.00	H
ATOM	1446	2HH2	ARG	B	369	4.948	2.203	-9.195	1.00	0.00	H
ATOM	1447	N	GLY	B	370	3.425	5.468	-2.259	1.00	20.00	N
ATOM	1448	CA	GLY	B	370	2.036	5.613	-2.028	1.00	20.00	C
ATOM	1449	C	GLY	B	370	1.499	5.744	-0.610	1.00	20.00	C
ATOM	1450	O	GLY	B	370	0.313	5.634	-0.388	1.00	20.00	O
ATOM	1451	H	GLY	B	370	4.057	6.269	-2.370	1.00	0.00	H
ATOM	1452	1HA	GLY	B	370	1.475	4.791	-2.516	1.00	0.00	H
ATOM	1453	2HA	GLY	B	370	1.693	6.514	-2.568	1.00	0.00	H
ATOM	1454	N	LEU	B	371	1.980	6.048	0.616	1.00	20.00	N
ATOM	1455	CA	LEU	B	371	1.562	6.576	1.902	1.00	20.00	C
ATOM	1456	C	LEU	B	371	1.774	8.063	1.949	1.00	20.00	C
ATOM	1457	O	LEU	B	371	0.945	8.860	2.524	1.00	20.00	O
ATOM	1458	CB	LEU	B	371	2.296	5.742	2.941	1.00	20.00	C
ATOM	1459	CG	LEU	B	371	2.134	6.342	4.334	1.00	20.00	C
ATOM	1460	CD1	LEU	B	371	0.634	6.498	4.689	1.00	20.00	C
ATOM	1461	CD2	LEU	B	371	3.107	5.555	5.191	1.00	20.00	C
ATOM	1462	H	LEU	B	371	2.983	5.823	0.546	1.00	0.00	H
ATOM	1463	HA	LEU	B	371	0.474	6.404	1.997	1.00	0.00	H
ATOM	1464	1HB	LEU	B	371	3.369	5.664	2.676	1.00	0.00	H
ATOM	1465	2HB	LEU	B	371	1.918	4.700	2.924	1.00	0.00	H
ATOM	1466	HG	LEU	B	371	2.537	7.363	4.357	1.00	0.00	H
ATOM	1467	1HD1	LEU	B	371	0.477	6.948	5.684	1.00	0.00	H
ATOM	1468	2HD1	LEU	B	371	0.088	7.173	4.015	1.00	0.00	H
ATOM	1469	3HD1	LEU	B	371	0.071	5.552	4.584	1.00	0.00	H
ATOM	1470	1HD2	LEU	B	371	3.132	5.934	6.215	1.00	0.00	H
ATOM	1471	2HD2	LEU	B	371	2.910	4.468	5.188	1.00	0.00	H
ATOM	1472	3HD2	LEU	B	371	4.131	5.709	4.834	1.00	0.00	H
ATOM	1473	N	LYS	B	372	2.605	8.459	1.340	1.00	20.00	N
ATOM	1474	CA	LYS	B	372	3.153	9.786	1.364	1.00	20.00	C
ATOM	1475	C	LYS	B	372	4.058	9.981	2.550	1.00	20.00	C
ATOM	1476	O	LYS	B	372	5.119	10.515	2.409	1.00	20.00	O
ATOM	1477	CB	LYS	B	372	2.357	10.950	0.692	1.00	20.00	C
ATOM	1478	CG	LYS	B	372	2.574	11.176	-0.824	1.00	20.00	C
ATOM	1479	CD	LYS	B	372	3.925	11.837	-1.171	1.00	20.00	C
ATOM	1480	CE	LYS	B	372	4.095	12.053	-2.682	1.00	20.00	C
ATOM	1481	NZ	LYS	B	372	5.398	12.690	-2.954	1.00	20.00	N
ATOM	1482	H	LYS	B	372	3.003	7.719	0.751	1.00	0.00	H
ATOM	1483	HA	LYS	B	372	3.950	9.637	0.611	1.00	0.00	H
ATOM	1484	1HB	LYS	B	372	2.551	11.900	1.225	1.00	0.00	H
ATOM	1485	2HB	LYS	B	372	1.279	10.755	0.826	1.00	0.00	H
ATOM	1486	1HG	LYS	B	372	1.756	11.818	-1.205	1.00	0.00	H
ATOM	1487	2HG	LYS	B	372	2.461	10.216	-1.365	1.00	0.00	H
ATOM	1488	1HD	LYS	B	372	4.758	11.220	-0.785	1.00	0.00	H
ATOM	1489	2HD	LYS	B	372	4.008	12.807	-0.642	1.00	0.00	H
ATOM	1490	1HE	LYS	B	372	3.280	12.693	-3.075	1.00	0.00	H
ATOM	1491	2HE	LYS	B	372	4.022	11.090	-3.225	1.00	0.00	H
ATOM	1492	1HZ	LYS	B	372	6.171	12.104	-2.618	1.00	0.00	H
ATOM	1493	2HZ	LYS	B	372	5.555	12.807	-3.963	1.00	0.00	H
ATOM	1494	N	MET	B	373	3.738	9.544	3.814	1.00	20.00	N
ATOM	1495	CA	MET	B	373	4.620	9.810	4.921	1.00	20.00	C
ATOM	1496	C	MET	B	373	4.556	8.711	5.954	1.00	20.00	C
ATOM	1497	O	MET	B	373	3.539	8.417	6.558	1.00	20.00	O
ATOM	1498	CB	MET	B	373	4.412	11.304	5.356	1.00	20.00	C
ATOM	1499	CG	MET	B	373	4.650	11.762	6.809	1.00	20.00	C
ATOM	1500	SD	MET	B	373	4.345	13.538	7.056	1.00	20.00	S
ATOM	1501	CE	MET	B	373	5.038	14.386	5.620	1.00	20.00	C
ATOM	1502	H	MET	B	373	2.761	9.242	3.918	1.00	0.00	H
ATOM	1503	HA	MET	B	373	5.643	9.717	4.544	1.00	0.00	H
ATOM	1504	1HB	MET	B	373	3.403	11.656	5.087	1.00	0.00	H

ATOM	1505	2HB	MET	B	373	5.055	11.907	4.690	1.00	0.00	H
ATOM	1506	1HG	MET	B	373	5.651	11.501	7.191	1.00	0.00	H
ATOM	1507	2HG	MET	B	373	3.932	11.237	7.463	1.00	0.00	H
ATOM	1508	1HE	MET	B	373	5.060	15.477	5.788	1.00	0.00	H
ATOM	1509	2HE	MET	B	373	6.069	14.047	5.418	1.00	0.00	H
ATOM	1510	3HE	MET	B	373	4.427	14.196	4.719	1.00	0.00	H
ATOM	1511	N	SER	B	374	5.743	8.217	6.513	1.00	20.00	N
ATOM	1512	CA	SER	B	374	5.872	6.931	7.127	1.00	20.00	C
ATOM	1513	C	SER	B	374	6.400	7.049	8.547	1.00	20.00	C
ATOM	1514	O	SER	B	374	7.000	7.996	8.987	1.00	20.00	O
ATOM	1515	CB	SER	B	374	6.744	5.938	6.377	1.00	20.00	C
ATOM	1516	OG	SER	B	374	8.044	6.430	6.119	1.00	20.00	O
ATOM	1517	H	SER	B	374	6.571	8.784	6.310	1.00	0.00	H
ATOM	1518	HA	SER	B	374	4.872	6.473	7.229	1.00	0.00	H
ATOM	1519	1HB	SER	B	374	6.192	5.724	5.489	1.00	0.00	H
ATOM	1520	2HB	SER	B	374	6.821	4.962	6.894	1.00	0.00	H
ATOM	1521	HG	SER	B	374	7.975	7.172	5.508	1.00	0.00	H
ATOM	1522	N	ALA	B	375	6.256	6.039	9.291	1.00	20.00	N
ATOM	1523	CA	ALA	B	375	6.629	5.877	10.681	1.00	20.00	C
ATOM	1524	C	ALA	B	375	6.941	4.458	10.990	1.00	20.00	C
ATOM	1525	O	ALA	B	375	6.124	3.561	10.828	1.00	20.00	O
ATOM	1526	CB	ALA	B	375	5.673	6.418	11.730	1.00	20.00	C
ATOM	1527	H	ALA	B	375	5.725	5.286	8.842	1.00	0.00	H
ATOM	1528	HA	ALA	B	375	7.548	6.486	10.835	1.00	0.00	H
ATOM	1529	1HB	ALA	B	375	6.031	6.276	12.768	1.00	0.00	H
ATOM	1530	2HB	ALA	B	375	5.599	7.496	11.565	1.00	0.00	H
ATOM	1531	3HB	ALA	B	375	4.676	5.962	11.646	1.00	0.00	H
ATOM	1532	N	THR	B	376	8.149	4.189	11.366	1.00	20.00	N
ATOM	1533	CA	THR	B	376	8.521	2.847	11.801	1.00	20.00	C
ATOM	1534	C	THR	B	376	8.972	2.948	13.258	1.00	20.00	C
ATOM	1535	O	THR	B	376	9.493	3.969	13.692	1.00	20.00	O
ATOM	1536	CB	THR	B	376	9.689	2.272	10.929	1.00	20.00	C
ATOM	1537	OG1	THR	B	376	9.506	2.582	9.556	1.00	20.00	O
ATOM	1538	CG2	THR	B	376	9.867	0.743	11.028	1.00	20.00	C
ATOM	1539	H	THR	B	376	8.886	4.953	11.322	1.00	0.00	H
ATOM	1540	HA	THR	B	376	7.682	2.128	11.720	1.00	0.00	H
ATOM	1541	HB	THR	B	376	10.635	2.747	11.243	1.00	0.00	H
ATOM	1542	HG1	THR	B	376	9.040	3.426	9.560	1.00	0.00	H
ATOM	1543	1HG2	THR	B	376	10.783	0.403	10.518	1.00	0.00	H
ATOM	1544	2HG2	THR	B	376	9.962	0.392	12.071	1.00	0.00	H
ATOM	1545	3HG2	THR	B	376	9.020	0.199	10.572	1.00	0.00	H
ATOM	1546	N	PHE	B	377	8.772	1.896	14.007	1.00	20.00	N
ATOM	1547	CA	PHE	B	377	9.109	1.894	15.437	1.00	20.00	C
ATOM	1548	C	PHE	B	377	9.757	0.619	15.855	1.00	20.00	C
ATOM	1549	O	PHE	B	377	9.409	-0.450	15.371	1.00	20.00	O
ATOM	1550	CB	PHE	B	377	7.811	2.211	16.239	1.00	20.00	C
ATOM	1551	CG	PHE	B	377	8.002	2.502	17.738	1.00	20.00	C
ATOM	1552	CD1	PHE	B	377	7.747	1.507	18.688	1.00	20.00	C
ATOM	1553	CD2	PHE	B	377	8.431	3.764	18.162	1.00	20.00	C
ATOM	1554	CE1	PHE	B	377	7.924	1.771	20.045	1.00	20.00	C
ATOM	1555	CE2	PHE	B	377	8.607	4.026	19.519	1.00	20.00	C
ATOM	1556	CZ	PHE	B	377	8.354	3.030	20.459	1.00	20.00	C
ATOM	1557	H	PHE	B	377	8.135	1.192	13.608	1.00	0.00	H
ATOM	1558	HA	PHE	B	377	9.851	2.688	15.667	1.00	0.00	H
ATOM	1559	HC	PHE	B	377	10.540	0.729	16.627	1.00	0.00	H
ATOM	1560	1HB	PHE	B	377	7.076	1.396	16.096	1.00	0.00	H
ATOM	1561	2HB	PHE	B	377	7.307	3.090	15.789	1.00	0.00	H
ATOM	1562	HD1	PHE	B	377	7.415	0.527	18.377	1.00	0.00	H
ATOM	1563	HD2	PHE	B	377	8.630	4.544	17.440	1.00	0.00	H
ATOM	1564	HE1	PHE	B	377	7.727	1.000	20.775	1.00	0.00	H
ATOM	1565	HE2	PHE	B	377	8.939	5.002	19.842	1.00	0.00	H
ATOM	1566	HZ	PHE	B	377	8.490	3.234	21.511	1.00	0.00	H
END											